0001144204-15-023068.txt : 20150415 0001144204-15-023068.hdr.sgml : 20150415 20150415172641 ACCESSION NUMBER: 0001144204-15-023068 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20150415 DATE AS OF CHANGE: 20150415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AmpliPhi Biosciences Corp CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23930 FILM NUMBER: 15772660 BUSINESS ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 BUSINESS PHONE: 650-888-2422 MAIL ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 FORMER COMPANY: FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/ DATE OF NAME CHANGE: 19940331 10-Q/A 1 v407149_10qa.htm FORM 10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _______________________

Commission file number: 000-23930

AMPLIPHI BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)

Washington (State or other jurisdiction of incorporation or organization)	91-1549568 I.R.S. Employer Identification Number)

4870 Sadler Road, Suite 300 Glen Allen, Virginia	23060 (Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code: (804) 205-5069

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company as defined in Rule 12b-2 of the Exchange Act. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a small reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

The number of shares of the Registrant’s Public Common Stock outstanding at October 20, 2014 was 187,159,093.

EXPLANATORY NOTE

Amended Financial Statements

The Company’s previously issued September 30, 2014 financial statements have been amended to:

reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000.

recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014.

reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014.

adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.

modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively.

As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period.

The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by $(5,139,000) to $(49,039,000). The net loss per share attributable to common stockholders increased by $(0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by $(7,098,000) to $(65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.

TABLE OF CONTENTS

		Page

PART I - FINANCIAL INFORMATION

Consolidated Balance Sheets		3

Consolidated Statements of Operations		4

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)		5

Consolidated Statements of Cash Flows		6

Condensed Notes to Consolidated Financial Statements		7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14

PART II. OTHER INFORMATION		19

Item 1.	Legal Proceedings	19

Item 1A.	Risk Factors	19

Item 1A.	Unregistered Sales of Equity Securities and Use of Proceeds	19

Item 3.	Defaults upon Senior Securities	19

Item 4.	Mine Safety Disclosures	19

Item 5.	Other Information	19

Item 6.	Exhibits	19

Signatures		21

AmpliPhi Biosciences Corporation
Consolidated Balance Sheets

	September 30, 2014			December 31, 2013
	(Unaudited)
	(Restated)			(Restated)
Assets
Current assets
Cash and cash equivalents	$	9,786,000		$	20,355,000
Accounts receivable		27,000			8,000
Prepaid expenses and other current assets		448,000			297,000
Total current assets		10,261,000			20,660,000
Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of September 30, 2014 and December 31, 2013, respectively		1,283,000			145,000
Intangible assets
In process research and development		12,446,000			12,446,000
Patents, net of accumulated amortization of $116,000 and $93,000 as of September 30, 2014 and December 31, 2013, respectively		377,000			400,000
Goodwill		7,562,000			7,562,000
Total intangible assets		20,385,000			20,408,000
Total assets	$	31,929,000		$	41,213,000
Liabilities, Series B Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities
Accounts payable and accrued expenses	$	1,840,000		$	2,147,000
Deferred revenue		246,000			244,000
Accrued severance		449,000			—
Total current liabilities		2,535,000			2,391,000
Long term liabilities
Derivative preferred shares conversion liability		14,043,000			40,791,000
Derivative warrants liability		6,035,000			16,871,000
Deferred tax liability		3,078,000			3,078,000
Accrued severance		210,000			—
Total long term liabilities		23,366,000			60,740,000
Total liabilities		25,901,000			63,131,000

Series B redeemable convertible preferred stock
$0.01 par value, 10,000,000 shares authorized, 8,859,978 shares issued and outstanding at December 31, 2013 (liquidation preference of $13,712,000 and 13,022,000 at September 30, 2014 and December 31, 2014, respectively)		1,660,000			707,000

Stockholders’ equity (deficit)
Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at September 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013		1,872,000			1,825,000
Additional paid-in capital		362,001,000			358,828,000
Paid-in-capital – contingent shares		1,837,000			1,837,000
Accumulated deficit		(361,342,000	)		(385,115,000	)
Total stockholders’ equity (deficit)		4,368,000			(22,625,000	)
Total liabilities, Series B redeemable convertible preferred stock and stockholders’ equity (deficit)	$	31,929,000		$	41,213,000

See accompanying condensed notes to consolidated financial statements.

AmpliPhi Biosciences Corporation

Consolidated Statements of Operations

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
	(Restated)			(Restated)			(Restated)			(Restated)
Revenue	$	103,000		$	(3,000	)	$	308,000		$	333,000
Operating expenses
Research and development		1,793,000			1,123,000			4,692,000			5,359,000
General and administrative		1,701,000			1,215,000			5,289,000			4,772,000
Severance charge		1,840,000			—			1,840,000			—
Total operating expenses		5,334,000			2,338,000			11,821,000			10,131,000
Loss from operations		(5,231,000	)		(2,341,000	)		(11,513,000	)		(9,798,000	)
Other income (expense)
Gain (loss) on derivative liabilities		26,438,000			(46,380,000	)		35,286,000			(52,350,000	)
Amortization of note discount and patents		—			(23,000	)		—			(2,660,000	)
Interest expense, net		—			(9,000	)		—			(233,000	)
Other income (expense), net		26,438,000			(46,412,000	)		35,286,000			(55,243,000	)
Net income (loss)		21,207,000			(48,753,000	)		23,773,000			(65,041,000
Accretion of Series B redeemable convertible preferred stock		(323,000	)		(286,000	)		(955,000	)		(389,000	)
Net loss attributable to common stockholders	$	20,884,000		$	(49,039,000	)	$	22,818,000		$	(65,430,000	)
Per share information:
Net income (loss) per share – basic	$	0.11		$	(0.49	)	$	0.12		$	(0.76	)
Net income (loss) per share – diluted		0.07			(0.49	)		0.07			(0.76	)
Weighted average number of shares of common stock outstanding – basic		187,159,093			99,156,809			184,445,172			85,688,356
Weighted average number of shares of common stock outstanding – diluted		315,990,084			99,156,809			323,604,642			85,688,356

See accompanying condensed notes to consolidated financial statements.

AmpliPhi Biosciences Corporation

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

	Redeemable Convertible Preferred Stock						Shareholders' Equity (Deficit)
	Series B						Common Stock					Additional Paid-in			Accumulated			Total Stockholders' Equity
	Shares			Amount			Shares			Amount		Capital			Deficit			(Deficit)
Balances, December 31, 2012 (Restated)		—		$	—			66,908,810		$	669,000	$	332,806,000		$	(320,532,000	)	$	12,943,000
Net income (loss)		—			—			—			—		—			(64,583,000	)		(64,583,000	)
Stock-based compensation		—			—			—			—		1,437,000			—			1,437,000
Beneficial conversion feature and warrants associated with issuance of convertible loan notes		—			—			—			—		2,635,000			—			2,635,000
Shares issued for Intrexon		—			—			24,000,000			240,000		2,760,000			—			3,000,000
Accretion of Series B convertible preferred stock to its redemption value		—			618,000			—			—		(618,000	)		—			(618,000	)
Issuance of preferred stock from conversion of convertible loan notes		5,016,081			50,000			—			—		—			—			—
Issuance of preferred stock		4,999,999			50,000			—			—		—			—			—
Preferred shares converted to common stock		(1,156,102	)		(11,000	)		11,561,020			115,000		6,969,000			—			7,084,000
Stock options exercised		—			—			61,018			1,000		12,000			—			13,000
Shares released from escrow		—			—			8,000,000			80,000		(80,000	)		—			—
Issuance of common stock for December financing		—			—			72,007,000			720,000		14,744,000			—			15,464,000
Escheat shares		—			—			(2,286	)		—		—			—			—
Balances, December 31, 2013 (Restated)		8,859,978			707,000			182,535,562			1,825,000		360,665,000			(385,115,000	)		(22,625,000	)
Net income (loss)		—			—			—			—		—			23,773,000			23,773,000
Accretion of Series B convertible preferred stock to its redemption value		—			955,000			—			—		(955,000	)		—			(955,000	)
Warrants exercised		—			—			2,734,151			28,000		1,566,000			—			1,594,000
Preferred stock converted to common stock		(188,938	)		(2,000	)		1,889,380			19,000		687,000			—			706,000
Stock-based compensation		—			—			—			—		714,000			—			714,000
Stock-based compensation - severance		—			—			—			—		1,161,000			—			1,161,000
Balances, September 30, 2014 (Unaudited) (Restated)		8,671,040		$	1,660,000			187,159,093		$	1,872,000	$	363,838,000		$	(361,342,000	)	$	4,368,000

See accompanying condensed notes to consolidated financial statements.

AmpliPhi Biosciences Corporation

Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	2014			2013
	(Unaudited)			(Unaudited)
	(Restated)			(Restated)
Cash flows from operating activities
Net income (loss) from operations	$	23,773,000		$	(65,041,000	)
Adjustments required to reconcile net income (loss) to cash used in operating activities:
Derivative liability (gain) loss		(35,286,000	)		52,350,000
Shares issued for technology access fee		—			3,000,000
Amortization of patents		23,000			23,000
Amortization of note discount		—			2,637,000
Warrants issued as investment fees		—			759,000
Depreciation		59,000			66,000
Stock-based compensation		714,000			1,206,000
Stock-based compensation - severance		1,161,000			—
Changes in operating assets and liabilities net of acquisitions:
Accounts receivable		(19,000	)		(125,000	)
Tax refund		—			618,000
Accounts payable and accrued expenses		(305,000	)		(453,000	)
Accrued severance		659,000			—
Prepaid expenses and other current assets		(151,000	)		(153,000	)
Interest on loan notes		—			233,000
Net cash used in operating activities		(9,372,000	)		(4,880,000	)
Cash flows from investing activities
Purchases of property and equipment		(1,197,000	)		(97,000	)
Net cash used in investing activities		(1,197,000	)		(97,000	)
Cash flows from financing activities
Proceeds from Series B redeemable convertible preferred stock		—			7,000,000
Proceeds from convertible loan notes		—			2,000,000
Payment of convertible loan note		—			(26,000	)
Net cash provided by financing activities		—			8,974,000
Net increase (decrease) in cash and cash equivalents		(10,569,000	)		3,997,000
Cash and cash equivalents, beginning of period		20,355,000			862,000
Cash and cash equivalents, end of period	$	9,786,000		$	4,859,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	$	955,000		$	618,000

See accompanying condensed notes to consolidated financial statements.

AmpliPhi Biosciences Corporation

Condensed Notes to Consolidated Financial Statements

September 30, 2014

(Unaudited) (Restated)

1. Nature of Business and Significant Accounting Policies

Nature of Business

AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.

Basis of Presentation

The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries - Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All amounts on the financial statements and disclosures have been rounded to the nearest $1,000 except share and per share data.

The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments, reclassifications, and non-recurring adjustments) necessary to present fairly our results of operations for the three months and nine months ended September 30, 2014 and 2013, our cash flows for the nine months ended September 30, 2014 and 2013 and our financial position as of September 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.

Accounts Receivable

Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of September 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.

Property and Equipment

Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.

Prepaid Expenses and Other Current Assets

Prepaid and other current assets as of September 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.

Goodwill

Investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.

In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. Goodwill in the amount of $3,929,000 was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.

In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. Goodwill in the amount of $3,633,000 was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.

Patents

Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.

In 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. Patents in the amount of $493,000 have been recorded. These patents are being amortized over their useful life through December 2026.

Stock-Based Compensation

The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.

Warrant and Preferred Shares Conversion Feature Liability

The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require such warrants and the Series B preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.

Fair Value of Financial Assets and Liabilities — Derivative Instruments

The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.

GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 — inputs that are unobservable.

The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.

The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.

Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.

Revenue Recognition

The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.

The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:

•

The delivered items have value to the customer on a stand-alone basis;

•

Any undelivered items have objective and reliable evidence of fair value; and

•

Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.

The Company classifies advance payments received in excess of amounts earned as deferred revenue.

Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.

Research and Development

Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.

In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. In 2012, IPR&D in the amount of $5,161,000 was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.

In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. In 2011, IPR&D in the amount of $7,285,000 was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.

Net Income (Loss) per Common Share

Net income (loss) per common share is based on net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three months ended September 30, 2014 and the nine months ended September 30, 2014, both basic and diluted net income (loss) are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended September 30, 2013 and the nine months ended September 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B Preferred shares were antidilutive with respect to computing the net loss per share and therefore were excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share was 150,283,630 shares for the three month period ending September 30, 2013 and 63,155,331 shares for the nine month period ending September 30, 2013.

Recent Accounting Pronouncements

On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.

2. Preferred Shares

On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $1.40 and par value of $0.01. Each Series B redeemable convertible preferred stock is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shall be entitled to receive dividends of 10% of the Series B redeemable convertible preferred stock stated value per annum.

In connection with the private placement of Series B Convertible Preferred Stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013(dates of issuance) and recorded the initial liability as part of the private placement proceeds.

On June 26, 2013, the Company issued 4,999,999 shares of the Company’s newly-created Series B redeemable convertible preferred stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $6,917,000. As part of the same transaction, the Company converted $5,491,001 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B redeemable convertible preferred stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $6,029,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B redeemable convertible preferred stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $2,386,000.

In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for the conversion feature that contains a provision that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision). The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds.

On May 16, 2014, 188,938 preferred shares were converted into 1,889,380 shares of common stock. Due to this conversion, $707,000 was reclassified out of the derivative liability account and into equity.

The Company re-measured the fair value of the conversion feature at September 30, 2014 and recorded an $19.4 million gain on derivative liabilities during the third quarter to adjust the liability associated with the conversion feature to an estimated fair value of $14.0 million. The change in fair value and the associated gain was primarily attributable to a decline in the market value of our common stock as of September 30, 2014.

3. Warrants and Warrants Liability

The Company follows ASC 815-40, Contracts in an Entity’s Own Equity, as it relates to outstanding warrants.

In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.

In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,195 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $1.4 million for the warrants issued to the placement agent.

We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:

	June 26, 2013			July 15, 2013			December 23, 2013
Warrants issued		28,394,834			1,645,361			4,320,420
Risk free interest rate		.0109			.0109			0.0167
Volatility		160.94	%		163.08	%		155.24	%
Expected term		5 years			5 years			5 years
Exercise price	$	0.14		$	0.14		$	0.25

From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity.

In 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity.

On June 26, 2014, 3,855,714 warrants, issued on June 26, 2013, were exercised. Due to this exercise, 2,734,151 shares of common stock were issued and $1,594,000 was classified out of the derivative liability account and into equity.

The Company re-measured the fair value of the liability warrants at September 30, 2014 and recorded a $7.1 million gain on derivative liabilities during the third quarter to adjust the liabilities associated with the warrants to their estimated fair values totaling $6.0 million. The change in fair value and the resulting gain was attributable to a decline in the market value of our common stock as of September 30, 2014.

4. Stock Options

In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to 35,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants.

In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to 4,200,000 shares of our common stock in stock incentive awards to employees, directors and consultants.

In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to 40,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014.

The Company’s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company’s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plans.

Under ASC 718 Stock Compensation, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.

Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three and nine month periods ended September 30, 2013 and 2014.

Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations:

	Three Months Ended				Nine Months Ended
	September 30, 2014		September 30, 2013		September 30, 2014		September 30, 2013
Income statement category:
Research and development	$	38,000	$	40,000	$	116,000	$	153,000
General and administrative		209,000		208,000		598,000		1,053,000
Severance charge		1,161,000		—		1,161,000		—
Total stock-based compensation expense	$	1,408,000	$	248,000	$	1,875,000	$	1,206,000

The following table summarizes Option activity:

	Shares		Weighted Average Exercise Price		Average Remaining Contractual Term (Years)		Intrinsic Value
Outstanding at December 31, 2013		25,721,000	$	0.19		9.15	$	6,451,441
Granted		—		—
Exercised		—		—
Forfeited		3,137,378		0.19
Expired		2,000		13.10
Outstanding at September 30, 2014		22,581,622	$	0.19		2.15	$	862,982
Exercisable at September 30, 2014		19,972,558	$	0.19		1.35	$	822,989

The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $0.22 on September 30, 2014.

As of September 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $559,358 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years.

As of September 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:

	Shares Reserved
Stock options outstanding		22,581,622
Available for future grants under the 2013 Stock Incentive Plan		39,250,000
Warrants		38,890,451
Total shares reserved		100,722,073

5. Severance Charge

On September 15, 2014, by mutual agreement of the Board of Directors (the “Board”) of the Company and Philip J. Young, Mr. Young stepped down from his role as President and Chief Executive Officer of the Company, effective September 15, 2014. In accordance with Mr. Young’s employment agreements, the Company recorded a severance charge in the quarter ended September 30, 2014 of $1,840,000 related to severance-period compensation and benefits, as well as stock-based compensation expense related to the accelerated vesting of stock options. The composition of the severance charge is as follows:

Compensation and benefits	$	679,000
Stock-based compensation expenses related to accelerated vesting		1,161,000
Total severance charge	$	1,840,000

6. Correction of Error

The Company’s previously issued September 30, 2014 financial statements have been amended to:

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with “Selected Consolidated Financial Data” and the Unaudited Condensed Consolidated Financial Statements and related Notes included in Part I Item 1 of this Form 10-Q.

This discussion contains forward-looking statements that involve risks and uncertainties. Such statements, which include statements concerning product development plans, the use of bacteriophages to kill bacterial pathogens, future revenue sources, selling and marketing expenses, general and administrative expenses, clinical trial and other research and development expenses, capital resources, capital expenditures, tax credits and carry-forwards, the Company’s ability to raise capital through additional financings or borrowings, are subject to risks and uncertainties, including, but not limited to, those discussed below and elsewhere in this Form 10-Q and in Item 1A of Amendment No. 4 to Form 10, filed on November 14, 2014, that could cause actual results to differ materially from those projected. The forward-looking statements set forth in this Form 10-Q are as of the close of business on November 14, 2014, and we do not intend to update this forward-looking information.

Overview

AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacterial pathogens, including the so-called multi-drug-resistant (MDR) or “Superbug” strains.

We are combining our proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current medicines.

Our lead program is AmpliPhage-002, for the treatment of methicillin-resistant S. aureus (MRSA) infections. We have two other product candidates in development: AmpliPhage-001 for the treatment of P. aeruginosa lung infections in CF patients and AmpliPhage-004 for the treatment of C. difficile infections.

We have incurred net losses since our inception. Our operations to date have been limited to research and development and raising capital. Since November 2010, we have raised approximately $5.6 million through the sale and issuance of convertible notes and warrants to purchase common stock. In June and July of 2013, we completed a private placement of shares of Series B redeemable convertible preferred stock and warrants to purchase common stock, with proceeds to the Company of approximately $7.0 million. At the same time we converted approximately $6.3 million in outstanding convertible notes to Series B redeemable convertible preferred stock. In December 2013, we completed a private placement of shares of common stock, with gross proceeds of approximately $18 million, prior to commissions. To date, we have not generated any meaningful revenue and have primarily financed our operations through the sale and issuance of convertible notes and the private placement of our equity securities. As of September 30, 2014, we had an accumulated deficit of $361.3 million. We recorded annual net losses attributable to common stockholders of $65.2 million in 2013 and $1.1 million in 2012. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and obtaining regulatory approval of our product candidates.

We expect our research and development expenses to expand as we increase our development activities and commence clinical trials to pursue regulatory approval for our product candidates. We also expect to incur additional expenses associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates.

We currently expect to use our existing cash and cash equivalents for the continued research and development of our product candidates and for working capital and other general corporate purposes.

We may also use a portion of our cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. We expect that our current cash and cash equivalents will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through other public offerings, debt financing, collaboration and licensing arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs.

Results of Operations

Revenue

We recognized $103,000 in revenues for the quarter ended September 30, 2014. For the nine month period ending September 30, 2014, we recognized revenues of $308,000 from sublicensing arrangements, a decline of $25,000 from $333,000 for the same period in 2013 as a result of reduced grant revenue.

Research and Development

Research and development expenses were $1.8 million for the quarter ended September 30, 2014, up $0.7 million from the $1.1 million recorded for the quarter ended September 30, 2013. Research and development expenses were $4.7 million for the nine month period ended September 30, 2014, compared to $5.4 million for the nine month period ended September 30, 2013. Research and development costs for the nine month period in 2013 included a $3.0 million non-cash one-time technology access fee which was incurred in April 2013. Adjusted for this one-time item, research and development expense for the nine months of 2014 represented an increase of $2.3 million. The increase in research and development expense for both the three month and nine month periods ended September 30, 2014 were due to an increase in discovery, laboratory, nonclinical testing, research and development collaborations, consulting, and clinical development planning expenses for all of our product candidates.

Adjusted for the one-time non-cash technology access fee incurred in 2013, research and development expenses are expected to increase in 2014 compared to 2013 as we plan to continue investing substantial resources to research and development as we prepare to initiate clinical trials and continue our discovery efforts.

General and Administrative

General and administrative expenses were $1.7 million for the quarter ended September 30, 2014 compared to $1.2 million for the quarter ended September 30, 2013. The $0.5 million increase in general and administrative expense was due primarily to a $0.3 million accrual for payments to certain shareholders as required by the terms of our Series B Preferred Stock Purchase Agreement and deferred expenses related to certain sublicensing arrangements of $0.2 million.

General and administrative expenses were $5.3 million for the nine month period ended September 30, 2014 compared to $4.8 million for the nine month period ended September 30, 2013. This increase of $0.5 million was attributable to the accrual of payments to certain shareholders outlined above and higher legal, accounting, and staffing expenses incurred to satisfy our obligations as a public company.

We currently expect our general and administrative expenses to increase in 2014 compared to 2013 due to additional costs associated with being a public company.

Severance Charge

The Company recorded a severance charge in the quarter ended September 30, 2014 of $1,840,000 related to severance-period compensation and benefits and stock-based compensation expense related to the acceleration of vested stock options related to the termination of the Company’s Chief Executive Officer during the quarter.

Derivative Liabilities

During the quarter ended September 30, 2014, we recognized a gain on derivative liabilities of $26.4 million related to reductions in the fair value of derivative liabilities for warrants issued in June, July, and December 2013 and the conversion feature of the shares of Series B redeemable convertible preferred stock issued in June and July 2013. The reduction in fair value was primarily attributable to a decline in the market value of our common stock at September 30, 2014 as compared to June 30, 2014. During the quarter ended September 30, 2013, we recognized a loss on derivative liabilities of $46.4 million for warrants issued in June 2013 and the conversion feature of the shares of Series B redeemable convertible preferred stock issued in June 2013.

For the nine month period ended September 30, 2014, we recognized a gain on derivative liabilities of $35.3 million compared to $52.4 million loss for the nine month period ended September 30, 2013, primarily attributable to a decline in the market value of our common stock at September 30, 2014 as compared to December 31, 2013.

Derivative liabilities are adjusted to fair value each reporting period and are influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On September 30, 2014, the price per share of the Company’s common stock was $0.22 per share compared to $0.50 per share at December 31, 2013.

Income Taxes

We incurred net operating losses for the years ended December 31, 2013 and 2012 and, accordingly, we did not pay any U.S. federal or state income taxes. As of December 31, 2013, we had accumulated approximately $175.4 million in U.S., Australian and UK operating loss carry-forwards and research tax credit carry-forwards of approximately $3.7 million. The carry-forwards began to expire in 2012. Our net operating loss carry-forwards are subject to certain limitations on annual utilization as a result of changes in ownership of the Company, as defined by federal and state tax laws.

Net Operating Losses

We have not recorded a benefit from our net operating loss or research credit carry-forwards because we believe that it is uncertain that we will have sufficient income from future operations to realize the carry-forwards prior to their expiration. Accordingly, we have established a 100% valuation allowance against the deferred tax asset arising from the carry-forwards.

Liquidity and Capital Resources

We have incurred net losses since inception through September 30, 2014 of $361.3 million, of which $315.5 million was incurred in the Company’s prior focus on gene therapy in 2010 and years earlier. We have not generated any product revenues and do not expect to generate revenue from the sale of product candidates in the near term.

We had cash and cash equivalents of $9.8 million and $20.4 million at September 30, 2014 and December 31, 2013, respectively.

Net cash used in operating activities for the nine month period ended September 30, 2014 was $9.4 million. We recorded net income for the nine-month period of $23.8 million, including a non-cash gain on derivative liabilities of $35.3 million. Other items in uses of funds from operations included non-cash charges related to stock-based compensation expense, depreciation expense, and patent amortization, which collectively totaled $2.0 million. Increases in accounts payable and accrued liabilities increased net cash from operating activities by $0.3 million and were partially offset by an increase in receivables and prepaid expenses of $0.2 million.

Net cash used in operating activities for the nine month period ended September 30, 2013 was $4.9 million. We recorded a net loss of $65.0 for the period, including a non-cash charge on derivative liabilities of $52.4 million. The net impact of these two factors was a use of funds of $12.7 million. Other items in uses of funds from operations included non-cash charges for a technology access, amortization of loan discount, stock-based compensation expense, depreciation expenses, warrant-based investment fees, and a loss on disposal of equipment, which collectively totaled $6.4 million. Net changes in accrued liabilities, receivables and other assets also generated $0.1 million in cash.

Net cash used in investing activities for the nine month period ended September 30, 2014 and September 30, 2013 were $1,197,000 and $97,000, respectively, due to purchases of equipment.

Net cash provided by financing activities for the nine month period ended September 30, 2013 was $9.0 million due to proceeds from our issuance of 1) shares of Series B redeemable convertible preferred stock and 2) convertible loan notes. We expect 2014 cash requirements to be in the range of $15.0 million to $17.0 million. We believe that our cash balances as of September 30, 2014, will be sufficient to fund our projected operating requirements through the first quarter of 2015.

Our total use of cash in the nine month period ended September 30, 2014 was $10.6 million.

We expect to need to raise additional capital or incur indebtedness to continue to fund our future operations. We may seek to raise capital through a variety of sources, including:

the public equity market;

private equity financing;

collaborative arrangements;

licensing arrangements; and/or

public or private debt.

Our ability to raise additional funds will depend on our clinical and regulatory developments, our product development activities, our ability to identify promising in-licensing opportunities and factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on satisfactory terms. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain of our products, technologies or potential markets, any of which could delay or require that we curtail our development programs or otherwise have a material adverse effect on our business, financial condition and results of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to our existing stockholders.

If we are unable to secure additional financing on a timely basis or on terms favorable to us, we may be required to cease or reduce certain research and development projects, to sell some or all of our technology or assets or to merge all or a portion of our business with another entity. Insufficient funds may require us to delay, scale back or eliminate some or all of our activities, and if we are unable to obtain additional funding, there is uncertainty regarding our continued existence.

Off-Balance Sheet Arrangements

As of September 30, 2014, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. Therefore, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

Recent Accounting Pronouncements

None.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer, have concluded that our financial disclosure controls and procedures were effective during the period covered by this report.

Changes in Internal Controls Over Financial Reporting.

There were no changes in our internal control over financial reporting during the first nine months of 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any material legal proceedings.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013 as amended and filed with the SEC on September 12, 2014.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

(a) Exhibits

Number		Description
	3.1	Amended and Restated Articles of Incorporation, effective May 21, 2009 (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form 10 filed December 16, 2013).
	3.2	Articles of Amendment to Amended and Restated Articles of Incorporation, effective June 26, 2013 (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form 10 filed December 16, 2013).
	3.3	Articles of Correction to Amended and Restated Articles of Incorporation, effective June 26, 2013 (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form 10 filed December 16, 2013).
	3.4	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form 10 filed December 16, 2013).
	4.1	Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form 10 filed December 16, 2013).
	4.2	Form of Warrant to Purchase Shares of Common Stock (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form 10 filed December 16, 2013).
	4.3	Subscription Agreement to Purchase Series B Preferred Stock and Warrants, dated June 26, 2013 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form 10 filed December 16, 2013).

	4.4		Registration Rights Agreement, dated December 16, 2013 (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form 10 filed December 16, 2013).
	4.5		Subscription Agreement, dated December 16, 2013 (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form 10 filed December 16, 2013).
	10.1*		Interim Chief Operating Officer Agreement, dated September 18, 2014, by and between the Company and Wendy S. Johnson.
	31.1*		Certification of the Chief Executive Officer required by Rule 13a-14(a)/Rule 15d-14(a).
	31.2*		Certification of Chief Financial Officer required by Rule 13a-14(a)/Rule 15d-14(a).
	32.1*		Certification of the Principal Executive Officer Required by 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	32.2*		Certification of the Principal Financial Officer Required by 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	101.INS		XBRL Instance Document.
	101.SCH		XBRL Taxonomy Extension Schema Document.
	101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
	101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.
	101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
	101.LAB		XBRL Taxonomy Extension Label Linkbase Document.

* Furnished electronically with this report.

AMPLIPHI BIOSCIENCES CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMPLIPHI BIOSCIENCES CORPORATION

Date: April 15, 2015	By	/s/ David E. Bosher
		Name: David E. Bosher
		Title: Interim Chief Financial Officer

EX-10.1 2 v407149_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

AMPLIPHI BIOSCIENCES CORPORATION

INTERIM CHIEF OPERATING OFFICER AGREEMENT

This Interim Chief Operating Officer Agreement (“Agreement”) is entered into by and between AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”) and Wendy S. Johnson (“Consultant”), on September 18, 2014, and shall be deemed to be effective as of September 1, 2014. The Company desires to retain Consultant as an independent contractor to perform services for the Company on an interim basis, and Consultant is willing to perform such services, on the terms described below. In consideration of the mutual promises contained herein, the parties agree as follows:

1. Services and Compensation. Consultant agrees to perform for the Company the services described in Exhibit A (the “Services”), and the Company agrees to pay Consultant the compensation described in Exhibit A for Consultant’s performance of the Services.

2. Confidentiality.

(a) Definition. “Confidential Information” means any and all information and materials, in whatever form, tangible or intangible, whether disclosed to or learned or developed by Consultant before or after the execution of this Agreement, whether or not marked or identified as confidential or proprietary, pertaining in any manner to the business of or used by the Company and its affiliates, or pertaining in any manner to any person or entity to whom the Company owes a duty of confidentiality. Confidential Information includes, but is not limited to, the following types of information and materials: (i) trade secrets, inventions, ideas, processes, formulas, algorithms, pre-clinical and clinical data, formulations, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques; (ii) information regarding plans for research, development, new products, marketing and selling, business plans, business methods, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; (iii) sensitive personnel information including the skills and compensation of other employees of the Company; and (iv) any other information or materials relating to the past, present, planned or foreseeable business, products, developments, technology or activities of the Company. Consultant understands that Confidential Information includes, but is not limited to, information pertaining to any aspect of the Company’s business which is either information not known by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company, or is otherwise proprietary information of the Company or its customers or suppliers, whether of a technical nature or otherwise. Consultant further understands that Confidential Information does not include any of the foregoing items which has become publicly and widely known and made generally available through no wrongful act of Consultant or of others who were under confidentiality obligations as to the item or items involved.

(b) Nonuse and Nondisclosure. Consultant will not, during or subsequent to the term of this Agreement, (i) use the Confidential Information for any purpose whatsoever other than the performance of the Services on behalf of the Company or (ii) disclose the Confidential Information to any third party except as reasonably required to perform the Services and under appropriate confidentiality agreements. Consultant agrees that all Confidential Information will remain the sole property of the Company. Consultant also agrees to take all reasonable precautions to prevent any unauthorized disclosure of such Confidential Information.

(c) Former Client Confidential Information. Consultant agrees that Consultant will not, during the term of this Agreement, improperly use or disclose any proprietary information or trade secrets of any former or current employer of Consultant or other person or entity with which Consultant has an agreement or duty to keep in confidence information acquired by Consultant, if any. Consultant also agrees that Consultant will not bring onto the Company’s premises any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity.

(d) Third Party Confidential Information. Consultant recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees that, during the term of this Agreement and thereafter, Consultant owes the Company and such third parties a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out the Services for the Company consistent with the Company’s agreement with such third party.

(e) Return of Materials. Upon the termination of this Agreement, or upon Company’s earlier request, Consultant will deliver to the Company all of the Company’s property, including but not limited to all electronically stored information and passwords to access such property, or Confidential Information that Consultant may have in Consultant’s possession or control.

3. Ownership.

(a) Assignment. Consultant agrees that all inventions (whether or not patentable), copyrightable material, notes, records, drawings, designs, improvements, developments, discoveries and trade secrets conceived, discovered, developed or reduced to practice by Consultant, solely or in collaboration with others, during the term of this Agreement that relate in any manner to the business of the Company that Consultant may be directed to undertake, investigate or experiment with or that Consultant may become associated with in work, investigation or experimentation in the Company’s line of business in performing the Services under this Agreement (collectively, “Inventions”),are the sole property of the Company. Consultant also agrees to assign (or cause to be assigned) and hereby assigns fully to the Company all Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating to all Inventions.

(b) Further Assurances. Consultant agrees to assist Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating to all Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with respect to all Inventions, the execution of all applications, specifications, oaths, assignments and all other instruments that the Company may deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and exclusive right, title and interest in and to all Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating to all Inventions. Consultant also agrees that Consultant’s obligation to execute or cause to be executed any such instrument or papers shall continue after the termination of this Agreement.

(c) Pre-Existing Materials. Attached as Exhibit B is a list describing with particularity all inventions, improvements, developments, concepts, discoveries or other proprietary information which were (i) made by Consultant prior to becoming a Consultant to the Company and (ii) could reasonably be deemed to be in or related to the business of the Company (collectively referred to as “Prior Inventions”),which belong solely to Consultant or belong to Consultant jointly with another, which relate in any way to any of the Company’s proposed businesses, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, Consultant represents that there are no such Prior Inventions. Subject to Section 3(a), Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention developed under this Agreement any Prior Invention owned by Consultant or in which Consultant has an interest, (i) Consultant will inform Company, in writing before incorporating such Prior Invention into any Invention, and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such Invention. Consultant will not incorporate any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any Invention without Company’s prior written permission.

(d) Attorney-in-Fact. Consultant agrees that, if the Company is unable because of Consultant’s unavailability, dissolution, mental or physical incapacity, or for any other reason, to secure Consultant’s signature for the purpose of applying for or pursuing any application for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company in Section 3(a), then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant’s agent and attorney-in-fact, to act for and on Consultant’s behalf to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by Consultant.

4. Conflicting Obligations. Consultant certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement or that would preclude Consultant from complying with the provisions of this Agreement. Consultant will not enter into any such conflicting agreement during the term of this Agreement. Consultant’s violation of this Section 4(a) will be considered a breach of a material provision of this Agreement under Section 6(b).

5. Reports. Consultant also agrees that Consultant will, from time to time during the term of this Agreement or any extension thereof, keep the Company advised as to Consultant’s progress in performing the Services under this Agreement. Consultant further agrees that Consultant will, as requested by the Company, prepare written reports with respect to such progress.

6. Term and Termination.

(a) Term. The term of this Agreement will begin on the date of this Agreement and will continue until the earliest of (i) December 31, 2014, (ii) such time as the Company hires a new Chief Executive Officer or (iii) termination as provided in Section 6(b). The term of this Agreement may be extended upon mutual written agreement of the parties.

(b) Termination. Either party may terminate this Agreement upon giving the other party 30 days’ prior written notice of such termination pursuant to Section 9(e) of this Agreement. The Company may terminate this Agreement immediately and without prior notice if Consultant refuses to or is unable to perform the Services or is in breach of any material provision of this Agreement.

(c) Survival. Upon such termination, all rights and duties of the Company and Consultant toward each other shall cease except:

(i) The Company will pay, within 30 days after the effective date of termination, all amounts owing to Consultant for Services completed and accepted by the Company prior to the termination date and related expenses, if any, submitted in accordance with the Company’s policies and in accordance with the provisions of Section 1 of this Agreement; and

(ii) Section 2 (Confidentiality), Section 3 (Ownership), Section 7 (Independent Contractor; Benefits) and Section 9 (Miscellaneous) will survive termination of this Agreement.

7. Independent Contractor; Benefits.

(a) Independent Contractor. It is the express intention of the Company and Consultant that Consultant perform the Services as an independent contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant as an employee of the Company. Consultant agrees to furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement and shall incur all expenses associated with performance, except as expressly provided in Exhibit A. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement. Consultant agrees to and acknowledges the obligation to pay all self-employment and other taxes on such income.

(b) Benefits. The Company and Consultant agree that Consultant will receive no Company-sponsored benefits from the Company. If Consultant is reclassified by a state or federal agency or court as Company’s employee, Consultant will become a reclassified employee and will receive no benefits from the Company, except those mandated by state or federal law, even if by the terms of the Company’s benefit plans or programs of the Company in effect at the time of such reclassification, Consultant would otherwise be eligible for such benefits.

8. Indemnification Agreement. The Company and Consultant acknowledge that the Company and Consultant have entered into that certain Indemnification Agreement, dated June 1, 2014 (the “Indemnification Agreement”), and that nothing herein is intended to limit or modify the parties’ rights or obligations under the Indemnification Agreement.

9. Miscellaneous.

(a) Governing Law. This Agreement shall be governed by the laws of the Commonwealth of Virginia without regard to conflicts of law rules.

(b) Assignability. Except as otherwise provided in this Agreement, Consultant may not sell, assign or delegate any rights or obligations under this Agreement. The Company may assign (i) this Agreement to a Company affiliate or (ii) this Agreement in the event of a merger, acquisition or sale of all or substantially all of the assets of the Company. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties hereto, their successors and assigns.

(c) Entire Agreement. This Agreement and the Indemnification Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and thereof and supersede all prior written and oral agreements between the parties regarding the subject matter hereof and thereof.

(d) Headings. Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.

(e) Notices. Any notice or other communication required or permitted by this Agreement to be given to a party shall be in writing and shall be deemed given if delivered personally or by commercial messenger or courier service, or mailed by U.S. registered or certified mail (return receipt requested), or sent via facsimile (with receipt of confirmation of complete transmission) to the party at the party’s address or facsimile number written below or at such other address or facsimile number as the party may have previously specified by like notice. If by mail, delivery shall be deemed effective 3 business days after mailing in accordance with this Section 9(e).

(i) If to the Company, to:

4870 Sadler Road, Suite 300

Glen Allen, VA 23060

Attention: Chief Executive Officer

(ii) If to Consultant, to the address for notice on the signature page to this Agreement or, if no such address is provided, to the last address of Consultant provided by Consultant to the Company.

(f) Attorneys’ Fees. In any court action at law or equity that is brought by one of the parties to this Agreement to enforce or interpret the provisions of this Agreement, the prevailing party will be entitled to reasonable attorneys’ fees, in addition to any other relief to which that party may be entitled.

(g) Severability. If any provision of this Agreement is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law.

(h) Amendments. This Agreement may be amended or waived only upon written consent of the Consultant and the Company.

(i) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

[Remainder of page intentionally left blank.]

IN WITNESS WHEREOF, the parties hereto have executed this Interim Chief Operating Officer Agreement as of the date first written above.

CONSULTANT		AMPLIPHI BIOSCIENCES CORPORATION

By:	/s/ Wendy S. Johnson	By:	/s/ Jeremy Laurence Curnock Cook

Name:	Wendy S. Johnson	Name:	Jeremy Laurence Curnock Cook

		Title:	Interim CEO

Address for Notice:

5350 Renaissance Avenue

San Diego CA 92122

Signature Page to Interim Chief Operating Officer Agreement

EXHIBIT A

SERVICES AND COMPENSATION

1. Services. Consultant shall serve as the interim Chief Operating Officer of the Company and shall perform the duties, and have the responsibilities, that are customary for persons serving in such office. Consultant will report to the Interim Chief Executive Officer of the Company.

2. Compensation.

A. The Company will compensate Consultant at a rate of $20,000 per month, payable on the last business day of each month, during the term of this Agreement.

B. The Company will reimburse Consultant for reasonable travel and other business expenses incurred by Consultant in the performance of her duties, consistent with the Company’s reimbursement policies. Consultant will provide receipts to the Company documenting such expenses.

3. Other Engagements. Consultant may accept other consulting assignments, and engage in other business activities, so long as they do not interfere with her obligations under this Agreement.

EXHIBIT B

LIST OF PRIOR INVENTIONS EXCLUDED UNDER SECTION 3(C)

Title	Date	Identifying Number or BriefDescription

x No inventions or improvements

¨ Additional Sheets Attached

Signature of Consultant:

/s/ Wendy Johnson

Print Name of Consultant:

Wendy Johnson

Date:

September 17, 2014

EX-31.1 3 v407149_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

AMPLIPHI BIOSCIENCES CORPORATION

CERTIFICATION

I, Jeremy Curnock Cook, certify that:

I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 15, 2015

	/s/ Jeremy Curnock Cook
	Jeremy Curnock Cook
	Chairman and Interim Chief Executive Officer

EX-31.2 4 v407149_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

AMPLIPHI BIOSCIENCES CORPORATION

CERTIFICATION

I, David E. Bosher, certify that:

I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 15, 2015

	/s/ David E. Bosher
	David E. Bosher
	Interim Chief Financial Officer

EX-32.1 5 v407149_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

AMPLIPHI BIOSCIENCES CORPORATION

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Jeremy Curnock Cook, Chairman and Interim Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: April 15, 2015

	/s/ Jeremy Curnock Cook
	Jeremy Curnock Cook
	Chairman and Interim Chief Executive Officer

EX-32.2 6 v407149_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

AMPLIPHI BIOSCIENCES CORPORATION

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, David E. Bosher, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: April 15, 2015

	/s/ David E. Bosher
	David E. Bosher
	Interim Chief Financial Officer

EX-101.INS 7 aphb-20140930.xml XBRL INSTANCE DOCUMENT 0000921114 2013-01-01 2013-09-30 0000921114 2013-01-01 2013-12-31 0000921114 2014-01-01 2014-09-30 0000921114 2013-04-01 2013-09-30 0000921114 2014-04-01 2014-09-30 0000921114 2013-07-01 2013-09-30 0000921114 2014-07-01 2014-09-30 0000921114 2014-09-30 0000921114 2014-10-20 0000921114 2013-12-31 0000921114 2012-12-31 0000921114 2013-09-30 0000921114 aphb:BiocontrolLimitedMember 2011-01-01 2011-12-31 0000921114 aphb:SphHoldingsPtyLtdMember 2012-01-01 2012-12-31 0000921114 aphb:BiocontrolLimitedMember 2011-12-31 0000921114 aphb:SphHoldingsPtyLtdMember 2012-12-31 0000921114 us-gaap:InProcessResearchAndDevelopmentMember aphb:BiocontrolLimitedMember 2011-12-31 0000921114 us-gaap:InProcessResearchAndDevelopmentMember aphb:SphHoldingsPtyLtdMember 2012-12-31 0000921114 us-gaap:PatentsMember 2011-12-31 0000921114 aphb:SeriesBConvertiblePreferredStockMember 2013-12-31 0000921114 aphb:SeriesBConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember aphb:SeriesBConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableTwoMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember 2013-01-01 2013-12-31 0000921114 aphb:SeriesBConvertiblePreferredStockMember aphb:ConvertibleNotesPayableTwoMember 2013-01-01 2013-12-31 0000921114 us-gaap:WarrantMember 2013-12-31 0000921114 us-gaap:PreferredStockMember 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember us-gaap:WarrantMember 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember us-gaap:PreferredStockMember 2013-12-31 0000921114 aphb:ConvertibleNotesPayableTwoMember us-gaap:WarrantMember 2013-12-31 0000921114 aphb:ConvertibleNotesPayableTwoMember us-gaap:PreferredStockMember 2013-12-31 0000921114 us-gaap:PreferredStockMember 2014-01-01 2014-09-30 0000921114 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnJuly152013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnDecember232013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnJuly152013MemberMember 2013-12-31 0000921114 aphb:WarrantsIssuedOnDecember232013MemberMember 2013-12-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2013-12-31 0000921114 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2013-01-01 2013-12-31 0000921114 aphb:SeriesBConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2013-01-01 2013-12-31 0000921114 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-12-31 0000921114 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2014-01-01 2014-09-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-09-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-09-30 0000921114 aphb:ResearchAndDevelopmentMember 2013-01-01 2013-09-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000921114 aphb:ResearchAndDevelopmentMember 2014-01-01 2014-09-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2013-07-01 2013-09-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2013-07-01 2013-09-30 0000921114 aphb:ResearchAndDevelopmentMember 2013-07-01 2013-09-30 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000921114 aphb:ResearchAndDevelopmentMember 2014-07-01 2014-09-30 0000921114 us-gaap:EmployeeStockOptionMember 2013-12-31 0000921114 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000921114 us-gaap:EmployeeStockOptionMember 2014-09-30 0000921114 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000921114 aphb:TwoThousandAndNineStockIncentivePlanMember 2014-09-30 0000921114 aphb:TwoThousandAndThirteenStockIncentivePlanMember 2014-09-30 0000921114 aphb:TwoThousandAndTwelveStockIncentivePlanMember 2014-09-30 0000921114 us-gaap:PatentsMember 2014-09-30 0000921114 us-gaap:PatentsMember 2013-12-31 0000921114 us-gaap:RedeemablePreferredStockMember 2012-12-31 0000921114 us-gaap:CommonStockMember 2012-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000921114 us-gaap:RetainedEarningsMember 2012-12-31 0000921114 us-gaap:RedeemablePreferredStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000921114 us-gaap:RedeemablePreferredStockMember 2014-01-01 2014-09-30 0000921114 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-09-30 0000921114 us-gaap:RetainedEarningsMember 2014-01-01 2014-09-30 0000921114 us-gaap:RedeemablePreferredStockMember 2013-12-31 0000921114 us-gaap:CommonStockMember 2013-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2013-12-31 0000921114 us-gaap:RedeemablePreferredStockMember 2014-09-30 0000921114 us-gaap:CommonStockMember 2014-09-30 0000921114 us-gaap:AdditionalPaidInCapitalMember 2014-09-30 0000921114 us-gaap:RetainedEarningsMember 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-01-01 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-07-01 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember aphb:BiocontrolMember 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember aphb:SphMember 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember 2014-04-01 2014-09-30 0000921114 us-gaap:RestatementAdjustmentMember 2013-01-01 2013-09-30 0000921114 us-gaap:RestatementAdjustmentMember 2013-04-01 2013-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">3. Warrants and Warrants Liability</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company follows ASC 815-40, <i> Contracts in an Entity’s Own Equity</i>, as it relates to outstanding warrants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In connection with the December 2013 private placement of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 72,007,000</font> shares of the Company's common stock at a price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font>, the Company issued an aggregate of warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,320,420</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font> per share to the placement agents. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> December 2018</font>. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,040,195</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">June 2018</font>. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million for the warrants issued to the placement agent.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 26, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July 15, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 23, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Warrants issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,394,834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,645,361</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,320,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,030,387</font> shares of its common stock. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February through May 2018</font> and are exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. These warrants are considered to be equity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,355,164</font> shares of its common stock. These warrants expire in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 2016</font> and are exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.46</font> per share. These warrants are considered to be equity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On June 26, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,855,714</font> warrants, issued on June 26, 2013, were exercised. Due to this exercise, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,734,151</font> shares of common stock were issued and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,594,000</font> was classified out of the derivative liability account and into equity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">   </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company re-measured the fair value of the liability warrants <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">at September 30, 2014</font> and recorded a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.1</font> million gain on derivative liabilities during the third quarter to adjust the liabilities associated with the warrants to their estimated fair values totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.0</font> million. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The change in fair value and the resulting gain was attributable to a decline in the market value of our common stock</font> as of September 30, 2014.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">4. Stock Options</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000,000</font> shares of our common stock in stock incentive awards to employees, directors and consultants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,200,000</font> shares of our common stock in stock incentive awards to employees, directors and consultants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40,000,000</font> shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company’s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company’s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plans.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Under ASC 718 <i>Stock Compensation</i>, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three and nine month periods ended September 30, 2013 and 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Income statement category:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>38,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>116,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>153,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>209,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>208,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>598,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,053,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Severance charge</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,161,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,161,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,408,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>248,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,875,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,206,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>      The following table summarizes Option activity:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Average Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Weighted Average</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Contractual Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Exercise Price</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,451,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,137,378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>13.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Outstanding at September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>22,581,622</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>862,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Exercisable at September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>19,972,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>822,989</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.22</font> on September 30, 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of September 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">559,358</font> net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of September 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="20%"> <div>Shares Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Stock options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="20%"> <div>22,581,622</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Available for future grants under the 2013 Stock Incentive Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%"> <div>39,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%"> <div>38,890,451</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>Total shares reserved</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="20%"> <div>100,722,073</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Stock-Based Compensation</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <i>Stock Compensation</i>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 26, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July 15, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 23, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Warrants issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,394,834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,645,361</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,320,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"><strong><font style="FONT-SIZE: 10pt">  </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine Months Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>30, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Income statement category:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>38,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>116,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>153,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>209,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>208,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>598,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,053,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Severance charge</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,161,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,161,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,408,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>248,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,875,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,206,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">      The following table summarizes Option activity:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Average Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Weighted Average</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Contractual Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>Exercise Price</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Intrinsic Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,451,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,137,378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>13.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Outstanding at September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>22,581,622</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>862,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Exercisable at September 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>19,972,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>822,989</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

8584000

7172000

3633000

3929000

7285000

5161000

63155331

150283630

three to seven years

493000

10016080

1.40

0.01

0.1

7000000 4999999 10894839 12499996 1645361 0.14 0.14 7000000

5491001

829277

4357936

658145

19400000

1886000

6917000

1644000

6029000

674000

2386000

4999999 0.14 0.14

759000

350000

188938

1889380

707000 28394834 1645361 4320420

0.000109

0.000167

1.6094

1.6308

1.5524

P5Y

0.14

0.25

0.14

72007000 0.25 December 2016 December 2018 June 2018 February through May 2018 1355164 30040195 7030387 4320420 0.46 0.14 0.14 0.25 1400000 3855714 2734151

7100000

1594000

9786000

20355000

27000

8000

448000

297000

10261000

20660000

1283000

145000

12446000

377000

400000

7562000

20385000

20408000

31929000

41213000

1840000

2147000

2535000

2391000

14043000 40791000 6035000 16871000

23366000

60740000

25901000

63131000

1660000

707000

1872000

1825000

362001000

358828000

1837000

-361342000

-385115000

4368000

-22625000

31929000

41213000

1206000

1053000

153000

1161000

116000

1875000

598000

248000

208000

40000

1408000

209000

1161000

38000

25721000

3137378

2000

22581622

19972558

0.19

13.10

0.19

P9Y1M24D

P2Y1M24D

P1Y4M6D

862982

822989

39250000

38890451

100722073

0.22

559358

P2Y6M

4200000

40000000

35000000

559000

473000

116000

93000

0.01

445000000

187159093

182535562

187159093

182535562

333000

308000

-3000

103000

5359000

4692000

1123000

1793000

4772000

5289000

1215000

1701000

10131000

11821000

2338000

5334000

-9798000

-11513000

-2341000

-5231000

-52350000

35286000

-46380000

26438000

2660000

23000

233000

9000

-55243000

35286000

-46412000

26438000

-65041000

23773000

-48753000

21207000

-0.76

0.12

-0.49

0.11

85688356

184445172

99156809

187159093

-0.76

0.07

-0.49

0.07

85688356

323604642

99156809

315990084

12943000

669000

332806000

-320532000

66908810

-64583000

23773000

1594000 0 28000 1566000 0 2734151 0

1437000

714000

2635000

3000000

240000

2760000

24000000

50000

5016081

0 0 0 0 50000 4999999 0 7084000 -11000 115000 6969000 706000 -2000 19000 687000 0 -1156102 11561020 -188938 1889380

13000

1000

12000

61018

0 0 80000 -80000 0 8000000 0 15464000 0 720000 14744000 0 72007000 0

2286

707000

1825000

360665000

-385115000

1660000

1872000

363838000

-361342000

8859978

182535562

8671040

187159093

3000000

23000

2637000

759000

66000

59000

1206000

714000

125000

19000

-618000

-453000

-305000

153000

151000

233000

-4880000

-9372000

97000

1197000

-97000

-1197000

7000000

2000000

26000

8974000

3997000

-10569000

862000

4859000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">1. Nature of Business and Significant Accounting Policies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Nature of Business</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of Presentation</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries - Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All amounts on the financial statements and disclosures have been rounded to the nearest $1,000 except share and per share data.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments, reclassifications, and non-recurring adjustments) necessary to present fairly our results of operations for the three months and nine months ended September 30, 2014 and 2013, our cash flows for the nine months ended September 30, 2014 and 2013 and our financial position as of September 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash and Cash Equivalents</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accounts Receivable</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of September 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> <b><i>   </i></b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and Equipment</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Prepaid Expenses and Other Current Assets</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Prepaid and other current assets as of September 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Goodwill</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,172,000</font>. Goodwill in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,929,000</font> was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,584,000</font>. Goodwill in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,633,000</font> was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Patents</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. Patents in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">493,000</font> have been recorded. These patents are being amortized over their useful life through December 2026.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <i>Stock Compensation</i>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Warrant and Preferred Shares Conversion Feature Liability</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, <i>Derivatives</i>, <i>and Hedging</i> and Emerging Issue Task Force Statement 07-5: <i>Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock</i>, which require such warrants and the Series B preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Assets and Liabilities  Derivative Instruments</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Level 1  quoted prices in active markets for identical assets or liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Level 2  quoted prices for similar assets and liabilities in active markets or inputs that are observable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Level 3  inputs that are unobservable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <i>Multiple Element Arrangements</i>, which requires the Company to satisfy the following before revenue can be recognized:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.5in"> <div>•</div> </td> <td> <div>The delivered items have value to the customer on a stand-alone basis;</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.5in"> <div>•</div> </td> <td> <div>Any undelivered items have objective and reliable evidence of fair value; and</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"></td> <td style="WIDTH: 0.5in"> <div>•</div> </td> <td> <div>Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.</div> </td> </tr> </table> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company classifies advance payments received in excess of amounts earned as deferred revenue.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> <b><i>   </i></b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Research and Development</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. In 2012, IPR&D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,161,000</font> was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. In 2011, IPR&D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,285,000</font> was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Net Income (Loss) per Common Share</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Net income (loss) per common share is based on net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three months ended September 30, 2014 and the nine months ended September 30, 2014, both basic and diluted net income (loss) are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended September 30, 2013 and the nine months ended September 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B Preferred shares were antidilutive with respect to computing the net loss per share and therefore were excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,283,630</font> shares for the three month period ending September 30, 2013 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 63,155,331</font> shares for the nine month period ending September 30, 2013.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Recent Accounting Pronouncements</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1161000

10-Q/A true 2014-09-30 2014 Q3 AmpliPhi Biosciences Corp 0000921114 --12-31 Smaller Reporting Company APHB 187159093

1161000

1840000

659000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>5. Severance Charge</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On September 15, 2014, by mutual agreement of the Board of Directors (the “Board”) of the Company and Philip J. Young, Mr. Young stepped down from his role as President and Chief Executive Officer of the Company, effective September 15, 2014. In accordance with Mr. Young’s employment agreements, the Company recorded a severance charge in the quarter ended September 30, 2014 of $1,840,000 related to severance-period compensation and benefits, as well as stock-based compensation expense related to the accelerated vesting of stock options.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> The composition of the severance charge is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Compensation and benefits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>679,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Stock-based compensation expenses related to accelerated vesting</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,161,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="77%"> <div>Total severance charge</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>1,840,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The composition of the severance charge is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Compensation and benefits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>679,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="77%"> <div>Stock-based compensation expenses related to accelerated vesting</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,161,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="77%"> <div>Total severance charge</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>1,840,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 679000

449000

246000

244000

3078000

0.01

10000000

8859978

13712000

13022000

389000

955000

286000

323000

-65430000

22818000

-49039000

20884000

618000

955000

6451441

-618000

618000

955000

-955000

210000 0 The Company’s previously issued September 30, 2014 financial statements have been amended to: reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000. recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014. reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014. adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively. As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period. The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by ($5,139,000) to ($49,039,000). The net loss per share attributable to common stockholders increased by ($0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by ($7,098,000) to ($65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>6. Correction of Error</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company’s previously issued September 30, 2014 financial statements have been amended to:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td> <div>modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by $(5,139,000) to $(49,039,000). The net loss per share attributable to common stockholders increased by $(0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by $(7,098,000) to $(65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

87000 1109000

1660000

1250000

2000

103000

88000

73000

195000

1685000

1548000

6410000

1260000

2104000

-7098000

56000

-49039000

-5139000

20884000

1496000

0.08

-0.49

-0.05

0.11

0.01

EX-101.SCH 8 aphb-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Preferred Shares link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Warrants and Warrants Liability link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stock Options link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Severance Charge link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Correction of Errors link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Warrants and Warrants Liability (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stock Options (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Severance Charge (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Nature of Business and Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Preferred Shares (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Warrants and Warrants Liability (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Warrants and Warrants Liability (Details Textual) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Stock Options (Details) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock Options (Details 1) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Stock Options (Details 2) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stock Options (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Severance Charge (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Correction of Errors (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 aphb-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 aphb-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 aphb-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Stockholders Equity Note [Abstract] Stockholders Equity Note Warrants Disclosure [Text Block] The entire disclosure for stockholders equity warrants and rights. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Trade and Other Accounts Receivable, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Other Current Assets [Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Warrant and Preferred Shares Conversion Feature Liability, Policy [Policy Text Block] Disclosure of company policy for warrant and preferred shares conversion feature liability. Derivatives, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block] Tabular disclosure of components of common shares reserved for future issuance. Significant Policies [Table] Class of Stock [Axis] Class of Stock [Domain] In Process Research and Development [Member] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] SPH Holdings Pty Ltd [Member] Biocontrol Limited [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Significant Policies [Line Items] Business Combination, Consideration Transferred, Total Goodwill Goodwill Intangible Assets, Net (Excluding Goodwill) In process research and development Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Property, Plant and Equipment, Estimated Useful Lives Finite-Lived Intangible Assets, Net Equity [Abstract] Schedule of Stock by Class [Table] Series B Convertible Preferred Stock [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Convertible Notes Payable One [Member] Convertible Notes Payable Two [Member] Investment Type [Axis] Investments [Domain] Warrant [Member] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Preferred Stock [Member] Class of Stock [Line Items] Preferred Stock, Shares Authorized Preferred Stock, Initial Stated Value Per Share Initial stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. Preferred Stock, Par or Stated Value Per Share Debt Instrument, Convertible, Number of Equity Instruments Preferred Stock, Dividend Rate, Percentage Debt Instrument, Convertible, If-initial public offering proceeds meets Least amount The amount by which the convertible debt's if-proceeds of an underwritten initial public offering of company meets the minimum amount agreed. Stock Issued During Period, Shares, New Issues1 Issuance of preferred stock (in shares) Number of new stock issued during the period Warrants Issued During the Period, Number of Warrants Warrants Issued This element represents that, the number of warrants issued during the period. Warrants Issued During the Period, Exercise Price of Warrants This element represents that, the exercise price of warrants issued during the period. Warrants Issued During the Period, Value of Warrants This element represents that, the value of warrants issued during the period. Debt Conversion, Original Debt, Amount Debt Conversion, Converted Instrument, Shares Issued Debt Instrument, Convertible, Beneficial Conversion Feature Derivative preferred shares conversion liability Derivative preferred shares conversion liability Fair value of derivative liability of convertible preferred shares as of the balance sheet date. Derivative Liability Warrants Issued During Period Number Of Warrants1 This element represents that, the number of warrants issued during the period. Warrants Issued During Period Exercise Price Of Warrants1 This element represents that, the exercise price of warrants issued during the period. Fair Value Adjustment of Warrants Warrants issued as investment fees Payments of Stock Issuance Costs Conversion of Stock, Shares Converted Reclassification From Derivative Liability To Equity Reclassified from the derivative liability to equity due to conversion. Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Warrants Issued on June 26, 2013 Member [Member] Warrants Issued on July 15, 2013 Member [Member] Warrants Issued on December 23, 2013 Member [Member] Class of Warrant or Right [Line Items] Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Fair Value Assumptions, Expected Volatility Rate Volatility Fair Value Assumptions, Expected Term Expected term Fair Value Assumptions, Exercise Price Exercise price Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Private Placement [Member] Convertible Notes Payable [Member] Stock Issued During Period, Shares, New Issues2 Issuance of common stock for December financing (in shares) Number of new stock issued during the period. Stock Issued During Period, Exercise Price, New Issues2 This element represents that, the exercise price of stock issued during the period. Warrants Issued During the Period, Terms Of Expiration This element represents the warrants issued during the period, terms of expiration. Warrants Issuance Costs This element represents that, the warrants issuance costs for during the period. Derivative warrants liability Derivative warrants liability Fair value of derivative liability of warrants as of the balance sheet date. Warrants Exercised During Period Value Value of warrants exercised during the period. Common Stock Issued During Period Value Warrants Exercised Value of common stock issued as a result of the exercise of warrants. Derivative, Gain on Derivative Reclassifications of Temporary to Permanent Equity Statement of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Accounts Receivable, Net, Current, Total Accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of September 30, 2014 and December 31, 2013, respectively Intangible Assets, Net (Including Goodwill) [Abstract] Intangible assets Finite-Lived Patents, Gross Patents, net of accumulated amortization of $116,000 and $93,000 as of September 30, 2014 and December 31, 2013, respectively Intangible Assets, Net (Including Goodwill) Total intangible assets Assets, Total Total assets Liabilities and Equity [Abstract] Liabilities, Series B Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Deferred Revenue, Current Deferred revenue Liabilities, Noncurrent [Abstract] Long term liabilities Deferred Tax Liabilities, Net, Noncurrent Deferred tax liability Liabilities, Total Total liabilities Temporary Equity, Carrying Amount, Attributable to Parent Series B redeemable convertible preferred stock $0.01 par value, 10,000,000 shares authorized, 8,859,978 shares issued and outstanding at December 31, 2013 (liquidation preference of $13,712,000 and 13,022,000 at September 30, 2014 and December 31, 2014, respectively) Common Stock, Value, Issued Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at September 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013 Additional Paid in Capital, Total Additional paid-in capital Other Additional Capital Paid-in-capital - contingent shares Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders' equity (deficit) Balances Balances Stockholders Equity Attributable to Parent [Abstract] Stockholders' equity (deficit) Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] General and Administrative Expense [Member] General and administrative expense [Member] Research and Development Expense [Member] Research and development expense [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Allocated Share-based Compensation Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity, Type [Domain] Employee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Shares, Outstanding at December 31, 2013 Shares, Outstanding at September 30, 2014 Stock options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Shares, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Shares, Exercised Stock options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Shares, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Shares, Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Shares, Exercisable at September 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Outstanding at December 31, 2013 Weighted Average Exercise Price, Outstanding at September 30, 2014 Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable at September 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Average Remaining Contractual Term (Years), Outstanding at September 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Average Remaining Contractual Term (Years), Exercisable at September 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic Value, Outstanding at September 30, 2014 Intrinsic Value, Outstanding at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Intrinsic Value, Exercisable at September 30, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Available for future grants under the 2013 Stock Incentive Plan Class of Warrant or Right, Outstanding Warrants Common Stock, Capital Shares Reserved for Future Issuance Total shares reserved Plan Name [Axis] Plan Name [Domain] Two Thousand And Twelve Stock Incentive Plan [Member] 2012 Stock Incentive Plan [Member] Two Thousand And Nine Stock Incentive Plan [Member] 2009 Stock Incentive Plan [Member] Two Thousand And Thirteen Stock Incentive Plan [Member] 2013 Stock Incentive Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars) Finite-Lived Intangible Assets, Accumulated Amortization Temporary Equity, Par or Stated Value Per Share Temporary Equity, par value (in dollars per share) Temporary Equity, Shares Authorized Temporary Equity, shares authorized Temporary Equity, Shares Issued Temporary Equity, shares issued Temporary Equity, Shares Outstanding Temporary Equity, shares outstanding Income Statement [Abstract] Legal Entity [Axis] Sales Revenue, Services, Net, Total Revenue Sales Revenue, Services, Net, Total Operating Expenses [Abstract] Operating expenses Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative General and Administrative Expense, Total Severance Costs Severance charge Total severance charge Operating Income (Loss), Total Loss from operations Other Expenses [Abstract] Other income (expense) Derivative, Gain (Loss) on Derivative, Net Gain (loss) on derivative liabilities Derivative liability (gain) loss Amortization of Deferred Charges Amortization of note discount and patents Interest Expense, Total Interest expense, net Other Nonoperating Income (Expense) Other income (expense), net Net Income (Loss) Attributable to Parent, Total Net income (loss) Net income (loss) Net income (loss) from operations Temporary Equity, Accretion to Redemption Value, Adjustment Accretion of Series B redeemable convertible preferred stock EX-101.PRE 12 aphb-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!S7WC=T0$``&D2```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%NVC`4AN\G[1TBWT[$ MV-LZ-A&X8-UEA[3N`3S[0"("T-XU;5NSO_:_!B!4I*V>4]0XJMH/$II./'\;WNP"I MP&J7*E;G''YPGG0-K4JE#^!P9N%CJS+>QB4/2J_4$K@<#F^X]BZ#RX/<]6"3 M\4]8J+7-Q>T6'^])(MC$BME^8:=5,16";;3*2,HWSKQ2&3PIE%C9KTEU$](G MQ&#\J$(W\W^!I[K?N#6Q,5#,5DF1RC]8M%H,%ZO M6]R!,H4(RJ0:(+>V[,>R58U[YCZAWR].O!_$E4&Z]^L;7\@AB7!\)L+QA0C' M5R(<-T0XOA'A&!'A^$Z$0PRI@%!Q5$'%4@453Q543%50<55!Q58%%5\55(Q5 M4'%62<59)15GE52<55)Q5DG%62459Y7OY:P9#]+`^^O;OY>^S9F37,H["^G* M?U_[IN>4:Q7!_,D1(X>K`[SL?89#*ZMG-9Z]K[P)A[ZG]#$0F$,X^NNI!P$80]=J M>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L M)MI<3_3_MCAQ(DN) MT$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04 M``8`"````"$`FBV37+@!```J$0``&@`(`7AL+U]R96QS+W=OS;O$R:&ED&N;?H"P%=O$EHVD/O+W%2:U&PC;B]F+ M02N\&F9W1V-O=M]U%7UJZ\K&)`(FL8BT29NL-'DBW@\O#RL1.:],IJK&Z$2< MM1.[[?W=YE57RH>77%&V+@I9C$M$X7W[**5+"UTK-VE:;<+.L;&U\F%I<]FJ M]*1R+3&.%]+^S2&V5SFC?98(N\_"^8=S&T[^/W=S/):I?F[2CUH;?^,(^=78 MDRNT]B&ILKGVB>A#3G8[JTE`+.1M,#!E1@-3$@XW.4"R@PMF=G!!L<-=*[)4 M"-S<`,7-DAG-D@(#R(P&D(3#30Z0[."?/5?C:&)2F6U.M`MSZ"Z3^ MPJCZVT_-P$@?N@P2K"EVN,>:G&IN:DAF@)L:(+E!=H]%FBPAWA.35'X[M#P```/__`P!02P,$%``&``@` M```A`/$UL=/;`@``Q0@```\```!X;"]W;W)K8F]O:RYX;6R4EEUOVC`4AN\G M[3]$N5_S1>F'"M5*.ZW2U%6#M9>6FYR`56-'MAGTW^\XC'"2L*I7[1^#5!`V5&X<*ZZC"*;+V#)[8FN0.%(J M50]\B7EO9!A(;MU=(1P4H_`40[V&U@NSJFY60N+H119G831NBGPT00$E7TDW MP_)VZNA7.DC3H?_26_$D8&WWDWP8;)Z%*O3:?XK6OC51A@FLZZ%G4;@%CL=Q MW+S[#F*^<+N7*!\1_=I!7*=^!JHN;^<(^ZH*=J><<&_L7FW=%QI;Z%V_Q\J2 M,#"7`G^8^R+QB5.5"9JHI2@X6L1NN.0J!S;U4RV12(E$>H0$>^1$)2,JM=?_ M363J,!_?;LMTR7Y60%0&1&7P;BYME5]0$!7TO3'E]`B5":>^#(E*S02MZ(&[ ME0%?P,W*"@76,MQ4;"KF2I2"Y)*>$9FS;C*/!DHP!MLS77"#>W'?V11W:E/% M>7?B,S>&>PO]JDWP0_`7(86C,A=$YJ(K,W4Z?\4>U/N-S,H0[F;Q).Y-`SQB M:IHFF/:<=C!K$7D`2:PV]\MY[^Z,T886G5$8DQZ-[[N.*]>H MZ(+(;L%Q(2V;P<:MJ`[%,CF2RU9"%,RD1^;['<+N-I7Y@[CQ&(-.9>T._2N+ M3J?`ICU@#TYGE)"4,HO!1]9GU(F4LHK!AP3JOG"\!?<^4%+3/JE=U@Y806E- M>[1.='_O[CFAF5!HM_=I5*>)MUS.98[7KW_4]]?@=+@U/=K]`QG_!0``__\# M`%!+`P04``8`"````"$`P^;5N]4%```^%P``&````'AL+W=O1*;1=OEAG>_K`U^8/WEK?EO^^LO\HVY>VQWGG0$,AW9A[KKN.+.L MMMCQ*F^G]9$?X,FF;JJ\@Z_-UFJ/#<_7%H7;Q4_=(JDX?N\`_O;77EL3VQ5,8:NRIO7M^.DJ*LC4+R4^[+[*4E-HRIF MW[>'NLE?]J#[DWEY<>*67P;T55DT=5MONBG06;8BBU@6L[7)2@0QVXT M?+,PG]@L.)PV^$EXX*6N7P7T^UHL MP69KL/M9>N#/QECS3?ZV[_ZJ/W[GY7;7@;M]4"2$S=8_4]X6<*)`,W5\P534 M>S``_C>J4H0&G$C^*3\_RG6W6YAN,/5#VV4`-UYXVSV7@M(TBK>VJZO_%(CU M5(K$Z4G@LR=ASM2)?.8'#["X/0M\7E@>-<7K2>#S0O*P*2!=G@I\7EA&FF*I M$Y8.2_,N7\Z;^L.`6P!GV!YS<:?8#(A/GE+G>O;=+=>!SP3)DV!9F*%I@%=: MB+?W96C/K7<(D:*'K*Y`&(8D)X@("$&;GA8NM&1+=D*(:`1%9UG@=%W6]<`[ M62_`POK3>U=J`;C/$X1@SA"1Z@@OB*&N$<]E M.L)W_5A'('G!(_($F,@+B#P%.0K2RXL\L)V99^N3N[OAM)$NV1EJOO)S4! M)I(B(DE!E"3?=84FC$ATA..ZPWN>Z@C&(F?H]@Q!;.8B"!(8/R)0@(G`&)N_ M4A`E<.([^,TJ)A'$<3UDG(2D",*8SX;W,D.8.(S122&-#+JI\5Z4:)SR(N*D M58_1('$$*4I M`KF0(()!R&8((YPNTLR%"$L5%5B3*KH?%_QS_V8Q5;>19%+:5SWF:C)(^H=] M7%Y+\_>V9V1[(`[AED!1AC6!7PA311L)HYT#4Y@;PM3#7M@P>Z?W=F?]P_.Q MH&N&_29*]GA9JL`C6;1M8`IS/T1U#(2HQU#U4O^X6-4E M(+&T46$*HYI[QXYDKX(+8X(P$R^VW6N7%1$Y$4-%3<9`AHD"7T;RK60D&@%- M\A?)2+4-D%'./V,BVL`PA=$K'UU)!YA,7\$^$55<,W!D`*K:CWQ"&Q&F,+'J M#:>,5,@$/9_84X\0I`A@3QFI-QEZ#@3AY0H@B0[I/L9)E+MPKQ5?G"PC8=5C ME,1P*FJ2]B_,)L3D!&VXIAD!1C!F:,.]0R`=CC@$#Y+9_8!TAIU.3/RXZC$J MM[(H9/#[*R8E-$&@.(9Y5&13?R,,BSS/\YDV'%"7#X$BH(E<_Y;?(3QI:(^0 M+'81OQ,WKF".>"DG+@B&3!*1\IH@T"W)B,AQ`QM*+'F;F%I>WG9#LAI+JBE7 MQ9LM3_A^WQI%_29&CB[1SZ)*>A9'W%9C"3@JD064]A?"K7K?,#F%X> M\RW_(V^VY:$U]GP#KX)K"%'5J/FG^M+51SES>ZD[F%O*/W&PO=V]R:W-H965T)P29ML\Y`$.'/.S/$P]NKZI2J= M9\(%976"`M='#JE3EM%ZFZ#?O^ZOYL@1$M<9+EE-$O1*!+I>?_ZTVC/^)`I" MI`,,M4A0(66S]#R1%J3"PF4-J>%)SGB%)5SRK2<:3G"F@ZK2F_C^U*LPK9%A M6/)+.%B>TY3]'Y[XB"[;]RFGVG-0&W89W4"FP8>U+0ATS= M@F!O%'VO5^`'=S*2XUTI?[+]-T*WA83ECJ$B5=@R>[TC(@5'@<:=Z#125D(" M\.U45+4&.()?].^>9K)(4#AUXYD?!@!W-D3(>ZHHD9/NA&357P,*5%*69-*2 MP&]+$L3N/(ZCZ7QVEL4S&>D"[[#$ZQ5G>P>Z!C1%@U4/!DM@/ET19*&P-PJ< MH!ER(%D!R_"\CL)@Y3V#=6F+N348^+:8(\(#4:L,:I7[E"H"H)%ZA01^3/+;S(PF$@W3K>N:"PXA8Y[WUD5E"`H MRKH6A<>"C*#!++3OT&C'Q[UZH;:NK:K>\_(J:"@?#NHUF+F6C^-%&,\MH)?` M]",)J*!A`I'E-_4;#+C0\2BVF%X.T*)=$][W7H&'VE/+:[0-9KS8:L)W7I_+ MNDL%G>LN@QD++CXBJ(*&%0[;V6!BO;QA[.N/-:%G;@#=W"WZ?7BA^;!UC M;PL:EQNHS*TS M)IMAU!=?6.;6Y+P%M@[]HCQLU$SWK[`';X!F_)(^9;6@NG)#F$ M^J[:C+DY(Y@+R1J]SVZ8A+U=_RW@+$=@&_-=`.>,R<.%.H78T^'Z'P```/__ M`P!02P,$%``&``@````A`,LFQPRW`@``%`<``!D```!X;"]W;W)K&ULE)5=;YLP%(;O)^T_6+XO'P9"$H543:INE59IFO9Q[8`) M5@$CVVG:?[]C.Q]`NK:[(3&\?OV<]QBSN'YN:O3$I.*BS7#H!1BQ-A<%;[<9 M_O7S[FJ*D=*T+6@M6I;A%Z;P]?+SI\5>R$=5,:81.+0JPY76W=SW55ZQABI/ M=*R%)Z60#=4PE%M?=9+1PDYJ:I\$P<1O*&^QMO!A7W#%^863/8O9M_9!GR7J&`EW=7ZA]A_ M97Q;:>AV`@69NN;%RRU3.00*-AY)C%,N:@"`*VJXV1D0"'VVOWM>Z"K#T<1+ MTB`*08XV3.D[;BPQRG=*B^:/$X4'*V="#B81T!^>$X],DS"9O._B.R);X"W5 M=+F08H]@T\":JJ-F"X9S<#:519#/ZY5!26;.C9EDIX):03>>EG$4+/PGB#`_ M:%:7&C)4K%]1Q">)#WPG2"B]#_DVG!%G&*YGN&!R\K4%K)PFMOF:BM:]&X.5 M(9+^RB:>^)^-/\9C)D&,`X)T1.`T/8+>C0%!/"1XNW8C'M9.IJ/85TZ3V+81 MDDS#"1E)U@-)DI(P",[M'=!!%N-\WM\^9M*8,AKEXS2.,IJ1!`C."+:):R>Q M$0Z8)D.FMQ,SXC'+>1>ZW>(T!Y;I=!;$23C$73O))4OZ/RQ&/&9)A@NMG,:Q M0%M20H)TE!V=W3+'JC<\E:AFI6PH0,OA2BE.];<0(O.OM\; MH>$XLG\K^/HP>%4"#\2E$/HX,`?GZ7NV_`L``/__`P!02P,$%``&``@````A M`/E`.FYD!```OQ```!D```!X;"]W;W)K&ULG)A= M;ZLX$(;O5]K_@+@_@`WD2TF."E5WC[1'6JWVXYH0)T$%'`%IVG^_8P\A>`)M MVINTX-?CQ^/QZSC+[Z]%;KV(JLYDN;*9X]F6*%.YSF4?FN:X<-TZ/8@BJ1UY%"6T[&15 M)`T\5GNW/E8BV>I.1>YRSYNX19*5-D985/?$D+M=EHI'F9X*4388I!)YT@!_ M?-`.!=!;^<\=^< M\N8O>?Y=9/M#`\L=PHS4Q!;;MT=1IY!1"./P4$5*90X`\&D5F2H-R$CRJO^> MLVUS6-G^Q`FGGL]`;FU$W3QE*J1MI:>ZD<5_*&)M*`S"VR`^T&,[YPX+O,G' M,5SDT=-[3)IDO:SDV8*:@1'K8Z(JD"T@[F5>2-'-=&RB,$,5Y$%%6=E3VX(Y MU+`Z+^O`"Y?N"V0T;341:N"STS!3$=\J?-_O-"X0=]B0BC[V\#)3*/'*AN!=#F#UNK@(AYJ@HXU[+XR1`W-D MM73!:$E>0>^%00"C]>>N"'S86N^OANI$FAM:U44%, MF6%O]>XD10LU#(9=C:LE11&2LOE\RL.0+J0>'OQ$N9#)I9SQ\USHIR;7S0&! MHCGN-(>1C1@S;!]@4@[Y>2;T59.)FC%#T6QP][>-`T`#UORQ,3*T61.(>G,K M&@$:,VKU5>4+&1JP:D8J)=*A5_;XJHT9-2-.?6>%#U@VK91(A[XP,=\A1A:W M[0,+1XS[3J8!!^?4P1F*QO,TVF[N/^+J=Q(.V#LG68D8BL8)Q]R=$7M73!]_ M$]&]B*M2QXQ:$=3U]1L3)]8;#XJNKF?DCP^<`!^SZEZ4E?I7*S)9B:'$G8@: M*_^2X>M>%(QZ1BM"SYA-^'Q&#R9#,0E"%@37ZC#SITSXTU[+T;H-:^/425H1 MGDLS#ICT!&@5M_L6KGY?H1HX`3@9,]*A5S8FCZ:FO2Q@G!X6WB/QHE6(:B]B MD>>UEX`?"@1<=#P'Q#LIF\N#*KKNIX?U_P```/__`P!02P,$ M%``&``@````A`)$0W&ULE%?;;J-($'U?:?\!\3Z&!GR5[5%LR.Y(L])JM3/[C*%MHP"-Z':< M_/U6T<#T)1DR+TE\U)>=^^W? MQT\KU^$BK?.T9#7=N:^4NY_WO_^VO;/VB5\I%0XHU'SG7H5H-I['LRNM4CYC M#:WA/V?65JF`C^W%XTU+T[P+JDHO\/V%5Z5%[4J%3?L1#78^%QF-67:K:"VD M2$O+5$#^_%HT?%"KLH_(56G[=&L^9:QJ0.)4E(5X[41=I\HV7RXU:]-3";Y? M2)1F@W;WP9*OBJQEG)W%#.0\F:CM>>VM/5#:;_,"' G9:>=^X#V20D=+W] MMBO0]X+>N?*WPZ_L_D=;Y%^+FD*UH4_8@1-C3TC]DB,$P9X5_=AUX._6R>DY MO97B'W;_DQ:7JX!VS\$1&MODKS'E&5049&;!')4R5D("\-.I"AP-J$CZTOV^ M%[FX[MQP,9LO_9``W3E1+AX+E'2=[,8%J_Z3)-)+29&@%X&(7H0$LV`U)_/% MM(HG,^H,QJE(]]N6W1V8&G@F;U*<0;(!Y<&9S&/T^IY5\(@B#ZBRN`RXX M].=Y'Z[76^\9:IKUG(/-61*=>DQ:.="(<9*1[[1XX/DK+JY(I&_ M\DT71Y411#8A5@EDM9Q;$HG&"/R%RM!L0MG5R<)63-O$(-.F,0T'R5%:80*Q M"20*H.6XL'.<'A<,FAH7R5%R-('8!!(%T'*$T^+7ZXA!9AW-<9&<>3=\,:TJ(3YVB8D*H'X\U!]AF82-P#C>)T>%@PR38;&>RLY2B-,(#:! M1`&T'-=VCM/#@D%3PR(Y2HXF$)M`H@!:C@0.DE\O9!=E5M(FIT3=2!DG:#P=G[P3KSO$FTP9E9\?FT3>>_JY&1DSTI.4!EA(;"&)BN@9 MXG6E9/BQ2XC(2PXN#>6$-VIXZ$EJIC+L!Q);G$1%]$SQBC(RG7[M8(.TWSMK M6B1)7D:A?30<>Q5)@/O6O*MBC0#S9C%PE<5$^@OOK=-%;JIRD:MH>Z%'6I;< MR=@-M]`0YG1$QPWY(W^O,)7%PK[G#\#\IDQ,7S`!XQ?AO;_`P`` M__\#`%!+`P04``8`"````"$`9D0HY*(&``#:'0``&0```'AL+W=OUOX_?W_^L/*]MLM/V_Q0G\JU_[UL_8]//__T^%8W7]I]678> M5#BU:W_?=>>'^;PM]N4Q;V?UN3S!.[NZ.>8=O&Q>YNVY*?.M3CH>YE$0+.;' MO#KY6.&AF5*CWNVJHI1U\7HL3QT6:(82S]6AZK[KHKYW+!Y^>SG53?Y\@'5_"^.\Z&OK%T[Y8U4T=5OONAF4FR-1 M=\WI/)U#I:?';04K4&WWFG*W]C^%#S(._?G3HV[0OU7YUI+?O79?O_W25-O? MJU,)W89]4COP7-=?%/2WK0I!\MS)_JQWX,_&VY:[_/70_56__5I6+_L.MCN! M%:F%/6R_R[(MH*-09A8EJE)1'X``?/>.E1H-Z$C^3?]\J[;=?NV+Q2Q9!B($ MN/=*U[>KC?PC2*QJ*1*8(_#1%PF061\ER=4L58:K`3U,E2F;1 M*@F3Q0U<8E,%?O93#!L/[VG*OS$#Y`Y;[+V).A M[S]J._1;%?FDJJS]I>]!1UN8E:]/8K5XG'^%_2T,9H,8^#Y@0AN1O5-%"!LC M>XP:'5C"L`[8(;J.]Z>DIZO`BJZ:&L5_@P'*+;+_;O8.(K8ATH4(D0P8BRU, MPG2V"@S32QHG5HS>!C'QL**,!R0)6%1@TZ=34>"U#PL=]C!F7=@@9*6'8!&( M)`B"H0>ZV1DB$HT(%ZMEZ$`D0O1R++)P356";K%@M;2X;Q"`73<1ABXBQ MLY($+&X+FYLZ20)4[_(DJB3.D1V+#6)&!AD/2!*P*,&!G-XN!;XV9H@A5'A` MDH!%1=DRTYGKW5%)K#L)GWS$$$H8P"V-5B*-5X+-J"0Y%LGT'I(JB9%(P8;.8&0CA22,V M4275-V]YB`)/)4:D3$$V!H1$PR2-'07)#(02Q/1)B168#::1Z3!I-J`@UD\/JC9+)64$Y97 MC@4*O\4NY5H=$G.!3$"PX='9$@B-A^ET(3/Q&.! MNF[WR3D61/P-KSY"3GG*-E^&/`Y@,];@?/4 M)6F2U=/H+L_069PH:\[&@"C1WA#4YY5@%BH7(5]L4R0M8).&S;Q]$"*5Q4@O M^'.#`5'2F#9&),78O)3HDP&]?(`CM(C+!\:`QK^>.1%)(S:?NWPD>L='W"GD MKI&9-*/&49S"URAT^E!)@]&KL9G>Y23JLSS?T<090^X;F4F+C1Q?'4-2P";- M7.7*=KMNDHZ^JONSB;AU9$Y$THA-YR;[B-`'KDP?-XO,I(WS*&G$YJ-TG)R& M:7(=H?K;YJA!6S2-]F(<&U$<)_=&!`EBVG&G?'!B\DC M3;(),F.9.*?H'98\IOR_@<(Q&"((Z`-F(B%PV/9EE,X[M\1&=QY>$/T`9$1F^(_,!'AO>YC\!E MUQW]U%F<)=='`Z(LT4<&?8S)38+NN+I[4\*K<[";>)6&MSO'LGDIL_)P:+VB M?E779!$\7P[1X0KO4Z2N#%@\@ZL]?0\V']Z`F[5S_E+^D3#>'+[KZK.^4GNL.[M3TKWNX0RWADB68`7A7UUW_0C5XN)5]^A\``/__ M`P!02P,$%``&``@````A`/QMMECS`@``%@@``!D```!X;"]W;W)K&ULE%7;CILP$'VOU'^P_+[<0JX*66U"MJW42E75R[,#!JP% MC&QGL_OW'>-`B-EN=U\2/)PYG#,S#.O;IZI$CU1(QNL(^XZ'$:T3GK(ZC_"O MG__3$@_TQE2((S"62<2?S`"193?SK[/XMK%+4&8Z+( M9BWX"<'0P#-E0_0(^BM@[IP9';W7?UD%CYKD3K-$>(X1N)#0GL=-&'IK]Q%J MFIPQVS%F[E]#=AU$5U#SQEW@PFNE[#N$;A]8ZGU!M8:^7NY4)U^#M?SNN5L3 M`.[>3V!)'2/F%B0>0RS$?HP8D%S9F;S'C@;#B`W4AZ%5MZW!A+WEG1V([&HRII+\(0=3ER>T[N!LBK'OQ\-Z+V;"5M0;#?\DVGLR^->NHHB*G.UJ6 M$B7\J'?I!"K51_LU?Q?HD;7B6W\%NV,N(*%W%X6\/VEL)4\!\`9YZH[Z-W3?]$W?P$``/__ M`P!02P,$%``&``@````A`)G)Z-=$!P``"R$``!D```!X;"]W;W)K&ULG%I=KZ)($'W?9/^#X5VE$?S*]4Y&H&&3W62SV8]GKJ*2 M43'`G3OS[[>:;K6KRA%VY^'.]7"JH$Y7=Q_L^_+IV^DX^)I7=5&>5XX8NKYR__I3#N3.HF^R\S8[E.5\YW_/:^?3Z\T\O'V7UI3[D>3.`#.=Z MY1R:YK(XLBNK4];`QVH_KB]5GFW;H--Q[+GN='S*BK.C M,RRK/CG*W:[8Y%&Y>3_EYT8GJ?)CUL#SUX?B4E^SG39]TIVRZLO[9;@I3Q=( M\58CE#W-^%GFVON]@-+?RHV55F7NV8$Z<;Z07G- MB_%B#)E>7[8%5*!D'U3Y;N5\%LO46SCCUY=6H+^+_*.V?A_4A_(CJ8KMK\4Y M![5AG-0(O)7E%T7]9:L@"!ZS:-F.P._58)OOLO=C\T?YD>;%_M#`<`=0D2IL MN?T>Y?4&%(4T(R]0F3;E$1X`?@Y.A6H-4"3[UO[_46R;P\J93$?!S)T(H`_> M\KJ1A4KI##;O=5.>_M$D85+I))Y)`DUED@AOY,T#$4R[LXSU$[4%1EF3O;Y4 MY<<`N@;N65\RU8-B"9FOE>GGN-7ZHU*A1I7DL\JR&5HA14>:,K8.>=X*#XRKD&R2MP#R+W2:Z,:TBJ@5;O,0AS M4PEZ/(*PZ>MW@6(*2#O#Q)VS6R2( M,.'W2*V42(TI5J-?FZL@JLJ,J*(Y1I69*]@SAXCAB8`Q(LVPA*&`M',$WGS! MJ/.D)B&R,Z0 MA(:D=HB8SF=HK)`DR@Q:.^WSU4.1L203NA9JBI9D!AZ`#4ZH&98DG2$Q#9&= M(0D-29^%($466)%^\T<%865\?TZZ17.T--[4G_!)']J4H3]M*:2Y(\VYZQ=3 M0-I9)C"'U!*.GR6Q*)HH1YP>))")YWESP44L09S@-?+5:4S4-J1TW+*>R M>;VGH-"F$.W@`;G7VI`6[0;FC@1QFB&Z/G1'/AF'"!%X@AA=?Y!`(@(DH,8. M78<$,[(%IX;P0"YE^/K+I>TAEHO(L1::=)]2(4,BAL0,D0Q)&)+:"&X#Y>^L MNGK.*NT*X:=EZ.B:+"SKV%J\D"$10V*&2(8D#$EM!->GW-M_KT][/CQ^I)G6 MPC*&ICZ*1(P3,T0:1*\^\QF;PPD+26T$EZOLF57N\XU5O;;3_2,@KY1K0[+; MU/*`;>$1X\0,D0;190KA\N4S84&IC>!"E=FR"NW9M]JBX7%E?6OY.#.N%(D$ M16*&2(.8@CUET\B*F;"@U$9PPR*J^8\RU<\)54Z=C.S"Q>/#J("S_929W5TS,8J1!3.\_ MN$_"8E(;03)XQ/D]EZ%E8\[TA0R*#:-D\X7*?'+,@B8*$]^";G80%I3:" M%8#^MN=$3P54%&X*G]K/M:=)M@(4B0S'-+:_X"\Y,:(,`_'@14$B3L"3)(@P MG+D+OI*DAM,^+]:(F+J.":-]&I1Z-W/,VWO,S#$D,LC5_[O$\,;H.KAOEWP% M*%G*!(5`!'FY3>T(+,'_\GW>(]]'GG)M2':;,-_'.#%#)$,2AJ0V@NLC1J_G M--#.#<;R/M3L>V5U@`)SQ:Z/(A'CQ`R1#$D8DMH(KD\9K-Y;GZ?MF-W"["LB MPS$S=SI_L/<9RKWRJ#LH9D&R.RAA0:F-8"6(\>LYT@\,(-\%->E>;^A1)&)( MS!#)D(0AJ8W@^I0?LD:Z9WW:175T,K5:H4>1B"$Q0R1#$H:D-H+K4_;)JJ]C M,=9FZWDG:XXY*@E\OC6$<`",YW!DD"=!,0N2W4$)"U*'S[=[:R7T6;(^:CWE MU3X/\^.Q'FS*=W5.[,/W13?T=H;]V5,'6P1?BR6X(R+NR;*X?U`UN?\;P^B\```#__P,`4$L#!!0`!@`(````(0#[8J5M ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O M;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[ M=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN M>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V% M2B6;E8KT81C+RSPA,S*A M/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2' M&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^> M?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q M%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*); MY`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ? MW7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#U MO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+ M33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD< ME9$".S1P1%H$B)Z9B1)?7B?-AOZ M'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V( M9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+ M=)$,\9BD/M)Z+_NH9IR4Q M>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3 MKX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQ MH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`? MJ5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H& M#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:] M69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5P MD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<+,MZ/?/__NOY(?6]KL_J9;9MZF+F?Q:=_VW^\T_3?=.^=INBZ#V(4'\B;:@MVGVO[3E\K>R+B#;L$]J M!UZ:YE6A/Y;J*[@X.+OZ6>_`'ZVW+%;9V[;_L]G_6I3K30_;'<$=J1N;+#^? MBBZ'C$*8$8]4I+S9@@#XUZM*51J0D>Q#_[\OE_UFYHMX%"6A8(![+T77/Y]\Q-.(1?'740)4I&_P*>NS^;1M]AY4#:S9 M[3)5@VP"D2_?$=R*8K\K6%\"8CO8AO)4]N(OLZKSHU MR>ZV"0735A3,21\B5BM:7Y#4C(:_.&07E@IBDI:Z,/XQP8&1)KH0('30-V/@Z$ M.PX,@XL+-N;C"PG$.,A(QAEI7BIPT$A@:.@0_CBOA#L3#&.UI_T-7?Q_.;]Z M>'([U;5^PV`&6*I+G#;S@B"<2=(F5.8@_V?G`T"X`\`PIH(N^8A#J!LXZJ?B M'/^_/9S8N?'+4V#3H;:O2WFIOI"0>NZ?+J>Z!KD^0PNW6U.ZMF\8D[1(7.I, M#&,0,2:#E'UR M\4'#0=/TV5NZD\LPELO9W]`<.1-`Y6C\=8K.)T'DU/@CMVV>I'[B@S#(J4(B;[9W*H%CV\B3UP#H=MMF/3+#K#0K6+!$>Z[2APOB]ZQ=EW7G;8L5:`U'":AM\8`3/_3-3I_X MO30]'$SJ/S=P$%W`\5DX`GC5-/WA@SI"/1YMS_\#``#__P,`4$L#!!0`!@`( M````(0"%='LT:@,``&D+```8````>&PO=V]R:W-H965T&UL MG)9O;]HP$,;?3]IWB/*^20PD$`14A:I;I4V:IOUY;1(#5I,XBMW2?ON=?2G8 MIJ7MW@!Q'A^_NW.>W.SRL:Z"!]9)+IIY2*(D#%A3B)(WVWGX^]?-Q20,I*)- M22O1L'GXQ&1XN?C\:;87W9W<,:8"B-#(>;A3JIW&L2QVK*8R$BUKX,Y&=#55 M<-EM8]EVC)9F4UW%@R3)XIKR)L0(T^X],<1FPPMV+8K[FC4*@W2LH@KXY8ZW M\CE:7;PG7$V[N_OVHA!U"R'6O.+JR00-@[J8WFX;T=%U!7D_DA$MGF.;BY/P M-2\Z(<5&11`N1M#3G/,XCR'28E9RR$"7/>C89AY>D>F*C,)X,3,%^L/97EJ_ M`[D3^R\=+[_QAD&UH4^Z`VLA[K3TMM1+L#D^V7UC.O"C"TJVH?>5^BGV7QG? M[A2T.X6,=&+3\NF:R0(J"F&B0:HC%:("`/@,:JZ/!E2$/IKO/2_5;AX.LR@= M)T,"\F#-I+KA.F08%/=2B?HOBD@?"H,,^B!#H._O#Z+!)"5I]G:4&(E,@M=4 MT<6L$_L`3@W\IVRI/H-D"I%U9D.HS\N904IZSY7>9+:"6D(['A9I-HL?H()% M+UF>2@:N8O6"8G20Q(!W8(3,?<;1J]5_9M2;YB%\'AG'A_`FC25*)IA`FB=) MX@I6MF`T'MH"!Q`*YP.^742]R0.[MU:NW';B1"W>^LUKL M0>7NORY1DAJHT2B%HMAU,95=G=-!(NW;G\;38Q-E'\+38P_-ZMD3)>3Q7CB9B-!K+(9^Y06C<)$\LS__K!$T:-M!LQ.71XV-@BM] M`XTW6+;JXFA[M<[0&SAHQ@Z.;^@$-38.KB#.9)+F^?AHLBZ-9^)OT)RZ=W8, MW/<)-38-KKR'QG/M=[Z73^T[\^T;YB1]R/&M1X9C`K.DYZ%ZEK(UR<#18-EP M6,)9HJ5;]IUV6][(H&(;>.,FT1A,ML-1"2^4:,W,L!8*1ASSPP)"_^`0``__\#`%!+`P04``8`"````"$`E;'T9P\^``";VP`` M%````'AL+W-H87)E9%-T&UL[)W;;AQ7NM_O`^0="@)W-@4T:9Y% MSMC:H"C)UD2VN$5ZC($Q%\7N(MGC9G=/5[<.@US,3:YRFYL-)("01]&C^$GR M^W_K4*L.339EV3,(@NR,Q:Y5:WWK.Y_6JB__[=W-*'M3S,KA9/S5@^W-K0=9 M,>Y/!L/QU5\.RZ_ M>G`]GT]_]\479?^ZN,G+S?\.;OZHIS.BGQ07A?%_&;TQ<[6 MUL$7-_EP_"#K3Q;C^5,OYX^?3OJ+ MFV(\SX['@^S9>#ZC-W\@/WE%_/'7WZAH6[X4?;M9#R_+ADZ*`;-IV?% M=#/;W>IE.UO;>\V'K_KS31YT/XQ@)&MG/[X#"=E?PCVBS([FYD,9LQ)GL^+/N,^U.1SX2*[&D^;RWNYWP^'!6S[(0!5Y-9:\*SFWRD MYZ^+Z60VAS,`[V::CUL#SV>Y&"<[>W]S,1DUX3H^_>9)\[>PI\G-S628OS;>--)WO5M`^+5PG(_[0Q@#Y/(03BFS MZ_Q-D5T4Q3B#024UV7SRNVQ6]$=Y60XOF8]!9Z`&LCR!#P8%DGXQTO)CE,=\ MJ'^?SHK+`M9C6=$QNYQ-;MP_KR>C`2H&(+-G?UU(?->?%I?#_G#^D(4RH("Q M\MG[K'!/!XO"?F=_I::RW3$QXX2'[++(YPM89#,[OQZ663[XRZ*<&VWY<3&: M`\*0K50;&/9S>S&?=Z%D,S9 MUQ2A?)./V"CK\4/)5AW;"YK#1P8*:E?/LKS?GQ6V`3>X&RMQ.C:SLV^;V10* M)E?CX=^*;!"H`Y<48Q;6[/''_J2$Q+-B!$^(^ED?LJ*BLW)QL3$:]HMQ*!]KKRA\]@2\S!%6U-:VMW;CWO+6R*__2WXS_?UQ M5KS#B+CWUQZY%YA'N)A?#V>#[*^+?#:'K9E1>MSV(GH/%GW#4[5HJ3%K.]6: M]5%="QX>VF@,C*TXEH9'/)0VR.[6UO'8EG'9174E]8BP2/808QUUMD)P!I M$H62V-[:BXI"6M2;A`!T7?<$[;R*?NC!M.6T0#F]*4;O-[-CF%L_8:S$*>P. MN4>XD4@3FYYM."75N)@+W,D-W#"?SX87B[E98*EJYSV9J?16*\IB'626DKKL M26]X2V^&R93U0%9P[^C`,,"T:SC"AX>&D,WLNVKY*4QBMFHE0&83=H:^6MO: MW-K.JG>UP-8FVC#^5%OD/GM>I6/-)F%'DQ*"_$*R[BXC*WM<7]OO;>^:<)C+M;ZVQQ_^!P>3&,S@ MN-]F:R*T+BKO/ZQH*D]B;7UK<^\H^;&QWGWVO0*I;T<#CM61T=>CX6"_MX=O MC-)XV`#KEZ+A,-EQ0,.C@_3'H%8\9S2C!7SK)?]!N^\N)F,3*D#8HI0&(W%33(0NSOFP@XD[[G'4NDE6=M M!\=&@5$?0'FLUC5Y<^6^C"D^9Q)[?T2$N"O]UOL7.?* M6\![.<&5)BRYB:X*CD9SN:>56P=W>M#,GI98KFM=1SFE?XUQ"XK1/^6"JD MR2@X"4J*F5O7"_Y3A:>]/0MHEB%JFQS"MM3=T>[=J%JB_+8/=WK[N_N]_8.= MN^=H(J-E?XX'`XL)T?"R#AMXY_U\.D3C-W=^ZAYO^,?9A@1#B4?TH`>D^0I" MG*A]0VASB&/=U$N^FP8M=B<[&=)@*S*X&.5^B]YF^'\\)3=**H)T$,G=/R]S M!%)T/$VL8`^>G8Y<+DF`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`\4P'L-WOM0M>OW$D#;C M#1)2*F9*.GTUT5+O36A.J]#,PA0_)0S*!"D??O*+)AA+.,DHMH$LLAZ+J19F MEJNYV!.,@M"OI$D5.OKRJ.G(&"(2<]=*"#+5EE$RN:HN M/ND#+B6OT+2SXEV[`V/YR-LV_2*!J$DU,T/)%E<&^K-,^HE0-ZEU&RP)TS=? M<^([L=(W1:-WQ:P_A#%6''8;[)Y.E,%4K"55K8J]^@TF;UNS.^)W#;UMA73+ MJ=185CQ&C+XGH=WG<<_7;X/DF=J3T$%.XIK;JS^];9ZHIAKZK.41QH$):9OZ MK/72#Z%DO)3,[1&W0;M,D6#IEZ:[(N#LD,3`\FZI.+"QPUM?.DFSVG4'W5+0 MST>3MTL==!MQ:2-2QQ0G-E=IC?1"6VVUO93TU0Z?]CBVD\A,$%5A*Z3U52VG MK8R"\N8+B1'VJ_*N*\!:GEB2R8L)O&Q=9XM M^OI6F;KEV(&1+X9^C:9578JE(8R M9D8ZUG4=/)0<&Q?(*[=_2!DLJ8H9AKL&]NBKNQJ.*5Q:EPT4I@KVF)+-$Y;P`&7@!@O4$\/'DS'94Q12U_Y;\O*=M=/IO2<+VKQ4G+)( M9$CG&.ZE.E=QM!5W:Q>G%"7I4VU)^*O954ZGF3FJ/74&^NJEDNV:[E0%+R`- MU;CGL1,Q,0,_'E\HK]&?MS)O$;2D(]+F[0`M^_&\>#?/GHQH'FQ-M$UI_[-L MN#U+DZY+>WMI=S0TK),_R7[^^_\B4IO24/OSW__WP]"80@>P1CE[HF'6KRDB M_0!A(<0'1ZYT[2?I93@Z`]\AYUY_/>Q?4TN@?O+'X0QN'.:T?91T MQ@S4&>G,FZ]`BL+C"<5(<(N$0@DX5MPU(9R'E!2IU`U,QXQ[-)E>*UQ?M_]0 M0S_5G_`/G6MC89G![[,)`>-LIJG?#&?8R)+V%KR+J059\`0+,&JN;)5+[?RD M?C(V/9R%=0#!/2\WFUA^0L["-&C*8Q]S*1/0,;[UD<(COOH)%(\0:1H6L92IIX MB]&0!*$(ZR;+;_P&7!]5YXXUG;)K))_46IO,-N-E.$4ND+8_IFBM[!K-0FJ7 M+=[U:3)V;K6A!$WE_Z+0EK>(]4ET&,#2LP)FKQJ5X1VJ#.)#UUP7F5\-X\@#]#0SKU-BNNU"=@/(U4:6]G!7QJ7J1MY=D[K+/:6YG\ M!D^'H;V,N/?LV,@RL>)(4K MF>#5L0Y+C#)<3"\G54]SJ:*B;\3V?^\1`BR1M42S54`U52O-EE M/IR)41?< M9Q:;3A-5W#J=N*92=:^!LXZB9<4>-_F@<%IQ^5;+!,3@$ M8\.QZ4EU8GHR5VYJF!X\7Q26$&ZJG&G:!O^F8X-S`5\3,A/7H! M$7/Z>O4&U9\@:YY':;LLYM4-E>`4'V[?8LLPJ/2&*WN0_P4.@:T=2B>O2H[1_*HB]QW$5^K[2-S0@<9O)Q\)T3=U^$@6/AW=E\`R?B!G$) MX:YW9DS2L/<+=_#;3&W2;Y,NMS- M[X0N*+K9.0 M\%#[`U+\4?KA_>#@U;3H*%5CSM?KI=V&<0BVT#-BLBN5_*G,3ZEP)U/9I#E M!8+-(FZ<10F#0JR(51UX_D2+^H5T(&N=+CF#AA0#SL(<#N:$ERPCW&,3S096 M`C!E)EV@P,L:V,J'!`CS[&U0U6]A:3@'N@&$,E104QM,L':\S"AK0S'5&YI3 M>\`1O"/BD+B/\:2:`O<.4\DQL.MF[KE]ESD."&G".W)6WO;[/7$T#5T\O\1KSK9M`/ M7]CD=@[V=^44MOKJP1255%`\>9Q\_))`DYU-A+YP-W\`JS=3=]9F.DB9R M/3A=HNAL!#P9^UUA"`7R3KLJKE!QE6-<.LA4H#KA,-2+4;#BXT5)RFQ$XR&* MS6DIZ2/72>NL0R^Q;RK+2"OPL;05VQ?<3WPI\ MW-F/'%ZLQ$&N<6JI[L5O3K@Z80I&-LEM>J,05"_. M13AL)4#U.O_'/\P#A#>EKX;`,IQ)\$UGF/+%J#',/5$;99S&#FY=<.;,"_A` M*@>J)K#:2FP1[)=3G$AMI5K#=2N@>MTQPT%#(N>/7]BIMQUWHF4F1C3'5:?` MON%<*+.5V2G2\'(^L*A)6F_C>O+62#&UY,)H>,'Q4*'73L3%@V/28ME%2%E! MA`M%O8K&G'O&XRL.+%[)>3%S)+ROT1?YR#H[-[/0S2RRF3JS0-E&[?:.=ERS MN-,WC@06]E6:RP#V$2"](Y,*KU*YIFX#SB&6YNT(6H3?EGY<@D::T`5GA<;D MS-I+@G[<2X/)Y_A_-1P>]O;#R:!;<7BPZUK0_SEP>`HC=)QH\#\W9,VY.89! M*5TB\HES@VS@4=##\GC\M4$6,$FH=-[4X&F_;@VQXNB`; M0]4M(B78$S1L]'>G]3^B-2X^6(V MX-3[A/]DZ\^/SYX\3)/AU8@3'?3T"9IL_?CLY&'VB*-D6&R`X4 M)J[0K^,"/0[A0!74TE)`(C%XP[*0@:P6/YBI4E:L5&=!G4993ML*2,=E3^P0 M:EVZ+UC)*YVM-O'TQL<4/RJVO51@3MP9'"E,.T$!3AJGVGU=)5N?OY]".\M" MLX9".]'?)84>.E@=3(I?+<.#D=0PS\Q@.''Q?'G4H,.1(6J5^3US/10G5:?. M10?8R'`>O9ZT_@>,!4GAQ&4ZA"Q?'+V^(KITQ"8U"($U#O0B9`8GUON1] M:X3REG4^W+"..!G;=0H8\ALV+%-L-0P"GQ!"=8L;\I$=;N__MN+QE.R".U'M MBU>_NEQTZZO?=M?R+[XI!I1]_+4G_Z!=FS0$]85))E:>XKL/"=)\7PR0Q(M M*V;J8NO1QO[O?E.]^=0'H`+L!\Y6Z*0BL?:+>#=#MHXU>49'Z@![F'FQ?<@F M&,,U//R&.N"-9R17YI3Q_H/K:W"D31^W#,!OHX(I19&>:>F#+L%V>HE`@:#0 M#I\%Q<"FB`V"'R`7-KTEP@(#:Y9Q^T]TM<*@G.5=-K!2I9W:\KGBHC^&RU`2 M0URE,8.")`;X^.'GO__/CQ\J64[(U*I)GU=JC)(@U+>E?YDJ^/CT^#U=,1+LKFR:P])8A(_0RY]$I8NYQQWO[M9,:U.'"2 M`T5HJ7#F4F71?O9]>2`M!^07*FQ5KX0M26K:T:H`))9M0B8J"@.$J:ZX158. M\;.\L*=\[9._E^0"D6DFCX.$=5H]("\M@[SMI>NO M"Q+%`T='2VJHR$SYRZ5K75Z43#EXT!5C7F@@8*`9#":@?DTP5M6%( M[U`D*D3)47^CCUB$IAPJR+B-OK#.3ZHN;*B-45E08URV`@HX`T';CJ6Y^N$ M\LN?RDV2)&]UH,<%_@$*I1?`OLOJ6'W`JPND'16EAHT4#.$RY'>I-)AE8`:G M\9M]6"YY0DX6!>Z3U]5!U+9!40=@"*(ZG<4[9S*7TIL9.`19R_U:6R6RK#]T]G`W2N8))?2%&FD MBQ*\B*$TCY<>,G2NB0K=-[>6%]=J8!6)8B9EPU4N,`><4,,VP'MU8=*'(/9Q MRX<(%$A/>"9A;[1_JMEO9<&0LDT55L@WUIB26'?.+5-_DR(QZ?OX8=>+C,$= MF1I>=D;A6_+?\'KCZA]K,]7EC((?]6YX5CI.\9L/'JK0"FT0JY5T!L=;S_SE M@&\FX-_NOE)C@ZZ!%'BP,H5H*517/HN28:8$EJ6.15W4_R5Z6GWK4H4T*ULU M>AX2(PD7U0G40NXS5VVMZUO#:$*L3LF"[^(&$PQ'!:`MPJ\P!%`$`Y$6[K03 M>H;^HN(0^C552W"A\PDD#"-V+]LWZ87;EV)02R$U5JZU2L6*3I(#PSMS;]K< M*GYC:6Z6IU.NF.D/KXNJ@A-FUY_9IJ?#SA_X.#TR!"P`<)ZD+GM.JXG:--B, M-%W2V;O`OGL>\"MY:@KHKB=BK3?D?>4D3`M4@2)[EV87W+Y(5K]4:S,[@R(K M:&;!#>OYUC-/AA)BH59!=!385"K!`IM@?MW"9)ES@FO5]:`N'6AAYU)/@-Z- MY(#=>J0_?^P/D&:O729=R8SFD//$#+DF`]=&X*[SLZYV(XQK"'>7]JF>&Z;V MD7C5,QZ&9%7V`VVH4JTQ/_U%[(^W9`5ZV6*ZP1KD7/QK7,-88$R2)7&15?G0 M[\99@7B.4B$!5U<]/GGS-UZ);0*-HTID8=#]9-VA*RX"ZH_2,2M@`O,9Q4]@ MB-D;5XQ=4*(0LE3HNEUV0JYR7'/@UJVNS1;%]RX6&='*OE9CIV MYZB@,F'7Y2^5.=+^!&\47XR5$S<84#X">5EB5>M*07KZ/'2Z""31VZ5>E(R# M/18;U)V'2VK$.F2A',S!UO[&SF^EO[C/(4SFX:*0FQ8YE=;H$"#;)9L#[U;#'$DV\.>__Y\Z[\P?2Y2Y M3@\M:76Y.=<'N\X.5Z9B?8$3FP/@YEQ]#./!AMW#;,=TR]\W9SVFCT'LU3'O M))H8J3IXBHRC&$2-\CX#7IG,WTMZFY,_==.BVH@"$XE$\<4V!\TM;\Z7TSPZ M+1UB;A8W0((_9G_?VKVY?;Z'QLI;4J$P%4@4_4`I!424Z(B@: M7O=1K-(1L2H;6C^<\G`N&9&L".$U4&M!5YJ(6D7."NK>]7#P&M.K$5B]%X3H MWAI7FJ,N?1ZH#G!-@Y>R+;(>K0GE;])9IKJB,:$X!,S+=8!W?+G14R8MVE@/ MB-,.^?F_AZ,59OD=G( MB!*[\);Z6$1>MO[B]+7]^O0AA-%=;:PYU;+87G\ECA4BS1%!S>.Q1Z`\0_@P M2G0,@A*KYJ$FUU4XQULX4]K0KUMWDGP6`5S*X5%O?MJI8'692H]0TYT1>E.^2;P0[\)?B$=^CE MR:3YBC*2=7BQ-HSMQX#)L,'030?CR`B+%/5"C"^!NGXL MEC/-)O#-F]`M,=+#T@Z-_2@`-W4L#SGII,";LZK3@K2*#G1S7L!?*P&F+V#B MR3@X,A&)8NU4H@J%R7`,!*P=]Q;^`F]L9M_+/R(+(%94ST^ZUJ7+W/K!==UE M/J\UJ.IV5JG!T'`A9\49+5;2C<\AL%N$KB*JP9X#F@@QB;534J&@;/%,7?Z$ M')!KZF(I@M$"3IG(5D"@M2JCEK78'_[&TJR[&WEO2B M.,S1)%/MLHVY1[T=?Q?T/Q7F=`KQA0LMUU_:53G8U\[,1UL$)VD%B06'"W8?07TIG:<>P'>I[,"558JD^'H@SU0/E8F)GT M2CV7;(KUP5-B?^[N[ MV\VI*O:_/*:.`??,&ESO;NQM1/:_0<#G<%_&V1+GI)/<=I2SL9:/(M/-$- MH2D*ZJIP"3')$,5K&EU6",V2"%K03\>O3E[X"YD%!VI,V30\*_A')971U!7A ME(3&=-%M(F)8&G%,)S9]PCCUK-=/\H\\=RG$2J[#W2@83E?..L(SW,.>P`!"-5:_@-SQE8SQ_SJ^%IZHZGN@OE&>UU)*%I&&G M"ZK+_8@&IT!NHXPT(NZASS3+Z;AT7PC2\314@X136-8)6:?*D?D0S.NTC1]7 MG6?/+QE=]?:IG4>.B].39`\[0?3T7`X)CG4X,-^]`,HRA57_]D?@`M@B=6$O MUYU(\F&A=XL]JS`T(*\-36$P2Z^HR<_5>PZ(ZGE&WZ.GKCSC@IE+-O M-OB#\`1`*N3@,Z#N=6FQ;MX^C":""1)XC%38DFA=R3:M@N? M":+5HH=6(O6"49GC-W92E;I*/@H18O70>Q:-24UFT3?WA=S/YJNW?A/.8M1@ M]NZN^U2&K(0LAW]9M6?D7*?VG.KX1""8CMKH!3[8@O-=,(EK+JV`,KP&L(Q= M*;#@MPL6'<(75P$:M%=&=Q;.9P1&\*J5\UCH:X8Z1HFG';"([O(63P_/X#9C MB'K7'JF:,E('IZE05UR5ZG?(".2*2RGOXP)F`7E/Q.@T5(U[NW;K5&]"C@9G M!&*%[40LTV00D>?\PZ293]A8L?/>#I1 MTM&/ZA+#%[0R@MO"]M:_A)W<(9R,MV] M_'?$43RY9((CPG"2*+6&9G;8"4S%KGPNDC1R^$R7."N7ZB,G]TX-$*X3%,D, M#4`6<'@7CY!Z>,F!7PLH_8$#5=NX7$`IO/9,6#71#BEBH@P.YFL1/V;=_1% MA.I9P'K\'!YND:(TZ,1_XS#'HVE;IW/KF+YJVE8"E>N#U+GG&[<=?`$GRDS: MZ7G33U52-S)M>Q6Z':285OB<5%@DYI=%S&J-P$T=2R!19LUW#IPU-T7VAP6. MG?=%=]>5EC8H0Y^2<_0CD;564*H5N4&@RBUAZ39G!07;XLU7#9#JO"4@T%-[ MO:,COF)P=!3,CA=]CPGS0W#E1^\W=!>5-%MDXQ4=!VGT$.M+D8>SBAG)S3U; M^R!9&[ZVG)%S4V0""9?=/9/>*@"@/M>TEY@'$PEL1V5TPA%WZ^L0[M8>;6X% M(^,8*GHNPGLB/17J0[W;6ZZX"87BW#ES>%A]X$1SW'O":?3`OJ6.\/9(*K2";YKL4Y-+YZ1YU+!Z9+93T&9=]4JG[ZNZ=8>)=\HLF[KM5WW M,<_HCT7S1@.UY1W@V/K7Y-B@CT;'5U@%+,(R?B3$13U:)JYB96-`+QVI"?VE MNB=%UV9FFC)1U8X45>5H&SCA^6JMG?`-UIV#V*N#URF*)`_O8JF_2Q"=O#H5Q&Q MG=ZN4\@M0RB'OWT?P">Y;JOQ75V4HX%/3ZQ8?(#1Z'`ES'WC=WWT5N(4'2$\ M'NC$GS2ZT6CA/F7LLM7VB4J[50&N,T="YKVRF/KIQ*6??0],8F9;I^:J)7WF MT[\:KQIQ6?]*7?S3.U_FCD5"&()I,G<03S+LML;&9/(:4Y(3$CXBZ`6WNTY3[/+,>!W;62W-IHIVNC M(T0+PA)O[CE_8MF^ENB<5WS#`AOW]XOS^<VCS;W@ MH66ZV$7-%AW`*]&>E/HL8HU?809+_EO`VGKERG4U(72)GAV="R$&47SMGHRU M[;W$B?SX0QHU_O`Q!93/W:QF*H&!\(O@[U$ZV/!N\])6XVM-XI^.M MEZ+NTDQZ'VB57.X^W)HR;]II2LR[L;?UVQY]/4&?A]98F=IG2EY4QS,=CAT9 M?O4,^6,+SSD]X0(B^IIZR5F\RD)&/M,BE+98O)V_L.N.G'Z MJO+H)";>NORKTKV)69)/HIGZ5L]W?I&%_M+%.WM_E"._M)U.G#PBK'$YQ@^(Z<<5R<+C`=NT@Q=&B.5#K(VWOV M&X^K_P.LO=F#`(HJ@>Z\D66P*L@2@Z2-5@_J1/$V!O_6.SOI?M%<03M;Y923 M:KJ#$:(ML41+^*Z3T^[I.(>#E>YN8.`-?8ED1$,&'$7;2*<8KFH9'AVQL0X$ M,I'^/LK`V_?B4'T%&/VT?90&`RW16"$QTN(RSXHN4[6U_?_9\$XVM-;1X/[> M[OZD['TWLQC[1`](RNP7Y/YLLMAMND8I+GI2(="(ZLAG%KJU5]MQH%+O,ZZF M<2LO)_C\;+NL+BM>.=5:G62(D%E4[,'#H3)+XN83>K[%@F(K&@<"_25R5G32 MJ)\XA.6/KD%;;_5;1XPE`!\_D*OE?[!73?='4OWQ`XG;[L=!D_-T=\F0'X(' MX[;37."U;L2T$X.$_N0"Z/PD[=UJJ_MC/*#8G.!?FC\\BY?!T`K;?+CO&B:: M/S^K)5:;3]>:/SQ76U3LU@DZ4H&/<*A^5T6SK5J(,&"'(=#M:@IA3"SI8CIT MF_6$[I^QTC]U`^)9(?('+!N3QXNIC#K>!,IR]_!1DC5QQQ4J/V*9$ERVDT,3 M)FM1OJ MD[\ORK;)YJIC=^\34`:$@?<%\\%JF-H[J)RF7X0I2]/1,>%K+,39NWR#>9^O M)>]%;PLTNL)&4P/[I%LH)M`A`>WBINA@Q+"DV['B'4#E*M"LAVMQN>-O^7A);%P5-810&>,Z&8+ MMB8-O16?A-SJ01*`FVF^-?YV'5-*RL;P^Q<'W:IHH@':^&R93E?F?^6^EM94 MIDDPS&QR,.*=9*_]M0`G.GK$5Y[5DN%/.Y^Z:W3+6^+P7SKQ+9\KV>-(CM7E MENP)3?:J/Y]<4"U'.W!T00F+"[NNCCT..IJ8U"^GOC?SN1%LWO)+T.=,14$E M?7T`.GCH;]7B29^)-"ITD,&W=S1&K0:HV_J/DOK,FB3BE]OUKND(NEST;[XJ MCNR:_%9A:3/5(N50DUVR.=D`BN2Z!*;%'F#K M6SMWN[.U=;0<5\QB8(5L3!U?6T?WQ]>2=^KX8Y!'_%WXV^NQ@7\(^E);A/^Q MC-OJ#+9K^ZIOEHS%JINUG?[ZN\U>(3IUND\59U>"XD`67T9'!E'8:['9.3+B MXQ?+_#-HMY-G7!RO;H\0,DA*@ND2.GHM)26X(C74M&FWXW, ME#\"RN!$U$FO63F4_PZX>S"<$]5Q/+2\[BK2:$L'ZAE?[0FX#Y=!6DI.B/1` MNNT$)X712HJ)3!YE]-@00N!"R\^T8X8DCSPIE,)N9I(UM37SN>N@@]YS;ZA/ M1<0S?%$<=13284:EL;A:>,0`Z5FM$"[?M`=`3+B@KHV>T.*=[P4ZY(B!13CC4`] MKK$*WW!.L+JLR59MF]8G)_-`B&Z=97F#F1U:Q+:='.BP)WD8#8N%T`FSJ*+' MH9+R&OI7!I]=A';+2&'&1VE((':&RQF^RKGQY'.'MET#)P]U][M+O44Y-I(; M&E/FKYO:IJ%:GEYWYE;-9-PNVVZO_G_T6SB[:TUF)YY>])T61_\D\<)D=LD]70M4E%(IKG(H M`5#6@E,5M,_;#7%1):##XIGABX+CU\/)C(,SK@>;2TS4)E[UAZ-L_?14'^WK M+]C)<$XLE:8`$28M917I%)?M\P5*.ZACONC8?>51JF3@O_A8TP\1XY#3GPCW MITN,1=BPA:0HYMIU3K5OQTIE&X_VJV-("7BF"2/D9EGTU!TJ$V.TSH2IT7[` ME*TX:-?T>Z4P&`%'@0C]BI,;D?K9"5D MB./9_.I,E-BO^L!8*R-XK@^-??R@).,U%WL^T^::,=MWW*QYQY"(CG:_"8DJ M!2M[S5G][ZTD)&I9)C+N`,,Q+ZY(E;5@YQ;2YJ3G=A3Q+AFNOR5-W_7)DE_G MC$QWR3:K.G7JJL'U\.A_+>Q/G`)S'APO<1<%M]V:OX+B(WJDQ-K"UC'J"?_L MXX?7X6:`.AKFCW_PIX\_?O!CFP-.O/>&BJ`+H"/A>I:<^JF^0/+,YUL_?CB5 M`]><=?U/.OWVL/GS"SQ%&H&&_8\?_JB;:9O/7R5'H+$',2@*W[=ICO_:F9WF MSP&X%M<_=YJO+0ZDG'$(6^,;\$2)R)8)@%\YI%GO?N%48;2'.DFAMQJUJ/>4Z2=V='9JX-42O*.EZ2%*H;@6LJ MG`MN,HNWW4AMQ;R/;HC!1D15O2!/;F=)@@<.3,DWKG"GU_;IT-S=/[0#SCP- M&MS:;+4Z8J++ZMU9UFNF\LTP>1,8G5KLA-,&[:]O.S&4I#MON`F<^1OA M1'K:F-H<>/PFYT)875.EH,M#8#Y7^A&'I:%U<[H??&*V^;O7VG47OCGH3.&- MA>4G#+QJZ8/F\RQ\Q_B6I&'KG22+N/Q8Y_PQ9T>:KS;!)6E?R8\_"Z';$_C@ M&K?;X&/%VZEDH<6D'<%X^#BQ/;)K_?U8+[_&AZ?77*8TS?ZPR2FKA;J-O\6? MLW]B1(OI%):V;PH%CS";32`H[',*Z^GR,1>:GG!/'Q]I?$=-T_*/KUR@'Z#S M*W*K=CS`W-Z?7=_2=+TC.,[;LIRA=59$##1\1NBT3=Y$F:M-T!TV> M-+GWX5AMVSZV4901U7#'#IKS>;EMT*@YZD3?K<(KP:*`@6>S&D^@_X]F)<+8+;A/:\84&G7-VF.U(Q399A M[P@/]L)Q`"0_NK;I-Y[MM@*893YI>6X__X__WH0`A([L9@=6Q)Z=D3("94^R MU]6A9IPU9,<=(3Z-_;A.]9LJL'_Z]#JBF;E>O&S]*=S?'W(*!BO)Q0I3KM,C M6G%57#I0?4NN/'0B99-IO"'&&87#)=+B;7%MC,9@+94$V*&B<_X*!4-_1*^[ M5N?$^.#`B3%_K0+T/;&A[&V\(AG*ULYQ(\MJ]'"F2=`(JA]GV#C2C/N.R/- M[$[]\=FU<"N&D0)5@ES5R:`C,"$*UW6Y/'57V1K>M]R7P[0Z*8?&R*_M@KSC M&*3KC4?N!1^=UCN4>:XHT'M.ELTPM%6+FBNY9M^%ZQK5M2#MYE+O;JDN?2%#EL$M^SQ,2TT@JBK5VN MA_F'M(#+5%ZB&O,L%QKMT*/6S>=M2GJ\PNAV9)4]+<&?E9$.<4B+\WSG>/PB M84!G@395T9(@G]/U`#8W7&D86G>?O(J*L!LYHV[8ND2$-Y[0ES(9ND67T MRN)N#D5\#OS-84P4`4Z$04A*X>R3IO3&53"K:6'/,?M/"V8V^ M->8**FJ]0AGNZ=B.1P*Y=5B)CF@0$>)7#0H*\ M>BYNJL-N_-S;IE#,*B9F=QV14"]*`-)J7FB4[:WJY)4TL#2G3;[H&Q>YSQY7HP?4[]BR(-M/MKS3.^3#@,92 M"305V*O`)4;C?B^SJJ[>)*YA#MW`U_37SAL2*CK;E7&KK'0;E7>745E;7J?A M;==$QYRYM?4]_O`_.&&*<-QO[W4!6X?H^P\;5.?'O:/DQ\9Z]]GW"I2_'0VX M;$=&;H^&`PZ*8PVAOS_G]SG0L"[>/TQV+/]Y#30\.DA_#,1L;5H9^ MHA2>+O,W6\L]1_9M2X+U)-`Y)>'?EX5=#_]JI5&Y.!N7`I50O=;+;/3[[$?_ MWUL"HN^1:UY^1@1KMT__!+R?8"X:\Z.95;'_)F"'I\M.$E2#+U8:K"-A+X6X9.< MDCAR)<[RR4`C[6D5G[I(RP6O=F6*_]1?]87.^R#H:72V[L5TKWT8!(\I)I.Q MOL^JK['S\=,2Z<7BE`Y40[[/7,_XP`8N,IB%^8TD]WE;=R]5@J^[SY-+*>\S MD:>6TT;QCY?A(&6V?BY);%=QSKC39K`@WX@226/WD&WXCO;W7A8GQ`%\[3Y0 M_J--F-VBFFRZT"ZR$@#/?+^B\B56H5_.XL?NLGH?V'L^T+>G(8.*^M:DRGE. M2X[?!F2Z_Z4"5=M*#XJY&MX]YT=(Y2':9#V4[G1(^[#C&:G+LNJ,>>XN6'\1 M&MU6V$=,\IVP"_((2PG>''CWW'*.<"I_81;T4RWG4SZS-AR5QFGDY1]FZ]^? M/<,:T>1G/KC9N9KC_[*QZH"FC[<;OJ&9XEM-_4I@_[C2XP_ MUYER&>J?FR]T:'5YL>O5(:?-Q] MA.>Y#HT5&WJ_TYB"CR9L2E=\P]T13IGRE8F7\T'VX[?6(-="<72^0,6%OV$? MD2)FT]$6AQD\DW'I,G6]S%+AS2631,1+/JVHY.>R!5]T?)A"CD)J/<*[V7^S MW,O*F[GGW/>`NF6W21ZO)DTG2E]'HW`KNS\M+N8X3.&+;D:&D-GN94^L6F/? M6VP[#4V"/*^^G1XJ2U<^5^]3Y5547@D.A/3 MW.]J6$);K$JZE2?T6UY*B>43G=,\L8Q^J[WU6?:3@L&$=^TG)F53$%?%:F-< ME+3C>#2G2=C6&R_\I3UG&&6,B/5#50'!G:^?TE6.9[W:V[>KVTI3*6K&BE:* MN<6?K6T\];>49J_9!M$']QL2/-.4UMS![3"\N-P(9\;CS;C882G5:;AU]X9O M$I5\#WT5\;G)!89$U2:;/69<`,1($F?N.[=]=ZJBYJP MF6:W@YW'J=UZ3$,8'ZAP.9ZEVD M/GH=HVH%&FIO)Q5W+[=`YI4H(=HUC$>G#DJ8-7TKSQ1*!>R"U+)@*I"GRKQ: M[(A&?,F8[*5!/F4EV$MVB8*VTQT1*VKK8&XLHY6^NIV"8:>))8NC/(X=G\JR ML^I[5.J14G3?V.-\JC4-P!C8\?BL*87PQ)Y%"G6.UE#X;?X$$BB_I=HI%(:R MFQBIY!LW.PMKV&P^)W5L=L#;+9ZO&<_![[[>I*A..$\*6<,VX;577&@ M]1\4;3\P"L#)A&B!YPZ6_"$)K)=CDN%OAR9:F,Y,E'3<(KRKC1WLYKQ#)!V%PYQV%,(J6ELO9ZZ1GK:PX&EITKN0 M=7(X4,YE%JYG\S7(7NXVZI"[]>BSF>#:-0.(_)_R"S"64KE>7=&H;4?1,N=T MH=`;=[[<_9-K!2@07RN[+VAS?T.CZ&;2E34]_4:%,IWI_QQ%9LH9^>( MQY@WLSV3>J#=B%G.:%#5[K;E:C.=IZFOGU)9###H4LV6ZYGZ1AL4$_2%F!!" M56SVXAIY1.D(93&Y/AD+7W83QV@0VAVF7[SO>]?ZONHM)P,[D*N?@VVP+H&) M+LE$>3@HG#\(^\"?D-U:J(`V/9[1&CYD,.@CH@DGH]0;/Q_%`Y^;8H/<5^-2 M&^8HQ\>CX$ES6L>./$:J!)A]+B+$.UH48V>6;[.F2"[)E=8YX6*)TLX\ M\\SL[.R22U[_\.2YVA<[W#N!/]<';_NZ9OOK8./X]W/]KW?FQ537]I'E;RPW M\.VY_FSO]1]N?OVKZWWT[-J?'VP[TD"$OY_K#U&TN^KU]NL'V[/V;X.=[<,W MVR#TK`@^AO>]_2ZTK&WEN;]CO7_8\R_'U6,*5MQ81XEGAXV%WL0Z\G14Y M*\=UHF\]=6'>S\(K94+4)\&AK5.9;,/!?&>LPZ#?;"-WH*X7K#=.FN[ MB'+6F_5`TLVU?_!,+]IKZ^#@1W-]F!W2XF\^;.;ZI:[%)B^##8#XW7\.0?3] M;^(_;_[PYDW_7]]]_X^?[,T_?_Y]\;N?O]-[J1HB$WQ0+?-MOU(L?!U+[B46 MW%QO`Y\88@!-R-;5HQ]\]4W\#H(!S,.?W5SO?]&^6"X<&2"\=>`&H1:!E\$^ M=L2W/#O^Q=)RG57HX,^VEN>XS_'A(1Y@@9'\SG/`37BP%VLXKYX5HDEMFB(, MSJ81'J$V>6"2A0>K;;+^?<0F3M>X7E<7_CA=S(IJNZ3I*L9%@<,NNC)?$3WA M_6JNFR;DD$&_C[12AYU(V6S9!WUG4W8Y/IME(W-D3J1:QL5BT6^H<&3*I+)& MH?EN\OYL=,I75F9=DH;/U0.PP\EET8&N6]&_)R:^SA$G9Q[03N,Q)I5+^JSK MY;GQSO'LO?;)_JK]%'B6C\3208W]FAN3N<`[C7@N!.2K.+'X,H*R`:K88QH[ M(>L@A!TY\IFO]Q`$CNMFA>UHC*4?'+FYAAH[LD/?A`]:\O[N>0>%GP_3`8R> M7OR[FE_?A];S8,C*'[$&^\!U-HCB?LG*S<3:Y>6MN;QE>@DR410E0DUS.3F! MT-O%;"D?Z7(VDRUT:,)+LM!W8WQ)%FK"?TMIG"8)WY`%,I.G10Y.#_MO)[/9 M;#JXG$ZG,V,T,`Q&\BJ):,??V$\VSABET51$,`8$L]%T=CD$('UCRE2=%<$( M`$S&X^EX,!L:\#\;84Z/0#:G8UVU5PD"15XE"!1YEA(R?])38+%&<5\E M"!1YE2!0Y-6)Y`P\4>Y5@D"15PD"15YEZVH2^RHL@BKNJP2!(J\2!(J\*JWX M3#+P3+E7"0)%7B4(SNW5=%JUO+TUV2I+L3*35A\GNK"(;ZZ+S1IAGKH*P@V< MK4I/P0P,F"/&QVZN77L;P8PT=.X?\&\4[.#?51!%<&[GYGKC6/>!;[GPMI>V M2/]6M(2S7W"B:ZY'#\[Z$91QBRLQ-[&*4VG(LIZ!LPEC8O0GQGAX&4_8)*GV M[(US$K69;J/QB70B-S6&TXX]#,E23CD"WP]]$+B/L$6S-7,TX(-(";2D!!L M(7#C;-:;\?KRN*ZJD6 M2(`?B9CC($B;(I^U38XP6MNFJ:V07PI]8S'$%ZN.CUA:TZ)H9TV#(U;6M!"U MD8^;U+N<\&SI`M/S$20O^.9^W@X&*(H;IGA>),$D/^'J;7S&0SC='3>W5CRQ M&B0T&ZZ$;2!*TC8OJ)5M=ZUXV9"2T1V*A;7MNI]Q^/[[-JL88!'NYOII2ZZN M@$M>\/(#O'@#W$*=_(VK@[B#^"1LD;#TD::M=NYSY\.WLH.378=#%/!CN** M>OYIPP?IGQ@%4(K MR](OZ*^PTN32;R>:2;Z%0,]IA@\5`#JI+$NQJE(,<3OTM)P"^%!!@0FCKIPA M;U"6\Y410I(N8,@9@310Q8B\J"0Y%W3F`*H964BL0TA08"I2#0'@*(%`'#%0 M-/X.*`9%(S"-!D5#,(7`C<%G[!/4$]P(J0@#X%'2*_(Z8<"-&&>D@4!0E2%) M-`Q5I4B*056.S%TQ5)4B"015&9)Z0E6*I!A4Y4CB"E4IDD``1I1D2.H)52F2 M8E"5(W-7C%2E2`)!588DGAB=.$7VZ+)IO(A*UD]AETCY4B@X*)W^O_35T[9V M(750-FD"66GS>/84SQS!%VPN1:;2N&?-2M=.M8<@='Z!22;N75O#8JH=ZKC7 M,7+6],C7T-K=V4\P%8W/4CUM.QE8@RG7#^O>NM9$N71^.F`1\'0-$;66X[I* M[;K\B\#@U[9K`Z06`UM84`T"N4XP2`\!25T$>ZYJFF"05(Z!N@H&S+IDV"B; MU08K58YD)`O><)@K8%JE4J7*7W>>(K3C6R'62X>L#J8.5`8<3E_%3#;YT>7)+ZW6V\8]SR;< MMZ+2QSR=K3PN2"^I:R2,8$@(5;0U%M'^BNS@@P@G"]> M+KV]KHYX%G02.^*)\8J&;)FS3YQU6\![G2-569%3S%5\5FJ53+^Y[-_"S>=/ M.=6=6L/]R'%E?K26(CF_`?3F*;]T9D3KJX3O:HN.FJ$H#Q3+@[9\5R>LT_+= MNAH[\2#0G-VR,."`UDT-)%1<1>1'HU:H\Q7A-H^&5NE::O8K6L$/*!)([XJ7 MZX)X38]XA=B*WXY!4@/W]09)^=P"NJ\XYT(C2LQQMP&EO'*KF7^VBHJD2#J: M+TK2&QQ>L>4,/!57U]&Z@&IT6JMT`>WU(,3\FZSKUDURI6>KUI$I-&@4>E+S M="#4O^3FW`+JU\\ZGX4+!C2GO57__#;=T+KNK"%=>M1TI9%VC7*^5\(G\5JN5=*3/H+6&/"-1'F-%=*3H^`T!H;& M;7(I";?0=&ZX;:*TLZEN);H0O]CI-:"JS6MVPKIX(K;=FF`-@&0&ZJPM]2)=LT MH.'-YN'A./W?:A?:NS72FRU_XN"].C@NW,@1ER!Q0\?ZL(=[B"WB@\DE^%6R MLDDQ%H=4%HP3366!A'CJ,<1-/@077$_85!:HCV6-P%HB"^XWTU@6;+Q*9.$6 MK!R7`9=9-\4%31)9//=C0>Z-8WYDFQ5S7&BR""XJ*_('*@G!K*BOSHP&.([+&@MQ?'O4C'ZNXLT@$ M%Y65^Y&/U9%@K%)9N1_Y6$63F^+*_0A2"5\&?-%45NY'/D\8@GF"VIC[D>=^ M+,C]RXS*1_Q0,.)C*;GOX!WA""L%$8YB*;G7^"@?"49Y+"7W%Q_?AF!\QU)R M3X$\8I$!7XA;E/EHQ+-K"+*[L#9IUN4#!L<9$1CP&+7UP87'VP7X<#RV8(3Z&<:=4$S%97^#IP7JKB1AH':/AXP_G MC$W$0.M8#)]4L7X2$?/!WQTR#_&Y%(=N$1$?'?_1WO"1PS,\!)`BDC[9ARBT MLOCCN]10D)A/>/N\3`:?(N*'XJ3W^DOJST]PM[R41-S%1_H.%O(BP/]RB`B- MV(H(&0KFI3LG@GNBIIV8$X&P1'#!MGZ,5P@0.DFX][N#4P_-4.H3/7_WN[F,S>WYK#BVE_,;TP M1O;X8C9>O+\8&\O%^_?FK#_L+_\'E.&32:_@T98=GOS)GE`*.X('QM7>A>># MAHFQ"?C/^;&Y3C[$\-F]6P$V[$Y)C>CMLR>GWOP?``#__P,`4$L#!!0`!@`( M````(0#SJ5'3H`,``,0+```8````>&PO=V]R:W-H965T&UL ME%9;CZLV$'ZOU/^`_)Z`R6V)0HXVK+8]4BM5;4_[[(!)T`*FMK/9_?>=L8-/ M,$J$FU*Z#PB`6]S453M*27?_GZ>/9!`:=86 MK!8M3\D[5^3+_N>?=ENP855+K(6MG&)#E&65\R>17QK>:FM$\IIIX*_.5:=Z M:TT^Q5S#Y,NEF^6BZ<#$L:HK_6Z,DJ#)MU]/K9#L6,.YW^B2Y;UM\S(RWU2Y M%$J4>@[F0DMT?.8D3$*PM-\5%9P`90\D+U/R2+<979%POS,"_5/QJ[I[#M19 M7'^15?%;U7)0&^*DV?$O7O-<\P(B1P*,R%&(%]SZ%98B<*(,`)VH_WHWCS%Z M"9V;^^?>Y;,)VQ\R*'C)+K7^4UQ_Y=7IK,'3"F1`-;;%^Q-7.80!?,UCPST7 M-9B`:]!4F$\@(WM+20SLJD*?4[)8SU>;:$$!'ARYTL\5FB1!?E%:-/]:$$6" MSLCB9@3N-R,4['V\.;1$S!F?F&;[G137`#(,7*F.8;[2+1C\\4'`.6(?$9R2 M#4B=$@5JONZC7?@*>N4WQ,$BX.H0=(C(>@1*#AP<$3C"="((1B(H"S([V(5[ MO['G=XQ8.,2`"*@PG0B"(8AWYUTZJY:912P=U>QN8>!W^1F_"#9IY'1>>7XM M`JX.L1XBLA[A1P(R<;H`"!X2V0S='"QB:=(EB2FEGD)9#_!YK#_#`\%#'@\> M#XM`'N5^-J/Q;`&I66(2SV@RQ&8]UJ<$J3]=&@0/*7EN#A9Q'R/J%5360WPF M^!N:7+<('C*A7ED>+&1`Q:^@'N)32894L"SW:RK&0N\JQ M"RN32?1A0U=)E'S?-"@F"@2FZV/0'ALO2P\WS$`AK^8RA_$EHMCU)H?+H#TZ M7O$>;AA+YV@E\9+8049L/M5K\>?BA\JO\1MF;7@L:4+]W+D!3#"'@<)V.%T9 MVSR!D>MJU*]SVC?8.XQ7>)G#C*0!03]!!]'#0,5>`1^HQ=C^%T>C[N>^CZAX M?1CK:ADE5^P]CTL;_R>!2S46.V,Y*='QHN3SSC=:V"7%QP MYJ$0?;?JAKA'.UVY#S`.=>S$?V?R5+4JJ'D)6Z/Y!IQ).U#9%RTZ,YT85KF\+>/4(-2"-V_H'1N_M[_#P``__\#`%!+`P04``8`"````"$`2[F2 M_.$#``!R#@``&0```'AL+W=O],_P/#_0))`-%1W]GM=MMWIIWI=/IQC1"562!,$M?=?]\G":`$M>"%BIZ< M\WSSL/[V697.!^6B8/7&15[@.K3.6%[4AXW[]U]O3XGK")G6>5JRFF[<+RK< M;]L??UB?&7\71TJE`PRUV+A'*9N5[XOL2*M4>*RA-?RS9[Q*)5SR@R\:3M-< M'ZI*'P=![%=I4;N&8<6G<+#]OLCH*\M.%:VE(>&T3"78+XY%(SJV*IM"5Z7\ M_=0\9:QJ@&)7E(7\TJ2N4V6K[X>:\717@M^?*$RSCEM?C.BK(N-,L+WT@,XW MAHY]7OI+'YBVZ[P`#U38'4[W&_<9K5XPQ=5W1QS9^1=>Y+\5 M-85H0YY4!G:,O2OH]US]!(?]T>DWG8$_N)/3?7HJY9_L_"LM#D<)Z8[`(^78 M*O]ZI2*#B`*-AR/%E+$2#(!WIRI4:4!$TD_]>2YR>=RX)/:B14`0P)T=%?*M M4)2NDYV$9-6_!H1:*D."6Q+X;$E0[(4X6B036'QCD7;P-97I=LW9V8&J`4W1 MI*H&T0J8.\^,';VO]UP%'Q7)LV+9N`O7`2\$Y.=C2Y)@[7]`3+,6\V(P\'[! M$-)C?+"G-PH,N3;J=I@[;056VBKLRI@7\\.U$`YOZY"ACG*>0'$\UE.'-BZ( M7/Q(4,]O3#"84!?5M6/A4/"QD`*#00,A;`D9S%@(RFIZ!!78]NB2&>.1P40Z MMS@ARS`A=X(:SY%6X*$T)K:/!K,(M3;Z^>F.+E3?=)<5V-:U73:83M>+@R59 M7KWZ3`Q*5XW\JWYZG&$%MJV(>EX3>(.!//?EADG<8P;:RSG:"FQK+WI>HVTP M2QWXP$-A,'A=BGY@!8(.N@[!M*[2IX;VD.22:6-/"QJ7.U+#97+8-?K_.JL% MW=":-9V0F4;#<6%76@LRW87B,"+QO>!:(^MQ?:'QK!JW5POJZOQN?Z%9PTNC MA_G$5^.^S:<97YVT%Y,@Z4MP6%2S!IJZ-X^*VVZL%C2IL]"LH:;1MN]V;[6@ MN=R09Q<.`;A3\K)F&S,!Z?-MJ03>T9LTP-!YB)!DUEP&9Y@H) M#D)\64T&18:MR?6XN33:SK)][VI!;85C;S!`@^#^W0S/FF@:;=MB!Z(%]=T6 M1??V(CQKQ&FT+6Y75PN:U&VPRL^8YAIMR]O=UH*Z;L,7\TP%F-7?;,85Y0?Z M$RU+X63LI-9Z!'?`_M?^D>,9Z_VN_P,V_B8]T-]3?BAJX91T#T<#;P'#B)MG M!G,A6:/W[AV3L.OKKT=XMJ.PNP8>@/>,R>Y"/97T3XO;_P```/__`P!02P,$ M%``&``@````A`'0=E,&J!0``21@``!D```!X;"]W;W)K&ULE)G;;N,V$(;O"_0=!-VO94J63XBSB$U176`+%$4/UXI,VT(LRY"4 MT]MW*%(V.9,ZRDT2?_O/A/_P,`SW[OM;>?1>9-T4U6GEL]'8]^0IK[;%:;_R M__Y+?)O[7M-FIVUVK$YRY;_+QO]^_^LO=Z]5_=0DJ/:[8I< M\BI_+N6IU4EJ>[OM@4X4&7W M:KE;^0]LF883/[B_ZPKT3R%?&^MGKSE4KVE=;'\6)PG5AGE2,_!854]*^F.K M$`0')%IT,_!'[6WE+GL^MG]6K[_)8G]H8;IC<*2,+;?O7#8Y5!32C,)89C2,&-,WST2KSRH3272<2U76N)-7@-YMVZG\&>'H_'KE^.0Q(,!`;IK:2./3C- M;'O]#KZ]>%40LAG-W$&OM<;RJ4'<^63A9#*E1G%,@H'`(+V9U7$ZI4XG$'W; MJ0K"3N?(J=888_$XG$?3"$WA1FNNU>!VT#1B<1Q%Z+1*<(S`(+6`8Q6.TJ]/ MJ@K"5A?(JM9<;6QZ8"]XY)WWFOZH2S`0&*06<(RIZYG5;V[/G1*[AJ;H,%QK MB>4'`XY!@H'`(+6`,_C%5P:OQ)^=@UICC1X#CD&"@<`@M8`S>@9]?7CM.[5; M_&B"%OC:B"P#A'!"$D*$(7H'3A81.5A2.\9UI9KYX!7%=.MWSW>\IHS(=J7# MKH0334*(("2UB>M"->/A+G3KAH9W[5*DQS(MNHYY0P@G)"%$$)+:Q'6A6K#E M8E@O8KIQNW."[G!K([+=6/V^NT1PHDD,T>MJQF:T-0L2E-K$M:=ZLF7O]N'% M=`=W;:'3V&AL5_@BP(DF,42[BA;A@FP708)2F[BN5`,>[DJW:]?5]=K83<1: M_9T&9Y]M"Q-.-`DA@I#4)JX+U4F'N]!]]Y,-9#5G?4MEF'!"$D($(:E-7!>J M;5HN!FX@W6S=.2$;R.K(Q@TFG&&2$"(,T8MO'L\G9/&E=I!K3S56R]XG&TBW M8=<6WD!6JS:N,.$,DX0088C94M/HHPYDI7%=J89KN5*3]OF]E.DV[;I#?Z*M MC2%9W[PQSHDD($82D-G'E>$FM[^H56/QJ6LM[+ MC3P>&R^OGM7K:P2O`1=Z>1E^"-6S&.(;MH3W.\H3MH0G.N#!)0`> MU?OBU'A'N8-?-1[-X!91ZZ=@_:&MSMT3YF/5PA-N]^,!GNPEO`R.1R#>557; M?U"_X/*?`/?_`0``__\#`%!+`P04``8`"````"$`B$#ZC+8(```&*P``&0`` M`'AL+W=OIL%L,9V4ATV]K0XO#]-__O[\TW(Z:;OBL"UV]:%\F'XOV^G/ MCS_^-U_:U[+L)CK#H7V8OG;=\6X^;S>OY;YH9_6Q/.A7GNMF7W3ZS^9E MWAZ;LMC:1?O=/%PLTOF^J`Y3R'#7C,E1/S]7FU+5F[=]>>@@25/NBD[S;U^K M8WO*MM^,2;.GWU::IV_JYF^ET^_EM7+:Z?;G>@K,A=VM_VNRG:C*ZK3S,+$9-K4.TU`_SO9 M5V9KZ(H4W^S_[]6V>WV81NDLR191H,,G3V7;?:Y,RNED\]9V]?X_"`HP%20) M,4FDV>/KX2Q<)D&27I$EQBSZ_U.6=!:'2;8+QOZO>)WGN: M>7LLS$X.[G3F4WW@:OJ*?50P72F3Y)/)\C#-IA-=BU9W^>MC%&?W\Z^Z,QN, M6?LQ`8_(3Q&F#2:M`D#_Z])&4;]HKB^AOPY=8WH=Y_M[HFN"#=W3&ZT!H&\4 M]F]CJ>1^1"9"E!\2QGT61E9OA/%D3;#>=K0(\;+/:]FM(2;N+RB7@"(`HZ)[ M3JF8_D=ZRH;K9Q8]3/7UNK[$*T$)8I9V,P2K>&%^>$@.(8ZU(@`CJ4?M>I)F M$2<9N[T#98.0!#C&BSCR.4((X4C7Q(ML%=`UC'7*60^7U`1SME$BZK6&F-C2 M%:_E\!I<2I:L*"F8I=-BHY9T4A"A%H;QR%BSAT6Y(3-2I.VC>2*&@_TYA$SF\`092H M1!3&K&!JM,OWFX&S-.I-6`YOL@"TGK-S8@_J@D$H+\OE*EJZ$MF0'$/E*,+Y&?D=SP_$FO/SCGQ$T;&A$E$!03@?(\+C^8!D7]A@ M1->1CT140!#.QRCQ>#Z@V[P^W@8CXHY\)*("0'H52:F1,H+A38Y@5TE'D).) M06[?YQZB*,)Y"0,8EM80%'RXD1A$^7C"3V,X']T4VLAQAA2:5;).\M"+0907 M+'.(PAAH:!*;`Z0[.G&B1GO)CAM)U*P21%-A/.L0@ARMW$,4(D`T7MF?7EXX M4>$%(XF"N+,125TI[$"L0^D`N8#IAOA M)O4;V720>U;'5)[K0N()H(L>HBC"ZV8$G/"ZT%>0^PMR0SP!^4A$A03A?(R` MC^<#HBC""R?LX4+A0/&')S+R;,%#%$4X'Z'\(S?\ M.0>0"AMY#N`A"I&^H4E$7(\3%18PDN@9*TCD2262PI][B$($B"[#59BY`S[G M>9,51.>LP)DU^#\&T8TGS4%AS)7^'QG!)KH\LK@@\TR?4ZG/-C6]3&%N\HO8A#^X49B$.7C^06-X7R$/5QH MI(D6]?$;"4&4CT14#`@T,LT^MJ]8V,3(/H(3\(&4]Z\V-1M(#U$4X743=G&A M;N``^J('/NF*/9OP$$41SD>XP@4^9]P@E6X0>V[@(0H1M"U]TYHNR.>9G.%- M?A"?\8/,'75P(J7ZY[C,[4&%"/A!,'.'4D[R)OV/S^A_)DT+@QREW$,4(B?3 M^N@S@%BXP?%PAR>R['90Y1B)P,?+F*EY$["'"F-[E. MC)%M%;NQ8==.; MG,BNDD1=_V!>,(@2]9R(QG!>PGB&YR4%YQB>%PRB?&"90Q2-X7QN\A?].*%W MXY)Y#84@QR+'90XQSR6:1-#0-%D&L;-3X`F/'<+S=/NR>2GSTA+X.KC33[^91W/Z%_13B,?BI?RC:%ZJ0SO9E<\ZY6*6 M:>5NX#E&^*.KC_8IOJ>ZT\\?VE]?]?.FI7Y^;C'3P<]UW9W^,&_0/\'Z^#\` M``#__P,`4$L#!!0`!@`(````(0"ON)@]20,``)L*```8````>&PO=V]R:W-H M965T&ULE%9;;YLP%'Z?M/^`>"]@0I(F"JG25=TJ;=(T[?+L M@$FL`D:VT[3_?N?8A$!";B\03HZ_S]^YV;.']R)WWIA47)2Q2[S`=5B9B)27 MJ]C]\_OY[MYUE*9E2G-1LMC]8,I]F'_^--L*^:K6C&D'$$H5NVNMJZGOJV3- M"JH\4;$2_LF$+*B&3[GR524936E:Q&F\AH,D64\84\BV12L MU!9$LIQJV+]:\TKMT(KD&KB"RM=-=9>(H@*()<^Y_C"@KE,DTY=5*21=YJ#[ MG40TV6&;CR/X@B=2*)%I#^!\N]%CS1-_X@/2?)9R4(!A=R3+8G=!IH]D[/KS MF0G07\ZVJO7;46NQ_2IY^IV7#*(-><(,+(5X1=>7%$VPV#]:_6PR\%,Z*_Q/8;XZNUAG0/01$*FZ8?3TPE$%&`\<(A(B4BAPW`TRDXE@9$A+Z;]Y:G M>AV[X<@C43`";V?)E'[FB.@ZR49I4?RS/J1&LAAAC0'O&F,P\H;C8$`N@_AV M/T;>$]5T/I-BZT#-`*6J*%8@F0)POQX0@KX+=([=L>O`7A4DX6T>!I.9_P:! M2VJ?1^L#S\:'-!X^D#;,P'8],SHC,T86M_)H#6V:L)]F<`L-.L6.0?UX.+NQRU):NG*A?SJ1+>YX*G;M4M>58#H'2.-1S57;,PB[)SM05 M-.P71,"K37Q>D?$^8$,`,'791B?8#D:%&;[C"4[:"VDC]9@PW6J;:F?J,H]/ M,-\T/8@=#=#535_M3#VY.Y@7*&H4>984'"^VOR=#PN2.^\V)\VG;Z&H_\64<<3PP#`:-M/=7L5L&=EP>2* M?6%YKIQ$;/"8#^'T:ZS-%601XOI#>S1=V*N)W_P#5X.*KM@/*E>\5$[.,L`, MS!R2]G)A/[2H(/AP0Q`:;@7FYQHN@0Q.P`!+)1-"[SZ`V6^NE?/_````__\# M`%!+`P04``8`"````"$`TA_?BSP.``"93```&````'AL+W=O[I\W[RWW_W__ZZ8=%OW-V,#BL7YOMZG"S^VC>$7G>[;>K(_ZY?QD]WA]WS\0;3#5JBY3XO!\L!9GJX>]I@#[SLO7WS?-__4MVZ:CCO M#Q[N@D+_V33?#^S_>X?7W?>_[#=/?]N\-Y`;"^67X.MN]XM/_?G)0Q@\*$;_ M%);@'_O>4_.\^O9V_.?N^U^;SL]Q2[Y/;M]^MTUAS4DQ30WHZF?:;U[ M`P'\M[?=^-J`)*O?PM_OFZ?CZWU_/+N9SH?C"NF]K\WA^-/&3]GOK;\=CKOM M?]ND*D[53C**D^!OG*2:WLRKX7(\QR0G!H[C0/R-`T3AN;_!])^%D\Z M;>XQ`;07:A_JE)&&.`8(AEAFQSJG%F71>(XXA@ MA07FK.SC);'QR:@*_&&+.E%T8A)VC25-95*=D[)L'!$,,='E#'UR8)CF?8S( MC-0I$,<1L>U9EVW[9+GMB.`/DV*FI,A)B;+CB*"#H^ER*7RRI!,1*N^Z0!Q' MQ+;]J5*YPFQ\0\9VL3'XB22OB!*:YDBDG99DX(J@N)=73->V3)9V(L(HI M$,<1L>T*IRZNT^F-AVRY]03)HEDH-2@KRR$@R$G(`D`>^)C(`_II=8K9Z6=,7M%;N5X1XGH5D(-CA](S"'@S9`3"*7@26I?81ERN6/15SBY"0K'94"N6 MLT@Q#DG%O(,RPF<4BW[+.46(*U9`SG=T_F`U%/.>R0A<7V'1?#FW"$F]*JU7 MSB*]."3UPER<[AF]?+9RB0@QDX(J(8L@)R!)P)LGT^L,@6BU7)0(81?)M&>Z M.:IR%HG"(K*2L+)B#)MY.OCTI?3Q"53%U"3D"2@/+UTU4T*LT[0;**5$=94Q:) M$N<*S"4G[ZH75]$H>C"KH@2Q*BHA)R!)P+LD(_`'JBCZ+2>7+9A7D>ZN1SF+ M!..0Y.M-E?$]LXC1@CFG"/$J*B#GCR)O8L:*>9N\G$`T54X@0K**=)\]REDD M"H>D*-Y,+^<4K9=SBA"OH@)R(PY)`MXF&8'0`@Q1]1TOPT?1;CFU"&';S(ET MOYT&T@XX`4FVWE,9VS,U%!V8<\JFS#GIKG>4LV@).20XC96;G^84LJ5C)TB6 ME>XL*2MS$I#DU,FQQZ5C)XA6I2XA)R!)0#FV+ZOQXII3W+AT\P2)PIKKQI*R M2+`X5]@KR;>3FX]+-T\0%RQF$>1$EB3@??/BRAY'EV65G2!117/=/5(6B1+G M*@US[*WT#FG")$"=9@3]4^0$Y`4Q?LF(^"K:#2]XGIN'`V8"`DE7>^RC.X9)_#9R@DB1%NKQP7D!"0)*#,_0Z"T['&$L(O9LL>Z M3:(DJJ$\KM#$^^;EFD27Y>O$C3?0$)#29*'OV-73=#:4PDURP!&&1 MLE[57#?;E)4%$Y#DV\FZ)Z5U)X@540DY`4D"AG5?*5AIW9/LP%PP76&418+E M@;K")IVL.V2K12Q\NDY9I*$3D!1,6?3KD]+7 M$\2+J/1UD24(3`U?G\(-.UZWA&FD'R1(JJ6O$2@KJR4@2;:3J?O=4(=<@IA: M)>0$)`DH4S_=&4Q+XTZ0/.3T10IED2AQKO*0FW8R[I"M%JHT[I1%.CD!25$, MX[[N/MRT-.X$B2I:Z(L4RB+!/C7N:2?C#ME*L+(?3UE<,)XE!?/V>;%)3J/9 M,I-,D*BBA;Y(H2P2)[G0URB417)]ZMO33KX=LI5+P369*`8>C7'(JSTLX3).72?3AED5R?VOFL MDYV';%7PW*C;2^.410HZ`4FYO*DRZ[RZY9Q%=^9+&2&IEV[1TT!.-P\LR@MS M<;JG>YB9SU9Z18BV5JI# MMM*KM/J4Q?7B64*ON;+ZTPL6LB6!!$E1="=.65D4`4E.G1Q]7CIZ@DB!NH2< M@"0!P]&KT?R*FYKSTM03)`7373IED6"?FOJ\DZF';+6(A8/7*8LT=`*2@AFF M?MW]J'EIZPD2@BUUETY9)-BGMNX?5;O-94C##UJMJ@E(TNUD[(O2V!/$]"HA)R!)P##VZWQJ41I[@J1@NENG+!+L M4V-?=#+VD*T6L33VE$4:.@%)P0QC;]NIT\??HK3Q!(WRLZ0U0?R05`V[L[.H M396$E;-3OWR&<+1J=G`N(L0)9^@D83.+^D1)V#@3Q%_ASS`N?7\1(99($/BPLX3N MSBB+#N(X5]@I2;?366)1GB42Q/6*600YD24(+(VSQ!4W*,(TTEX2Q-7"ZV[J M<5C*RFH)2)+M=(Y8EN>(!'%.U8QJN;T(IRSB%.DN^V+.6T<"Y6A'B:A602P.-$O(.RP@$SQHMK[BD7$:O MYN0B)`73K5H:2+O@!"0%PUR<[YF2]]FJY"-$6ZN7!>0$)`D8)G]=J[8L73Y! M(,2.1]VJ4195V*IVR2$,G("%8-50V?WK)VG1)(6/2IU1# M5K.T+(S$%+%.EEX-2T_/&"D!%MROXQNA`E,LE(F'(W`(Q^C8-(2;U:K8,R8+ MBGK4]J3#TIAPGW;_U;"3Q[?I>D7+"X"<1V+BA6R>IX3SKLJLZUQ=11-F_E1Y MF;UDLJZH(T[RY#0F#\<4L4ZF7@U+5\\828&Z*GU=8HJ%-U\FCZ^K:H:7O3%- MY]**1BZTBY@L+=W/5,.H/EV75HL%KNWD[2OY[0ODVV;_ MTM3-V]NAM]Y]\Z_;>Q$?[C+>?@W@$<>$_QY`N&0I8V,?"V\SE[&)CX6ME[&I MCX67^\O8S,="CZ5C2X1P2H2`162.2"B2(K)`9&&.62*RM"(P2\\A?,9`SP=; M\['P-0$=6V(8.F>+'P:AI;4BD!==I!6!N&COK`BD17ME12`LFAPCL@`#W'BQ M(F"`NQY6!`QP[\&*0&]<`%H1Z(W++RL"O7$19$3F8(W#T8I@Q7$?U(J``>Y& M6A$PP&U"*P(&N%EG1!98.=P7,R(SC,$O-D9DCC'XD<2*0&O\>F%%H#5^.K`B MT!HW\*T(5AMWSXW(#&/P2ZX5P1C\D&I%H#5^SK0BT!H_)EH1:(V?]*P(M,8/ M:D9DBC%XX,.*8`R>M[`BT!I//1B1&;3&(P96!%KCMW\K`JWQV[L1F6(,+H6L M",;@`2PK`JWQ&)05@=9X!LF*0&L\'&1%H#4>T3$B$XS!8Y]6!&/P/*85@=9X M*M**0&L\DVA%H#6>##0B4VB-Q_",R!AC\)2X$9E@#)['MB+0&@]*6Q%HC:>4 MK0BTQK/"5@1:XT%=(S+&&+P:8D4P!N]L6!%HC3UK`BTQCM41F0,K?':DA6!UGB?R(I`:[S,8T1&&(.W M1JT(QN!U3BL"K?%2I16!UGBCT8I`:[Q7:$6@-5[X,R(5QN`]TSP?H< M7$'K]A>K(@*M\9*S-1NTQJO&1F0$K?%2KQ'!$'-$A1'XO(,QHH+2^.Z"%8'2 M^,2!%8'2[==BBKV!TNVW%50$WV_Z8L^%`=8V_#);N#^@#/S+Y/9+_#Z4VO*C M/SB-$8]81G,5L8CFNF,)S:,%"QC6;Y`WC.]"?:Q>FK^O]B^;]T/OK7E&(SL, MO?V^_;)4^X_C[@,-+KX.M3OBBU#A?U_Q";`&GRD:^GL\S[O=,?T#RS#('Q5[ M^!\```#__P,`4$L#!!0`!@`(````(0`>=8BOK`4``!$8```8````>&PO=V]R M:W-H965T&ULG%A=;^HX$'U?:?]#E'=(['P`5>E5:=7=*^V5 M5JO]>$Z#@:B$H"1M[_WW._88\$P2-NQ+*E M+Z:A[ZE#7JV+PW;I__7GRV3N>TV;'=;9OCJHI?]#-?Z7AY]_NO^LZK=FIU3K M081#L_1W;7N\"X(FWZDR:Z;541W@S::JRZR%K_4V:(ZURM9F4+D/9!BF09D5 M!Q\CW-5C8E2;39&KYRI_+]6AQ2"UVF'*K'Y[/T[RJCQ" MB-=B7[0_3%#?*_.[K]M#56>O>UCW=Q%G^2FV^=()7Q9Y7375IIU"N`")=M>\ M"!8!1'JX7Q>P`BV[5ZO-TG\4=T]1[`\VN^ORE+M:_%0<% M:D.>=`9>J^I-0[^N]2,8''1&OY@,_%Y[:[7)WO?M']7GKZK8[EI(=P(KT@N[ M6_]X5DT.BD*8J4QTI+S:`P'XZY6%WAJ@2/;=?'X6ZW:W]*-TFLS"2`#<>U5- M^U+HD+Z7OS=M5?Z#(&%#81!I@\"G#2+D5,X3D:0W1(EL%/B\1!E)) MLS9[N*^K3P^V'A!OCIG>R.(.`I_DP<6#HA=#Z!WIDCR.9R[$_=B8H&:RHZE9K;"A]`[#,WR>;M M(F87"&$""HUGHL&P79R)A9S1J5>(,?O?L'UR'I"9XUMFUN"E#\LZ+UG(.9L9 M,7.3+!G-9E$8AA3RY$(F:1+&PL40>E`+KC!Z&\6#579*E1[$!5I0#BO$.`(Y M#PB#E#*XODDTF`D4L=6O$),8@291(N>INWK,EHM)9)0`XA*&T(/:<`6Z3D^# M.3W!A$%,;.A=YD1:^`ZIZ[P.LM)=SJG^ZZPTF+.ZU`D6&V)P9MFSI8;?$[46 MM_#28,XK8FHAIE\M?&\7`;-><6,EP7U$[,OD=DL60P3T\XY M.H\"?9;80Y1P8@C"N>G4N,=L%`2DI#9(*H5VU_'R>=TJ+]5+A6.6KSTU@AUX MO4@%FC;$OWA_U&G%"')_;PC7W2102<:Q^ M!!(GQ(>I?CX\`H7&#*BS6`D?)U.T'GV"-BV(JX.)M2]17!E=(7930Y!]#8$?Q"S(ENTBFL$/ M69;\)XJ)Y[H^+AB28:D=>K2O�[*G:VG@4YKN8^H;-K_QT_.[JUZVHBYN[Y$.Z?\^,G,@J[SPT"G'),54'XW=07]&Q<< M'Q9_Z4DQ[YH6Y&8/AW5[DF2N/\X=S"A6?C$_CUG00/FY[J_%&=[=S/[_(W]= MVQ>+&3E-DDVO#U^N:8S;=F849\A=WX).Q1DF:<^QB("BQ17[B)C] MCV3:TP9BW@9,Z-/I3891TG/^()AY2AH%590U@9$\]2BF:')I,W@.B1"$BBYF M?3_>"22>T[,*Y:E]VVD7(WFBVQ/;2WC;B!#DV)[[A+)@36$DBVYSF/,*A@M8 MK2A>!BUZ4^HB>@^^>`.+=XNEJK?J2>WWC9=7[_IV5<(]Q?GI^>;W4>IK.O9\ M!3?"YOHT.+^`"]ECME7?LGI;'!IOKS80,IS.H$'4>*6+7]KJ:&XT7ZL6KF+- MOSNX>E=P#1A.`;RIJO;T15\RGB_S'_X%``#__P,`4$L#!!0`!@`(````(0!F M\^NSN@<``(4D```8````>&PO=V]R:W-H965T&ULG%I;;^(X M%'Y?:?\#XIT2YTY5.AJ(O;O2KK1:[>4YA=!&`P21=#KS[_?X`O@SG8_80C$?5?M6LZ_WK?/S/WV*2CT=M5^[7 MY;;95_/Q]ZH=?WK^^:>GC^;XI7VKJFX$'O;M?/S6=8?'Z;1=O56[LGUH#M4> M9C;-<5=V\.?Q==H>CE6Y5D:[[30,@G2Z*^O]6'MX/`[QT6PV]:HJFM7[KMIW MVLFQVI8=K+]]JP_MR=MN-<3=KCQ^>3],5LWN`"Y>ZFW=?5=.QZ/=ZO&WUWUS M+%^VP/L;B\O5R;?ZPW&_JU?'IFTVW0.XF^J%NIQGT]D4/#T_K6M@(,,^.E:; M^?@S>Q11,IX^/ZD`_5M7'ZWU^ZA]:SY^.=;KW^M]!=&&/,D,O#3-%PG];2V' MP'CJ6`N5@3^/HW6U*=^WW5_-QZ]5_?K60;H38"2)/:Z_%U6[@HB"FX=0+6/5 M;&$!\'.TJV5I0$3*;^KSHUYW;_-QE#XD61`Q@(]>JK83M70Y'JW>VZ[9_:=! M3"[J["0T3N#3.&'L;B>1<0*?QDD8/[`X2.]82&Q\P.>)#?PZD`7P5:&`S]," M9H.-4V,,GZB/@@3/Q_#S$H4<7WFA(;D*$0MG<10$`88L;4B:SAQ`80.B M*,R#U,%P&S.)PB"!__1*P@9=5H'X0V,,YR_!A/\,DUMH2*PZ65;.4@\D*B"2 M;9ZSRU)4<174AM,!<1J0A7>Q1D2@)8<3D6!,)">%N-`0O>Y)&B>Y)Y,:$RMN MEV5I4CUS?(!OX;='E&%/L2G+3HYN=K(TPM09K9N%QIRXL]RIK*5&^)G?M.8] MUL*V3O&E$7G8NNXG+XTH>48J6&,T^2S(8Y>\C6`L<0"%#4AGGA;G&N&-G["M M)PRR31ICUA]'F1U2M?RE1GCS4=RTYCW6PC^'^((@L/G* M/HZA#?IY2R/*^W+&*58+C=&\PS1R*W6I$7[>-ZUYC[7PSR'>##8KFW@_886F MC.FN;4":LMRQW50C2"C;F]8R1F3R]"40;B#>P(DKDYB[E"B#BYQI00/G^5EY ML(#HHH4!67UK1DP!**J42>%8<6=$V".8A508%HMA1Q#3N@2S(1)N84#>""_[ M)HN^2=XW*Q"WB7#MFRGCXX4#H8[(\*,:`KQ3/WS'Y9,RH7A)+2XP"0NU:"/ M#>5R/M879Q[=BP%V?$U5VA*&N3X,HDK5:J)X:RU]L"LJ>IA5+$L MS8B.`X@>1IJU<$RX,R+.(SWW+DR*A.%LM*3`;*CD42YE(>++FK[3'C0QJ>XO M^YQ)H`V8>!"\S[^X,HDS*`6"Q7G@T:%E!>9.90\[:0_Y.$G=A)H1B[!+F1IQ MQXTXC^"@(EXA$37#>"DK(FX8%3<&9/HRB5//O0G"9++U:&X1@L59['KA!N.M M'G%E$D>!R)N!4?#('$9E3JA!UA9K1G1<)&=7X!>.%7=&Q'FD+[U0>G;9]A^1 MH433M%*E8T#>8"_[)HN^2=XW*:Y,XAP2E7.#JD?=T`US$9ZTS+DSS8C.W20, M'RDZ[+1&(Y1Y(@2!1&J2IZX[U:6 M",$\7]`@0)J[;$5/I>3Z+ M]!B022U\S4M[<6D0WKP4-\UYG[FX M,HE3>I>FBCR:*G1(:Y!)'(/[5)?U27;ACM/W>N8B/?;<0+Q1$UV[Q%?D M$5\AOKO>BMH0'9_8RU5\:264"_LR\<,^Z,R!=-Y/5U M?>1IQH*8\M(ODNBW#`[E:_5'>7RM]^UH6VW@>77PD(&+HWZ-1/_1-0?U-L%+ MT\'K'^K7-WC=IX(OC(,'`&^:ICO](5]4.;]`]/P_````__\#`%!+`P04``8` M"````"$`A/<,A"$U0*@DGLQ^K[6Z]>;D^#RX&YV>KE[O-_?KE MZ_7YO_Y(?IN=G^WVRY?[Y=/F975]_N=J=_[[S=__]NGG9OMM][A:[<_(PLON M^OQQOW^]NKS[B\WKZH5:'C;;Y^6>_MQ^O=R];E?+^T[I^>DR'`PF ME\_+]Z^/Z]>]MK(=O6TW%/_=X_KUQU;>[Y[C[GG MY?;;]]??[C;/KV3BR_IIO?^S,WI^]GQWE7]]V6R77YYHW+^"T?*.;7=_@/GG M]=UVL]L\["_(W*7N*(YY?CF_)$LWG^[7-`+E]K/MZN'Z_'-PU8Z'YY]S\3+?K^VK]LB)O4YQ4!+YL-M^4:'ZO$"E?@G;21>`?V[/[ MU:).D#_GCVO M56J01Y:_KL]#NO#Z?O]X?3Z<7(RG@V%`XF=?5KM]LE8FS\_NON_VF^?_:*'` MF-)&AL8(?1HCP?RHPL@HT"=?]6(:#.;#*5WTR(6HM>LM?;(>>>R(PL0HT.?[ M>C8U"O3)5WA7SV@^=3VC3]8+Q8]'>DB.ZA3I\WT]#&C$G8;Z#U_K77T,.-CJ M/ZPYNIB-QZ/)[`W/!Y0@^JJ2*6\$.>"T4/_AR[VOHYP?@21(.'F?*J>(F@1' M'7JI9T(WL:+E?GGS:;OY>4:K%3EG][I4:U]PI:SPE-)!/$RROYIC-+F4E<_* MS/4YY1%-GQTM##]NPM'PT^4/FLQW1N8690)78L$2:N8JLY$/8A\D/DA]D/D@ M]T'A@]('E0]J'S0^:"UP2;X^.)PRZO_A<&5&.9Q==F#R@>U#QH?M!9PO$N3#[P[HK3NOT-P]BHMNAK M96AVL_L60"(@,9`$2`HD`Y(#*8"40"H@-9`&2&L3Q[FT/CG./>Y4)4VK"GU8 M:\+8\ZH1H@A90A-7:'$08M='0&(@"9`42`8D!U(`*8%40&H@#9#6)HZCR1TG M.%I)=XYF]]P:(JO#`D@$)`:2`$F!9$!R(`60$D@%I`;2`&EMXKB0]D`GN%!) MNRXTQ+VC3;W$/`BQYR,@,9`$2`HD`Y(#*8"40"H@-9`&2&L3QZODCA.\JJ1= MKQIB)2:0"$@,)`&2`LF`Y$`*("60"D@-I`'2VL1QH:I%[0W7\4542;LN-(3L M6ROFS$O,@]`A,8'$0!(@*9`,2`ZD`%("J8#40!H@K4T:L.`I3[ MG8P>#_R,/DBQ8B2*C&)$":(4488H1U0@*A%5B&I$#:+60:[[5;U@N__X'4V= MC_@9;9"=T8`B5A2I&%&"*$64(*AH[<;V3\T5PD)+$!12C5((H190A MRA$5B$I$%:(:48.H=9#K956RG.!E4^'87M9H(FBAOLZAQ+50A"A&E"!*$66( M2X-/1K/?VUSX7Z7FS_N+[[=KNA'0=MH7L2>DA?[^@O M?3HK[A+!:';80R\0108-Z0)RB#'V3MQCD>*L3Q"EB#)$N4&49&RK$"F[$]X! M=2E2K%@AJA$UB%J#="?<>*@R[_TI'BIQS_$&R0`7+"4H,DA](V(YWCMOCT6* MQYP8-`P/_DM%ZHBM3*385FZ0$PO=^^/]*M%699#5KUJDCO2K$2GN5VM07WCZ M*LQ@?.ITP?HR-$A"M$`4&>1-%^\P.A8I'E&"ME*1LKWCG1]F(L6V)V.&D M2@4=,9VYID=DV3.=BQTV70@Z8KIT30?!!&Q78HAMUX*.V&X\V^,AV&[%$-EV MPZV*V!/";6I>.]P:#:GRDG![MZ"%>AZ+[G"4=CRXB)'<@F*#AE/]Q,E@#B-) M6$L,I8S$4.8;PBS)64L,%8S$4.D:&L_14,5:8JAF)(8:UU`PZ(V2[20W2JJL MM:/TL?V=*8[MX&DTI.I#@N>M^(M0"SESU>C-#_&,C=1HT`6/4CSHB1Y82HW: M4"QE;(DV$8=.A1.8BV"K0%LEVSK2J\K(6..KT5+#EH[VJG5LN3%4=?3_'D-3 MC=LQU,B]JTW\`\#02$F:1@:-G-LA+KA:<:3JA!\WP6B`/A"&WG1L1:.@K6.FJ[9"G3<7I($!*R0N,UJQTUWK"4,1X.<$5O'>-N+JAJ M_U@N_+%Y_:MZC5:20\%F#@W$[;>4Q%TI04N)-7?\DS.1DN7XH,@H1JD$48HH M0Y0C*A"5B"I$-:(&4>L@U_NG'4"$>`#!B*:&Y67_F$>DV*41HAA1@BA%E"'* M$16(2D05HAI1@ZAUD./EH7\FT7/V8.5R)^[6P(RL\TE$$:(848(H190ARA$5 MB$I$%:(:48.H=9#K4E56V\O&&R[553A]+<+Y=ZMJ3G72('?;A4%TF,%2$4K% MC&2_GC`26RG:REA*%'.4*EA*;)6,:%VRYIAWJ%2QE"C6:+YA*>E$RZA3=+U, M*_\I7E;B7N(:))U:T(E&)R4]B!B)5,Q(I!)&(I4:9$4L$V0[RRNZ>9NSE,S&@FU)OTJ6\VV M9$EM>FU-O=UVZ]ARI\MI!P;J6,"?+AJY&]BIOX$UBB3%+HT,&DD08Y;2QP/A M>!KVE"$L)'OAE)%]:`&'#YF1(F>HO?#@(O!E@S>AH!QN6TL.?C,;!:.0YLF69SK@;2E6`GG!_T?6J4L)8H%(S%?,I+I7C$2J9J1 MV&H8B6++J%-T8Z'*VQ-BH:MA)Q8:.0;=(C0,AM/AU+N-)*B6,A+C&2-MJ6\Y@PX5 MK",=*AE)7E>,1*IF)-=O&(EBRZAG0J@"U0["QW8'ILRU]\0:J?!+;L.!M0J= M/T\T&LN].C92]+1B]\X<'#@D;$9R.&4=R3<#[S!M\Z_7$"3$>Z/3./WK2F":,>+N##JO<_:=!9=&LF M@[Q-H+?57H@4^S$R:"P^B1GI=2V8SZ?A>.POD6Q*$^P MV;),J(*17*QTS0070W\3B#HUZQSM8&.DQGKXLY""[>U36\>V&VQU0G!LF>5H M'S][&)F#!IF"MXSD!K!`%"&*$26(4D09HAQ1@:A$5"&J$36(6@>YKC[MH$&= MTWN5$R.Z35NW+B_3%R(ED\;8DEC$*)4@2A%EB')$!:(2486H1M0@:AWD>MD_ M57@C M5O7O"5[6Y;+C98/LQ`44J:>TU+HB4C&B!%&**$.4(RH0E8@J1#6B!E'K(->E MJD`]P:5*W-NF&.0D[LP[E%C0&:+GT@A1C"A!E"+*$.6("D0EH@I1C:A!U#K( M];*J&D_PLA+WO&R0I.1B!"A"%"-*$*6(,D0YH@)1B:A"5"-J$+4.@,$CQMD)3@"R-E?;T0L:)(Q0:I+LO68^;5J8FCZ(Y(E3(\(IHN;]Q" M=.'C+&ZF%J*=C-4!KZI9T"F)&K)]O,5(]N(QHZ/5(0MU>LY8Z`3`&8L*#OWD MCWKFY_BP.D4W]0U2SPY8P_)/[42*;X,1(ZL.,H@ZKDXCAO-0/0'AK56)H^<. MRRX%*$0?RCGUXJ8WNPUR2[V9?Q@F4C)$;_`P=QU*@K\?05]2^]Z1^D>EYMOZX6JZ>GW=G=YKOZ%3>J MA&X^';#^B;G;T?1*K7LT6FBA7Y\CE;Z6D%JZZAITAM32A1E:1M32=15:QM32 M_;P0W>O&WKX7\1N^O]K60W_2RZ_G&M MIX54>C5(H5>>W-R;&^2P7A^3NWJ]%9"WZ"5^[!$]C'^E'K7'%GJT_DH].(\M M]*#\E7H,'EOHL?'B%K?2T%M:@W/=`E]&8'7:=K MN3QTFG[>\77Y=54OMU_7+[NSI]4#+1R#[LV,K?Z!2/W'WCP@]V6SIQ]VI%LH MW9[HASQ7]"MS`W4P^;#9[/D/NO3EX:=!;_XK`````/__`P!02P,$%``&``@` M```A`#1V[5`*"0``ART``!@```!X;"]W;W)K^?=;3E)Q M[)?#=J2=BX%^7"['KZLBVR_/(T-$:3X2"][/-#=GE]&O[W M/\Z7Y7!0E+O+87?*+^G3\%=:#/]X_OVWQX_\^KTXIFDY(`^7XFEX+,NW]7A< M[(_I>5>,\K?T0B4O^?6\*^G/Z^NX>+NFNT-5Z7P:FY/)8GS>99=A[6%]_8R/ M_.4EVZ=6OG\_IY>R=G)-3[N2GK\X9F\%>SOO/^/NO+M^?W_[LL_/;^3B6W;* MRE^5T^'@O%_[KY?\NOMVHG[_-&:[/?NN_@#WYVQ_S8O\I1R1NW']H-CGU7@U M)D_/CX>,>B!D'US3EZ?A5V.=F,OA^/FQ$NA_6?I1=+X/BF/^X5ZS0Y1=4E*; MQDF,P+<\_RY,_8-`5'D,M9UJ!/YU'1S2E]W[J?QW_N&EV>NQI.&>4X]$Q]:' M7U9:[$E1!; M6I1.)EP.!_OWHLS/?]9&1N.J=F(V3J;T].CD3L594Y$^FXK+D;F<&_.%:/U. M12JM'IL^^[6X:"K29U/1,$?&;/)W#3XT]>BS7X.4:-63TF>_+JZ:BO39KT6# M@J@>4Q%-S7A]JI-&&PWTI6>C'`,&?>G748/"IG[>WO%C<`")+Y_IZK@._RJ; MK%VY>WZ\YA\#FJ*HP\7;3DQXQEHXXSRJ8[#-K/^76)11PLM7X>9I2$%".5/0 M;/#CV30GC^,?E,'[QF:#-H9JL64+D:["K:4#6P>.#EP=>#KP=1#H(-1!I(-8 M!TD'C$G:5E^*BG]"7^%&Z,O*;!AT!-?$9`NN8NG`UH&C`U<'G@Y\'00Z"'40 MZ2#60=(!BIB4)XJ8MR=[CDEA3=.Z$I-:Q&UJ&\I$5FD+Q`)B`W&`N$`\(#Z0 M`$@()`(2`TFZ1)&04KR'A,*:9@;ZZ.2UJ0;:IC&B5U+':*H:;5LC%MH"8@-Q M@+A`/"`^D`!(""0"$@-)ND21E3K?0U9A7("\8#X0`(@(9`( M2`PDZ1)%7EJQ*_+>?ST+:U7#AG3B$8@%Q`;B`'&!>$!\(`&0$$@$)`:2=(DB MF-BQ*(J)U?>4MH+]([)RI1B\A#Y",*$(6((D0Q MHD1!JMQBD=[-__L!*G:%6H0RZH0H(@N1CQM/JD2-K(S;)0E(U)!_TD&RMN*(E*S*R$3F(7$0>(A]1@"A$%"&* M$24*4B45"_4>DC;K^JZD#>J&)"!+G#74PDO]`#EHY2+R$/F(`D0AH@A1C"A1 MD*J?6)%W]:O/+T8/-(.6QVS_?9/3E$J)?"/5IW1.T9Q>-.OZKJP-JHXP*ZNM MV`8)#5=M/%L-FE(#G=?^4HUG6UJQ^`[Z<1(^D\9E0_^FQJ3F;Z@5K"-I5S=1C$GJ'',#1;#-G^QJB1J4SNN,\8!M9+60D MG4>,I%7,B)TO'N#)$[:IJJFC0.+U&05AKB5#C;1DT,]6Q.M43X:V(B>MW5A- M)TVX3D8K2(6V5C?W-"L7F_,8R3#W]>:FH\ER(O]!HGRFZ9#;Z>9.6Y%[&FM- MS^,H=CP]LJG9('6SJ49:-NG;0Z.QDC%I,9(Q:3.B745G M@M26]0Y;R8HN(^G>8R2M?$9WW0=L)2N&C*3[B)&TBAG==9^P5551'0NQF>HQ M%L).7Y=1K)M MC]'=MOW&ZK-M!](KMQTRDFU'C.ZV'>MMFUIT)](--::,J:EO@^\O&BIS=4P9 MR4#;(K(0V8@<1"XB#Y&/*$`4(HH0Q8@2!:GZ]=O7FKBO941S:6=.T1::6VG% MX6(ALA$YB%Q$'B(?48`H1!0ABA$E"E(EI6#O,MXT*_=GG9"T@U29LF9]D+?8A\1`&B$%&$ M*$:4*$B55&QG>DRW8BLB*G:C%)"-5@XB%Y&'R$<4(`H1 M18AB1(F"5$G[;=_HUB)(6J-J0U>[KN\EUC>ISNGU-=VFIU,QV.?OXLXA#>_S M8XOK"Y$;SU.N:$O%47+J%$W..L;CU"";5#"X`;[9C4#KW';I10=V[VACISLR_+-?W: M>,//:DT_JMW@!O6#?O^Y54+]H%\VL(3.<-?BA!9+Z/AU+0Y7L81.3M?B7!1+ MZ-KKUYN:B.9OV&^$B+9O]$$09=A\Y(NP%9?CW3A.:6+>1/QF_E+ MGI?\!RDQ;J]0/_\%``#__P,`4$L#!!0`!@`(````(0!548NB4P0``%4/```9 M````>&PO=V]R:W-H965TOXL18:2!#+M;FJ2S/OF6)^,2R2$SXF>5X<^!%%I7X61PM<2Y8M*^"LM1R M;7MN95&2FW4&OW@D!S\8`=EN%.RP-K>.'SH+T]JL*H-^).PJI/\-<>+7WXID_T>2 M,[B-=:(5>.'\E:C?]@0AV!I$/UUJ8WG\P6MN>`;KPP43XG ME-(TXHLH>?9O37*:5'42MTF"9Y.$)-P(\)H`/)L`=S)U9XNG:M0;@=,F$,]/ MR[7JJ5=.AE$9;58%OQHH3TQ.G",J=L='XM;"6D9GZL\\A9F49$M9UN;"-&"7 M0"&\;=SE=&6]8?'BAA,,.8[*V+4,6BE*&TJ`!;V=:'C]/XBF+"2Z'2YH`6D6 MFL*6T8:$$J`HQ.+J"CW4]WAEMBY2$&I0<7&F*@AJCN-UJG<#))0111466%9U M6PV1415X2(LZU^0T)%2\1%JHI%U'ZFR3$44A$CVND,B5PC9O4",+R9T!$LJ( M,O9<'9L^!7=3U#IH$;JY"VQ)]\16<:K:%I+D]M`MO6,L MSW;'[76H0VO5\+2DW?:.O56@IKCN]HZLN(-N*AYA>;;W$\74L37%SGSV0$5` MF%X2+21+;EAX2!U1+^$^L&=Y=K]CJE5!_5R2?+MPL34,9#:0],&WK!X*%4@5 M0.U:$E`=$FS,\).-D?82[:-J(;2;SB[/UC:]7<_J>J,"J6I1?++:.W816RO$ M!NJ]V=&1CE@]%"J0*H#ZMFY7TW0^ZUBS!4R[%ADXW:X@.Z;MR[N>U3O6!0)2 M!5.S;P5C6>\XUFP-LJ8:JI`ZV^JKU/"`KB0C_,#U<98;Y@D\'\>I M(;Z=^MNZ&O0!,(O126`.HU/`#,8F$"Q\[,'#@0,'BN`?WEC=T+C4G*,C^S,J MCDDNC)0=8+)=];2BOA;5/TI^AOFXVO`2UYGJWQ.NKPQG;9MVF0/G9?N#!N@N MQ)O_````__\#`%!+`P04``8`"````"$`5::A%:<#```R"P``&0```'AL+W=O M8EKQ!W:X@9^N5!6(P%3=G5YRS`JU**Z<@//B]T:D<;6"BE[1H-> M+B3'1YK?:MP(+<)PA03$STO2\EZMSI^1JQ%[N;6?J M`+\SJ\`7=*O$'_3^*R;74D"U%V!(^DJ+]R/F.2049)Q@(95R6D$`\->JB>P, M2`AZ4^.=%*+S(`"%79@+%;FSC)8A'%R?)?7;@Z)2K#1R30=LWHW8*N M!<^\17(/^&EL6WUJ=1Z&9'\OUY!D*;*3*AM[:5N010[]\;H-@]7:?86BYAUG M;W+\*>/0,V0%I>QQ#ISF0#8"7'`TV(*L_@^VI(JTU0>T[X&'SV#FH6?T2XYS MX#0'LA$P\1!./7S<[7T%)!GZ>E2!(%E.8]MKCA\.?@X&M@>#1-Z,U"[DB3S@KG?3.0AJ0;R,E`LC$R<0&;Z7D7DJQ<]-_> M=\BC:PX&I'`P?\`/4SC_3'P7I3O5,7.=*(63QN3O%RGL<,#=80$\65IT MQ;\A=B4-MRI\`2N>:A6F'SUZ(KHDGJF`MXK*9PEO4PPWIN=`7UTH%?U$?F!X M[6[_`0``__\#`%!+`P04``8`"````"$`U=*"QS`,``!(-P``&0```'AL+W=O M]`\1Z#),2M;)\RZ'Y- MI4Z29Q;+-K7&<@&[>\ZW3X]F6CTS3;!Q\F+LG[O_FNF>6POI]K<_]J^#G\WA MN&O?[H;.S7@X:-ZV[>/N[?EN^,_?H[_-AX/C:?/VN'EMWYJ[X9_-[XI/>PW)_CS\#PZ MOA^:S6/GM'\=N>/Q=+3?[-Z&4F%Y^(Q&^_2TVS9!N_VQ;]Y.4N30O&Y.T/[C MR^[]B&K[[6?D]IO#]Q_O?]NV^W>0^+9[W9W^[$2'@_UVF3Z_M8?-MU?H]Q_. M9+-%[>X/)K_?;0_ML7TZW8#<2#:4]WDQ6HQ`Z?[V<0<]$&$?')JGN^&#LZP] M?SBZO^T"]*]=\^NH_3XXOK2_XL/NL=B]-1!MR)/(P+>V_2Y,TT>!P'G$O*,N M`W\_#!Z;I\V/U],_VE])LWM^.4&Z?>B1Z-CR\<^@.6XAHB!SXW;-V+:OT`#X M.=COQ-"`B&S^N!NZ<.'=X^GE;NA-;_S9V'/`?/"M.9ZBG9`<#K8_CJ=V_V]I MY(A&]2(3)0*?2L2YF?O^9#J??5X$++N6P">*3&[_XTRN:,E,J\(DJUS<% M)D?7%/A$$?_JH#B0RTY%_((RU[?%P0R)7U#F^A0Y'K8&?D&9+[0&4^UHN78_ MK3.2HZ\;S,'FM+F_/;2_!K!"0-^.[QNQWCA+,7QQ&,M!UP_L_S:N82P*E0$W,.0/<)D_'GON?[MZ"=,H*VR67$;Q[18HX48XD(VL$%H@\@&L0T2&Z0V MR&R0VZ"P06F#R@:U!D80ZS[@,-__'P$7,B+@&*H5`LJ`:T47+=`EL$%H@\@& ML0T2&Z0VR&R0VZ"P06F#R@:U!HSHPAQCT9W`L#Z_*N/H%5ZP_FJCUYU,S.BM MI`W,9@S?FI&`D9"1B)&8D821E)&,D9R1@I&2D8J16B=&<&'E,8)[.:C"&E85 M^-#6A*D5566D+QRN[YE&Z]X(0Q\P$C(2,1(SDC"2,I(QDC-2,%(R4C%2Z\0( M-`S8*P(MK+M`8WA6DDPG-%89"1@)&8D8B1E)&$D9R1C)&2D8*1FI&*EU8H1P M:H50[FLWXEAT>MEMOZ]:>;@Z,X8]V+_DKB9$S,@J,J?(,A)(XL$&T`]\U[>6 MD[`WPJ1%C,2,)(RDDCC4H*RWT2]O[<5Y;X27+Q@I&:D8J261ES?B#S/ZBB$L MK,U`*T+]6C,22"*6=RW0U@H3]D;8TT@2S^US&/9N<2' MO1%V)6)"<6^CQV1N"B6]$0JE3"CK;70AJT5Y;X1"!1,J>QM=R&I1U1NA4*T+ M&9-F867IS.($%1FN3L+:3(TBE,0CFXAYQ=6ZEQ%5408:@_]R6#MS,ZX*>;!A]X&=64OJ6AFY M-!D"0N3G>M8`"5%=9!;JIOEX/#93%I$.CJ&8T`7IQ)2>@+(EG9(.2F>$+DCG MIK3C3)EV04*H71*ZH%U9VK['M&L2`FTSW:+RTM>Z#](M"S4XIV(C5Z+@AYGE MP>9&Z;;VE;4RI%0AHB$ MF`YL@ZT$B>1!XLLI0\ M:W%?*S]CKBJ_13\.0F4U&7?)@R'NG,F>=-.48N7FD5*"2A".OE'NE,U%II5Q MK1RU+K2J4#9:JTJN5*'2Q5;5AI:90U$I_N\Y5/6F/@$E,C>R*;M;I*QHF`;B M9AO,W`D$DN+,%UQE)0[Z/^^=R9C/@0B5J%4QHHOB"5I)<7?"M5-EHBT=&7I= MU,[12C4<;O*R`5EP\1+=+HI7:*7$W3%?T6M#W!P+HIB]-!9^;]]A4_WH3HRX M76`=:A3J$F%>4A1_^B4_6.AEK2CD^K'AN=;*L!+W0$4#X"3=6[E3^XX$6>&F M$7`4%&=ZX+]VVI,EGG':4XAB MN'84HK8&"DVFVME.6DU@/FCKO+4;1*A%\C%JT=*5*.2:YRBKS$O1BF9CAEK4 MKARM3"VKAB^4%7Q@NDO4HG959[5FUJFS-K2,Z0+#T,S:Y0VV,S<+9X7,@]S, M/LB1%?8F4&A"20S12I;)KC]SSQS'T8C.A#$B?=]G17BBK."6AS@3CF\<*^0I MRE`%E"FD-3(W918WCC51"Y2A!I:(+C:P0BO9_>G$=R83*Y`UVG3B9BIA/!D3 M\(-4"G,KE1(9=94[8]\Q2BN71F$@IH78A?14*@1S4)M\UL",N&.,B.031!>U M4K0BQPP1M2M'1-.J0$16)2+2JA"18XVH?P:W(AS*U<2&3!JQ`2(:?:%"'LSU2[E06N08HQ;))Y_22KECAHCD<]+"1:'@5B4B:D3% M'6NT.C,O1"FH;TP?S`M9.>H[$%1Q(LK6O+`.,VME96(MR6OE"(,$1UJ@D$][=8C(Z7(##]NQY4I>#+J) M,C'ZD'*"2%79WHVUAJ?*0&M-AHB4P*^VN) MZ0MO;.M*/%DQ7& M,5#(IYB$B.2ZYBP6,]?WV1(IVV#,1(FFQBYGWQA,E/I4SO%SR5;*-*$R;#=- MJ-R4<6X\:\4IN$^)/A<;6"DK7W9_[D*RK7-J;6B;R1:U/TNV3U\"8[8_V`/5 M+00]PQ)UQ+SD=04W[(5J":>1XKE6>E=H92P>-+E5J)!Y M#V-N'2@BP]'LD2C#/C](Q",?-5E1;U0%2*MFB%87]W$TZOS, MSH@*1>^,2(\[%0_??_3TIZQM],$/C^+P\\G<+K#(BOJE'+4M2UGAH7[ABB]M MK-4J0JG.S^R7.*ACOV#[^=JHDZ=]HXNJ`(`&TZX\M^L6N!_2!8(VO`"1GCII MY+:$9QDYSV9+>#21 M\W*VA"<-@8_ZAL)[3.^;YZ;<')YW;\?!:_,$`VO<'20/\DTH^<=)?>?[K3W! M&TRPZ\'R!6^L-?!JQUC4&$]M>\(_Q`7Z=^#N_P,``/__`P!02P,$%``&``@` M```A`+XAF_H&!```^PP``!D```!X;"]W;W)K&UL MK%=-CZ,X$+V/M/\!<1^^0B"@)*,DP,Q(L])J-;M[)N`DJ`$C['2Z__V4,:9M MG(ERV$O3O*YZ5:^J;*K77]Z:VGA%/:EPNS%=RS$-U!:XK-KSQOSG9_9Y91J$ MYFV9U[A%&_,=$?/+]H]/ZQON7\@%(6H`0TLVYH72+K9M4EQ0DQ,+=ZB%OYQP MW^047ONS3;H>Y>7@U-2VYSB!W>15:W*&N'^&`Y].58$27%P;U%).TJ,ZIY`_ MN50=$6Q-\0Q=D_UZ*-"_%;H1 MZ7>#7/#M:U^5/ZH60;6A3ZP#1XQ?F.GWDD'@;&O>V="!OWJC1*?\6M._\>T; MJLX7"NU>@B(F+"[?$T0*J"C06-Z2,16XA@3@I]%4;#2@(OG;QO0@<%72R\9< M!-8R=!8NF!M'1&A6,4K3**Z$XN8_;C0HFD@6(PD\1Q(WL+S5TET&C.6!IS]Z MPE.$MWQO&:Z&\`\<@7;(&YXBY-(*72=:A(\C!J,C/(7CXUQM7K&A`4E.\^VZ MQS<#IAIJ0KJ9[TU(O?M0)ZP$AVC&5CAJ8!528P/Z];;Q6L[5?H M>3':['4;5[4X"`O68$:;S(%T#F028(.B219,PO\@B[$P62*AO0`DG3,-PD*X M)',@G0.9!"@:8!!E#?17,>%`A8N]' MY&-J#AJ2:$BJ(9F,*/G!,97S8TC8+AP@S!RG%FO,IE8416IJM@,>5`">JF* MESV&-[A8[TA=0"A^XS,"52E'`L8R?00B;S8\H]'J0^F(1!.27"[B&WBW_/+/8Y?5[;0***&Z$0Z"5UBYFZT4INI'"$>GXX:IT45A[7 MO/)!\KR7"KDJFGT%I1F=B_Z)N]\U%#8;T5%8\.8M':%A+GE$OL+Q#:)!_1D= M4%T3H\!7MIY%0#:AT^JX\UAO9_B>K93W<"^&#^(=^T4,WQT=W_GQCJ^F\P!^ M#%>\[K!?QG"UWL&#&"ZI.W@8P^4`N#T%@-6SR\_HS[P_5RTQ:G0"[M^Q!26SJ$%%_@G`\%JX[#[^H0Q%2\LP/1OR_87````__\#`%!+`P04 M``8`"````"$`$QNE--@%```N%P``&0```'AL+W=O&_N7"C)J',02$BT6NWQ3!.2H`XA`OKZ]E/& M-F!7;R:1=AX&\NNJ?^%RE3$>__C,SLI[4I1I?IFHIF:H2G*)\WUZ.4[4O__R MGH:J4E;191^=\TLR4;^24OTQ_?VW\4=>O):G)*D44+B4$_5455=7U\OXE&11 MJ>77Y`)_.>1%%E7PLSCJY;5(HGWME)UURS#Z>A:E%Y4JN,4]&OGAD,;)(H_? MLN1249$B.4<5/']Y2J\E5\OB>^2RJ'A]NS[%>78%B9?TG%9?M:BJ9+$;'"]Y M$;V<8=R?IA/%7+O^@>2S-"[R,C]4&LCI]$'QF$?Z2`>EZ7B?P@A(VI4B.4S4 M9]/=F9:J3\=U@OY)DX^R4XOP,#P#_ M*UE*2@,R$GW6UX]T7YTFJMW7>@/#-L%<>4G*RDN)I*K$;V659_]2(Y-)41&+ MB<"5B]@W'>"O=52X,@=SH#E6;S"LP]X(Y3!/N/)0]SG":.J0<.4A.P.]$;'/ M'.'*'!UMV.LY_>$`M&XX#I@C7'G$.P<)S5D_*UP?&^2(.<*5A[S]C"84')U_ M4GET;N\V4S'WS:/+:(3<\["\&R8O&;*OF]B!UVB5U MTRVB*IJ.B_Q#@94,AEI>([(NFBY1X^U&RZ!IP/_J/V@\HO),9"8J%`:T5@F+ MQOO4MNRQ_@Z-'C.;&;8Q18LYMR!=3607,EC*P)/!2@:^#`(9K&6PD4$H@ZT, M=AV@0VJ;_$(Y_!_Y)3(DOSPS,P[:A%M2,KD%=UG(8"D#3P8K&?@R"&2PEL%& M!J$,MC+8=8"03&@0(9G?OQ-X31)K6/T[-6E94L7-J`UT'L_2')$%(DM$/$16 MB/B(!(BL$=D@$B*R1637)4(*H<4?2"&QAI4!+IV^=L1"FS&C;O-;UD`TFC=& M/-$+1):(>(BL$/$1"1!9([)!)$1DB\BN2X2TPGK]0%J)=9U6GHP9(VV#SQ%9 M(+)$Q$-DA8B/2(#(&I$-(B$B6T1V72(D##8?0L+H>T+_2M0T3$/#(R;/N9D5%#%I38L&(W16U90[%>EXT1GR(/":T0\1NOKO1( ME`X:(RZ]1D(;1,+&JR-M&Z+TMC'BTKNND#`!T*["!'R3:-@P\TP3:S'3E%BP M5+=9M*7E=2$1+K?6H-[9$SM*4EQFN"\7&MD+*/E`-&^K6R MV7=Z=E]ZP#42WB#A$`EO&:&/[-B6X5C23.RZPD+>R7=J=\-U.^_$6LP[)1;H M=_(NO_N94=L&B\:-9W#)R(AF1S-&RR=)QD-.*R3L(YO@U\)KY+1!PB&RV4K" M_0%ZXEW724@[?$`\D'9B+::=$JG/&PV[%L+V>9DD/OVM\O@\E M3!SYH'M@YFIS<>H8DEJF)RZ=7HIOR.6]6.XER0KYS[%R_R02VU$4-2'\F; M16[5:22.Q/>-_-9F5JR[#,UTVGHG=U+->ZTJK]X51VULGZ.;L8,'8Z];51Y[ MPU$;.^3H9NRM'-N2JGO7RD`P<4Y!^9$Y)>92?U%4O]*I-#W4I3D MVU]_[%X&WS:'XW;_>C?,;L;#P>9UO7_8OC[=#?_S[T^_E,/!\;1Z?5B][%\W M=\.?F^/PU_N__N7V^_[PY?B\V9P&B/!ZO!L^GTYOB]'HN'[>[%;'F_W;YA66 MQ_UAMSKAGX>GT?'ML%D]V$:[EU$^'L]&N]7V==A%6!PNB;%_?-RN-^U^_76W M>3UU00Z;E]4)^1^?MV]''VVWOB3<;G7X\O7ME_5^]X80G[/JZ\OI7_OO?]]LGYY/&.\INF1ZMGCX MV6Z.:U"*,#?YU$1:[U^0`/X[V&U-;8"2U0_[]_OVX?1\-RQF-]/YN,C@/OB\ M.9X^;4W(X6#]]7C:[_[7.=D>A2"Y"X*_+D@VO9EGXZJ8(\B9AH5KB+^N87XS MR:?STE[]3,.):XB_O=,>=1181MO5:75_>]A_'Z!.T3="O4LFD:HQ8C%;%KP M#.K.)RM"UHU"VAAA66&`XZS2\\5G8YQ1%?@3#6HITG%.L\@IFPJG)C@%VF*$ M90B.+L_0.-L,?=S:(32FC4+:&&'71B?B:YNI,(Q3R92#PQ MA^#:H>2RV5CP%)P"3S'"6&&1)4BU9J\?)8M@WB:1C4O3]-I;$R`@XCN!C*M1B"&>`)&%*,$C/Z4 ME=G!])U8ACQ1RA[B%2,6EX:\B#`7R_:*YVN$-,KW@XIQLAL3UD&)BC'"=WED M)Y-(--1"D0G5J#/GQ2MF(K2%O(B`T!`0)\!HY.5I&F\QC1T45XR"6LQ?*B*> M@!&^*($_4#%.0N/1":I*M&:SJ20L>!%A,<3S-6(9Y?M!Q3AIC7/J(%TQN1#; M\Y&MMQT*ZEJ1"?FLO1>OF)D@@+P"`0QB!.2]1-9Z\XKQ4%0Q&FH9Q!,06FRW M^V.`/??[>5!IW^O:0ZC6,`VSF;@):,C+-VP9Q+,U6GEQO>1.6:-Z<5"B7H36 M?E`O04^I:[A7Y)50Y\Z+UXM8N1KR(@)"0T"<@%X2:U8*H3`>BNO%>1'4,B^> M@!&_:`1,O13E-6M2[F0T'AT'L8J9"^%N?,,XW]!0$6:T,LKW@W%URAKGU$&) MBC&J=GEDIX$8V3`9BDPLMW7NO-"=X)7-A0XUY$45$QHJ`GI);*XEUD-$=Z.A MED&L8@JAQ*9B\ND5=U$V$%<_#_&"$?.P(:_`%X-XNKT4N=#;7@?I@BF$U)XO M1>NMEB2Q/:F]5UPPA7!JR(GZ[^1Z9K;KO/^])+;0$NNAJ%XTU#*()V#$+YI7 MIEYFQ0V=H5U\.UDX&8UFLX=XP8AIV)`7$>9BV5[Q?'M)2;C<)9.7;]@RB.?;2\(++>$.TI(T$=I\?BBLMY(DT;7: M>V'\(P+D+IF\`@$,8@1,>FFR]>85XR$K=_8DN=%0RR">@)#NJ]>PB=XF>X@7 MC-PFDQ?QY6)I29KTTG#K+?ARLA[-,.]%4,L@SE="PZ<8Q)XW%1,MX![B;*GS MY5BMNR<'U!`$\F1[";@YM!=ZY*#$]#(:>+'239QB(O_'I)6\J MR(O*Q8772_[$*.7E:1IO42X.HMIH;$QX$=0RB(]`0I"O.^B::$'V$*N84MY4 MD!<1%I1<54PO09YH07:0KIAI+T&VWG8HXHH1TE%[+U8QI;RI(*]``(/8@)FY M?'G%6&]>,1ZB\F@TU#*()Y`0Y.R*8XNIUF,/\7J1]Q3D172]J\?37GILO05= MG1XGZB4AM#DR[RFTTR"T<2$)5:V]%R\DN7DF+V+&A=?2,^VEO=9;,*-VRHWW MHMIJ&<0+R:ABI'UF93=EUY=`)ZYVA.R"4T\=Q.M([IS)B]@*#0'Q9!$K3O;\ M=FUJO`5;#B)J&N]%4,L@GD!"J*^:=EJFIT%MJ02S4FPN&_(BND)#15*^8J].%]" M_<_KP2R(O.];[2%.BM#]AKQ\PY9!/*=>BC[3NVD/$0.-AEH&\002BI[E\RL. M'&=:U#W$"9.[;_(BPMX5]1EB72[JUEM4D0D`*"9,0:UO:+TX80E1O^[`;:9E MW4.,L$KNOLF+"'M7UF>]9-UZ"\*$*:CU#35A\X2L9]GDFB-*&XIGYR'. MF-RNDU=@C$%LA.>]A-UZBYPZ8=?[S[E0[/,*9+UM9%KCBTS,GMI[8<:$^^"L MDAMP\B("G%+K;>:\EU);;T%`K,'=`9+WHBIJ&<1'0"BUV0E<]>[/7(NXAWC! MR&TY>1%?+E:BPGN)N#F:%SL!#Q$YC89:!G&^$B)^G2;-M8A[B!,F=^;D182] M*^)SQ+IYY>UTZ98]S);Q7G$#LQ1-(K!)7'$:4>HWP4,P6/E+A M+ZPTY!4DCT$\V5YK1*G7"`=9_GAD(?X?3*\@\#1QBEQTK2Z=%_Z$344^EKLJ M\B("0D-`/$VCS]'1T0=I.C6/R\5!5!M-J:"603R!A.9?4RYZ"2@=A&PBMN06 MC+R(K=!0L66T]G*VG#+';#DH9DM!;1E#C*TJH=]Y7EUQ7V@C<4'W$"=,[L'( M*Q#&()YO+_6NM'I[*"),0RV#>`()];YN#U9I^?80)TSNPW%!$ENJAKR(`*?N^BZGZJ7(UEL0 MX$0ZKA@%M;ZA]>(58[0RFN-VO1\CWY[+?>4T-YK]'N+U0GO+[IZ,O(@N%RN1 M+6+%V7XPJL9;T-5!B7H1POQ!Y*"_<;T(L:TKY\7KA?:JCH#@103$$!\NHY71 M<'V0IE/6>%!BL74)**BM8H@ED(T3FHQ7RJ\Y2>EB\0$*&*\:VBYW.4=N@36. MB:Q[*;/Y\%56CL>BTNF^;>V^Q-QM#D^;9O/RBL]BZZ\[690&+_?Q1M4%GL8'5;9;E#`2E MVZ"SV`;J-G4YAR5):HF^8C.4:H.^8DN2L%3H*A;_E`5?2V-53EAFB(9CR81E MCF@X_].6Y3Q?++'3UA:&*0LR`VG]2D+#Z+)=Z4T!:\[X*>)OLS17]P@Y1J@_[@E0YM64YP';S@I2UXT1&Y M):\SP77P,F&J#:Z#5_E2%M0U7JA+65`[>'M-6Y8%YC;>[=06O!>^:/':=\J" MZ^#EZY0%U\&;SRD+:A3O'Z8/_C((=&F0!W@ M>P)M66:8"UFR#2PM/BW4;>H,O'6GP'(URY!;ELIMF:-&\653(AHL+;X^2UE0 MH_@L+&5![>`3K(0%%*1[@ZO@0V+=8IFA0O%#'-J"#W;1)GF5#!7:_9R!8@!5 M@"]2=33\P,@R'0L-$OZUZ6(*-Y,C@2]1F/B<65^X-G,SA1M53^$8]^2P8]23 MA8\QMT,^"ES@=TO>5D^;WU>'I^WK<3^<&RWS(?NET^Z?YSV;]@-X]=+ M]B?\8HG]WV?\1,T&/Z,Q-H<>C_O]R?\#'1N%'[VY_S\```#__P,`4$L#!!0` M!@`(````(0#DG7J$,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0! M**```0`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````"&>TMIG3&D98F:G5QBXHR+-X1O*[%0`FBW?R_KNCJC)X_D?7EXOH]JOM-M M\@G.J\[4B&0Y2L"(3BJSK='S:I'>H,0';B1O.P,UVH-'?@T746 M7%#@DT@RG@I;HR8$2S'VH@'-?18;)H:;SFD>XM%ML>7BG6\!%WE^C34$+GG@ M^`!,[41$(U**"6D_7#L`I,#0@@83/"89P=_=`$[[/R\,R5E3J["W<:91]YPM MQ3&&UL(*($`2B@``$````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````G%513]LP$'Z?M/\0Y1U2"D(3+2,)1F%)H:V"4OH%/S_//G]C$V1H<*O`)01@_2N>( M]5F6>3F'A?"'9#9DJ:Q;"*2MFV6VJI2$*RN7"S"8#0>#TPQ>$4P)Y4'=`J8- MXMD*_Q>TM#+P\X_3MYH(Y^RBKK62`DEE_EU)9[VM,+E^E:!9UC4R8E>`7#J% M;_F`9=TM*Z30,";@O!+:`\NV!^P&1$C:1"CG<[;"LQ5(M"[QZB>E;9@FS\)# MH#-*5\(I89!H!;=FLU[KVJ/+GZQ[\7,`]"PCA^9PO>SZ=M?J)!^>KCUHU?<, M"`T3,O0Y3A5J\'?51#B,43[MFY-<&*5_\FVFJK6R7>:MA M;(VW6I4"H>270@LC@1<[2C_BSR?B[R$*I$CAI7EN*WY74\%:[)#Z1DB/5?_* M/93_>F4L>E5KH_P0N'00>%PNO3+@/:>FXH6:&56I:)2)@PJ_-QG?S<);95[\0SVU5S1!-L.^?\C635G2&-S8MP?LAN:\TP&$ M&LC,H-SX[!K"U_38_+_YT^/%2T/14-UZ?N>D7E0E%C:P M'T90Q+XLD9\&[K?K[@A*FN/%I<)DX$,"L]UNM'?)7X*+K+J!Q4!H;3TAB@^4 MG0QE)>[-H]3L6L?Z1%DKN44"4X"L-JK:N`\@8K]`ZCT2[0:_R/V M"P``__\#`%!+`0(M`!0`!@`(````(0!S7WC=T0$``&D2```3```````````` M``````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A`+55 M,"/U````3`(```L`````````````````"@0``%]R96QS+RYR96QS4$L!`BT` M%``&``@````A`)HMDURX`0``*A$``!H`````````````````,`<``'AL+U]R M96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/E`.FYD M!```OQ```!D`````````````````G1D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/QMMECS`@``%@@``!D````` M````````````)"D``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT` M%``&``@````A`,-VO1F)!0``'Q<``!@`````````````````CCH``'AL+W=O M&PO&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(A`^HRV"``` M!BL``!D`````````````````@IP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-(? MWXL\#@``F4P``!@`````````````````[J@``'AL+W=O=8BOK`4``!$8```8```````````` M`````&"W``!X;"]W;W)K&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`(3W+E<@$```7U0``!D````` M````````````,L4``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`%51BZ)3!```50\` M`!D`````````````````R=X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+XAF_H&!```^PP``!D````````````` M````F/,``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`.2=>H0R`0``0`(``!$`````````````````W@L!`&1O8U!R M;W!S+V-O&UL4$L!`BT`%``&``@````A`.GU2OJ&`@``KP<``!`````` M````````````1PX!`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$` M'(0:_I4```"I````$``````````````````#$@$`>&PO8V%L8T-H86EN+GAM 7;%!+!08`````)``D`*4)``#&$@$````` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9

Severance Charge (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Severance Charge [Line Items]

Compensation and benefits $ 679,000aphb_CompensationAndBenefits

Stock-based compensation expenses related to accelerated vesting 1,161,000 0

Total severance charge $ 1,840,000us-gaap_SeveranceCosts1 $ 0us-gaap_SeveranceCosts1 $ 1,840,000us-gaap_SeveranceCosts1 $ 0us-gaap_SeveranceCosts1

X

- Definition

This element represents amount of compensation and benefits.

+ References

No definition available.

+ Details

Name: aphb_CompensationAndBenefits

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: aphb_SeveranceChargeLineItems

Namespace Prefix: aphb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(10)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9

Warrants and Warrants Liability
9 Months Ended

Sep. 30, 2014

Stockholders Equity Note [Abstract]

Stockholders Equity Note Warrants Disclosure [Text Block]

3. Warrants and Warrants Liability

The Company follows ASC 815-40, Contracts in an Entity’s Own Equity, as it relates to outstanding warrants.

In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.

In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,195 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $1.4 million for the warrants issued to the placement agent.

We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:

June 26, 2013

July 15, 2013

December 23, 2013

Warrants issued

28,394,834

1,645,361

4,320,420

Risk free interest rate

.0109

.0109

0.0167

Volatility

160.94

%

163.08

%

155.24

%

Expected term

5 years

5 years

5 years

Exercise price

$

0.14

$

0.14

$

0.25

From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity.

In 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity.

On June 26, 2014, 3,855,714 warrants, issued on June 26, 2013, were exercised. Due to this exercise, 2,734,151 shares of common stock were issued and $1,594,000 was classified out of the derivative liability account and into equity.



The Company re-measured the fair value of the liability warrants at September 30, 2014 and recorded a $7.1 million gain on derivative liabilities during the third quarter to adjust the liabilities associated with the warrants to their estimated fair values totaling $6.0 million. The change in fair value and the resulting gain was attributable to a decline in the market value of our common stock as of September 30, 2014.

X

- Definition

The entire disclosure for stockholders equity warrants and rights.

+ References

No definition available.

+ Details

Name: aphb_StockholdersEquityNoteWarrantsDisclosureTextBlock

Namespace Prefix: aphb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A-F1A M.&)C8V%E-CDB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E=A#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;G,\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O M#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;G-?5&%B;&5S/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I%>&-E;%=O'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E=A#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K7T]P=&EO;G-?1&5T86EL#I%>&-E;%=O'1U M86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2 M968],T0B5V]R:W-H965T3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A M-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Q M,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@8VAA2!296=I2!#96YT3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#DR,3$Q-#QS<&%N/CPO M'0^+2TQ,BTS,3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^05!(0CQS<&%N/CPO'0^,3`M42]!/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^=')U93QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q-#QS M<&%N/CPO28C.#(Q-SMS('!R979I;W5S;'D@:7-S=65D M(%-E<'1E;6)E2!I=',@4V5R:65S($(@4F5D M965M86)L92!#;VYV97)T:6)L92!02`H1&5F:6-I="D@=&\@=&5M<&]R87)Y M(&5Q=6ET>2!D=64@=&\@=&AE('-T;V-K)B,X,C$W.W,@2`H1&5F:6-I="D@=&\@ M4V5R:65S($(@4F5D965M86)L92!#;VYV97)T:6)L92!0'!E;G-E(&]F M("0W,RPP,#`@:6X@=&AE('1H:7)D('%U87)T97(@;V8@,C`Q-"!A;F0@82!R M961U8W1I;VX@:6X@2!T:&4@:V5Y(&%S65D('1O('9A;'5E('1H92!C;VUP;W5N9"!D97)I=F%T M:79E(&%S2!A;F0@82!D96-R96%S92!I;B!T:&4@ M;&EA8FEL:71Y(&9O2`D,BPQ,#0L,#`P(&%N9"`D,2PR-C`L,#`P(&9O2`D M,"XP,2!P97(@7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&%C8W)U M960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA"!L:6%B:6QI M='D\+W1D/@T*("`@("`@("`\=&0@8VQAF5D M+"`X+#@U.2PY-S@@2`H9&5F:6-I="D\+W-TF5D+"`Q.#2`H9&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@8VQA M2`H9&5F:6-I="D\ M+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#4L,#`P M+#`P,#QS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@;&EQ=6ED871I;VX@<')E9F5R96YC93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B M,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A M938Y+U=O'0O:'1M;#L@8VAA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES960@*&EN('-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2`H9V%I;BD@;&]S'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E M-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R M8E\T8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@ M/"]D:78^(#QD:78@6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@ M,'!T)SX@/&(^/&D^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2P@ M:&5A9'%U87)T97)E9"!I;B!2:6-H;6]N9"P@5FER9VEN:6$L(&ES(&1E9&EC M871E9"!T;R!D979E;&]P:6YG(&YO=F5L(&%N=&EB86-T97)I86P@6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!I;G1E2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S M:61I87)I97,@+2!":6]C;VYT6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/E1H92!I;G1E&-H M86YG92!#;VUM:7-S:6]N+"!O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^/&9O;G0@2!O9B!M;VYE>2!M87)K970@86-C;W5N=',N/"]F;VYT/CPO9&EV/B`\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@2!O9B!P6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T M)SX@/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^26YV97-T;65N=',@:6X@<'5R8VAA&-E6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@ M,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/DEN(#(P,3(L('1H92!R:6=H=',@=&\@4U!(($AO;&1I;F=S(%!T>2!,=&0F M(S@R,3<[6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@,C`Q,2P@=&AE M(')I9VAT6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^4&%T96YT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG MF5D(&]V97(@=&AE:7(@=7-E9G5L(&QI9F4@=&AR;W5G:"!$96-E;6)E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@ M/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R('-T;V-K M+6)A6UE;G1S('5N9&5R('1H92!G=6ED86YC92!O9B!&:6YA;F-I M86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A7!I8V%L;'D@=&AE('9E M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@3PO9F]N=#X\+VD^/"]B/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G M/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/D=!05`@9&5F:6YE&-H86YG92!P&ET('!R:6-E*2!I;B!T:&4@<')I;F-I<&%L(&]R(&UO2!I;B!A M;B!OF4@=&AE('5S92!O9B!U;F]B6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN M(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G M/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DQE=F5L(#(F(S$V M,#LF(S$U,3LF(S$V,#MQ=6]T960@<')I8V5S(&9O6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN M(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/B`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`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ M(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@9V5N M97)A=&5S(')E=F5N=64@9G)O;2!T96-H;F]L;V=Y(&QI8V5N2!A8V-E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(')E8V]G;FEZ97,@6QE M/3-$)U=)1%1(.B`P+C6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G M/B`\=&0@6QE M/3-$)U=)1%1(.B`P+C5I;B<^(#QD:78^)B,X,C(V.SPO9&EV/B`\+W1D/B`\ M=&0^(#QD:78^06YY('5N9&5L:79E6QE/3-$)TU!4D=) M3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9% M4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C5I;B<^(#QD:78^)B,X M,C(V.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^1&5L:79E28C.#(Q M-SMS(&-O;G1R;VP@9F]R(&%N>2!D96QI=F5R960@:71E;7,@=&AA="!H879E M(&$@2!C;&%S6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P M.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SQB/CQI/B`F(S$V M,#LF(S$V,#L\+VD^/"]B/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U! M4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/E)E6%L='D@86YD(&QI8V5N2P@;V-C=7!A;F-Y(&%N9"!U=&EL:71Y M(&5X<&5N2!E>'!E;G-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U! M4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!,=&0F(S@R,3<[6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/DEN(#(P,3$L('1H92!R:6=H=',@=&\@0FEO8V]N M=')O;"!,:6UI=&5D)B,X,C$W.W,@<&%T96YT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@ M/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^3F5T(&EN8V]M92`H;&]S6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G M/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@65A2!E;&5C=&5D('1O M(&5A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT M-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P M:6X@,'!T)SX@/&(^/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IU;F4@,3,L(#(P M,3,L('1H92!#;VUP86YY)B,X,C$W.W,@0F]A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!B92!C;VYV97)T960@=&\@ M8V]M;6]N('-T;V-K(&)Y('1H92!H;VQD97(@;V8@=&AE('-H87)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG&-H86YG92X@5&AE(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@<')I=F%T92!P;&%C M96UE;G0@;V8@4V5R:65S($(@0V]N=F5R=&EB;&4@4')E9F5R2!R96-O2!F;W(@82!C;VUP M;&5X(&5M8F5D9&5D(&1E2!E2`Q-2P@,C`Q,RAD871E2!A6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P M<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($IU;F4@ M,C8L(#(P,3,L('1H92!#;VUP86YY(&ES2UC&5R M8VES92!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!R96QA=&5D('1O('1H92!W87)R86YT6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2!R96QA=&5D('1O('1H92!W87)R86YT6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!R96QA=&5D('1O('1H92!P M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P M<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN(&-O;FYE M8W1I;VX@=VET:"!T:&4@<')I=F%T92!P;&%C96UE;G0@;V8@4V5R:65S($(@ M2!M96%S=7)E9"!T:&4@9F%I2!A6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]N($UA M>2`Q-BP@,C`Q-"P@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!.;W1E(%M!8G-T2!.;W1E(%=A'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^,RX@5V%R3PO9F]N=#X\+W-T6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@9F]L;&]W6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^26X@8V]N;F5C=&EO;B!W:71H('1H92!$96-E;6)E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R`H)B,X,C(P.V1O=VXM6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!A8V-O=6YT960@9F]R('1H97-E('=A2!M96%S=7)E9"!T:&4@9F%I6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN M(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!I;G!U=',@87,@9F]L M;&]W6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P M,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E' M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C@L M,SDT+#@S-#PO9&EV/B`\+W1D/B`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`G5&EM M97,@3F5W(%)O;6%N)RPG'!I&5R M8VES86)L92!A="!A('!R:6-E(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B2X\+V9O;G0^/"]D:78^(#QD:78@ M6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN(#(P,3$L(&EN(&-O M;FYE8W1I;VX@=VET:"!T:&4@0FEO8V]N=')O;"!B=7-I;F5S6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG'!I&5R8VES86)L92!A="!A('!R M:6-E(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B2X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/D]N($IU;F4@,C8L(#(P,30L(#QF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES960N($1U92!T M;R!T:&ES(&5X97)C:7-E+"`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;B3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R M,U]B,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB M8V-A938Y+U=O'0O:'1M;#L@8VAA'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^(#QD:78@F5D('1O(&ES M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG65EF5D('1O(&ES6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2`R,#$T+CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GDF(S@R,3<[2!T:&4@0V]M<&%N>28C.#(Q-SMS M($)O87)D(&]F($1I&5R8VES92!P&5R8VES86)L92!O=F5R(&$@9F]U&5R8VES92!O9B!/<'1I;VYS+"!T M:&4@0V]M<&%N>2!I6QE/3-$)T9/3E0M4TE:13H@,3!P="<^56YD97(@05-#(#2!I'!E;G-E('1H92!F86ER('9A;'5E(&]F('-H87)E+6)A6UE;G1S(&=R86YT960@;W9E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE28C.#(Q-SMS(&5S=&EM871E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!T:&4@ M86UO=6YT(&EN8VQU9&5D(&%S('-T;V-K+6)A'!E;G-E(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL M93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P6QE/3-$ M)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q M<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z M(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)W=H M:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@ M6QE/3-$)W=H:71E+7-P86-E M.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@ M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^)B,Q-C`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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S@L,#`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,C`X+#`P,#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,24^(#QD:78^ M4V5V97)A;F-E(&-H87)G93PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!T:6UE'!E;G-E/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,C0X+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PX-S4L M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@ M6QE/3-$ M)TU!4D=)3CH@,&EN.R!724142#H@,3`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`[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO6QE/3-$)W=H:71E M+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,"XQ.3PO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T], M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`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`P,#`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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,"XQ.3PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,30\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!# M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$R)3X@/&1I=CXQ.2PY-S(L-34X/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\ M9&EV/C`N,3D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/C$N,S4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/E1H92!A9V=R96=A=&4@:6YT6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/D%S(&]F(%-E<'1E;6)E2`D/&9O;G0@F4@;W9E&EM871E;'D@='=O(&%N9"!A(&AA;&8@>65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!H860@6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$ M)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0R,"4^(#QD:78^,C(L-3@Q+#8R,CPO9&EV/B`\+W1D M/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M"!S M;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P M="!4:6UE"!S;VQI9#L@34%21TE..B`P<'@Z875T M;SL@5TE$5$@Z(#DP)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9% M4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M"!S M;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@1D].5#H@,3!P="!4:6UE MF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T2!I6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQF;VYT/B8C.#DP,3L\+V9O M;G0^/"]D:78^(#PO=&0^(#QT9#X@/&1I=CYR96-L87-S:69Y(&ET6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV M/CQF;VYT/B8C.#DP,3L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9#X@/&1I=CYR M96-O9VYI>F4@9&5F97)R960@'!E;G-E(&]F("0W,RPP,#`@:6X@=&AE('1H:7)D('%U87)T97(@;V8@ M,C`Q-"!A;F0@82!R961U8W1I;VX@:6X@6QE/3-$)TU! M4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`P M+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I M=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0^(#QD:78^ M2!C97)T86EN('=A2!I;G-T2!I;G-T6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4 M:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U=)1%1(.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=7 M24142#H@,"XR-6EN)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV M/B`\+W1D/B`\=&0^(#QD:78^861J=7-T(&=O;V1W:6QL(&9O6QE/3-$)U9% M4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQF M;VYT/B8C.#DP,3L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9#X@/&1I=CYM;V1I M9GD@=&AE(&ME>2!A28C.#(Q-SMS(#(P,3,@=V%R2!F;W(@,C`Q,R!W87)R86YT2X\+V1I=CX@ M/"]T9#X@/"]T#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2`D,"XP,2!P97(@#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2`D*#6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P M.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE2!T:&4@0V]M<&%N>2P@=VET:&]U="!A=61I="P@ M<'5R28C.#(Q-SMS(&UA;F%G96UE M;G0L(&%L;"!A9&IU2!T;R!P2!O=7(@65A6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D-E2P@=&AE2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^57-E(&]F($5S=&EM871E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!C;VYS:61E2!C;VYV97)T:6)L92!I;G1O(&-A&EM871E6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^06-C;W5N=',@4F5C96EV86)L93PO9F]N=#X\+VD^ M/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/E!R;W!E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!I;B`P M:6X@,'!T)SX@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4')E<&%I9"!A;F0@;W1H97(@8W5R M2!O9B!P'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DEN=F5S=&UE;G1S(&EN('!U6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DEN(#(P,3$L('1H92!R:6=H=',@ M=&\@0FEO8V]N=')O;"!,:6UI=&5D)B,X,C$W.W,@<&%T96YT2!497AT($)L;V-K73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^4&%T96YT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPGF5D(&]V97(@=&AE:7(@=7-E9G5L(&QI9F4@=&AR;W5G:"!$ M96-E;6)E&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T2!497AT M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6UE;G1S('5N M9&5R('1H92!G=6ED86YC92!O9B!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N M9&%R9',@0F]A7!I8V%L;'D@=&AE('9E2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,&EN(#!I;B`P<'0G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE3PO9F]N=#X\+VD^/"]B M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U! M4D=)3CH@,&EN(#!I;B`P<'0G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!M M96%S=7)E2!T;R!M M87AI;6EZ92!T:&4@=7-E(&]F(&]B2!B92!U6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DQE=F5L(#$F(S$V,#LF(S$U,3LF(S$V,#MQ=6]T960@<')I M8V5S(&EN(&%C=&EV92!M87)K971S(&9O6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^3&5V96P@,B8C,38P.R8C,34Q.R8C,38P.W%U M;W1E9"!P6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DQE=F5L(#,F(S$V,#LF(S$U,3LF(S$V,#MI;G!U=',@=&AA M="!A6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@9&]E2!H87,@96YT97)E M9"!I;G1O(&-E2!C;&%S2!R:7-K2!A;F0@8VQO2!R96QA=&5D('1O M(&AO2!B92!N970M8V%S:"!S971T M;&5D(&)Y('1H92!C;W5N=&5R<&%R='DN(%1H97-E(&EN6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN M(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE2!E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!T;RP@8VAA;F=E(&]V97(@=&AE(&1U'1E M'1E&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^4F5V96YU92!296-O9VYI=&EO;CPO9F]N=#X\+VD^/"]B M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@2!A8V-E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(')E8V]G M;FEZ97,@6QE/3-$)U=)1%1(.B`P+C6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1) M0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C5I;B<^(#QD:78^)B,X,C(V M.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^06YY('5N9&5L:79E6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P M+C5I;B<^(#QD:78^)B,X,C(V.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^1&5L M:79E28C.#(Q-SMS(&-O;G1R;VP@9F]R(&%N>2!D96QI=F5R960@ M:71E;7,@=&AA="!H879E(&$@2!C;&%S6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!;4&]L:6-Y(%1E>'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^26X@4')O8V5S2!A8W%U:7)E9"!T:')O=6=H(&)U2!A(&)U2!A(&)U&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T2!497AT($)L;V-K73PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V9O;G0^ M/"]I/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U! M4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/D]N($9E8G)U87)Y(#4L(#(P,3,L('1H92!&05-"(&ES65A M2!A9&]P="!T:&ES('-T86YD87)D('=H:6-H M(&1I9"!N;W0@2!C:&%N9V5S('1O('1H92!C;VYS;VQI M9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]F;VYT/CPO9&EV/B`\+V1I M=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L M92UL87EO=70Z9FEX960[)R!C96QL3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!? M.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE M/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)W=H:71E+7-P86-E M.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`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`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,&EN(#!I M;B`P<'0G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE6EN9R!C;VYS;VQI9&%T M960@6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)W=H M:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`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`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$V+#`P M,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^,34S+#`P,#PO9&EV/B`\+W1D/B`\=&0@ M#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0U,24^(#QD:78^1V5N97)A;"!A;F0@861M M:6YI6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C`Y+#`P,#PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PP M-3,L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PQ-C$L,#`P/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-3$[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,2PQ-C$L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^)B,Q-3$[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!# M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^/'1A M8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T2!; M5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5. M5#H@,&EN.R!724142#H@,3`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`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`Q<'@@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD:78^1W)A;G1E9#PO9&EV/B`\ M+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M0T],3U(Z(",P,#`P,#`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`P,#`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`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,RPQ,S6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO'!I"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,B4^(#QD:78^,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD M:78^,C(L-3@Q+#8R,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,"XQ.3PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U M8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP+C$Y M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXQ+C,U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@R,BPY.#D\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U! M4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/D%S(&]F(%-E<'1E;6)E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[0TQ%05(Z(&)O=&@G(&%L:6=N/3-$8V5N=&5R/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P M:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE M/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`X-24[($)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0R,"4^(#QD:78^,SDL,C4P M+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$ M14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@,'!X('-O;&ED.R!" M3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@"!S;VQI M9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B M7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A938Y M+U=O'0O M:'1M;#L@8VAA'1U86PI M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&-L=61E9"!F'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!,=&0@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61I;F<@1V]O9'=I;&PI/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!? M.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@3VYE(%M-96UB97)=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@3VYE(%M-96UB97)=('P@4')E9F5R6%B;&4@3VYE(%M-96UB97)=('P@5V%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B M;&4@5'=O(%M-96UB97)=('P@4')E9F5R6%B;&4@5'=O(%M-96UB97)=('P@5V%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T M,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@8VAA M2`H1&5T M86EL65A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E M8W1E9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!P3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T M8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES960\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%B;&4@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^1&5C96UB97(@,C`Q.#QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E(%-E M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(%!E'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$V,2PP,#`\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA65E(%-T;V-K($]P=&EO;B!;365M M8F5R72P@55-$("0I/&)R/CPO6UE;G0@07=A&5R M8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES86)L92!A M="!397!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES M92!0'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!I&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,30\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^.2!Y96%R7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA65E(%-T;V-K M($]P=&EO;B!;365M8F5R72D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A M-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Q M,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A938Y+U=O'0O:'1M;#L@8VAA6UE;G0@07=A2!3:&%R92UB87-E9"!087EM M96YT($%W87)D+"!/<'1I;VYS+"!'2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D+"!.=6UB97(@;V8@4VAA6UE;G0@07=A6UE;G0@07=A2!3:&%R92UB87-E9"!087EM96YT M($%W87)D+"!.=6UB97(@;V8@4VAA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P.#$S,F(R,U]B M,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T8CDP7SDT-#)?839D83AB8V-A M938Y+U=O'0O:'1M;#L@8VAA2P@4&%R(%9A;'5E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-C8P+#`P,#QS<&%N/CPO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!!8V-R971I;VX@5&\@4&%R(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\2!%<75I='DL($%C8W)E=&EO;B!T;R!2961E;7!T:6]N(%9A M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\P.#$S,F(R,U]B,C)B7S1B.3!?.30T,E]A-F1A.&)C8V%E-CD-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#@Q,S)B,C-?8C(R8E\T8CDP M7SDT-#)?839D83AB8V-A938Y+U=O&UL#0I# M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I# M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 18 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Preferred Shares
9 Months Ended

Sep. 30, 2014

Equity [Abstract]

Preferred Stock [Text Block]

2. Preferred Shares

On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $1.40 and par value of $0.01. Each Series B redeemable convertible preferred stock is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B redeemable convertible preferred stock  stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shall be entitled to receive dividends of 10% of the Series B redeemable convertible preferred stock stated value per annum.

In connection with the private placement of Series B Convertible Preferred Stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013(dates of issuance) and recorded the initial liability as part of the private placement proceeds.

On June 26, 2013, the Company issued 4,999,999 shares of the Company’s newly-created Series B redeemable convertible preferred stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $6,917,000. As part of the same transaction, the Company converted $5,491,001 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B redeemable convertible preferred stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $6,029,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B redeemable convertible preferred stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $2,386,000.



In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for the conversion feature that contains a provision that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision). The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds.

On May 16, 2014, 188,938 preferred shares were converted into 1,889,380 shares of common stock. Due to this conversion, $707,000 was reclassified out of the derivative liability account and into equity.

The Company re-measured the fair value of the conversion feature at September 30, 2014 and recorded an $19.4 million gain on derivative liabilities during the third quarter to adjust the liability associated with the conversion feature to an estimated fair value of $14.0 million. The change in fair value and the associated gain was primarily attributable to a decline in the market value of our common stock as of September 30, 2014.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Balance Sheets (USD $)

Sep. 30, 2014

Dec. 31, 2013

Current assets

Cash and cash equivalents $ 9,786,000 $ 20,355,000

Accounts receivable 27,000us-gaap_AccountsReceivableNetCurrent 8,000us-gaap_AccountsReceivableNetCurrent

Prepaid expenses and other current assets 448,000 297,000

Total current assets 10,261,000us-gaap_AssetsCurrent 20,660,000us-gaap_AssetsCurrent

Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of September 30, 2014 and December 31, 2013, respectively 1,283,000us-gaap_PropertyPlantAndEquipmentNet 145,000us-gaap_PropertyPlantAndEquipmentNet

Intangible assets

In process research and development 12,446,000 12,446,000

Patents, net of accumulated amortization of $116,000 and $93,000 as of September 30, 2014 and December 31, 2013, respectively 377,000us-gaap_FiniteLivedPatentsGross 400,000us-gaap_FiniteLivedPatentsGross

Goodwill 7,562,000us-gaap_Goodwill 7,562,000us-gaap_Goodwill

Total intangible assets 20,385,000 20,408,000

Total assets 31,929,000us-gaap_Assets 41,213,000us-gaap_Assets

Current liabilities

Accounts payable and accrued expenses 1,840,000 2,147,000

Deferred revenue 246,000us-gaap_DeferredRevenueCurrent 244,000us-gaap_DeferredRevenueCurrent

Accrued severance 449,000 0

Total current liabilities 2,535,000us-gaap_LiabilitiesCurrent 2,391,000us-gaap_LiabilitiesCurrent

Long term liabilities

Derivative preferred shares conversion liability 14,043,000 40,791,000

Derivative warrants liability 6,035,000aphb_DerivativeWarrantsLiability 16,871,000aphb_DerivativeWarrantsLiability

Deferred tax liability 3,078,000 3,078,000

Accrued severance 210,000 0

Total long term liabilities 23,366,000us-gaap_LiabilitiesNoncurrent 60,740,000us-gaap_LiabilitiesNoncurrent

Total liabilities 25,901,000us-gaap_Liabilities 63,131,000us-gaap_Liabilities

Series B redeemable convertible preferred stock $0.01 par value, 10,000,000 shares authorized, 8,859,978 shares issued and outstanding at December 31, 2013 (liquidation preference of $13,712,000 and 13,022,000 at September 30, 2014 and December 31, 2014, respectively) 1,660,000 707,000

Stockholders' equity (deficit)

Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at September 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013 1,872,000us-gaap_CommonStockValue 1,825,000us-gaap_CommonStockValue

Additional paid-in capital 362,001,000us-gaap_AdditionalPaidInCapital 358,828,000us-gaap_AdditionalPaidInCapital

Paid-in-capital - contingent shares 1,837,000us-gaap_OtherAdditionalCapital 1,837,000us-gaap_OtherAdditionalCapital

Accumulated deficit (361,342,000) (385,115,000)

Total stockholders' equity (deficit) 4,368,000us-gaap_StockholdersEquity (22,625,000)us-gaap_StockholdersEquity

Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity (deficit) $ 31,929,000 $ 41,213,000

X

- Definition

Fair value of derivative liability of convertible preferred shares as of the balance sheet date.

+ References

No definition available.

+ Details

Name: aphb_DerivativePreferredSharesConversionLiability

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value of derivative liability of warrants as of the balance sheet date.

+ References

No definition available.

+ Details

Name: aphb_DerivativeWarrantsLiability

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the non current portion of the liabilities.

+ References

No definition available.

+ Details

Name: aphb_EmployeeRelatedLiabilitiesNonCurrent

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedPatentsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.

+ References

No definition available.

+ Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional paid-in capital or capital from other sources not otherwise defined. Use this element if the registrant wishes to distinguish between Additional paid-in capital from Other Additional Capital. The following adjustments are some examples of Other Additional Capital: recording the issuance of debt issued with a beneficial conversion feature, the issuance of convertible debt at a substantial premium, certain tax consequences of equity instruments awarded to employees, and accounting for certain expenses and liabilities paid for by the principal shareholder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section T

+ Details

Name: us-gaap_OtherAdditionalCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References

No definition available.

+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statements of Cash Flows (USD $)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Cash flows from operating activities

Net income (loss) from operations $ 23,773,000us-gaap_NetIncomeLoss $ (65,041,000)us-gaap_NetIncomeLoss

Adjustments required to reconcile net income (loss) to cash used in operating activities:

Derivative liability (gain) loss (35,286,000) 52,350,000

Shares issued for technology access fee 0 3,000,000

Amortization of patents 23,000us-gaap_AmortizationOfIntangibleAssets 23,000us-gaap_AmortizationOfIntangibleAssets

Amortization of note discount 0 2,637,000

Warrants issued as investment fees 0us-gaap_FairValueAdjustmentOfWarrants 759,000us-gaap_FairValueAdjustmentOfWarrants

Depreciation 59,000us-gaap_Depreciation 66,000us-gaap_Depreciation

Stock-based compensation 714,000us-gaap_ShareBasedCompensation 1,206,000us-gaap_ShareBasedCompensation

Stock-based compensation - severance 1,161,000 0

Changes in operating assets and liabilities net of acquisitions:

Accounts receivable (19,000) (125,000)

Tax refund 0 618,000

Accounts payable and accrued expenses (305,000) (453,000)

Accrued severance 659,000 0

Prepaid expenses and other current assets (151,000) (153,000)

Interest on loan notes 0 233,000

Net cash used in operating activities (9,372,000) (4,880,000)

Cash flows from investing activities

Purchases of property and equipment (1,197,000) (97,000)

Net cash used in investing activities (1,197,000) (97,000)

Cash flows from financing activities

Proceeds from Series B redeemable convertible preferred stock 0 7,000,000

Proceeds from convertible loan notes 0us-gaap_ProceedsFromConvertibleDebt 2,000,000us-gaap_ProceedsFromConvertibleDebt

Payment of convertible loan note 0us-gaap_RepaymentsOfConvertibleDebt (26,000)us-gaap_RepaymentsOfConvertibleDebt

Net cash provided by financing activities 0 8,974,000

Net increase (decrease) in cash and cash equivalents (10,569,000) 3,997,000

Cash and cash equivalents, beginning of period 20,355,000 862,000

Cash and cash equivalents, end of period 9,786,000 4,859,000

Supplemental schedule of non-cash financing activities:

Accretion of Series B redeemable convertible preferred stock $ 955,000 $ 618,000

X

- Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

ZIP 21 0001144204-15-023068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-023068-xbrl.zip M4$L#!!0````(`&&+CT8F"%4HL(D``#4:!P`1`!P`87!H8BTR,#$T,#DS,"YX M;6Q55`D``Z;7+E6FURY5=7@+``$$)0X```0Y`0``[%U[<^)(DO__(NX[U'IW M9^XB`$L\_,#=L^%7]WC7;1PVLS-[%Q>.0BJ@MH6D*0G;[,5]]\LL/9"$P"\> M$E3']#2@>F7F+[,R2U+FI[\\CRSRR(3''?OSGE[3]@BS#TVM'!#^TJJ>NJ-8U MO47^6VNVM5:[T?P?\K^WW_Z/7-YW294\/3W53!C!ER/4#&=$JM5HGC/JP1PP MSF]G=]>D7M/#:\\]8?$V_I_`LFVO3=UA[_/>T/?=]OX^#DE'KL7=(>]Q!\?< MAQ4TM>,&4!5TL+C]/=4!!ZLY8@`MM<8^7N[!Y%%SO&KRN$.R\<%^<#%N.C/T M4T.VU8^/C_?EU;BIQ_,:PJ#Z_F_?KN^-(1O1*K<]G]I&:BU\P=JS[;GG-.OZ MX:(>08NH@\E3 M--L\9M0&SN-^>!$ETZAJ>K6AQ]W&0@#VYO4+KTJ1ICN:C.?W@0LYS=FS,KJ+QXW\#G`AK[GOBCGMX4I.A[%7 M'5#JQGWZU.M)R887Q&_\K>A8/W/>ZCAU4B+:\^>N4?V8:#`4)P[ML^>?7+/#!_L MCS02,$5@)HSP(@".F5T!Z+7PP=RR MGR*8:7HTSO1:-%2"'#/1Z;C:T*:3FV&7Y)(2DT<_A3P,QWZ)L7K]H:'O&F/U M.JC+*AG;3""V64;&-M_#V.;J$-O<(E/0+)(I:&X18M_.V!4B]G"+$'M8),0> M;A%BW\[8U2'VU.O8I6-H$$#Y.9R)KBR),SJRI;2;"<>ZYB/N M,_,;&_68&'MX,G`V]KC-/._4^'W,/8XSG#YS;\T,SVZ`;`!4^_%\X043%O+L M6MS@?D`",2/N?-X+3SK:-[N5&T@*2HR:L8-!]8RK@MQ;@M`Z8[9B'+B.V=M-NW("?;]Y)@ M_,)MT.QK_LC,*QNF'?">Q4X]C_G>V>0;_:X^$> MQF#>V;EC/S+A(W-N!>LS(9@I=7EW]^;`5KR*/1N!R.J.,/,?$U!0*1=42O&\ M1!IA"=[=.#[S;NF$PN>.S5+8&CK"[S(QNF`]OSMQ6>!W[3@Z\Y@2(O,EMB[7 M^5)ZLBD]Z3XY+^K)3B$\9HA"TVJL[DZAZ17V4J'I([9IY_?P%>^O5`B:/DR\DJ\E(`O*;U?S:(FNI4C?LI@Y(^57V*W+W\=`PKDSU]&YY?%8LHV_L. MOU[9WHU@5=G>C:%7V=[%[\#N(#;+@(A"O_.;#R1@Y,BQ%8I2*)IABH+0@K/I MT)WPKCQOS,R._=>QS>H'>"G@4A)7X1ELV*4C[OA@Z)<;4PM(DCOGZ]BC3G7? MA#!KHK<4PN8B+(\]"F%O0-@%,R1WZ@V%LCDHF\\BA;3Y=ZB4#2N'#=O$884R M0J4T0D6`BO*Y"^US;_(!\_=$^`^W@C_"]5N+&FSF+:UQS^,FIV)R3RVV7<$ M+>U4IX:^04, M45!:LJ=18AB5ZUY"42&4OAVEXII2Q35EN5LU39#W$!1PL$YM\]0<<9M[OJ`^ M?V27SRY(([7O7=F&,V*QGE\[!BU_;HF%1$6-7L6D4-7 M>,&C!,'_RXVHU](7M9_+KO6!:Y/O5>`J';C64H=USE-\ M"BUE0TN1G_/+F*+ND],=.F./0A1LFS?<#O@&_B<2_(A/;J?0AM]OZ*CD3QRG MJ9#^].L9L6569R$@ND,N?,9L!8I7,&.G@/'$K$=E*UYFQ7:#0M7;*E6]K=7B M(OF.G$%F7"QIM?DZP]WS&1L1-7;FS-O2B[FS$90L::JC77UGEK!WE/;!`9. M35-6,*76+>5@/,^IRWUJ*3Q$S18R:+NQ<<=\"@&Y>4F%C?5L%2BFNT8>9[8, M#7/.194O471?HLCGH'-`I;:ABS:]@SR/, M`97:_$JX^94#6FKS*\7F5S`P9>XJJ$VOZ)O>9DI*J=/C@IX>KPT#RG,IA^>R M"6PHUZ.HKL?:T*`"YW+Z$&M[CDGY$(7U(=:&`>5#E,Z'6!LVE`]1`A]B#6_F MS+R<'#'IU/SG."COG`N->X/9%";>$DBDR4F\ZSZ/'>HX:_$[[@I&!8=1T5YL M5_`I-'PVX:.<<0S;E>S0&[7_*S_"D9%AE'1 M4OTW%8Q*"J.W6Z.EPFAL\P!#WI`*EI7]B%%O+-A/X?)DDVBXZ%IR"AQMSOB_ MW%_,&9Q[3K.N'[:AQ?O'?@""'^YQ@9E93/X(<,M*`;O>C$=,4-\16:R]>FE) MAF='S)GP@MG.B-N+IWR)U=DY9P>-KB8H?P4/W?$,Z])+P@:ODL^G/U2KEY94 M,W+/##S=KU:#IH%+B#=_AHYEQBEWL`1C5/7L@GN&Y>#H70#KF05M28C<.]:? M>VZZ)XGX0F$Z\T'?^^D'RS\!!A#/GUA@F[Z=WGV]NFD3S?7A[_,)^=*YZ;:) MCM^[8$@\R)TSHG8E^*%"L/QIG^S],/!/2&:X\^O+T[MVS_&'P4C5+Z?? MKJ[_T"EDE< M]_*W;O7JYN)2"JX%OY"%]+Y$X0]TY)[\43_03F8I*?C2NT-&\-X)M2>D[UB6 M\^21T_MSE'8-E./-)Y@I^E&DK2 M9;\*H=##)X)9L+5XQ'>(,_8Q>#*Y/2!/(1AJI>-D@%^3%#QX^5'STT?#^&U&9600[K%4T[ MA+]:BH,DV+%P.G^*SA\]6#/>\(>IT9!3GU!5RKEEIU+5*LSZ7<3.LL@E[ M9L+@L)*`:2MG54(LP`=DVQ1)=(!W:FL$K`\L*.87>,Q<+)E525`?I18X,SWZ M!A1TR17.(\=P`"0X!.;!=Q]TA82.!ND+9P3@,YEA<9NA.43J)!BFS$W@)&4C M4Y+YC^A273LQG2>[*IRQ;<8_ZB?3M?RGW#NC)=H,N,-\/_2-IBNND8MQQ'`I MZ^A"&KG4,&`F'\#;=T38-N8#&&PKW)HY0W/O^8R:2!23QEW9ZLW;ZESKC&XF M+.X,-MOH63GL')4GAT[A@W,!_"KD:`OP%,\.00])SQ@0D" MLV+98%(_J`0;`^+PKV-K`M0%OU1@/L_%%3XR:U(0$]G0*AHX,/IQJT@V4F_. ML9'KL(6!&)497)89)$GG.8QC33E^GW)!'JDUCGB0'/=EA9*_"&8XP@P'Q+Q= MG%KQ@B:X.I<*/^+QK#T`F@W&S"#F8D%%!W.Y>-9K&3B/N&6AF0JY.:4Y-`/Y MCH#:3]:Y]"7*/T7\KXPPS^7WV]:5^S/HR;H@56?D)^O;KH_HS-M3]/2?"E(Y(]/LLT M/R%GG;N+R[OJ>>?Z^O3V'B8U0";4]=@)Z?S]\N[+=>?7-D$S#J/M$8-9EN=2 M`X3^>4\+OKO4-*/OU.(#^_.>!0M-K$1$R_CY\NKKSRB!NON,J)7F'_$E`VU@H)`,)$!+YZY-_JC)/S-*=$*`KN[5^>EU M-!4(Q7=&8<-?PS4>:D#/$S?]X>>]`SW!V%"^&0@DI;[OFP4GKID@;AFT@4OK MLRHB@[5MYTE0-T;66:?;[7R+5TQT]YEXCL7-$,D?YLC'Q:L#"Q#WL'X`;WV& M'>@X3%D"'D3B"QA!)?^MIFW;L6U-IBP!7UAA>X=HVVYL1Z>0"4@W%+ZCS^*# M#IHEO=&W<^'L]/QO7^\ZO]Q<`"L,B);[_56P)L]G^S4=&;]#^)LE>L1-TV)K MM'?%D'%HD;J=VUQSM#9N"#X8EID=VBP_ZD>5QG&SW2/PKU1]BU2]$-M\^M&5,H)C>T.@OORSKA#HCGO?25\P MO+L)82SS?"*HSS:%BW<37TX;N3I9%],(KI#>'"M7TW3M6(FVV.0JQ56*JQ2W MA$A6BJL4-TNP!II[<*AD6[B@8KWW5?[N6-2?OE16IOBRG%:MB.%TH0]3WG90 M>J#5CG?CALB?2T>E4EBEL+,*VZAI1SLA6Z6P!2=7*>QK%+;5JM75#EN8<&&] M]R`NG_&]17PSB8E1Z8+'EKDI=2T.N M4E>EKK&ZAMDRMUV@[P@6]F6^H.1`'TQ<-,U5E9Q^5>.FOJPDT]:2EI].1:5A M)O&2Y:**TV@U:A]/I/4%TQE^83TQIF(2I\+\1B=ACDN>GX@3W]^G=I#L$#4N MG6_3&<%U!\:S'9]YN:DQ62`"]R3R=N"R0N<=-)H(,ASVF\N1N)$\NX$:? MJZ?3BG:DAZD"F2?1WL-Z%]!PHZJI5QJM5D4_:'Y4-8'V92XLF3O[8,,:V3Q0 M&EFNI7?2>6Z;E>4J3:-R!$ISF+74$0PJD1)GT^U6@NRA4:IG,Y$JF'OQSTM> M;+URV&A6])8^3\-3^9"3Z4U1T9:;M+?2.F[.%EUXHF!B+.IY6$S+Q!H=46IA M4"/,+F3L@TMJ#+ MA!O%RDVN'^PCX(!*4S"[E\39KNERT7Y8RZA$27X'-]4'$@#J5%9\2S$/NX#N.`:G^#19['4D/0CX#KR/[S9V:>O)B5.!Y?Q)_,>&7)CV+Z,3H,^;3_OI)G49&V MJ'3AM$FGCU:"V9[T@.]D@2;SW/%\3U:_.P-OU[RE$TS4[KV_@EI=55#[:`6U M9HU(L9..BY+R9E&]QGII>'19VI.BI2P>0LV.X3MA8%2O2./45&1Y0J/9#W<;;]H'V]3( M+[;)1/I'=&IEX$/'_M`1@&P9^`3%.%80L39:Z$$N*MV5-=AHV*,/$(4S@'GWZ@`.-8U[7@^RD%*4NQ179@TTK7C MMR-]3I\T\J'1)I#?K-05\+22XLFSNT'Y+)-Y<5VGY$TO"QS/*KX^ M-8,;4!M!3L./85P'(XSDK3+'KD)(;06G3<$I4M0[0*$3^+IRD$[T.2S6!JAB M&&IC("]O_\>7!M,ZPYA13G#Y=E=P#YVF&T^]S@X5?H'%"4RIA!4SXUWSD7M2#@]V`>`Q+VLLP"\OM MXK6GH1/)@(#6/\*PT8E"M-B`K$S]NOZ4=62$1Q:VXR.]%M[\\"%DGQX)9>-M MO#!&,V9-,'"/S$;0PPRK^$F^U>(IPIL0MD,PDA3A#,P.GHT.ZL7-=)>$`S.8 MH)8U(8^8!A!_ZC$P3NG["V!(!*%`U5A4<4@25*9/%(C*65RNL\Q@I(G$8"0] M,@K,_8*2=3D00/PP"XOB@33@1R;!GP%WP!Z$<2XB0S:`?EB59,!.RNIU! MO2&:Z#A$!VK<4`2QI*%]K!TSM["\S/E+*$8IB?`S_`5$A17P8KT>QUS+XT3: M/*C:S>M<>H!G+-%]J!_)'K+,=F"WD^E1=H5;CDI.+$5,)'"JT$Q4VC*@\GW+\E2`MD<&\'&C=5;IT?KCN@S[H]A-\*4 MLL$A/_Z.AF_(`29@AJD5[]WR]>_P20#8>8;TD3NB1JZ"S0!V83#FQ!Y'.\1T M>`_V_'Z?)7>W/(,9K2QCHW'["&Y\A/<4`AU#Q\(V!,.G#<`HFRS\G,\%F_3' MDM(`L8&#`U_E3438BST.R@&>B-QK$[.(X+Q7>B;R]-Z+?+2%%,0^H#_$U+VH M@#:J$<01H*GA&@@Z,>;L@7Q0V51Y_"6N^4E2U'^)72_01K"LX]$(8[K0BZ(C M>8\8P&R-Y;V]5UCH$(.X!4@4XMCH.6.J<1IX3O!/`&&,8@%Q+JS>2]>): M,^SHXN8ZY0E6-!YZT^^7N+TJ$&PY"&ZXK3"PLK?+B\0'9>W?H>AK5N.W%,%Y M2VG0.$@JF\#?S1"%AZW$@Q+XC@E<&0"%!^7F*3=/Q7.O4^S4VP]*T%LOZ(82 M]&X(6FGTC@AZ=S5ZZ[,YYOEF5[9\!BV^XT@,^#!PQ*3]#ARHW%-EJEQ=R)RV MA2KD76)T*&50RJ"402F#4@:E#$H9E#(H95BW,JPRG+P]O;BXNOE:O;[\(C/J M1!DF-EX7)"_$O&,>D^]8XX/1)GMDEN-BJ+DIL*BJ**LC=\G)C2.=C$K5.\,JIN:0O5VDKO+J-;U`P7K[21WIV'=:BA8ER8,6^^= MOJ]!`HHP4]N(VQQ?$L<4!RIJ+S:Y12I/^4%SN-X2-'7M>)/F4.%;X7O%^-[H MD8/"M\+W2O'=.E;X+@&Y"M_OQ+=>T38;L!41X04.V%97@SPO8+O'%'XR0Y@Q MI&*PL3"MB%']E-RW/8"]M:7HW\N0`IY\O=.4Z@>Z.OM26J*TY.4G=5KZ;MP* M4&JBU$1M)DI+E):HS60;PM="'&3DA:I=K.WW8N)3=SE\< MCJS@:?K7/J_Q1CX5^(QPF<_>ZY5F,6X"*652RE1V9:HW"Z%*:I_:/#J4:BU[ MGSHZ;"GE4LJEE&L5RE77-OH\>Q&5*QF(3TN,1P-]L(!$7/%BR84I\L?=5)6/ M>,ZWU?5X75D/\L:AUE>;IJ"%:')YL?"3K%26*!T8%"^1!6QD+;&P;!\6L7_D M_J0XY67>@X^UK#TP6ZIDS!J3NR5W@^;A=N153A&X[#2%117>MM&6DEM]RXA; MMN"4TI48F$IXY56$M%V^$(<>XH/O`[^G[TG[6T<.?9[@/P'PB]!9@#9RT/G M3'8!C>V9]7O>L6%[=Y!/@S;9LIBE2(6'/!FUT<#5I*^RW42`"-/+HC@%?(8G-IE^/"73JV[Q+=#XB5P/I$W8F@9:U@ M.V89%&&&"#.:3>2JI7-?QRG5B<6;"OTR;_!Q3%SJ-9"I!5G%J6EEC'W]@[JZ MZ:7RU/>NJ8L@IXGUW!^RSXXZH*?;` M:@]NG6QWHS8(M):B]5I:KR](7F]PZV3.&\7AARR(;`ZU3TR6Q6[!<=/WQ*17 ML/.QL'.-0Z]];WY-35=L?=7F!-PZYBEV?P)NO?<65-'^=@P24D.5<2P2HF@7 M2O,DI)G1WS$I!+&7<>H<<`(:0(C$:8I$3<:L['WYRX=CD!J> MO]QHZ1);G/4'MXYJY!C%(R<*4`\X]^6H^*4>"D.8G9K(5;^KM@9]X='5+[0^ M2)\B.V>\5J%U(]-O.U6^.QE9EUYQG3!6XTVLS=&8M\DU:`UZ$&!W#E;$6\83EJ5RR^BI&V,TS M/GN*L'_R,>9,OJ;O@<\17BYOKXXOED MDC-B/UXZDRFQ9QP9?57I??0DW9E,'!L6X.A_XG5_RUU3Q+7_F(/^'ZU_>-0U M1_]88,TS[K^%VXX1PB5XU6*6XJ)Q1&DP/PT])/,B$5II%I'&!+C)=JGNO-CF M?X&U@$^FU/:(;P()=EM;.KC#(3TQY3JOH?+C\&4 MG%?`")'>PN/,)<)/,9>FL!K'6`3+?W,D8L-U@#!K),WPP#3!S?M<>H5LE0%^ M=3$!_J+N*S"+QXX]Q=M,?TZQ`B]*HP!Y$32V%Q`;E#+QX&?+B#?+NY>OH5;P"/L6@MS#.* M5A,C>?KC`PE$WY$O_/WV&,%)^]V>/\(*]&!'\C4`__M#AR[S[=WWSY(KZ9G MPA//))U:%A["!V;]YS.9?Y\2PXB^%ZVG\6=G=XN'>VUWB&%MCB@\LK/!Q?&; M$?1J3F@9GHX=(^$AM!\G2^BCW[K-4V"//."*_.6D1KIQ*0>1[V[J.)B#G8B4 MIQ8/7ZA<1Y:HB6[<7:UIGFX`9JY:E(;=!2._(A1P_4D>8U49'[=1^_$9?I MP\;9RF;JNCJZ!J5 MWH-\ZC/^__%=D@Y8A"\/=/3SV;VL?(?_X>[RDR,/OFLR^WPFF0;0B^B^:7S7 MSGZ98Y=D:]''[45.,4XL:8ZL+?Y#2WI$XDK5[YNN4ZI5]?YPZ(\J;T8=E M.]N,?KB'?X]^A.TS7EAD_/AY/SWO2*Z;O&>_BQHX$[>ZS`E*#C-YO,;'M(FM MF^C\`:4H$TVX4K<"@[(D(>%RZ,V5P+&B':S2>!L[EC63G#)99(+:6C!6LP7 MVQR9.@3H?-EZ]-9H-7@WW`&J1N<;0&/R"BJ24ENBECD!J``Z_C`R"0&P&0"Y M$./CC%B/I9_F.I@P945:>+=-T47VI;\IF$62Z`^=@KI@CC-[R)2ZX3?`+Q&5 M3'7G<4,:4Y?"JQ**3UTZ!0(:TO,LS?$M<(_\,5A7B02&Z;>D:>!B(9(?L88; M6)1SDDM?`HO$A7SXQT>J!Z[IF^$5US_T,;%?V,,GIN?!I2W)<:7'Z\L+Z88S MJC,U;:P5+*D]!;22%P80R!.RNO%O$"0.X#O$@>FA!<5'<`\3*_4"UV63I))K M6_BS16`9*'-LW5P^;<<^S[WC/0B"3CV/N#,$?\I5O30BIHO*('`QB`PLKC8< M$(H0&[@=@<#X8Y=2:0(4'7.$V*8=?Z=,X!8KQ]B%N&G18F_0B3>61EC^%3]V MK:>P#_B@A#^FCF>R^DQ24+R68I,),>B%A$Q7#*H7Z..8)WD))(`+RL%V_!B# M)F#,M`V&^=>XU#A\$J`]>CS@^9F&59>\.I/KLP`(CW630MGL<>F7U/4)W&3: M(Q0LSC1S1H2+'*-NJ&M,+ME`?>I%:H/8=@"LEZND$FX#83;`L89G`-F=B>DS M%H"X$)_AK:'XP":"#74Q!+!FK77O!MOF!):!C.A2P@"">_X=V,P*,PV9;"TR M/L:0,H2'FY.4+1:%#,?^_SN00QU'19@>VO'.&T1X^PGQ@$ZH9Z. M*27"F\.[?MQMXYH8:%/@]*%,H<8V_1G75B264&SU@3NFZ,6]4!O,+^IN^#MZ M`;'N_MUF.NW19Q+JTO\$)NKZQ!-#O3XA?]*XD8*K-_"N@DE8K.:/"7B1HQ$8 M@G?$#YG%R]T5GAL,P`6PW MLER.ET+3T>C^K!:?U_&7X+8.;0/_=0W,\THL1/ZVZ:V.4/W[4?U(-R8$[$.* M@L(&'-X&1,DI%OJ";O!XD$@3*H51%+BQKG^.;9^@U['UCML'IIB9TTU`A_L8 ML<\B]8F[,:@((>R'V-T+56DJC`7''$P'JE&7>\<8V,%*7B%4P`84]+(=OB#D M'_X:C"#2V2X+U*R%C\;N5&[,7-/[$Q;AN^9SP!4?1MS@+8/>!_W*$PG,MC$W M'K-3+M.GG$73P/.5H?N/RMUG;8A1:U^J+\]C@3Q@P/V3^KQ/EAN',*6`EG+" M`U=8*8!/9]'%48+N:)3Y2NIZ7L<_N<2@<-<=,(X;Q@#>`\3[<#^\@=^]MH[O M"AV_'QT?44Q*2":T^V&7'I/$C4D2>Z>HU9@;:X2Z&G37B.C)!:B6);9]@-VB MV#MZ(=V[#C8&1IDZK&7P1X&5VF%P::H7^IFPW(O-?&S/8XY^Z$N#VGQFZ\'F M0\H3(?-QN7ZC@LJ^V:$-B&\3GHC MF>D$W'8%=O0B?.F[*=]0!7OBL;1BG)Q$BT!8KH=UR[)HAVW'$`P[X)G>^Y9D MPDNBC,Z;BVDEC)Y@$2\$#!.W?"FL%37U,H"N@#3\5Z45YFE385$*#MM)GEF` M?80\#*Z,H[$E*YF%>5L"C`H1E3_#PGP?;D8K-$6,;ALR]!IA3E;0'36W)A$! M^<9/1+W#&Y03'PN3(0N-R)+K(O,$#N[ITBG\S606(1D5@UO76/9V;K'M)^J/ M<=+%:]AED]B0P*.HXRSSE<;[@M$,$)ZZ::423SRV`)7O8>8EFHRQ(KZ;HQ-7 M56_S:I'IT,O`=>'2(4/>YIJP+S3AGC0AG1(3=[_#_"'*%2.D%%)2XJ04RO'@ MRI%3*O%3]9!`48YY+4
#(()9IJ7JE]<1SC MS;0LT(,WMD_L%W3Q^3W1GS;,'0R$BMN+BLN]IHIJX8C^0C4>6#7>I/+%<&^4 M#N8#WHAM\E0L%@9ZL9?'>JZM&3J,++/*1P]B519--&IVEX[HX`A%U4@9G]23 M7D)>B#86X4WX!U9(`JH5(VH3UF*ZN$J64X@2XKB/R?Y"C5;R&/9_J02`@2D) M\#Q3:^4SVF`)+O6F#C^+,'F'9#F>ETR!6Q:QUY"JC69(M+$JGZO&^F_8+L?C M_:_2KXZ%E/*D>XAS;L%BI8L',?-T/G;>>-WJ&*?T6>:SRXMWWR@6M.H\`<,R M2=(S1CS(U,#HSUA@&U?\8,8J'K`9\W:E$PM[+:67G!D?D>="BM1BM#W/4WZ5 MOUYK#=3!PNO#+!473%:WF>2[,J@.2SE;F/F*I0X3=BQ9%TGDFDZ5$+*]"YDR M+V1)A;MT:TZP,B1#]RGQX_JVNDM8O]7IMP\I85U-:Y:$[<3/:UAPLW+$LD:H M,_]]PY!'D47,LY^T#M=RS8A,-@CI2JS6_B%4MP^^[B.K5);J!C7O^FQP=36) M[M`4[MEIJ01?AW);*EG\=H[+BD[*A13QU&Z=A/8@QT5(]>K%CL(3:VN8IAC] MF;(6IIBK([:%"#=FUQ%K3'*"EW'B"ZBRVCV:5.3:1G?>:B=]W.E.;SZTGCTT M'".'NSD;VVVE$79[)>FLN>5FP__.&3VE-$'K8.B:J[?1X^?GJ??\6E8\0- MH=*[X>/E>ZFG]%M2S&)\=N0"X["_166E28<$)=BR$%5.+1Z'@>!A$RMKG\Z" M*)$WMB+B9_*G=B9CRN9;AOVW+!$9M8(LOBKV6=CJ/#!_$HX\PI->PH,JWOFS M*8#.-^(AY*9>JK?A/5\K7U/Y4Y8^X!77.9F_$/RH?WV.M;52UFV_TP$I)?:63,E)7L()7UEKO MI:U3_'<$]%=JO$23X]F/O%9O0EW\6;KQ/#`W3\3[4_KLN/"BQZAI3I)[YYT/ MZ9?Q(E>\Z]N8LLH)8DLW-H3.`;OA'2#Y&B(+`X/N4##>PQO@&H/^X&8$[K@& MS/A95-Z]V7Q::LL:XZ4G8 M6N8:`9MN#RLU9O,!58H[MS9[S1AQU7RS]QF9_H]H$R;E9B?MM[=)^VW*2O!/ M'25E.1+ZIY1$0U*I)V(?P\#%XXW3F?*-I(VZH/4ZIP7CRW!X'^EM@XXPEY9Z M:@O3J*![3&^,]9'2R"43^N:X_`0TOI1L&4DK#'G",$L/!Y.D!Y&09QQ;E%IZ M*A83I^WM<^E(_!RJHYEE*?1H+!0_=92UH[XE`U>P422<_$-X)Y*/7:>LB!*G MR>`\M!$[?S&QV.\(%B.9/G_D^RA!&\XZ`,Y%MF*)?^,5#!QYH4[@1=VA0;+-5_XSU([!E3`MX`OBHU@RV="\#P_8))!43_GI/E M_PR2QB9UB:N/9PNY!821.4Q\^,(/GMB`E)B82Z=:U!`S MC2>JN@Y165(5M(!%W%(CGJ$[DCTEV;B_E&@-0?&]4UPKI_@\K=(Z7E#K0&ZU MX5#>L(R&UTC"H,2G-I.`"`WFF!HO;/YAZ-6&PS3.<01D*_(V\+@KQZ7FBWW. M.U;T&1N@X5U(OSIOP"SN_/G#."G2YY71;#Y'Z#_G+R,<@L%ZJ"%69OD6XF6F M?%@.>",VF_#'_'V#^@2\.MX@GCK1>"%-$Y]KS%MC%K-E2Y_$K@H3.2EVIR;+ M0YGO&;K):,13.^@\@<>4'?S9DDRXCDZ>'2-$'+M)MRA!/X_!#V$%'MV=.KY\ MC`YD"B^H'_$YHI;R615EG>D+GJ(LVC//H-ME\9-X&%B2@=8 M39Z72O%,2ENWLIM$0KP/)-[)]+.$&%$Q4$;@/2GP@7;_1<^::?,$`5IH9?F8 MU>C)@1?&XK]A@DRZ!,9T4N-R?*J/;?,_/*B"N(?Q,AN#9EE)UVVT[9<>R_:. MS^EDU4XN8?]^=7".+P8\."-W0GAFE\T-8I$&'Q$4:Q_F4[2P3LK\DT;?6'B. M,WQ&&!NPT3QSXW-3,8X_+P2"@?>X]'!H6S;(8UR[S$"UI(1Y+A).`(&X;)[00_>3?QC>F5[ M"ZEWXNCE2,ZR\L/&;>7\A<_%I@2ITEI;J"^G11*.ZU,/` M=9M8-,#'/G(R>$`L^"L.\HH,CY_)O2$0\'QG0GD7%=AMBX]U-+T8^YVIP$B5<[T=5;-EG;VXIS2!!)2[$\Y@ M8>9L2ETV@QVU_`2,#@1%-L\=0\QB8Z-KLGYNK8)IF(>&<,J$IZ:G><5#NU*/ MX@G[>`0PF4X!1CZ"[`5\.N&G'9+528';!>%4"?#)'#[B)PY4HVV7 MV"'"HZI"1X!E#XP+K.*P4W=$1^-,`LO'4=$2M:+IR>FTPLBQV,$46([2E3OG M:KHBY;?HWFM^KS3$^)TWM65J5.9V.=(OP+E`8&2]$8^D^?O07WJFF/^(40$^ M953/P5NS][S),*^3U['`(3\4'SW'':&,H>?'^^$R5GY-M+KXC$/DLF6^4GQ6 MGIP^'3`Y+W3^T#W?F:8NBT\%_'9S]?0K8JD':$J:`7-/$(ROC2Z-")8(B+!D4>W58#LRGD_# M^4M+C@44)*R`A$/,BMBY1'3B2))7"6"F#+76*VY;\8@J"6=8V9N@Y`$I><5I M.&/;^BF_!H+)>,PH$A(=G]`;R:NZC%J[>*7`;$&^TW.N64\8G_#O!ZY]L2G] M-W0WFN!B1"ER]"JQ2@+;!*+>B[@J(S/T)9H\RSU0GJT.$_JA91;^XAZ7_BGK M]K/AMY&GSTEGLA,J+(L\.V'R+''MLZY=2/`<5N!#?QT^)G[Q@;C-8>-,^M!% M"V<'HWY.)A6$0I_N89PE^:F8B5)=+O_E_!4Y?*Q6A6^N+#BSQY)B6IHX6LPT M\5!@:!M722`0CB'M M\'64I".&^;PP[^$[7BX7^+,B!6V'D2II5"WX58(Q+TZ/U@.E`[? MJ'-T/0!5K?-[`KY_%Q]:E,TOQ4<9E60+/)XI6%&-UI!031]@<.\ZS+&*&8X! MA/^D]8'T[N;^(?[+U?NHG,NET?&D.IF:/K&8R62;-E.+^C0A?6B-0_\X<]IQ M-`(AF@^0-P4!]YIX00@O(\ML*(7EGJDC"M(3_E@/:VK+D3-IMMB<9ZKFEVHF M\Y$XDT9M_'$Y8N0.I`YA?`:11-?%&U/*3HL9LZU#5BH\Y<=,XJPIU[!"?_8M M[&7BV]/ADZ,3;$`\<2N+[ZT%K(LH\,*S42-'.(WZU#@&WGH6U33C\EFN%:*4 MQBMJ20MFP3%![\#$+MV%&:MU#4*9;&,&'/ M9IA3GAI0YG=T([V`);-Q;D3Z72/>`Q5>G'4S,TBA`'Q3%^P2)$/MP@G]@948I1GYTL MB:QL`5O[\>A)MD6\ZV&$S[.B46FXO+_%DP)3B\E"L]L9)9V6TE4J&&3&=I"S M"\\<\=&,J8&-'L#3@+F!Q<+PMWB@7R0(RGX%H==2^YW&"D*3HN&EP>U\/'Q- M7+0OWCUU61?KUG47S3B:K/FQ\%\W.C=K>-Y[S%AA&8>JX$9*454?&"- MCR0**\+>63&)HH+M,8L*O.0\,7OA*5@/5VRMUT138`=-C?+!- M_%"/A M4&P%N.)%V%@2DW>F)O44E^G0Y#$YK1D@O)M2GCWEMA#]69>.L:R.-4SCH]># M3%L',HV;[30X;-`Y$C2F)"L:(9.XAY.C(>?:9ZH3+/AD,XY8X3XOH03%%U7P MM]*G.7.R\HK/>(3#_?P(!^X.P$U\C,8KC6H\,;W-@B2,3P(_8H>A" M5.FI@-C+X*S@".(Y9R5<]FB1PZ)!490+7`&C5;K*KM92.IV6IBFEBTP8>^D: MC\8'6N+0S/L_@/)DXMF]Z]CP4>=:IZ(15.)PO7UM#NBL@BJ97Y'XKVR&IU(;1@0YL%*DUD643%< MN.&*Z2A6T``!9;1'S_80^`DJ>C`)>&5?>(95QGV(/)/AW>7->VZU)1M MW*[@Q;X1!,Y^TD$)W@=NA3!S:O(TZ`*>DK%,*:\,?D]>5?`B]*ZFP3/HPQ@- MK="3**8,:SL7EW[@-+R&UAYL7)D7LR(]^2^?)SU;$?$Q4U'UI/"GI$)XY!K7"/+:Z<3MJHJ4LCRV3:W)E/AN`7/)$/PX^W MB[`++9HTXT7EX&+`R[*E\P+-6SJ"YV:]*/2APJ++N3+/Q;K3Q/\%)6>S#UZ$?I[H_KA\^W=]\^2#A;$IZVO."46.:+_?.9!0O- M*SC]]?KFRZ](`77Z(Z_2-`6KI+/Q`U'(]_2O6UB;C76?5A9_DL\0B%;790B4 M`):[AP_2_\CL/PM!XT=IONX5B.([D_#";^$:>W)20-M5_I[10CDL4%S+6D?@ MVBG@JH`-[+5/SY$SZ`?;>7/)-.:LJ&`Y7+&D3'](S&"'G+PU1K8GKP(H0+Z' M]0/SJ@OH^-_`I@E*U&XK]064H*#_4<-V[+QMS1*4@'/N$8#MNWHZ"UA1+ M:X*_%SM6-G/0+.:-KH^%3\/+__ORE=97&,L.)\+X0]2,2]5J8^79+4^566Y4;RQS'&P*- MV'_V%0(]Q!,WV=XM]5B?$ST47VP,?#-UY.YH74\EN$-X<[3H,K M!%<(KA#V"BOWNJ_P1'P?0N/BRF5JMCN%TK9,I MZR5*N_+%X#0V1/[>."B%P`J!7118[4+NGP1MA<#6'%PAL*L(;*=SH0H+6YMP M8;][$#B#A?>`47?2N."QF?JLCK'R\>1!.KQM4A"WWN`*T16B*T2WD;PL1%>( MKA!=L?V0'T]05S>]\&3AQD65S51M>PVB_W8B>1'Y0CF-K$B#^5>(JQ!7(:Z- M`5>(JQ#76%S5SDD0=(-@8>[40F/KP47QT+.*!R+E/[>A(]TV'LE6/-OM>C*U MG!FEC_RD*#;VE9WSAP/XJ.VQN5Q#?CP4?+H;/<3GY=VST7V7>+#3%K/?!F+V MVWZ&D'V.1[29'AX^'$PF.$TT/!`G/+TB/&V,G0+!IFN?\Q'K>HH;HM.-XH,O M=)T/:\1G9^8K>IDIY$X\A?S`IV>GL!>-(.-3.F(Q]7S7L5^B;\LP.W^X=@:P M[*/$N+?C&_?6.;:Q0;V*W=UFCPU2M?38H,X".IYPFGV"D]_860C)]VL<@2R8 MX,B9X*MI"Q[8V29#G?`@M/T&@KYG,5YG%L(Z$^+BHS^:1O"-$2+XX2CY01#\ MQ`@N%(#@!^'F"3=/Q'.K"79T**,@]&D0NHF3G06AA40+0@N)KMX1JWD)0YYO M%A[G'>\X2CI\>''O#T\+\1\H!XEKCYFQY<; M])5:SA1#S4,QBVB.WQVX%?>X1'S^P%_>J0V?YZE!K=^"IY\$F057GPQ7MV7! MU<<)[BESM:)T!5L?)[@GS=8=3;!U8\*P_>[T?:$V=8G%HC!B3$S;]'SL*WP5 MHWQJ#FZ=II1MJ0[W.XE`E0>'5(>"OP5_[YB_#YIR$/PM^'NG_-T9"/YN`+B" MOS<]GZ$E'S9@JR.'USA@V]THVKR`[9&^0L!FZU32Q\1]$8='YX*[7@'VT4XD MWA0A-6B@/`PG>,;WUP8TT\U3A'6&7MO=)J MUV,32`B3$*:F"Y/:KH4H"3MU>.X0HE6UG>KW.D*XA'`)X=J%<*GR0>O9ZRA< MXMB=^AR[4_%I.<7'\N0_F9WZ$(+.Z4'^,>3.-TE$M*]/F?H;(*3O:R= MZV9Q+LX>)]BE35Z[=QS#HS,`5CV+L:[$.S;8,G13CPRXJ@DGA*[!C"F(UUS! MJQ-LO27!^A"K>E]2IUX]T`DQ;7!J&@BLT*#'RZB-!JXNQ1QUPD,E@46=@#MF MZ3P9$RF"BM,VB;6&+XV[INV9>H*+/X@5;-*,>6ABUR78JD?U_5KQUUW@>SZQL71.(KYT174Z>::N MI"D;'_I:A>O,&%TFDLKYR(:#3.6#1:(KJM=D=IM=M*X_BD MH6.B:COE."\R_>(2&ZMI#L0;]1XL5Q]P]VXA=N=)[Y#DQ;6,8DI>[<&M\3$& M@L6/A>8G)M'5G'9_D+FF@KZU![=.&KL>\`IV;G[\M=^=P:C.YV`1F,CG'EP8 M&K>7T3#WM#DT/S&)%BQ^>C0_,8FNQF7=[[F(@KY-`;=.&KL>\`IV;GX$MM\= ML,^..Z*FV`.K/;AULMV-VB#06HK6:VF]OB!YO<&MDSEO%(#_T/H@?8KLG/%:A=:-3+_M5/GN9&1=>L5UPEB--[$V1V/>)M>@->A! M@-TY6!%O';.<#16T[3GD"-R<>LF7&*E:?W#KJ$B.4CYRX@#E0A-S587E$9:G MBRBB(6FSXYK4/?G,UA%=*0,+N:#(LM_ M_RBQ:\XM,G,"_\/(_$&-CV>23BT+3YPQ[1=V'WZ?$L,(O\?/=^-/1O3II_1' M-_D8K?B?/P7>^0LATP^/^I@:@47O1NS$ND_$H\:E,YE2VR.^Z=B/OJ/_>3?% MC]Y0]\U7TY\]X6.>Z`__DP5__.6O?_GK7R3IGV0Z?DX]#AXR"6^_)%/3)Q8_ M$N^!>M1]I<9GQ_T<^(%+;SPO(+9.LT^5=,?VX2:?Q\]IG`LHSOJG+V2TC0",._#1^^W`!#`)?`/Z$H M>T#>:_$?6M(C=WD&6 MC5=FVOR?J7^6STD'>/\(,!^]<^Y9[**A)SFCG$1+2_+'5$+F(?9,&A-#,D@#%'V4OMUQ#\8^HTSNXN!S/ MG)T\%:D-6FI'/F1'3W!%[;1AM8:QMT0;/CD^L:+\N[MY/J7FH-=2-=;1):CAKO=>R\J7I2`5 M66[U(."6>YI@FY4VOK??88JWLBO>(,M_[O(OR5Y5W7;MJ]UCCW;NHUJ`3X%G MVM3SX+'/ILVV_R\=VS,!!>S+$_C5WHBZ+C64@OUYYX_*7?Z0-[RTDUPSH0[`!Z-06]^OUQ.O[5L9#PWKT_N_77AUXKA;ZG]-3* MH/_B.,:;:5E9R(;>G5TI/=NE$&E=3\Z.OP!M0%Q]?'0-J[H*[6N#"4JC';P/5#YX%EN($/A/]N]$U<6T&$'69D1A.G,#V"Q29 MEBJSTK*0]5.0\;`B#=S-U\]GOW0UI=/1-"6!KY*U[@,!O>4(&"Q'@-*1U3XH M,WG'&`!6GU+7GV%JWP=&OP:.9&Q^[8&+"=QM_.[140!:XY5Z:U?4:<"I_MBE M5/(=R0,9LJ49B)27`+76^^<7_]D$+%+\DY'#_J7Z\!X>;?M>6BI+GO9I]AOY MM^,R*5^05$TIE=3V(&N0RA>]2!_*S2U3+=PW&P;^V''-_U*C!$3M.]8A4N\3 MV.]7P#"^)?NP]=6WIJ[`N+(,H4!?3I.X#(1,[6?VTAMXE0D.*:[-^(-8`8UX M>=]PSWE1WX%EO[.%I,%7`?B+MARZV*N"4D[P>^+>N35`0'M%!,@7LE)$^2)8 MYC%P19_]&]OSW8"M*X'B:X#K!LT&.L*?)9<4Z24MY4OO!"MIYVX:9)$AHR@D MJ%@?J'+&N#)?P2FWC0=8*"`2=VC)"ST4(KHEB%"0*PJ9(A^.C%(H1-W-R.1B M=1\\6Z9^-X+G@L5CWALU0+>#2KVEQ/.7.2J[14Z)(W?>!:>7)V="M5$5L-F2 M>J:"(("GQE7`[H)['8.KXJ_TC?W)*PI)=XZ@%?S!]H#])TI?K`9/!@?1GM[B M;9$$1E>LA(:T!#L^]>[)#!,C=S;-(`",G/]$W0F2]6DVI3PVJ!Z%JWB4P5W?>5: MGL#LJP.UUZL,VG#5F"B(/$+NXW"FV3FE=R$DO16X<7#EK MVG[A*_`=STI@7MFQ,2FQ"$IY\K,[4'K[`&4;);`[)$;6#@8Z_7UB)-X_)*;+0L2A\>^`*ZK])1*R\)9[>SC[NS_#6RJ=O%/ MG()I.H:!;GC+G?N`->.+-&POIZ':UW"_8[GBW6>2?Q$5UDSI;(6*SL'3_95@ MXHKJ#'95VPH;JWAK\(:VNCP/6X2-17L&MT[XK(D'T_OSLTOI#8X.@3`"M[4/ M)2.]DDWY+BO5D&5%'N09Z'*`]HR(K26D?Q2(J$A`!JL@H]O;#3*N?TRICO4_ MC@5F".W/`06D)Y>@HHW%7%UYT"Y'1#Y`>T?%MB+24Y:B0I/[#4!%-4+24Y>A MH]-1=\X9&)8<2C2TLU_N._]:#4)P$ME128I5=D"J) MU5TKO;(R&+N%NR)BKIYL4SNU@;T"Q;->2FUMN-W0L$?MO:E$@(K0KT*IC*H;0;"^O):`K4! M]"L&RZAY00Y`$9N\I7(_;;!]Y>R72#7A<*_EM8\+"ZT8P'JPA9I%2[]F:-D( MPAV4F/3!(43M7D<<%63ZUTOS]\$S_$R?W0#0*?ECUPE>QM)O9+9;@%?,G%6M M"U9)&6J=CM*M5_*T-L*P0I)1D^6VK`PZM4)@-9*R0@5?3]9DK=^K&?!;;ASU M5^E3V3*W7&GY>-5J8["R"]5>[EXKJ,NMR[J(6*_&HC:25+(OSBJ%VT6=%PNU&9DK(NPMMF>L5*I0?7IDL&3X M3;_3Z2V(1S$4&:!3G%O0D[+PP$-A84GQ84]K*YUHMWL#L(K+,[\0T\847_1] M[9KV04G_".L14A9*VHO>/;_*^8(/P.,3!37C@@@^.0#OA-BQ`CH4YC>_!?>,$KJ"%4N/XEK'$&+)`CR"6U-X-^Z=('O;F*UY7> M7M&2$Y6<77)Y?9XJ0XRW_9J'NHZM3![0BL(MZ`50_S(`=3[?_<;GT%J%3D\CZ'_L;+`]LW)::!&S.V1P'[=_Z8NGP>S/I8+&],:+>S MZUSAW94LMQ"IY?5LZJ"W[7(WQ6.YG04\STW?VF81A=A98N;D;E=>?1&%@Y9R M)R45(J:\_U%1^]H.VW*!4L^34?*QP2-<7U_%RVF&*$*LLJ=CN9;5*P?LV7E81\I0E8\+F'+\5 ME[4^WRGE-J+7Z69'@FXQ0',>`TO*EU=]E@;LMM+3V4 M;/4U5+CX0@R7VY&VW`M17-7BHT3()HA>TBXLA[RY[(V;KZP0B^5&1.GV>[E8 M+%Q:#D-_=6Q];6DNMR.JIG6[10*4O&_#114BJ]S*=.7>G"I?=U%KX*?P`EB*4+QDQ'#7^509**FF^7I94T988EO[<@0/S;UI_)84X*[<2 M2E_MK+62H6&P?7%BW1/3N+'#XS+60,VRDPM4>4YR"UZY\5VXASK0O<0@T/4N^6"F6R/'U/;:A&>YEK'V&AE(V;)*E M8N6LD[S:.G:W^N]?J$U=8F%.P)B8MNGY+@LGPF=D)S#ISH3&I1^W#M_\7=A- M5I8,GU3DCE8O).2?*+,5"LHM9/V!WPSJ974$!Z=[MI)B!W1?DEJ^GM,Z*-@,]G+/2:M"`/(O'N*FT0M;WJ=9%$V343D_-LDGE8%>-UR^\EMOFE>\YQ4L%_M\N,+S"N,D*49L#>6XRKF@X M0@KR-7L?=H&[%<97SN?]U@*L:K[[[+@C:N*H_9@$!\.=MAQWFJ+UM%Z_.N[+ M@;]J%"=]YX='\2J3.2M5G#G`'\`D[1BK*W3LJVJG#]I!;9!)"G4.B8_!W#M> M5^CD5P:#GMKI5*@1%L#>(;]^H]B(18WA*X02+W3UV4Z[P/8:$^0'.V'C,FRL M301O+;=C=4+L45FO-&U+7L\9JPXME5,D>GJ]B;+2F(6*B;(69BJG2XZ+5$?* M]-88V+"._JH8/3L0FP4/JY;D676$A*)=*-4*SUKXJ8VUWS$YUCAVM0'6?G6? MKE9$T`Y"A!6QD4N$Y^6O?5Z;]@]T0DPL$[O$$4B`G/]O[WN;VT9RO-]?U7T' M/KG9W:1*\HCZ2R6[4^78SHSO,K'/\>P\\[R9HL6VS1V*U)*4'<^G?P!T-]FD MR"8ED;*<:.]V8UL4&T!W`V@T\,/2]A"/IAYF91L3@TC$T]_,G_O#TYS<=RN` M_9V#]@T&(B;WO\(Y*-]^9234Z[W3QAR,80[,WX8_CQN<@@WX;]$HG\-(KA^Y ML\I4^E8$K+_PL\;]J=5.S"C+=XMK/#N0N7,)ZR\4K3Y(.&];6V&\L34LT0GY M+<'Q@^UZ.!R<0^CPOG,!UP"['DS[N4YL;7&_4J%2A'RD;(-=2\NJ<7TYL*QI M;SA2^K)7<:&IRQ'U#%Q<>%D=/C`'I/5AB4=6B;*V0=R*B2Y+=NXC.^#$$?5ZK?KQ^#Z/EA&H$N/ M?>>3ZW--=P[ZPZ?*=,_.*#S\_9,]7X5)->M@=U-E5QNF,&%VGZ1Y?>^&,6/^ MQA*MTS*PU_NF1/K(O(?-EV@-@'#>-G>G`LW4!RY"H(=&@)\]1D,!Z_,@C-T_ MZ>^EP&!K&`[]P6"4ZX_<%(&[8[RLJBZ/%)[/$IX,=L*X`J&5!T!2AE1?K=TC M`H9+W02:$=X__6S_*PC)KU[=(WGL[XH2EO4Y:4,6*O)SD[+0%X-,!PV+0G'Q M+^WP(J2\60X%#*X#J9'Z>WP-N.Z>67C,**.A$;++=F@>,7LG9*]CD7+DUL@J M&PY7;(IF[*W(+)5J'>>L63)Y:N<:DJR3\61-3+!-T^)CL3KNQN252K"&[X#( M'8/1:-S?GKR:89HO5^!_SP89*U`R;C;D5=^?NU7P#\/+=$UUBJ M%3C5W>&8%.%S4*T3=04ZRGB84]]K$ZW&-R]N3P6N]0D"F3J^I002.ZGP`^R)GWCY5,!1-T=C?K# MG/NEI:`1>G6"U-N,5?/<(KEU%J'>8H!A'IK]7=.K$V]%RYP5D[P>N;RASL:' MF`J!OS$Q=19:Q6%E:$U.C$TU51YQ^ M#HI?2XR$KI9WI^_MR)VMOWKRV-2EE[G=WM%DK&3@%0V_#8T:P>41JW6%:/T6 M2*RQTO*PU3HQ#JMX7`X,B?]/6"ISAZHD1XPG9HP3;WI'G&DFZ1:&04KM_5; ML93?;J>NMXQ+(<-TTU$+H*-:LPL"MJ-3)^1:F!4\G6C2$IDU5G<>>WE3#=\( MG1IQYN&1FQ5GR=(63U?DF]19M:,:$'6U-7T96>UPI9N4.N!QX,GWX.A3K>UW MPU:=/5'#+-?6^+OE2C=9-4SS`'3^M->SAHVQM58GDGZ.XJK.VM-9*C:^B9C1F10I*"[LA#UW? MW&[06^7V>&A@-]2^.FR8]&9W0Q[^<&=L-+0;\OB`FUUK4#?L$E1U*H22_;'7 M0HK/45J1)SF:#M/.W&O1TBX73>[W/'+=ZFK;.^ZWUQ23BCP<:S^GO6$]4]'5 M<23ZO^^=&)K24Y5>1SN<<]_\V99^C3@]*(6AB:A%&[#1M@2:5'TU"@PK5D&% M$)*,+N=?RR@FC-OKH&07%^.573&8T^YW^*X-D/S$;8VO5/9!5@;OWQ8+3V^JM#Z7-*H$EC M5`'U]K5);GOC4H$'][4)K%ECD<>C^T9V:R/:/P^*M_N%IXOI?F*/],D&61%3 M_?%CL(+%6H>,UFAO5/G6/@D\,\\-J,V*BN/A7LUQPUJOHF)M,MXKYIO25[6] MU2;YY5<+.U_=-;`,^\.:BBS'PCH3G:KPBUM%PW]F,W@R=C?0SH,*Z,.:TUA) MV,ZY;%"/#RKP%_.M7UZ6G+;>'8,*_,>7*YI&S<2@`HCRY8JI&8,RJ,#`W+%\ MN);>/U54H[1DU#/'/ M9@W"V^*U@2FO=$CW@,V&34IE;N_SLYREN`+6="\H;E)?5\"B"M>Q89YS)XS= M,UVC.F%4BZIH"[?H&R:=;D5P#[CJ>B0/A%"*H\:6E0`1,\Z=5, MP]\[-AM5*!60Q?V7*J/M]4D%3++Y4G=)P^JD`I=Y;$U>JIP:\MTJ,*!W)YN: ML8B=.S49N.D29Q_AYL=FKU_'V]]#:36@C6K@W`@9U:JMV0LAM6;6^C6"G%W3 MLJ8#ZX4*JX$55:N5'HJHX055)PA/GXEFX56%;)I3904XN%D`2;0.03OAJ-%] MT7`4@NUF`2;1_(FG(6:N/!]^6'+@V?_ M(-]&#D)W/O,>J9'):_OH6,=_H806] M9SBN>1&94M$2X8U.WO9!RO;YW7[SYOM/Y.^$^NMF4[3&:[-6;*CW\\SA9+A' MJ[H16S705K90-+LUXLKI*"]NAN=,)J@XD^.]?;[\U\PXX]9K99>Y/O`++'C#=D M;D;KE;`TSS%78[M:V#5B8?V^-5Z#:TY_FVPWJ,7J=!U99\HUS-?M4]`L?WKG M:9+K$KA*Z):L-+!"*[(!K?ZH718:5JCZ,-1@W!N/6V:H*459T1!S8(UDJF:S MK+23:5#1G\3,MQYOG)?MMTI%8Q+3FJS=E60]%IK=*F.][S$8#ZQ'2>[<[7;YP]J.APLH)LLQ8Y;?"BR;>OW^%D*RZ.YT$8NW\2%MW%[;D/$W>' MB6;'4<3B3::@`A\NFR*F'[T16C4BKFAATB"M"/ETZD:S8.G'H&+F[G*^OFBK M.I:,\W#&520T1;-.Q+7/\6M3^\%V0SK;I_!;%[=RY6\@W8J[C%&VSY]V]"9( MU0FU-C##6E2>LD4([Z$9V$!^^C/N.-M54!UK`SITPM&?5'/3J*.#K-G[/&#G M!I*IR)KMYSLN%HZ[%74Z>574=>7P9.L1=^[/0KQN/F7\WW/_>$9[.;IB,^8^ MH*NU@2`K#H>Y&$0=(AHD7"/CBK8*YK0%NGFOJFO["]M*YA4-"[ICTZH@OI"0 M9NG7B;ZV`6J,^<;T*U)72B=#;I^YP-*BYBG1T MM:I`CAR4#5/JT0T2+AN#NH?%C>@ M&?YT8D?WEV'PX#K,>?_T"YC_<_]BP4*P_O[=,1#Q0!OL!`AW_27\37P8^)ML MEXHJZJ%E9<_QVQ&X$W8UDU'XZ=*# M4P)L0PP7+?"1]6>R`KQ[FCVPUJ>D<1YTTU/113WW'V![MK#/*A"N MNSG&MB-O)\SJIK'"PUB9QV;9A=?,&',BS+]-`W;9<#.L#?X'!A_27S:8TZJK MYEP(=#.Z6N5.-XFU.\TTSY=2A8O1J0VFIL*[T$U-;O#MZ=0)N;8SL0:%5^#C M<;V8J6?>4))534@R@+@290;^=A.V4MWSK4 MM,");GZJC'AO-)ZVS,LQ3'P8/L%\%F1%9B[(^SGB]:;9&O=K4)X;O2&22U>. MWMX.K5$=:5?0_'X9N3Z+HE,6S4*7JGAY]`;C.9C3%WCN##;2-9#\WMO$;QCV M)J]^^*L7OW//[IK=%;Q/#?+^^,#Q>?KM\:)OY^[/77N_B=D7O=R<>SXZNW-T%\S]_4_7#\\_G' MW][F7O6./OM\_O_.^%#OKL_^[W7W_-/I&0[>.QJY_CLC(56,*WRY&^3\9LFM.U19U0XM85PU_M^>+=?YGCWKM5OMSV.6R8F]49?1:N M,O-FCN`O^FG;9I+VG/3C^<)S+^]=X[T;1+!]X-P2&2=!N`BX8V&\CN^9P1FT M^OW>.[RDL_VGY"_FNS?&HQT9KC\3WV(._&+@UR+,#\+9_A74-^S1&-X''YE3 M:WID7,,#XF4=XY[9SK^7=HB!0_KZE3N[GP>^TS'^Z89WKN_:'<.-P%@XL/%Q MB#B`7QZ8%RQP\_L!_`C:`;Q<4-"@5&W/B`)O*;PVRN!=B3S> MVQ&L4UCSER&+8*'0+CIHN>@9YVC`/ZO0R](E._Q,HI![[CVD7$,:B12/!PB>R9'E=3@M^$;?H3N**JX M>_N!&3>,^0;SW#EP!=SQE]ESP0#7R84'J%K_M M,\S'C(WOS`ZXZ0;[,F/@W5(^)[T$SJ/B-Y"OO6.]=UCC:Z]Q!RQOR&"H=,87 M>'F*5OCF25WQ'>/1C>^#)5B[I>/&'6.Q##$(&LNE$2X]QE=2R.Z6G@B8B&VC M=(?!)\Z^S.YM_XY>/GLM]`.^ M*%T?BR"B.@_#)L(+OIPND[GM,.[$E;,:+6?WR9I<4(1$^%E!G$C0!8FY/KEU M[@.3TQW(J\?D]2#G&P8:9\%FM*H%S[=+F/@G4$L'9;-#TD]8B!4T,'&WN+'X MHLD9$;[E:':%KA''`IA]%DFU8?O^$I9>H9)*5QML9@=S.!S4$L'"O7-2"4BC707R)2HV=@_&!K%D7$#J>/77MFW*OBBA+F MIL0G0UV!"A7K%TF9V&E\Z+!O;\'..+8(0WYJ<)&[Q>284 MEZ=D:69-`#XXH[NJ.QRY[#M\%$>$BLK.*-PC*Z,G9`_,7_(S"./I?I'A4`&_ M\AT2([DA:`;B)3F$W+N8D5YW7&`[E(8EB!0Q'53S035O/Z-XCT6+E'Y0;K0. M.OKY=;2,[=#)$0NT^1F+I;,D#B'@!89Q%WS&.>A=3-[B^IL4)_FL-NC8&`^\ M3U*]@18A]0:G9CCZ1D+5*:=`\&M!M:.:"[ESB>>B69JZ@4YJP`G"]<.'00=< M#19Y&!''5P.]2VYL0C?Z`XB(0_=F&5/%`QY8P=FD&+;!S^%D>UR1MFN$I._X M$E69YY2A]XS*%_-7(CAX/]Z[<,JS%XLP^"(L"IZ#00+A'RPF2AA7WN)$CI9L MSL]]0"FPSY[DPS*^=5"V!V6[_8S*`@XCK;4YJ-EGOFZ44Q*F%5C2C4/U0OZ> M(Y0F*)%;>Y8^X/$,@">,]06/F']Y9%"Z5)1$G)Q@>1/?+CTE4AZF3AQ>`5(, MP2=G-(K((Q9.)^BO&U$1YGF,'^C)$8P6;(8*UI@MHSB8@W^8"<,'6%-B_.$' MCSZ2&P=`P7!I&1B<<0PR-XS``B[FRP$-P$*5([+HOO(4.G M,#7\KV9'Q!N5\X/"AQ^D[RR1/G(N3B'.5Z/4&]_"69UI*!]F=WJ1KFIS][\4 M12_K(?C=@BR&>'Y=7\?Z?\7*/C,M+*F7*7(C>1`"KPUE^3Q\ABE"=R*1)+3= MN_NXZ]$-!X.S.2A><(WITU2]+R.&ZL=SP2F7>CUD'KD"7".!YUI3W-ZRN#CJ'%C?5F!IG,MJ$*YCJ2XV398@I0@8O-#VHH6=70WRF M4F=M)B9(1B37\H:*C[$+,0AX6\N0'"**A3*Z4OUZSK,'7=+&5+7VXA^#P'ET M/>^@@YYYT9\K84+XKHP"8DP,8XXNC\!A.E64."Z8>!5Z6.3``VH42:-<%I:J MKNSEB8WUP3*'(^-F1<:=6`ORO@=&P@_H^AUT&)[?7*#%#9%*.L'*."A>+]$G MS.FDKZ'_48Z;#AZ`P9E2:*61X#6@;:-%P&$&TS$,+X@H$!#<^>Z?E>?#/9S5 M%[T@T9CU.]Q%1M^:@MN?+W\R?@H\G*G(N`37_6/L9%*N,,[1O0\>>;8?)5)[ M[DW(4QX?&:8!\AIUNI*TC1M9N0$+_0;3$I,\"8R/W-V%[`[7;K*VOVM2%TXZ MYJ2/B8J9Z3DRI%J4MZ8\P-3X\(/.M#]=&5[$1/C&I&RW-+J2$;5(@.M@G"79 M=1@>HM"0W)%K>B^'3;;S36;F-UF:%VQ\=.=X89^9]X4=)UE!^[[#K,[(&C[G M#AL/!B]KA[TL!W)?=];A$+$:D.!JXV6X^B_NSC/'87_[T\RE5/.Z<*C-,6P; M"X8*V[+S@K0&Y/5&7%/M6MWAM,#F*B5#B>6]INSJA;+0 M;QA54B2K6BY;.#(FR_66ZB."Y=U]:ES[O?[XJPFBO;3M\%(L(`$N=0E*V%"Q MA/?!8+RH"6\SN2Y)#:`"(9HQGI0A`8MXW(OTU]W2Y4D/H,$^)#G!"N;#9^P* M88=.9+P/X!_C]8?CS^_?%#]Q$CA)?9?Q^OCSR1MC8EH=(UF['$%L9>'09S+- M+4HY_66)8@N946Z"'$$7WJOOHGJA>'=E)P0[/Y>&5T)Q2Q8+A#99-M.2*;0XVY&!#RJ<*6\H8_Y3A:<7/ M2^O%%,3]E>3(D:D(-=WJRHY[(3&Q/5HZ;1H;X3E'O-(O<[&=UOV5U`H6I$+_ M>'Q\*96@PVXQ***\M8/Q,/O&:`'/#K5&/#/O..W*SL:+@E1K'&9\ MYS,^T,]X?JY4'7^8K6=RJYV`\<)!-+Q.>@Q*?6HW/1"AP;QGSAWA:0FO5E27 M=Q%2K".]#=B9L*.9>^=W>=+\[(DJRJ,CXZ?@$19+V,G`(F+R#/,EBBN^4OC/ MQ62(JG"J98PZ/'AA1YFR=R\`;\0GQ"CR]QT6V^#5\4)-[$HMHTGYF(G2( M[/S5T%/EF^@I$151ECMS*:CCOB%QV[>W/$["1-OY#)!G\5=`@(`]1I[*5(?!?%8B![B MD[Q\S4@[9$DQIHCRS(!7EP=YE#6C:.M.]I;BL+V?:7NG<#WI9,BLCLR&CXQE M#'/W)WK6I,U3`0R$E2@5W_8$'I7X148!$I``<(0=Q^5V(J!=(RZ*DTW'E;;8 M-KR@(F(^5G@\4*!>&1.A/.4^R^X?PI\I^(0#Q80N1B@6#.OBDF(4!=B`/:F[ M^LCX[*)1K?0PD&X7;ZTY3AF?A@@F"SY%9!MI>.),[`V9<*E)+J\O`;OM<1PR M-THX1S-+P8`B(4OI'NX<#G<.Y5-U)?#BKM+?<1(LU]$[6[$(:%]4"_P+3P"=(SEH@MC8%D: M_QIX_NC^*N]#L,4HHK^3SI&ZDRM*F;^4]:Z2\K:4$]"F@4`X(/NQ8"&!Z*): MG8.6AU.(SX.U<$CPL>8NI9^;A^5"!'[A_.+"6U48FP2M1GD5CY`G()'V8@$\ M/?-8[Q MP,SK:S(9%KEK!74`1-T`]R&ZY4=7/AXZ*#<,`PZ)*,")D]D(O$ITQU']O$Y> MIZ^76`_99:H2R_'X!+E\B.[UQ26U$*L_C*2N^_[B^OKB9_KV*V/&/"]:V-@Y M$#NKT>\+=#?%[X^N$]__XY79Z_TE7;=Q**GYY]G5]?G)\2P[#*@8). M,9L+X'!Q`N0PXPEV%U9&`T6PI[JV!]H15:H;Z0?]/@Z5GPE'[C"%#4[A,88A M_,))#)*C&[^6Q]`4:BWLD2F">^GY@9*V#C/YC#-YRN?PB>[1%;\&3F\)OAY. M)#H^PALIRAF413'\:OYI97^K2*M43<,QH.-EZ!]M.O\;NALOP<60,6GT*C$M M`1/#9;9]D@:1P9^0D(O<`^7A81%!%Y;YX"_ND/3W6;>?4!^EI\^GSB4,<\^S M;V3COM2US[IV8L(+E@)'NPPX4/'J"_%>P4=49.&B"=!,U,]IT;38]&KUUU,: M$$H6D5+7\"=?7]+AH^00?INQXLP>8CHEBSD;63D`2*X?#E*.6J?I4>L0$WKF M97Y5?@:.E--L9'N$C]$1?\<4M66,X$6*#@M"$=<6GX@:*;Q#")YL3^2VR^B/ M4#]X/0!'4]YS]!8\.'YYA>U!09O.^'>6_$XKZ3R1#0$E_2@T!_J('^9K:KH] MG*B77IU]&0;D^R0+CAC"_ZKZP'A]?GF5?'+Z1J8XA4RV@)O9"S>V/;)J=)&Q M\%C,TJD7!E.XL)F.DK*^6Q8_%Y5XX_T+3Y+@J5692Q:1`JG`9ZMX8%18J%S# M\46:3<#FP:0\J6Z*IL(7*9R>[R@Y0Z;H28NM-+JZ@2V)WD5TSQBU%+BGZS1* MGUWP5EZ(3!,ZGG`Y'T6Q#+^R%6^6;0Y@>^+U#K]O6E*9RC(2_>>DKZJ*7JDU MY[5-,L\7R:=P*!PDNIYP?'/\=.2-(08/%+RR6)1-8FFI9XBYI8M!>/$-;.K` MEY'8TJW.,%V$-GLV"*PX4S`SOZ"G%RTIWHQ%\>I8M[S(1CR<]>WHSHS:^]@) M4+]W,5DI$G\6APZ7LP;*.$Z`ZNC9M&[KLYJD,6`G)^R[!%5.(R7+3+@##J&.. MS09@C^A6-4MX!G[^96",O30XA9>&,E:^&;Y+X+_D1C!WNQ$FG;XU>K$;X1L^ ML!Y.G?#+)S"MYSS9Y?7'((K>4/OL$YZ+2C7TA_/G,Z]:G"*1C_3:2Z9(I@M3 MHW/0'$E7&7_E<>#)==(4W4>&^AD5R0,+4>GZ2](8'-6E$AU2\I$)'2>EC M*+L7?BAJ)*UM^5RW/W3'0*G3K=A,]'/TEDCQ*F\4T>-UD6ERP8EZ"/B<-K<$ M#B_2[M#4`@\\QY#=8U(7E>OBJ]?C;+`.9P-N(%5V"(`X;5GO\BOJR)XG%81< M#`7/WK"9C>F&!/%":>,\@0\\6)D_WE&;7_)IY?F&237^9;X:GQM>^!)'1'A@ M,L,08[UT',&3P#*6RZ&`,"&1D,=HZ87LB^B_+!LFPU')FXD6[92-62H3[N/' M`9RKE*4JJ%TYPFH'BB1T=8Y@--9-JEC8]CUP"Q`:-.<6"+(+FK!+G!S&-US) M0FN4RO&@8XY&G<'`U!*9+NQ*&@_>QL';T,:X9Y2KDV)C78:!#S_/E,2=@Z_Q M?&OV`F&2;L(E5C&,5).%H&94S@2:]?CS+W`L.:)/N[V^[+[I.'!:`4J5YLLB M[4I<[6%4A:[.X5PD;X,I%,[;!LR6\R7/(1,=4C*V69K]XXN3\S?<)"`=+L4" MN;FE@C)OP>O&JN:X7`T4KSEE"-%PO/`;H$% M?:/A_!>GQ7%@VC&B3[;*Y=&\%3FE\#6*RP-_3XO8M/)T> M1DV^EOJ4`@RRM='-",;N$;')+Z,NY"Q(O@9P397$..%,B MYU_@]TF$#]>A>>1MNSEJPE.RGF2NE^J"%DY5:TI6KW3D+Y0[0[DP-X3X0#E` M@A1*!7J+F4#O#'JFZ]E/L-K?WKI?F/.N,I7^8_.0DQ*@_ANF/,@_F[]\O MH^Z=;2_>OA?AGE."8B#/]MAW4MMQ"?*=P>*Y9E_B]QZXOS_\YW_\YW\8QM_E M"Q+7EO"JDL?()89?KMCM/UY=]LS?X?_QU'$=]*:_#WKT\RO#=6!*L$;<^7W8 MLU[]D%/8:3)FO%Y"IO&J2?T?N7^RMX:%1LLPS:->+I&J5;^BCA<1Q6#?[_"W M/DUS^ON1D?T\C]R7>WS7X=PUX,.W<0=VX]0TXQC\]Q*.`:AB4Z^@*&^.HZ"" M73P%^S+C-]X+LL/8B`=F-A!`>P[#(CE>FM?LX:O7Z9GC3L\J/GL!:A[=2U.+,%Z.FL:$!%$)#RE-\?H2+\J& MRVB,(K%R=U.9]_RZSB*>IM/IN9%,-I`UM^+M**G?$'J.Z[TS`4ZVU2JBB!_" M?*UL]9*5PV1K`QZ(+/C2C0XD,U"+T9@4?&+R)90L*,=O+#;O!B M+FE5I8BD5A%N]SD+#1NVS`+^BY31QHLQLP07A!(+>F_G=^??=,CEG$KC?+$E ME$0@JK M)S@M-^[M,A2H];PN$&OR/@N2+7/$]4?1BT1V9$2NG\-X!;\$M.FD)8!RTR18 M-QUTRAX9]HJ,TL=6H8(%1(YMI%C-F.DUNR>$`8'3G#OK)S@F6?C/1.<4`!+S MUC=V"4#)/'"8EQTD281;A1@M&2(0+G9_K,3[_WL)!EE&-UX[1#5FQ@M@H3=) M%CM-,L^Y[$CGLT?OJ3L+&;]07=-84JV5Q+,".RD;SS9L&_N=(7$WKGI>2L37U!N68FF'ELE1K]#[Y5HKHYL*4+@RT&"41)`` ME(%V:?:LV[&L\6H^E;QE7YO2%;CYQBD>=Z;FI*`!Y7%6[]*=OH*JF]WPZ:&K MX33-X133-',WO(35DSK6)6!WKU-(X22L#L;S3?,'>=!-@]&D,QV4[MX]U3J] MCC4==JQ!J4[=*ZVSAYM]/%SMW;K?F[U7T%`YM]GQ5E)X:(5FO?V%66GK]VI= MKD13LPYSLX9P5-`/FX=3W8:5[V#46QU*KM3$^[;O^-7M,3\DT:6B7$7BYM"_ MZW"LPQ*=S=4U)5KE@G8 M0!I$T)VR<[%`<$8=I$5.$[E'J;(HAV91-$UEO[:4E#=?21SP$/1[J=L7O*6? M;9C(L2QT:-9$6Q8K4"OKI!\U& M0*9'.1]6IB7<8<\*RI,J:HJ@5F31C;GQ[R7H>P0O"$1S3/I,M0BKY?[%K3?1 MVT6GS*&X.RX+2J;!QN@4:.K;P4/JK"=]988LDAIL:K-W<#EU,XXWCT+U9 M\DQ79"WO<@@P\H1!1/]6]9.R'DKJ;BMV_PO-OBU)GLWGV)[-%U[PQ-A[YK-; M-XZ.?8?R-PDM3.UC7I)U.U"R;@>YK-OI*V,)?@U]XY?/IZ]PZF!>O0BY_*&7 MTEJ;B*:IU^0,FSTM]:8YAAG>A@>'N6]/@QE!W5\_+=@&))I`1Z_[O]\?__W[ M_-O448ZQ8`$_^.#9=QL,TW_U0QPN&1\D\[(B7BXI4__,=T[17UU_M,&K'_"O MW=ZT.^AE&6C\P)W'3LT:L?_G=0 M-++R6G5LWMWYBMVY$5Y+Q9_P@FK]8<>O?CB&Q>M>WKL(^!#-7$1%Q=;KX8)3 M4S30*B$G#`&B/>I`_3_L:0-*)J`5X#_3OFG**2A\M3KV";644J9H\Y5GO?JA MVS7[W8')QRY[]2KK'UR/A2?PT5T0;L+X]-4/GT&UP$N,JZ1R2#A)JAPRXZAD M7/,TP<]/\YO`6Y^`/FBTX\N?WO.Q,B\KF&>RKF16>*K_139$G`Y]'%WX)HY7 M-*2IZ%=^M%!5[/FG#Z#B&[9W20PM<&/EZ'%+`\>&$L'XN^.J!_ M;=CUB?_,W82Q!O;$T1"--?W M5_OCNC3FAMJ,$ITZGNC7BC7L9=;*5O1,:DC&VHED)C4DHS]3K"N90QFN+HJQST-_7LLZ-R4BI2$LG1T=&(CV#BX\._;GBRIW"XVW(5WD; MDSVE^,)7`D;B^@;AC9Z,^3+&:K,$(5T&+`O*)U_CWY5;+GI$N>!ZDR\$PM`8 MG,8\=V'\]Y'Q6[#$_)&?0_$CR(DM%IBF'SSZ_"(.0^]A0%B;6$X040-T#I!T M[[);X^P+FW$LH(O;6W>6%J2)$3M*T?XJO[S+X`PCJ;0&*?J8D).YV6-DO45: M3"EVO+R8C))E/:-E+6-Z,A):"D:%@4RS`\H>[P34N_7DC5V!=#-3'1Z.0'G47,PQ'@2B*U8:JB!.[0$$T/TDDAD(6%Z9 MH+HB3@*$%GV8WKZ4/:?1$ON//\2[J\RH?S5,5$8\*!O1,X6ZM!BVY][Y_WC% MGTY5?Z:+S/N+J].SJZ05S']-V=*WZFW6"B: M$#'%"+7X]LG%QX_'EY^!%P([7T0,E-\_SZX^?+SX]:V!U^]`4_(T];0I)^7J M_,>?BFBI;F)3)I&DC#B^.1_?KRZ^.73*?``.QUTX\HR>F?D&^K`@HF#N7CP5T$FN*-)9Y[) MY"\9)P-_/BE33ZLW#X4M>)Z/W;GK.+@B2MDU5[G5[.Q]8Z]R-@O8^VX#K@AK MMYBMR^/3T_-//\K=-)*:=/>L]E9Y'4_2+-Q]GL<6EZG:!^H9%=0M_:HP"UZK@526RH[T6-Y(]ZC_QAF:CGW>%GL7@#M*44I%7!W+JX2.MI2 MDF8&8_\;W05[HB:W,X>3"C5Y3>BV^0/8MVP=*_?^`/:^$RSI6/'\LYTYV*QJ MI]+%L(4;N*9*L,ZWO'DT+4:W#U2D$9#2-+?6<"W;"^#L M?V9>S7L0W;7)-;YMFQN3P;[>F+012#R$20]ATD.8]"6XUX@B3?IW+ M=$_._X0B3[IGR.X1)#V'20YAT/\.D+S/FF`TB M9L*-ZCG[V'=D#<8&@49]M0LDE41S4:>W6GM62IV^&F4X MS":[5X[<`*EF__>!651+4+LH96TJ3T4-VQ4L#W_)UI>BODJE/QQGI%@\W*9$ MEZ2=)C9?3[EFGM#T,U-M-(CX31A>/G8+I_'.FF2'_<[_$F'<\1YW$#$(B1WJ,8F_E33SU"&F9`-Q5Z#R%O@#9E MH!B3XQC1M^_(CWG_E#YR:5-)\/&C'3H7O#I6<3#/_3AT?9AE4IU:3TK&.&B! M\#>I3A3_"Z%$P4$T(&<]C+BR%BI[Q:,:Z?V0,2A4.!PJB!)M,:[O?IW8FHO; MU-9@]B#AF98N]ML-XOB,]+[0=V\?M@C032$Y#.N#6ZR M/[SG.*CRD/9Y#AL[28[U7M5>":$U&+:QWA/+&\L]$L+VVGRL]]GVD^UFM?E8 M[^QU]WC^F]+FM:^7]H?W'`=Z_ZV).:1;RO+KM4_@-Z][#S2NN*8R>^G]:)V1 M&R"UU%Q6PCBO364&1_B41;/076R&TCP!"JY+NHPL0O;@!LO(2]JV%2`)B09= MF)4D=TUDW-L/S+AAS#?L.<<@BH.W::!\\E'1G2>V1KJTS!VI23[8*L0;? MJ<;K4W;KSMSX#0$-R6B3Z%)@.,NDJ[T";2ZX7>W.'&$C$ZQM20-DO#L9-8V@ M7F6R=8+H#6W'Y6!+XS$'6T((]3686%-*'=%P6B+C+^QL/X"(*6THOK.H)T2* M)"\WZ?V#]"T!7RJV$:)?GC#.$$U9S>&3"$ MZ/71\J;KN3,X%U*?F00#2\R%0,+/S`-VS>,H>M09VD]&)-IZ@X3'U2=_).:. M$Y@J_,:$?T%`:65;"\#G-*7T-A3&DO[((8_M+IJ,$/DU\1KQ- M'A<$D"T0I6NO0=SNUD@NHX3@'`B:2F?*`E$!+Q@-K:H7J-]"F5W^=(0=F'!- MX,=_,.IYL>3[56++\:_SS1O+`K^EGVE:7]0I8UUU+95*D66A'D[)LH/!89YK MM)1*VV"H;&5U6=C[99F_*U1]2 M6=&V!-MS2")I9X&R,'O#1&&@-AUGB<[J("G8.GJB@])9<&!"[ZF@Q2:C?I9A MR/NI99$&&4>N[A:[_K M]SJ6->2"_90.GS9-K4-(&`"'*&7,.U&^BP/TCDQ3[9CX:3,>ZTU$,$7\0=.6T+'>DSGAH'9'KW)3??KWM%P^B;?(G,COFM,N5X,X'A-+44,XU%G M..BU(0:K0`R3L?K'W`K)M2E1CA?Y<^DQ[P8&EO&$%AMBC9^A_3Q)-#="!SD+G=G,'?<9_+O,?C?LWN93Y[2?$.UD$=&*EC<;"1K MREB^*\*JIP&C((!IPH7AU"A13UB1)?E24R M].WUEF\5X$!2B:*6HJ1E:OF:CSA8%%6K"4`%OEQ?Y:H8*I_-%(AH4"YXWQIE M#UK3GEG1)S%+0WZT0^3GJX_\;%IG=-C"+V8+O[S`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`*B&8AT9MP5D/C3`QBV'17-#8C M_6%]UGJC%EG3J851[15BFKLBL1GIC^NO_5J<_?W_=+L?@B#^%,28`L`3#>'M MW:YDW'/]/][>PB,^//(1?C&^T)_@9,?^\>H^CA=OO__^\?'QZ,M-Z!T%X=WW M_5YO\#U^_#T^^$H\'S\MX'D0$@7M7_U`+_]^Y>WP][]_CZ]RW^+_$A7_'U!+ M`P04````"`!ABX]&X3[79:X)``!HA0``%0`<`&%P:&(M,C`Q-#`Y,S!?8V%L M+GAM;%54"0`#IM`L``00E#@``!#D!``#M75%OX[@1?B_0_Z#Z MGAW'2;;=!)L>'#L)`N361I)M"Q3%@I;&,;N2Z",IQVYQ__U(64IL6:(HQZY' M3I_6JW!&,_/-#(?D2/KR\RSPG2EP05EXV6@?'3<<"%WFT?#YLO'MZ:;YN>'\ M_-<__N'+GYI-YQ9"X$2"YPSG3H](\L2)^T.D]$[[J'WTV=$_/C4[$]X\.6Y_ M7ER%,<9,SAR&6!TVSJ^_@T_#$D M`APE6"@N&V,I)Q>MEAX_&W+_B/'GULGQ\6DK'=A8C+R8";HR^N4T'=MN_>.7 M^T=W#`%ITE!($KIO5)I-'EW[_/R\%?]5#17T0L3T]\PE,C95J5Q.X0C]OV8Z MK*DO-=LGS=/VT4QX#64#Q_G"F0\/,')B`2[D?`*7#4&#B:\%CZ^-.8PN&V0R M'FHSGQV?GQYK^I\>)7-_]"=:2-%P-)]O#WCBEL(()2B/^I/=$JHZ&TVS'8H(\8W/7K8A\A*O+4@\4->!%0 M1;XURFWX(JC,KJ.NJW@^0Q4WS%)N7YH-0K:`P:ML+O'=R(\=\%Y)LB(CS"2$ M'GBIE)KC>S)8G.?5/7WFKMS'US,,XZO&2&X33R,C(H;Q7!*)YC,ADY8V4@M\ M*=(KL=F:Q^UD2ODIN?R](T2<.Q>+T`?1Y+]7M?".AC:!4(#RP+X<`[=-CU;4=<'02IE\*$]Q0,E422OG`S7U2R6^ MSB,373DJ5S1B:")#`UXQ:B;Q$4?>72A)^$Q5JE@HJ.2]"UT_TMLAMXQY+]3W M#;#9D:.'STX-Q%&7H\#U[%TPYI`C@+&*NUJ`G*,DXMKFAH;*.O=T"MY`+:_4 M1'_+F3`M;PHI:@YEH5Z(,ZU%&!Y,J&V0,Y6FKP/]%E0<#" M6)HNF5!)_,5>U@,(X,JY;QB_B63$X4Z(*-G$+UR*5N>UGT"(Q;HB`CPELJYR M$]_FRMWB/<:K^=N0`9GK2YT7PKT$L'XD]8F&]L.O43`$;C#*#NZ%(#0W=IML MG.[`/(CGSXVU7>C6'RVLW)FJ?*$7U\K,MXK6M*S9W2W_[X8V5D)<#W1](D1_ M]'>BU91]_J#E60HH4ZHO)3TD[RC7%F>187'DMX>28U'&L0#N5<'\&C%/;`FN M,?.5`86*-NH:O+`RI_W$V8J8MNJ@B*`-H?JC7M)GNV@B-;93FNEJBV:)7ICKS;M0`@=A46&N MC:PM7&N:E$]^^P/H"8()XX3/=<^0G'=UT;JVX4XHEU7&4>#H7]H::6V`I,$+C$=L)EK;&V@A'* M'6)_LWR!=6YHJ!;I.T@FUHP1>,X.DXFU&1`OL95.+H`G;I3ATK/R_NCMZ4== M&RGS+2Z`?MY.7S'WVF_$$(&K;">,Z8E9]+T*FX83YN/^KSK M$QJ8`KHBGX-UAXIV0)S*5P^@LH]F69_(K1,>+/9EBN>#?88/;%VB]JB(W^R@ M5J`!C0)KO'-I/PCDN;KGH_X)`^HWA/+,T=3K0P_&9WS-=`>+=HG>^4C_&0/2 M/9AP<&FLGK&06QYVL#BNJID/VU\PP);_E)JI@;"`X&"A+%(X']3/&$"]#B8^ MFP-<00@C*H6J$2OC7(''P4)?P0;YWG".P1NRFT9WX?HKM8P=5#;D!^L#=NH7 M;;O@6(&OJ;#8,7HB,]C4!PHX?"`W*+!`@2?@.+`O=N8!F6OY]=,/KLLC\.XI M&5(_MM-&R<',\`/YB9U!"MP&Q9% MQTH>82.9*8AR/P]`)CIJYKEA_QR?3'VR\I M07)K&R`Y]>O>'C?9^X<;E@H^;; MBAU#/EN2L_Q%\WF#<6%D`4<=/LMALQ%@_U$'*RZX<+3\T(.59HAQ3M=LR?N5 MRB$M(J@5>D5*(&XU3ZN;!_!U?5`I#"UH:P6?A3Z(.\F6Q/W*0K?*G+<\'A=B M%M/>LO`[";2"->U;^VGF>W6+IQ!$7,`OI,RK:C?@@0N:=2=;60-74VTG4UDI M<&E3406<BJ=-)5%Q%5&! MMB[X5%`)<9=RYE4KZ2<".X%>F72DY'08R<5+7`:D)/8VX(4+[$I[(QMHBSCE M5MJ<*]F.JQN2>2,1U_Y++U,J_;#IVE`$,-D#LRX^XEV0CN?1A5P#0KV[,/E< M@FEGJXBB5B`5:H$XVRUZ"EX%+X>JB*!62!4I@3C7/>B#]!"\:\)#-;F*CNM& M01376JHNIBXUOR.AG+A6`-HH9%UKYA]+?FGI.P^)@-@POP-02P,$%`````@` M88N/1HX",VB-/GE4^OS\:<#D@1I&"7/OWSZ;7AS>/;IX*__^L__ M]/._'!X>?"4)H7Y.PH/'MX,K/_>'U`_^GLWK'[0^MSZ?';`_NH>]"3T\.6YU M#_[[N//3G=N=_#OYW\.O_'5P_#`\.#[Y___XYA!;RHH7/03H^.#QDWXFC MY.^/?D8.0+`D^^73*,\G/QT=L?*OCS3^G-+GHY/CX_;1O."GLN1/KUFT4OI[ M>UZV=?1?O]X]!",R]@^C),O])%C48LWPZK7.S\^/BG^%HEGT4U;4OTL#/R]4 MI93K0%B"_=_AO-@A^^FP=7+8;GU^S<)WN:!,F+]_9KF![E'YCY]`70<'/],T M)O?DZ:"0]:?\;4)^^91%XTG,,!:_C2AY^N63/QD],D8ZQ^?M8_:IOWSS\RDE M_:>+:18E),MZ2?@0/2?14Q3X2=X+@G2:Y-`1!FD<,Y-5J;3M2FRO;I%$+&"[3)(,>&+(9[L*/ MV33Q,"(D-]&WI`T+$C[D:?#W_H3-0)EY7^#6=B-5JYY8+5=RG=23Z\257.9C M0]:(R[$P@&DOR4P9^+18AU`K::LO^.TCB$C=CUG]-B>H3%-"^8Z>G06Z!?2BM;HBP=\D80>SPY`\^=,XMR@@IVV+ MXJ9C/TK<2#MKNK:P13N'8S)^)-2FI*OMUA5S!!+18/I(#M]58%%8;NMU14[2 MO&=U+,T;?!<,>FR41&PRN(/F5CX$LP%)0A+./\4DLHYWNK37M2_;D.TG#.0JRGO= MUHI,"QY[=%4ZZ$OSQF?=RF@"?Z+IV$1/LT^GNABF&+6RR'+8VBSL==L.:1*M_PN.]'3.YTF` MAD]0>W<)\C;V8RZ)6MU7.F1J`8O/6*M^.23]Y>=I-+P0CBDZ@/B\]GMRD^W_=PP9_3*"MU+%_5 M!#6\;G=7US09(CY=IYCH8G]20I3SI[*NUSU%L=[)^-!G*4\"BJ__XGS^P> MI9=E),\NWG[U_TAIL<%2;#8,6O&ZY[NZ`3%%*>"ZA9#KA?3?_+%Z73-LR3L] M1K%C,270N!L(P0NZ0F,FER:[`JX-3U-]0K4E:C5F[1GX.;M[5MH(5LIYIRZM MX)HK=I61R>=S$YN`I<8L///=R64Z?HR2XNJ=^1!$XY\Z@,4D!V8^:?KVD:?H\65T$<(N=%O-,&C7)U2%H!(""@,8/. M^G3RC>37KT$\98M6VO=.G5K[W'4+>^@% M_::"T,/$UCMA&1G9J-VO%. M&S2)U.D'YB@%?%6$(>,:L`2>!C,S```]FC5WS5Y4[`N!39GOE1G3DUX5CPHSH3VFL$:/;, MC^JLAQ1@E1(?.*VA!4.0<*:GAG3FV<^BN5 M4/.:3"W!0>;U9),K9(N6-=*VY]6T-#=_2W.2#?PW-BGT$R)?KU3UO+,&;^L06NO74)6,6'S>[H%F;.<[5TU]@V;A;TS MEPZ"6]@T""!A>=-7C_83B8^*QMPL'F)?1NH2FSG[`;US1A MGDVZ%EU>/>]\7ZRZ0G38'(#6!%4>QKCEO7-D!EZA^OFTB4%AR11>N%L5O7,$=BI3;P$-2'(W&0MVJE49;IG._+B8 MQ\/_].,IF7O;B>Q5NO6]&K,++(J_,"G?:I'JED#WCF",-AZ MPTX*34!K8R829F^]3;*<%MD5E^VJ4Z:C_E.Y;BR*R(YPYHUYYPBB;DWIK@A3 M0'US05HE"DH3WT&^AQP8@MO^L/Y[YU;US!/:6>J-9`DQ`J#W/$6%' MNRW5Z,>#Z6,HV#%DV92$5]-"'I`JG7D8?R/?BW_*>%%W)M4!#(*02B,>C9`) M:*I@LQ'0-$_.ORG0?&F8EQ`QI=\"0$)PZ#6L-`"!DZ>=JD,;%)B"K,>,. M6Z;+Q9G9B_LT>HY`,/9KN?S*XLR5=0'R#MIX-&$)_-`;\WY9%7NVX6+17/,] M6+EDE_U4GU950Z",'3(3U<$H(+PQ@Y%PAWU!DN)%##]>0+PA1>;P*K8%27.@ MF!VT)E5'*N@"]A*87\'*\>*S\.JU(,>%0._O4HD/G?IM`*P=L@]5A"=@K3&[ MT`+!7-!(&E/.+0_0=M#T(X$B8,F>L4?_<"0\YALTX;5:NV:R,48GH,R>5<;X M1%2!.5%+`''7;#5500IX;,S5YL:/:'%ZZH5_3$M//NDA4ZL>0-TAIR4/A_?SD>S8 MJ*P+D'?(N&,(2\"DO>BD>Q(PR8O4+NPK+-G2YF[J;9B6=Z.B=="P&0"W0Z?[ MZ@@%(>K;SVVC\XIR`XAJ7+>B"M!/VHZ MYXU4R8+938%G'[+?<#$J8B6$=4"9:`(E5.094+Z`AC/_S:JTNGE6>+4`)8Z( M"04/!N0M`\.9'<K#8CP MG+S%0T=I4)'CLY9'1YNI^*W5K0W4MQE08K2730>%:=H+G6&UP;*@$TUHB'=O&99!_7(B5W4?9WV\H M(;=PFJ$DRYDOLI:=6=X$X,=S/5[A=&B&TUI^'G<\7[].2,#"1M+8SPN;2@6F M^8V`#O#NL8T9G2I MKM=JX[F=MT;I!D!YOB!<9NWF\[?;MVYW<=G-ZEBWVRX/AK6LV\KWW85X]L&Z M_3!]S*(P\NG;@_^>,T>5"4A4!]3B\C1IS;K=%F?VE$-#9MU>DI$]8==_*EXM M\P,FGSHYJ[(R8';J?Z^?'4C.BH!*37S(3-Y;X!27`=PAN0[LX+9"NYD_`1G$ M?E"L#1II:W@5`",".Y#N0.,S*4.&+;>\D\QYK3::O+$5UTPU/&19Y^WD8FNU M<62*U=`_GS@)+&2IYZT1AFSIL\Z<@_SS&-+GM=H(+&B2X2(X/_)Q(#-TVWW= MJ]79"?\FC=6,#PV;W;KN^U&M#@YW)H7:I0::#3S8;-$62$*Z<-5G2YGQU5YT M[%8>^FIU\#@K;0P,SG6\"2QL.>;M//;5ZJ!Y[:OBDB6&A2[YO+4WI%H=S`]^ M%2Z$2F1(4M M[_S%-(L2DF6]`(Z?6:EC^2HGJ`'P7!J+M[#.28%ARTO/$Y;]28EZ#E76!@?1>EVG;I8V@BT[9I&R MR\"P)9QWPA^N9)!P]GJ3/!AR0C_(F(*\WJ``9KQ.6= MS,76'*/SW/`":5; M1NS=QB:"]]]=6>\T`O8W"X-JF_?<5P7FKQ8$D5V>?*7!^"(%\CLY3^Z]"+JW M&W)QBB:`D$>8@EH^'&2!]K4=^$^1A0KRM2Z]_MK`@RQPW@)'N.XJ+9*%-A"^ MEV6P[O<>LYSZ`>\=;'Y!K_4%P=G9;#'C(4`6X%Z*>#FE%$!ID[)6'I`A.!/S MM"WCA0L"6=CZI9^->DG(_L/V]2]^7,0*YY=P?'B#D[O((&54'Y`C./U*2!', M>_K8D,6V]X*`/0N;P8F.@-S,-9WD,^2RL2>I!C@1'&Z-.51#0A;4/J!DXDP#IB1D$_N$[;=@6I".*W$U`(K@UE]_2915B5 M*$'0VR2(IR$LPE_3-/P>Q;'&UM*D&5`$`A<`?5+-L=D+C7=&\O7K&@(SJ M`W`$#@3F5&E3+D",+<;^ABF=W$4O)!S`<1>V9U]IFDF?4>77`'@(7!%L$2H% MB2WJ7F-(+CKA&0++BBV65E%A"Z[705ESB03@"(PQ#F=1`6)L8?BEO,HC!0B/ MQOBB;SLKI<86.#_W%8L(2QM?&,1':0Q"9>6EN,8F5+<)4``">XN9.=H,&[;H M^B7I]!:!A#-5H!-2`P MUZAHDAM(M6':B[&WY:E79A:[)R\DF1(UL?P*7@=#WNMJ',H080O'OQY/XO2- MD'L2,U\MHR&IK`N0$>QUJI&H"0Y;@+X1@=PY96>'G0@-MAC\)3F_I4E096^S M60^@(C"06M[>B&`Z#\)?^%,O,F46(W'V#OUB"LA;]QBMV6,B,^_$WIC9=7IY3J/':$;B]XWU8<4(5+"9G&SG%95"KSJ\)H+_#?^NM&2B?LM:(`",'5 M@TKA?)KX6.S%_%NZ8@C#J!1FX$?A;7+I3Z+6P^AIV)T8X$0"&PBE6C3(1&0!%:_Y8:?BW>R3&NL[J- M`Z$$J8#:LZUGQB@$[!>"9%=LZH@;R8DQ-U4]$/H2L>0<<(:Z\#,2LL@A$)I^PI;#N@ ME$D]7'P/QH-+$X$T-XB3OB"8X]WI[B,_R7JV@I-CEP=`).R881B,+(G_12E;'Z[1V MD1=-7-ARMYO"V*#/PW]E/ONT]#'=-U_<:]D^8B\1:'-B6.3`1$WT)=\QO0 MO5V:$.49JRW1K#)$6U'1A_%YPX;49AY3\AG5+T& M0`=XWA[8QO1JHA9D5FB9Z$/XN')LZS4`V'&\=6!"E3G9ZX"1V:JW2#:NR7V; MK*.U:+_;)Q;G<*6E4U@'D"*P7)N,13ZO"H#(S-:5CYTSLTM_FF>YG[#,>.63 MP"XL&:)OP8D7@97.\:7)\M-KX%*D60J`E[3^0J#=NS!!:/4+\3]G(V"7LOA/K/9+XY M&=`HD-Y0;T<"4#\"5R3\*XA=\OTZ1(FS3UXR&AXQ-5K]ZN-$#+CV%H;D*MV-X7JJL(\5`7 M*:+EL+=7D`9HP9"A$G5OKZQ6;*\O6;20W@+>*,FB0)5MV-DW0<4?US#UE(?M MZ2F+`W45[I8FW;6/@I)_C$L7A]J3OZ75;$3QR4=$,:>O=)HSI^Y61'''I0'4 M>41Q1QB^8%E%'Q'%&T&"'9=6Q:9"WCHM88>2:V+?(HH[3EU\;404=\3O<0CP M[%M$<:>-*^C,(ED?$<4=A-F"'4ZO)FKY42.*.SC2"IM094[V.N`?-:*X@RP_ M\399_U$BBCL(K-XF8Y'/JP+@1T2QO6^!1O?$F"89GNQK/?B M1S';6]VDM/"S==$;%9\$_>Z)$[2#3JFE.VP!QK,SV>\^PY?WZ3V[;UP:5^IS MJK"J=]+=$Z]B<6?1TP&V4.&E5TQGSRR6?98EX:4O)(0N>S-E;J!LB^`G4C\P MX[9`)7OBB2OI%M64(@_B;?;R:0@M34&JCRNHS8YPVEP8UFY=075W.JGMJ?!< M9%E%'U=0&U;E[CXFM>U626K;W<.DMEWT26V[1GE2NWN8U+:[.TEM3P4U MB/WDFS\FBGESN1C@V<<$M>*I'P.XE?RHN#6SCP)NPM+2:=_+DC MDS8`'0+C)&\4K')3$9BURQ4MNK[!L:<>6;(6X"R%P#18B2HU+-?/AJUUG5%$ M]MMTJ[:#3>7LM*R_]$I@BP*)J.13ZP"X+ZE>UQ/ M4P[_=^7G:X%K#IV2M+X/JD?@V^;X?F=[BL26Z%'KY==O:?)",A:GSD!GPS3W MX^5_9Z^_?DOSOY%\\2[L\AVSSISF\ON@^CV)[1;WX2TJ$EM:1V?0R_%\D]+9 M3ZR<+/9[NX(`&7OB0MI`KY9H=.?2.FIZ+$[S44H9]BUXEKY_"U2*P&J+=/L@ M5YH\\^(6W<4N8>9/XRADK[9?^#%S:'L8$9)G`Q`[R4^.#6NV'!?^B(TJ8CP[)O[TI<.+BNG1;+0NB_=DY"0,9LL!M`J MH71V6%0:,N45O8[;\&B]+:-HX/"9TT&$S&_IANF4W$4O)+Q-OMIKG3%`9#Y1$OD7TFLY31FV!-K`X?9KS*!Q M1Q##1Q;UWFAGP+5`-]I-2G,S>;@4_[M-!$6%Q0#P@M#-$2OC5;@//.SI%L!`V;,]F:\`87 M/HJ:`!>!8W`M)OF0L/F#<84NGZTW9:^L!3`Q/!95G[EE.-@\P+@"ZZ57454% MP$[==+?&WP8F;"Y0:U+?1?"?<+:U8[8\(L^0HE,=@"-PT*Q%I@07-G^@I?0L M%?8X&K5A>X?`0FU&IS8L;.XO2X(;[&LDM0`F!H_6JNSQX6![IG-#8.5>1E`# MX"&P+]5D:QD*MK06;]I_Z$S%X^ MW45?K$YG]WRQSIM[O+!")9+W'K'A)6D*5L`X@Q&DHDY"E`(/,DX`4=+$X+QY&9 MZ!+*I/4`*0*+F8((/GL:N+#YTWPE"0"-F5-0.`8U,Y`L`Y6:1$5-@(O`B%:) M1BUDV+QC'J##41;;R,*%,^D3WZLEO4X+P319B2@N$FS.+1O(3-8R0(_``;$2 M.0(LV#Q7WL6\38)T3.[23(N@16FO?8S36TQGF[$.`YN'2C\?$6JR&>25!V@X MOBD6R*^@!]:7^LGB-_DY2UD7("/P`Y.PP:=/$Q^G41J#D-F%GT6![EA5MP3J0&"4K#&:=2$*&&_.XR(=3R@9 ML5NK%U+"`5S]IZ'_JG$XB9ACUU?/)/5/)I+CMNJ$6?4#J@"P86< MV819`:"`Z\9L,@((L_YI$K)@V!+L`';N7J(21`'CS2::70YL6&17NV2IGFD> M;21:ZR7A\H:\/*==@8!!E.]B-$2[NQ9-$2[Y71#8B$:HM"ZX`PNP+-GT1"`"8=?L@.R?KS, MM!C>V1(-'#YS.HB09:9][Z'E+HX9Z]*$[01UUS)>/="1RY.YZ_5,#`E9OMDU M0953)K<\[-Z<'KW,5S:Q_@7F%#$L9+$=U@A#NLQ98PYMWM:E^RCE`K=1%I`A M\`^3#!?A#0X/![+XCEX81J4L`S\*;Y-+?Q+E?JQD25H/D")P!S-F3`,3MMB. M>Y(#*!+.;>,:VT=>!0"'8-MH3)@,#+;@C:4\K(6#%.>"5SWH=-L`%2#P'#,? M@&;XL(6!;)IWI4>!]<(`"L$]JJFADH\"6PB(R24,YP[B!.>UFHP8/@ALP1\5 M_2Y/$%QAF_'!`8`MR&/MNFKN05A>;I4>A%=1%J13J;^E02M>I[MSX\H8GKWX M#W\R>BRX.SYO'Q?,L5_**;A,WWU,X>WJNCLQ7V8T5;.VW5Y$[0"T'`Z0AH2)X5G+SBDPH`K;_^S8D98 M\@1X(`&4S"/"C=JVT*K71OJ>094AJ0O77A!)E3%JG6K=9@'\'HUB7;S8HE06 M<139,!58C@J$C^O/;M\3."AE43Y/U5-J8^F5]V(02&UO;C\-\R@"@ZO9OFP[ M.L$6+',]GL3I&R$7)`&*\HSYF'&?>I?=ENBVX75:"*RZ9MW"$!RVT!B=7KTT M:5Z1Q_SW*!\MYM0;XN=3Z6,"MCX!`V3G>H==[-@B<61;K&_D>_$O5M5$;"_XJ()YZ7T:JV1&6M0&*#MC>3>&)0\6 MG4`LS.W7.:X!"0UY@6VD+V%67&DE(`6Q M$XV9\:2=UA+QDL9`*3MW:JZ*4D!]!>-9A96SE.Z>Q(19?FY`!=<9Z.A[E754 MU!;`W)FS<$V0`BXK&,JJK+&6R)0W!D!WY@Q<%Z6`S@JFJSJ;VI-:F]H3@+(S MYU5C6`*&*ABB:FUJ32E:KPY@=N;4:(Y+0%*S9J4RO(Z$?7KIQS&GJZDV-,H& M`/S.G":K(!/0VJQ%2"9[V3OK\%JV`/!WY@A:"9J`V2]H\HI<^MGH)DZ_[^1[ MJ>UN8P%GE3.$=%WN^8PSA'1UWTLMY/[($+*1+Z#K]PF*T+>UT$CRTVRY)'V+4T"4$?1F5D6=]B]!5%,5C`,4TV-:4P'KC\-^D;@ MMNZ^DVU'C\A2M#A^(.H4P?7H=GCE]RE-%2'+^L)LH^SIQOG^+`GG(5LW*9V_ M4]RGL"^+I*8%HW9`$PAN5)OL+!74A2TISKEV4DUW^D;+TB M8$5P/]MDU]#1#[84-^N/M#WF\P#K`27C:#K6[@^E/^7E!L=3-0'HE>%+X".M6] M]A<$IG13HG3I%N'%]TKVNN3EB!CZKZ0JU]P6`#X"H[8KNB60L3W!+>ZK`_^- MB0UK&\O6-B7A7>0_1K$J.K):@Z` M>BY>;&F9-B4?4#+QH_!JEK=Q]@P]]-TBQ;#2I%RM01@%"&XA7'4&?0U@2YC$ M6^-R0DF6S^8T^56E3G4`CN"6P=V6@(\76^:D>O?\SKRF0%D_^'V##?UAR[0D MP'2;O,!(<>BJ9_@!4!Z"ZXVMN'E9TQ:V!%`P[\[SE05_3B-*`"6(GK\-8C_) M80EF6?@G,[=^47?2;P24@&!3:Y-0?I/Y M]/('`O]8_");X"HUZ+7/$-CN;1(M6.QJ:,=>N>3&:;M)7\?`JF);4`)@);O7NFE2K`EI.KGDJ<[3A`60ALNN[[ MBPTMVIRP)RMQ6_7ZJ3D+.I,3< MU^,TFU*B<0:MV[37Z2+8+9KWA/J8[24DL^4&_I@O4CC/]CELW0*AITPWO3'S M7>!EY35M`A2`8.-HAT9^%S'3A#SMV1:S*%VE02E=$E[#SB1_NTV>4CHN/88K M)U#*2/#Y.7T!$%'9'>&/]5X(/WGSKR]]]$Z2.$E5Q>L% MX20MDJ[Z2V&$J776BX#$3H\&RJ1'0BUN*GM3;B?)C1QJ&D?JHAHJ=YRBR$SU M]^0Y8AN()/_FCT5+!*\HC.8&KY*K+A1B)$X2_YAQ<0E@J!_?PD[I]3_(FY2, MM;*`H<&;V7IL<*$X2>2C2\?EE%(0Z@8VV7[\-^+3ZR2\@C.9@!%1<4#2X%UF M55+D:)PDJC$;)C=13.@E2/2<4OD@62D)4V^#UX'UA@@'B)/D,+I$#*D?PGGT MX6W\F,8""E;*@,P-&E:J*I\#P4EJ%<-E(AV/TZ2XQ"V3'_>G>9;["1-5OF9( M*@*Z!HT@-1<0)2XW25!,#^1#:%9Q"&=%`.P.4K&)P$V.$5VE]T"8D`ET$_NB M8;%2!H1N\#ZPJMHY$-QD]##M[.4MDWSCQ"T+(!H,N*C;_3E0W*3B,.6CW,^5 MXMW`;RH;YD9Y`-/@+5E=7@1PW&3,J,8-VVOK,_->&H`T>#%MAY1S:0R+,^;/$ZZ(&\$,J<&R]AD_=,KDCN1['A M2QJBUY)6F[Z3W/-(RWL=F^^2KGY$=(3FWU_3]*2<`:[#]=4YK2;'9:&4)[ M4Q"M@>?_0+?)\R+K4Y0\7V=Y!,=#Z7''H+;7.6\L(.`A&)%P&I/^DUA0Y=N! MNFUXG3.7NSOILX+:/`A&C1G&O3I^/00D\6F4ZAZ]ELN#.EP:V'C3C4'$< MVT2)["@V%_"W))N0('J*2*C<[0OK`$*G1FSS@]FF_D4C5PH)V=G,.FE(3VI6 MV$/[9N$]R>9`%SFF?EW9R7%C=(6U`"V"[`Z*H<1G4(FJ40?"B@[CYRX/W=M; MU(38&O4B-/9M/G?J]E'-B_R-83VJH7+5HV+N'NHA2ML\' M3,*IGUL.I&S8D6.SFW+,>'RQK?GYB2[W)B.Y-M\+@#P-W^]KJ7%-7GL>=P(% M#LEXDE*?OK'P9Q@Z04!)$6J4#GPJ"@O7K`D0$*2&J'C4-\)HST=/0-,BU>SL MV:EYRFF>Y[:B!HB,($Z_#BTJ;-@>XUKK1D7'N7X-XBESK>V%851*.O"C\#:9 M)2*6G`RJ-`>*09"RLJ;9K3IP;.]XB2>6>Q+"O[&_54DYM-L`%2#(-VF7>Q5: M;&]X/?@Q>R[DA213,G]M5IY575`#X"$X^]>UG\NP87M0ZRM)"/5C]JY'.`95 MLY!']L#T+,&_A$)%3:_K-#7`=JC4PFCOR2OA_FC^[/?\64Z-#9*P"@B-(']- MO1V2`ARVMZF^IFGX/8IEVYYY$0"`(=%,S6&S`@;;NU&+[J/W$A"W/$#;W>.? M!C)LKSDM1/T*BF%/5/23Q6_RS8:R+D!&\'Z+-3*E*+&]WK3R[$COQ8]B9L$? MIDL!FZ,T!B&S"S^+`@G-ABV!.A`D:ZQ)>B7,V%YHNO9I`L!9TLFY,YV4:&YY M@+:[AA\-9/+7EKA^:S\?L8\\^ADIM/+_4$L#!!0````(`&&+CT8W[EV#ET0` M`*7-`P`5`!P`87!H8BTR,#$T,#DS,%]L86(N>&UL550)``.FURY5IM^%4$`";X`J)[]8K&\B+/T+U^=OGSU%<)IF$5Q^OB7KWZ^?W_R_5?H?_[K?_]O M?_X?)R?H1YSB/"AQA!Z>T450!O=Y$/Z]J.G1Z//M?Z+_>_O3_T.7'^_1"?KTZ=/+B'`H&8>78;9%)R?T.TF< M_OTA*#`B'4N+OWRU*?%,W_(JW_.%S$1^T M_O2F;GOZS?_YZ?ICN,';X"1.BS)(PY:*LAFB.WW[]NTW[*^D:1'_4##ZZRP, M2C94VGXA:0OZTTG=[(3^ZN3T]?B^@K,@8(_3G/$GR'UXAUX(?R>8?_ M\E41;W<)[3C[W2;'Z^%>)'G^#:7_)L6/=++H%][2+YS^@7[A=]6OKX,'G'R% M:,N?[ZZD`KT]X%41?4-Z::N?MSB/L^@R'=?A/K7]GG\L@[RWV=E MD(SJ=Y?29H\_X''CW-)9'5]B-/&X\>U0SMWC4NRM\:`*HYG0GZ])'PYZAS^7 M.(UP5/>/4BOL*F/.[#$SD91M%AXP3*AQSO)!>1FO=5`\,(;[XN0Q"':$\>FW MW^"D+.K?T"7KVY-7IY4U_EWUZ[]^++/P[YLLBH'J4#@7)<9/L\Q$8CQ,?^L$/!`[A#9%DD9'3UQ^G)SQ^_ M^M(4B)*@7VNB__PS_VI/E+/\<'J"/*S[1?ZID:5J\4V8D<5Z5YX,?S0WT@^\TN0YT%:%A=Q$299L<_Q M/=&(=X3QWP?P-):1-7R-EA2,MYH-:OF@7RDGQ%A)4#A9X"@+]UNC2"-$)Y_+@IBY?N]'`:SFN]G`/D]M:$ MMBLWZ_-LN\-IP3!RAQ.Z2I]G15E\W`0YIFY^=!L\4Q05@#5C*F/K:\KDD>BK M0D?#LS7JLD053\28KA!C>\+XHIJQ5RO3/"CIKUQS0L1#C7G7[;5J69R-L[\Z M(QV+N95&NY1ZJ39JJ(S6&PA.["G.3?X8I/%OK*OG65ID21RQ'\[2Z):@LW9/ M;M;OXS1(PSA(/I+?8.B*,Q-_ZTHTU[CT5:G+=X4..#-_J\N;*EO#';7LO5J% M9@507ZD60(\]U2**'A)DZ-?J_UXM%F9SV(?OF`FTA\^?"[)4719EO"4:4RAPV&]H'6]"3_NX M(@THJIHF?H-J>.#[X%&-NCV0G`?%AAA;^C^Z97X*$FI:X38,2&\=4E"Y^DBC M!&RA9O_HD/H-.:-I["-QQ!S:`^A]'D28].ZFW."\LK3%'0XQZ>=#@GDO%0`% MTEL'*%0NX:R/TC&$,LIZI2U02^LW5(TFM`_5$;-I#ZJW>;;#>?E\2R:L))VD MRK2CKBKL@71]S-:D!)B4F*&W(?<;K:9SV@?LN`FU>#Y`%>E\G^>D M2V=%@6&'9DHJ^WMYI0S"#IV9S:HYXNT].\("3(JPDX;.B#UH_9AET:KW`]%QLZL.9J_( ML*5E_(2I3Z.'_2AN]H.;1LDL1*!TKL>Z?%:(U3Q1\T'S%>#R6,$"M1:<*P.[]]#HAY!^HQV7'P: MQO6I,YB[9C`+/IAA.YCK:C"3N@>N`[OF5KR#>*]EM,YB4`O.XZ>`VCR#`W<5 MD?U0%)4$`LK;QGY[?/IY$8)#@)-B#UMW^`FG>WR'P^PQC:E=@T,,0&L=:1!Y M^H"K:%"'R&_@@2>MCS_#&;,)PP*30:#72Q>DCTG&SCXO/U/_3W]W`Z)V`$6( M3"(8.15;PSMTJ"+T'9G@>12Q:3B)]M!Y&>1IG#X6MSAGC@/<1&HIK:-2+TL? MD34%(B3<,?<;@\#9ZN//:*KL8>\#_M2)&\JSE/PSY(%MIG%DYJRLHW.$M'VX M$A:=L#)TR,1OY(Z=ZSZ4ITVTQ0/$<(.C?8)OUNHG.3?Y'7M^!`'Y!)[V#Q,G MR"\<*5:\Z,F`[(';JGWAEN6(\T2_WM.("+\483(PA$/%>5#A0C4NM[LD>\;X M(\Z?XA`/'X^>)4F5-^)F77GWO]7/^]F3`S/5F?V;#E5K_O%3J5[]-51]#LF/ M^MMO4L+VJXA_EC^E\5P]%P*G7'T71::3E6]0`F:E^)U'<1:6\1.Q4PP(ADO@ M:.8NU\+Q(Z)<%*6*R%A7-V_$0ZRY>ZYZ4X&C6")G09_G[/3VYORJ*/E['D>_XF.8W4#EW<' M;LT'+JX^Y_H&;G:=.TRYL(S"3;$Q,?$*UG$85"&V,2[8EZ0F0]K>L@60]UM0 MZ+8IJMM6^NEP)0.-_B%X0$-O,U53];3T/`F*HMI2GGV.56_G%#0.$C3)^R^\ M($8^WL(S-\U@V\/(57J;9R$NBN&[L9_P]@'G"M@`Z:TC"2I7'UQ7*:H( MD?2:]%=.[0'BC&:O#\(14VRDE[+>SD;O\-U4T1:8M(8P]6.LC8 M'^[D(`,_`0?OXHQTN21]OXZW<8DU.)`VMXL#>:\%F]&T1%537U"@&?D#%("& MW=YB]#Y.22>NXR?4"R1U0S)JP,<4T8>N6$C M)]H`TOI9MI@C)2CI'8KVB*/7SGZVDUX_A90F_.\>+-/*D172DVS0:9#=Q$CF0O[1PGGV?8A3IL,H7%$ MZTB1'^[S("WXH[]3P*D"C(VS`P:@E-*SA@X]SSK;<$`=%BO$"NRXMU5C)E=V M"F$^L_;3AR@`VC9QENQC`%CUGQ:*\7C"^4/65"*:OX,N\H/(<#H\P38OFPZ] MP0^XO/P<)GMZ6@/`)XST6^J/E0[OJ)BWO MWJ1%[163>XTQ0:1X?V8*1WN:=I:6<10G>_H._",.]WE<$D^*=P]'[\DXT+C+ M?9W2O/\P[6Q+7_8H5'$F_M9U=:YQZ8.]RQ>UC%'-&5'HH0YO%L@_\.J1?\&] M8LP*H+[F+(`>#U*KU@FTHY\+O-XG]/Q#=9IKR,>?)*L2.0TSK39<$&>#&!_W MP!\UO>!4J_JY]>)8ERQEXTYQ&:%/A[9<$M,S6D+E'HFP^3$X?!4FQV)Z`_8, M$E#$I]_0?O*"?D^%7`7\L:M/A7&&1U?(/J`86F M#-IGT_0VL[K'=!TI;S`KFO?.\BF97F/\^T%?BCOR==T MCS*&VSM(*CO<;S%M+&EW4I*&B+9<(=K6FW@+Y>B+65ZU0^\0-]I8"2F%>^Q( M8Q\DZ/$FP$$S"UH$S1Q3VK%Q-$-(<1L\T^7S)L7JA4U/9W=)`\@A/.+IK&&, M!E5$B%#YLHI!Y^=@_3*;G/G1<_\I&X6>#IT7Z.G*`4)$OCIYGF3&@6:+&&8SEW"!(D_H"D/LMPY#'BU7RJ$?OMA0CKO%I!MM\B'MPC30UG[*C8'^BMNM-E67 M1ZN4=*B%=!OJ<;89.P*ZO5`W=Q`)`KJ?\.\J`C+L8NB&/Y<-W30QUXI7+)KV M3M/X7"M>K_0S^5S[\&X%-/BJA#Z2D7=E97CNN[-]N:';-AR![8U(Z-CR#$BB ML4&K.I]D2^0>6+#I4=LE]=Q,.%0^_,P5K>`3),P[C_X]2/:XCL&4'2[#Z>T> M,AO(I<5418TX.6+T;0RORURD$Z2LA2JX4$],J!T1BB46I4:Z4^V/F>LT2\D/ M&&_9P7N6H\Y/!>ER\HR"$I4;\K=='?),?Z+I2''N.AFI*=`/3NG'H=S5"G`; MY#$122:;68T%+0FBBQNU5"-X7JU0(V?S:K33Z45VE1YLRB=:^\ M]M3=OEGS'7W;1.7TCF'FH#KE"(G%JI4/)6J;K+J!8"O$.;%W)?Q;6UH,MR3*J.B5VGVV-Z%XO MNMBS+[+B2/SDX@/^Q/Y4#"5,,2.W'+T/EDJ(C66;9DZ*.&U5AJL^I:+OSCZA MBH.;-_\396Q*M`P<%[R(ZR(E2^4S@)5K&2U4W$M^ZZ6_8@U5H-_H.*"P+^(_K*#ZREZ*S#P15]%R4;H*;^_\%X]];+J MU?*I%O6(M5&"9J`6*J%L]QJ''S04-$]3'C_&:9#0W_*C!%4R5`"MDTL:G3R# MQX$MT0K59-4#6%_R>8'G:NBZQ6"B7*&O.O"B26_J,S"^8^7:`X>BGI%C7`(D MU8*TX7%PDEW%2JEV8.X@"YU@-7[-9M>#&_%W.,7K.(R#I!7B/0YH]=HQ=^)* M=O[P7*5*O]Y'4< M/,1)7#[+[QM->-B^4S223P1I3=X]&><6-VQQF=0L'![D?1F2`F\_)XGZ/HCS M=C\2M8(WPO'KR?:^4QB1H*CC(A^"A-V=%!N,2Q0%I?."[6-4NGEKJUGOK@9$O6?].9F^!)X-*!MWMV,4$V5'V6?2W/4\QH[S@`=+93S^ND6-PU\`O M;%H*]T$<8\7YI:=89$<3MVFUUMB'K/X@J`FIU.$XLUFU\ID]:J@>&]<1=^=9 MH=09-9F#FI9**<02E[QY^U:\B31D).X!!ID6L0(F=$YLIB]IKGK6G9?&S;FY MZB(%0.L@O8E>GN'LDD7U9/7P(7E#Z!YRX*D2TZ$8S=,$E_X.AS0Q`BOH29U" M6MI'W,P_WV?\S9;,GS=F8]>9-Y>RC[@^!T19H*&3&W2?5>_[7#KQB MCOC@"6J9("0?>#UF[%(4W%P MBS:E;`#$U?3H]9NC0)U^+I7(@TZD8R_M&I[@5$KHAZ]V#4EY*KIKUQYF/]5, M$/6NE4%Y$M M\0I1 MZ,VA/'#%Z<:3^J@Y:KDN#R)"?=6=`:S!E$<*-(NUV/8/11S%0?[\,4AP%5NB MJ\,FI[%?@TW1?R&;7]-VA6CK3A433R[SM+,AU&"#385%/+7=^!!LR3_O\R`M M@I`B7E\^'4!L'V$0B02H=>&U0I20_M@A]>BJ#SYG`OP,)\QF'F\:C(-ODR!D M+PX`=;N&"1SDZI;T7,S.S1JBIJ4'9^&PX1?S;^O'WG8XK5#.&U`94$GG*(Q6 M+@>\0+L_N`+-S7#L+&AB%L^=_%IVE0Q1JJ4&ZA#M!.%\D].^%!UCX\KQ]2+H1Z4X9&_JFO67DYZ-VB+QRO<3Z5^LK=A7`0DIP\Q'7 M>CD"W<`W[!IHSZ21JA>UJL;NM$SU>O9`GW2/9NTKC*KK^B7K0$&8<"'EQ;QF M[]8K)<:D&C#A4;`V5U_]'8/4?`,DKC+Q#?5>D?^JP8I?6?9\E<(P@QY$#%C" MO$;"XTB.)]4A22X\C0+-L(;5WJN8-5RWH*DHW:QN2EFD2UU#U:@1OYO%WD]"`<7/&@")R@)N?L>$VR\V.?$CHCTYM1K.PJTCAIQ1-] M=B0I/S>I8D9$#72I;?/(WJC?P;ELF^XH(*YIL4_*>K%JCE$Z&NM:*R=@_D!- M)P/>16;7'X,XI0]AZI\5-V\J(H_]U4] M%_8@U4_64=RL[_%VE^5!_GR?$278!BFQ2=)T-B/Y6`>>J9RZA#;,CV\XT"0N M#0]E.AN;^!PUMWW(3IA8BX%59-'$/)W=>WZ?&"2W61'3#I\]%&4>A$,EP)@H9'5XH/IPF!FEY<`YX##S5VAXAKQ;/?#BJN?7KF*Q]N*3PD8VT/(F=% M@QL0*52T]`[.^_W6_`Z^P+<'+,,258+$8[!P4F[,THO^C^YNG(*%W MM6?E>9#GSW'Z*+N`,*2W'_P,E$M`%B%`01HA]H\.Z0H%):JI^;GI"MUG99"X M59G)@H;T'[@E74@515>Y"4HR^]Z"6@K!::B: MH[8]C;,M&S?""WLX5JB\:>]><2#P$KP*,+9L/L+#NR".:):`M,!$FV_*#*^Y6>:8)ASE9P:3+F'2A9XZZ`2+% M1XJ&<'2T785N4UUO3_7;TF77DY+R-MJ0#O28==`[E(/P[`5R;_.,>*OE\RT9 MU9+H%'7U=O3$DBQ>RJ5!1>9@35!*(=I+WGR%&`$SEPU)Y5(MBGR<0Y:"43(Q M87`K3(K9'5T0AOOM/@EH&J2(AH2',2^:0O[V^^^^>[MZ]>H5(_W]MW]\PW_@ MA:,(VODCRC>O6-[7;UFKYFGEFU.>#79%HWEH+J+X"2<>W$M#<"TN,%!0V]// MJ[0DLTQ?3G-S0;IRE8;)/B([L!^S+/H4)PG@?-2,C77]-912>`7'.&` M7C0\4,WD:V].6N<3V9=%;PQ4^RHX'J<6\YW%:5SB:V+HHEMB3\F6[\<\*Y2U M-V44]G.;2?LN/#I@+4]84U2U72'6VG$:,[`(3:\'UL!@F^5E_%N[!IZ>_J%= M`]]^"4N@!J="AC0(2/U:^"8N>)XN=-,6.)>;M9'2\3U)DPI,#"2F*?8'NX10/'SVX@E_]A"_&!=EEL5<1FRR)R*:81_@"]C-P M%M8A;"!='T(=TN9,@NSH%]^R@,XCYI%K1=RIG,KW#MWA".,MRV_6S7QV2Y"& M\YSX:/S9%!V([M?^Y7??OS[]XY_JP7EQ@==Q&)>2A<^FSIGBNJ^5XT#M1&_A MD5DJ(I>ZJ8]Q.D"M;X%:1I+4G4]:(J^T!1BW!862_3"$*J$AT5KRFWR/([&K M@*@$$!=G00HP&:77^W4J2VK.*P9H2,.\BF&8*/.N(W-0R5S?T;I7P!'@E<4\ M&"/7YGM6[DW<[K%>&V4$#MZQ2GHNOF&M'*:JY=*Q#"!WT;SW.6_I7C'4 MD!'?V^KQXL1'^T"D'>.F#=&Y]-0&Y5`Z:RV%C_X:3)Z,IB?!^=9;ITT.+X7? MIL.6_77A/O@\V#_`"B$G=;96**21VEU"<^B)L?B'EM:'562,7"612Y/MR\6J MH@.<;'V!HK[[]ZNWO[Q^_J/=38L&JZ]+XN2_(,. ML<`[@JO*![\_?;/ZX^GK)GZ!_/CJ=?5C"8U?^/8P?L&#\_31JMLW0Q/UUF;E MFR9/F/;=I]#407T;H;>J!'BK^M$F3X'FTE;`>U[PG@N*_NVWWZDT_?3[/ZY. M:53MVS=Z79!T_U]*^%T+D*.K;`#^[^+0?\ M205X=$*]U)(L!?3(DZ\5[I5`#:.^#D`P9#-E91G$*8XN@YPF+2C.VM#A*MY$ MH0X08@?)*0$2B1DI.1&JJ="+#AVJ0V\66CG>(Q30S#J,$O#L MX-T7:^7>,L"U2\P4:J9:-G/P]<.U%!9BJ+&#''P#/1XL^58UJD/NAL]^/#A" M!4G$3U*+@XC"-V__Q-Y,TGC"2!E/.%D0@S0\(''>\1H?RV8-`F33F:&S=G,X MRM15S.&HUE67)@:4=]BCV&BCJ&&XZ?'FEG^T?"8FR*V:Z#,F^Q:V_#''H,V7H&&VQ6TJY:JK9Y]C5>"!DLK!NT^5#.)S3]H: MM?FOZ_9DH2,4'J`9,"?B@TC@A#A'UD6V)9M,HUH&H'9SB0V023[DY517WT]!YIF\S"!=UA/-/UPP0*1Y\&\+1GI[-L\6X M!I2NF?U+UO5W_K'JJ\/\.^AKGVKO+`2VOKHMBC2+(4V\AS@:%J`R'ZH()R`# M^P%/4,F$"]&:4*H8]:KH'NQFTR=$%8V8.Q>GLA+EHO5P']DVKGCWW+:Y#9[I M[\X^!7D$/XF=_`V'IZ_3QT=UXBK5@NX'T,/S0RX+9>`5.`\D&P7.%:(\/#J[-9M($Y#* M9M'!;I?><_.N:L^2%#3N=J`#_9?O)=EKMPJ,_IRG:.="NJU33X1%+UCG1LB\ M",AQR1S,[?N]C@F!H]`9QH- M2%"PN[$0']4Z#@VU,13,3%\!&O6#KK/-L"!C/-Q[.>_4@:EL55RN\C M="5*%OG:T:UIPV.VY*K&OTA?8?-O>E%BQ>(PUD,@RP=Q3#9*H7%S6RFMNEE^ ME<)3>ESL9_X['8VVL7E9YR',9%'989&,'/SBL54XB6-2/V=CAUQF5UE MOO'IR+:41"8O>R;+=."?X;HE>D&FC;_:]^7)SRA]'GP*-$&9C\?7>I_E:QR7 M>R)7;9,7]+4&OW9TOM;PF"UI)CM?],10VAO"5OPOP=-2Z-O0 MQD@M?@LS\*TCM$_B>%G8:M+OU;Z2E5J\Y>^'? M"C;K&(]9Q=3/F([VHR1VXFO^RK>[4T=<:7DU`P%&9WE%&87;K.\$B')$!'KC(/@-:4WQ,$04+F8?9C?$DVW!$YGC@SM*=1VS8 ME>,SQ^:CO;!7/!#C\&6;X^DS`/",CR5T8B'CL(!G/,$R>&2,X3>QCBXPP3WP MS_3.-K;6PC;89K4AOS_/ M4E8N91\D]SC?OM997=N]<6.!K8^YNW"2IE>HTRU$^^7<`78^"_HQ0B_^`P=Y M\?7Q1$>X,2>#AMNE+3D>(RY?HV2BGBYHQ$?UYNB,^+@Q=^=2?YE&?)Y9,#'B MQ^)QNS$G,X\.NO5%9$H3HLX_/<@V5L*T^Y_\^C.-53C9\UW;KZ, MV*>/_>3"9$Q[HKO+?^4F"GWR^`#CS(_IZ$9KTA:,CE;9LZ/T[`\%LN3`"Q\] M9C]='$%K[KB/ZX*M014,WS^7"RW1VP4]9:72'H%#S!]?5B4MBK.G($ZH6.^S MG(5E+^$/:S]Y/.ZP?O06L'K\HTWYE@(UWT7K+.=O$XXTA:#Y>![*OM[3V"GT MR)^Z[-.(C%.YP$D2?6;T'-GY;O/`F*XF;] M2T`E*&_R.WIRT?%-%19,3VK=$@&DZ6L`(Z'6H")"1`\8V<&NQZU!&"%6U5:2 M#-6FAD(1UM/`E9(4J-O7Z6S-B2Q!GA6I>2QWX9^3[6JV;0?![^J$J M/R7**T(/='(LA@4EG09@>UI+O94/P19K2K0=-K.N:[U>]M%$_XSHW[TIJ38T MK'V,R,?4_O1KRZ#U&SJ#@+2L60<$WA0M&QY>&1#&%B$+=IL'-L&OWKYYQ::7 M_N:O]Y^R^TVV+XA;<)9&]Y]P\L2+5#5[%?IA::&Q$3RL@6*,?,(2]"E#-3TB M#!#G,+B?CY'-AKJ,AFNM21.Q.IN2?8C3B2JFYN!2P32R:=6+ MTA^)7B=/W2RZA?P2H>1Z)F M(T26GKCZJ6I0X*K6,2/4'L'5D*3:#/GI(BBQM;@IX/>/Y]+(<%QM%Z"B1\BT M([![]*.X*AF#Y*6+-@%@[*"N-W`_8Q6\TJ+B]I#[!9@%;@3?9WGU*]I.%65GNR-?CJ&0 MC?1R%H/V8M!L\*ZP2[).9[Y@^Z%$N35#`H#X$6Q&>M$G^W*3Y50Z"P%JG6\= MSR9#,5Y60M*:#[K7[\4PMU1HE01P]K3T+`SWVWU"MB?1!=[E.(R9).3?"68B MI='9-LO+^#?V^]L\V^&\?*9G'27YV^4_]O&."J=0SOD^85TG9QP=(9JQ98VZ MO%>HX8[8&6*'/UE8JR^LV`%;N6)-FL^X?')Z9$/%:K%&69+0YZ?N#=?<:MBW M5\OHH#TS]3XFW@R^CI]P=)66!!SQ0X+/B@*714>TK@@*@S2&F773,TKBON9P M)B>,"VK9(,YGA;J:U67E7B'&3W@?^E-GVQ[([_%VE^5!_DS5C2A?D-_D'TO: M.W9B2+Q[YC4HD`WF8!W.<-F$&[6:$G%28L^#G$8^H>G!FF4(U[Y>CL*J,V4TV(QJ*5TK'V"C*.(1N-MSHFBC M!*H"G0./MJ]`S&DTR9>MY6"W:&RUN?;45'YH3B,#6&LXA7<:8R!(I2VQ0A#G MFG*(+9"6#`'+L8;`'K3I2?W0%?7++ZG"+/^<;;S6F(I4J4ZF$\FY_@`>NIG! MSIXF7:5AML7,?61'K0\%2UZE4"`IA76]D?==3/E`6Z*F*?JU;NS!NPK-%/21 M!!I_4P`5.'SYF#U]$^&88X?\HP\9\JN_7N/'(+E,2P)AR2.KP5;6H#'<[NMKV.(#5N;`D%'8ORB4]EVX[J,M M4=5T5=_W%RM$FJ\0NU)VG#T"+$K5:*D,/_2Y:UJRT[\?]W$T]!3:[@Q8O355 M*X-P]PG1!'NJ?+/#M'1'^GCYF5[$DIVO?O%7T%A79U7_^W!JVJ*ZL=8%L*7* MX\3`56/W2J"%45\-@!BRIPCT'3L1>G.61A=$.Y.,W=A5O5,H@X;.ND+HY!"7 M!MZ>7?!V*&H=\6*EFR14U%*X5Q00S/K*8H`Q>PKS(TZ)"B?T[CO:QFE,U9<^ MY-&KC);2NM+H9>DCK*+@D1,'-%XISC3!@@,:/[Q'ZU-ETSH`=:IO'XP4RN(V M$=.LZ$1P&FU;*)/#]EO:WQ8*?14V(W4+%K@M\;FL;?T,NAMN@OS1:7XE?6^K M[$F@/EO=W`U#6-C4J?#K8#/'CP>OLT+UEFRPM;L-W$&?Y7N>ZA3W!6WX];)K M+`C;L/[37R,*+Y3Q]EX\"%/@1;I?DX'%(LK+#!!PI82-`'<]9NP!_@+G\1-SZ'X,XI2JWDW:_DY]\`Z@M:X( M$'GZJ&K_OD*4JEH`4):B[I\(L5LM&2,;ER>IY8F:YBB)@X$8O'@G]UX@*Z]XD@!6K;QX,MU4 MMJ+;CCWLP\8\O?#(S)T5I9Y_+`O M6>V7,J/OOW"Z<``32!D@HM3(9YLCE[',OG06N`TU[JY_AY.#&MDW)@IU=/80 MX2P,<_8L_#Z[PQ'Y&_TW>Y5W%OUM7Y2:A`^CN+E^K@"461_NWS"BIJIE55?I M:[FY]63G$;\5EB:$P7F,"_0.D:T0QEMFKD.:QHALE>B_=WF]IRUHQC/W"CH! M]IJ'$>:8=^0H-,6][K-.?91-ED1D37D7%'$(=24@G-PZ&R!9`>Y(4X>.*'BW M6E#%:848+V\'CD*=J?8FZB;D2JM]$5,]=EJ53.R ME&S(9BM^PKS#I.BT^R>$/4N`=NJS<9"W"81W4=AW'ID2ZH$20^ M*-/#QTD69;8I&?#=]087SL-E'F2M?"K4\1V;8M?J$1Z-YU21<]=D0BUGZ`?F MF_(AP10D_1)OL^HFD")[-_P8I]1,D%U9!4`4;-!#1^'Q6^GRML(@Q<6)LJ(,UDG M&5A*&IY*G5@7;CYXLE<4%"@@-J38)^PHC[BRC;3TYT\5XY>.J_R.4LZ#(K\3 M-'-^H\*]D*E61&J_Q4M\3 M0_68TTBYIT'OJ6//N!U#^QV-#=[4L;%%M:/K;N2*YI.>6CU#VP%VLTP-QU)^ MU^QF$<[6"[MH,`H&AK%*[G^DEG'"F(!-XU'X>*.&H'7Z#DJ)#-C'@?WF$5M* M4WL"=QB7L)5SQ9S4;QR*^TP2KL!D>.A7T+W#_]C'15S6B:6YO)URUFR54(:M M+/UI!Y$OBX^F&#S3?)):J%XL#6IC:5:*XO'-UYM"\]4RT.F`%RE&'0PP4^QJ MU,(.0_='\[9T5XQJLJFX%F.EM[LD>\;X'4[Q.BZ+LS0:+AZN,&H&/.S'5!O( M)\195[2H)F:98606Q>7CZ2E2RG0=G;3I0AT'EA^G=+N,:'W\Y$:\NG(!\51Y M;!-9)X,PQ`E]?TY^?,)%Z46I+V,#)$39C[,^?KF;'0?Y`C^4O\3EIO6?W^.@ MW"L+*\_W"2_=1^#H3'`3N[M\^@GTB7RC>Q)0?<5_3W#D6''M"6,R.)W=[)JW M9^M>WC?)@I1E5O,@U\7<.CC&/3170)NO@^2' MGA_P)_875=8>(+V#UT$PN48$BA!RWL!UIOJQ(AZ<:O;H0;GJ>,7]P&>6"DY^:>23XSR+SIBL MT(8*X]QZ`"^[QJ[H1V0_X",QQ@,X6@LR?EAF,2%'Y%[,;4]&:=!"@8R-\S,J M8+%+[44`CBC3I!VTA^$T>@D5ZNEA;(Q>GBKO2;S=!6$3VM)$#:9DLM21@R_I M6^ED'Q&;T,$K3;/R1Q2%B2`:,,R%8HH'$R61K1/*6]/WL: M-B/1:7`@H4RAG;LSK'?L;S?LD9KR:<<$7KXX+4IY1]@TWJ3BY?JIQ_RR9Y5@ MFO=D'K@4>B";[$H`*%[(<>!.S!U.,+W/?$_$ORS(^'P:XT;(>?GC5"CD':.. M?"&JV7&WF3/TU.4PD9\+EQ\(AY<4;K(#8B#=5'>$';(6\B'RV;/0*3W8SX!I M_%+/%&:R73IF7A@OK<1C#CV.RGR9CX!<.8_BH8'KR79MJF!*#G\QX,I8'>[( M7D\ZH'GMB3D299IT0//:/W.CE[![0'/PBHEZ!A*1CW4:9H6,W!/Q5K9!NK M8Q\5"!TOGEGAL/%2'NJ9A_>F<%P:*]T0*)W4)C@/BLW[)/M4F)4D&"!S68E@ M2`IE`0)*@!B%KW4'I!.C*#>@F16K->5H7V[S["F.RP;Q*;W95A=RS ML(R?6##`>9:27^S)[ZH_9BD$BG-]P$4%NGE&9JC*"T-US1H]/*,7E#O95'R- MF@^@]@LLR*?Z!FH_XDT9J,7&BHW3FFE_MTHL&86@8>G>&,RK1`/%W6;7("=O M_#Z0T22"7!$C6-#RFG1TXP0?%*^[SX"R`DS/\I]V^29PJ=%4O!5JCB'UU MQ0OE5A]&8C5&6H/1S-!Y8]'<#C3*:6J$G#].SIL13H7Z8#0+$1WA/1_40?OX M@WL#:7[+*^R:11D-Y,$\5:U)3?D8]W< MF!2I9XZ0OONATX284WK M$%`E;$D0IW&\RD^59T=V]*E,"JLK+`ACPOIH`#!7^D(S`M0%(6YSO(WW6[#* M#-(ZUIIA>71`8ZDW:C+THB)<*@)DE/J,$XP^Q4&1LLJ+.SU28$^M2EK@V=.F M"[PC.XA8EZKLL)EU'>GULH^:[I^]2#UHT%_WH!Z"0!^_\OFW7-?.)+^>-\GT MX&G)I%DW/0#UY.1J[J%NEB'-KW1H5VF8TP"_"\S_?Y6>A6P%*>YPB..G@'AF MJLT\B-S^'AXFE;!UK\C0BYKP:WK`5=.BEMCMK?I(\1HYZ]!]C&7J@@T#)31>]BAT[Q:X8H@Y' M+YS(V0:CD7K7D3JHI*ZS^/JHU":PAR^C<,P[5OF)"NZI.D]1WKZ>>JB@('5D M9X%\31195+Y9);/V(+;LH-SK4726,9>J!Z0,F!REAQ M0Q4;MJ0P1M5UU$(KZ%1G=^0@U-(V*>^IN!D3MR[1&2ANX=RJL@GD]7 MZMZ$G%0)L@'!;B9,/%!KA81`56[#QRH6R\>.@5XS39+U?$-^HN$;!Z%<#)U, M>9-V<6+18-F:>,2\B@X-]O0@U,L=#\55K5#EDJ:-[X`[X$S9N/ MC&'0?/.!XP^:GSY6_:#YN!F<(PB:'ZE$P*#Y21IDS\"0O7Y=,2-D@T:3HYJ^A5B'%9LN6R8>.'7 M3Y.9=&H34">>)=7DA$Q(7%.YUVESW/;U=BQHCV7Q7VS1/[K%?M%%?MF3\)+R M7G9YEXS.P6./+W%=7V8]]\Q6O*\3ZRRU43#^@"^VPWQD#&U(\X'CWRA,'ZO^ M1J%)^'0,!F6D$@$-RR0-LKA1R+,0XZB@*>':MS"W=<[U^E$,_P4F?V2_46T: M1C*TOX$8*[EX2,X9<17HOAAKF'7>CK7\^"_=6H:%!N$CSND!XSN4L\0H[/*] M6T,#E-/?ZKYCDAH(>Y`9=,"-">@5T@3JN4#E5)E%&=1@[1>H]4W.%==;9P4.U&HR=**NMZHI:ACZZV=;\PU!)Z8G869B9)=2HD MK>7D7D<`Z.KK"!A:Q[)?76R?>G3[TT7WI?Z>;4T;'7:VM>N,SI>X'5UF&^K* M7M`N$T^8_H^>RS\%"35G/'%B_QI?81W,V%BW!892#IZRT+TC^T>'PZI*#XH& M(EP\4/*)8G_@R8HJP:)NZ$Y8CPC[!VZ9N]?N,8CNZ_)X.-O3W'?[(DYQ45S0 MJA(Q*]_$(\MIK#E-?IHE<4BLS3W^7+Y+U&=&(WA9U^$Q\O817?-`'2;U4XR* M#:KYH%\I)\18>9"N=/1T][$]<:YM'HMTCVL@,)92.#@.D?5](,+WX(C2+]1I MYD`\-`!,@//-$##OIOEF",S8E\T0?"262X'K@9^TR.AHLSJZU^YY]&/>;+>S M%42ZJ&K3T(@C\IGR^2I=9_F6?45Q+V]`:[<8$E`>(8]-18;.:#0=(T0=2B]2 MLAO/UT%9&_/),EV!"AR^?,R>OHEPS!*7@M'J=6K M5=X6T<;$*XD0;>X6'KJA[R($-N[+FHWW<8+S<_+1QRQ7&XU>2PQ0>1,GN]*J=]*=*/V['UO/[C@.;3?% M05QJ9L_(YR+ZR?=)(#,3O396Y[;?/S'#>/5W1!NXG=W!L>Q.KV(@E]9FE$\!T)[\![\KNA2RQ->R?(&.JW M%!W5WK$""6ON!T*DHS^$$LW0VT$*W;O"<=)I[1`EW3[K,,+.%[Q#B##JT][#:#4O#JB/Y=:0ASH;G6D$S$LGO6BVP; MQ$,U'\0F#O:A3>\D.\Y?>0/'V#H(U;J1MY$)X"Z3CK9"?,Q)_LRE*8].-&-!AQ6VR@Q&1ZRRJ#\P=LEL=Q MB-R##(Z#4H%K#'#:.J'YBA8/]BTK,E#`2A*R^/OT9M,$A9`Z`VH(3@BTNL,% M<5)#&C!_@9]PDK'D3C_A[0/.!]0$0&,WL$K3?_%-)F_.XL8[!.A73N(ZC@HR M'0?Q4_"YF`"2CW7.\?--D#_B.BY+%XBG);,+%;T40IVMF@)Q$E2W]2?P#C@U M!Y@QFI?Y8$,+,B99L<^QZCD`F-(I>(9ET>*G)0,\%9@L4%3M*0?+^$T2['Z# M$6%,$S]&K4BTVG71$_FE7_JAP*!*1;0`G$]+6#"CJ8+TB9SJAB"!5BUX$"KR M4R.TXI`&^R3(NYJ0K5%)5,1S91B&FDH/5#B;605,D.\#X.$X]\QE&(RT!@[U MA#GO5OPDSNL[G.)U/%A%1=W<[LS+>RW$2G9:LMW&0]76S3[;\]Z###.\^_>; MN$`XP6QKE]/2R@7+PQ-L6?UVEL=&(J!K&ZW1BP,%!2F%O:.WR^TNR9XQOL,) MRT'4%LNH0FX5YVX`6NN';A!YA(N(BN8DYT2']0$K.K=';6/$\K#Z&!AM_?,U M0ZC-Y]<(%X`:WT9R`6C=O[E67,.*/LZU#U>PH.%7.3N2L;=G3(VLIQ?F$F1( MALRA![=TH+[S:[JZ=%NB*RAITQC"K=^"YDYN6#]DJ1S$!K1VS2!0'ID+@.Y$ M%P`1RH6]`&65M"ER`7T`.WN!D3)4-^W\>"8,\OR9WK<_!EF9_O'#?E_4+6DNXFZ9C(]$NV2U5YA MF9%AS)_B$-/?T=+AY)Q;A0#Y% MABU!):L83_^TSHE0N-W1();9@WR2*&^"PY*)F!(@UJ9LE^5L'U1)W[%LKG=# M)B;E8#DWMR=.EG:R:V.O2#99$A&]I?G*RJ'W@'!2E\N^3!J%$]#4B:*EHWQR M`Z"R<(N2=-T:P_SM;`B*SK?^Y7=OWOZ)Y>4KGVGJOG4Y,^\&]Q!)"1#Q$3HH8+7T9P]_*NCTEG"1>P<7;$?&8;XU>Q"F* MB)<:Y`7:$0$+2N_!DF8`3"'-K"DJG:@;?YY\MB\W61[_AB.8FHE4+M5K0`:U M6E5/S5L*;U0)+DJE0@47)="(XDAG9.A2Z(H:6@YUA)8:,M./FL*];C1]A^C% M"O'FGBF%3H9#A8@5(CA5AD,8:15A"$,.E4"=H01&YEX=U-E)AG5"FY?$F6*` MI#G4CLR')"LF(-/JR6P)5J94L*I/A%DA7%U^U1!3I! M$:?S]BA#`S,A"@J",7=*`BB^+B=QKB:*-V6BGBQ?Z!RTB!K(<-NH1=RFJ_C! M/Q70%1^'($OR"X\<-4<(S&F#QB#_LZ;)ULQ8\X'=!$8<*S3#D8UU=3.7L MXZ^F1Q4#Q#G0^`4QR^0*,39N%Z'9)`XJB=-&XGK+QV+:FZU@=PM(%J\'RI/<9=>@:%G/_./SJ4,[@')Y4S<9RP][*T]3&,N'63GAQC5^:+)-;,Q)U\.,A2R3CS*\.)$?4:I1QYG=,_B?3_0 MT`$?>*0!0[T]-6]KCI]OR-2RT/[+/,_R\XPL1"%[[@0XP#!C8UW!#:4<<-;K MRO05/7_O0CF@#@LO\LE-F=D^B,=/JU\(AA2N-^3C)895^:W@(-8F\/(-QM+D M5S/,K3T@?ZQ.]6[6O)-7:=OMRZ*,MT$IS:DU@H=U`)O()QQ_=DX\.35-@-R! M=,W`?7*NT=/9!^W(N;0(6/I4@FY7/H8X#?(X._L94`LFB>\"/VDO0^XP]HF:4+O,1C9*+/_BF67<:`:NL M'V6&XK+H/*".]C2I#TO/LV-5!UUGYH&#\B`OCRDB)ZC-NS@C@I1$(G4Y$[&= M7948Z&`>3+9Z9*BC9E9;"[I0J^RX&(U45MZY25#5O\O\]NUR@ MC*2X:U-FTQ6G39L=U>+11S!D'7HBWWQJ,\8]NUZ5]#@[`#H49,YR4K$5\?)S MF.SI7=]9%,5TCH/D-HBCJ_0\V,5E(`!7GE`(R,YUSBJHU/I$3QK?T&%N)Z.9 MU>1Z&C&MSA#=\?CH<\TMBU61;6)&\'"-7:5\>L"V.QNR!6@9>`IB_61JD*N; M22(CEYGLJO].?B8_D7\\$)/-!N'_`U!+`P04````"`!ABX]&.&=^0O(P```K M8P,`%0`<`&%P:&(M,C`Q-#`Y,S!?<')E+GAM;%54"0`#IM`L` M`00E#@``!#D!``#M?5USX[BVW7NJ\A^<>&R7[B,;_>O`S M<@0-B[/?/CSE^>+73Y_8\R\/:?13DLX^#3]_'GU:/_BA?/+7EXSN//U]M'YV M\.E__7YY%SR1N?^1QEGNQ\&F%*N&5V[PYCXH&_)J_+LAO'S(Z M7T2LX<7OGE+R^-L'?_'TP&@>?_XR^LS*_]MI$BSG),ZG<7@6YS1_O8@?DW1> MM/K#$:OWC]N+G>;[4"U=/-$'FC`=/K%G/LFK^02M;-C./_TT]>,\@Q>L?[RD M_@.-X%T&[9178Z&==WD2_.MZP7!G!NW:+6:C'01Z&;/&&5]A"FZ[\?)F2Z\>3949CDC&3N*.SF#[2`,QB&@3) M$BPYGMTD$0THR=;_-VAY_5>TW&/N_8?("(E.999[CW$;>87M]R3S9O'+.[#@ M4Y+[-,KNR4N^]*,6[;CZ(BLC2)Q![2&;3ISX$>/S[HF0W&P@$=9AH84W\'L" M(U5X!SHW(%M13\LCP^IUEH:&M]H.TVISLDTJM3R^F3/-+=U.JP;-FC5HJUW# M9NT:MM4N<\N356+_JU7#V`05M#(;K,VBNJHVOSTW,$#'^1/)X3MHUFJ]"BVW M_0[6SX2MTK+KQ^L%6YH;KE)T*FNQS;@17:^^MG3>91\MR'H5ET.YJDMSDS;F.G5 MG]MMM68!_P3NBUYT"2_?:1:,920.2;AN&*NKH4^F\!O!>Z,DV'E5Q#Q62:JB M@/W&D[U@^I`Q7UV^KBCR'TA45.]IE_5&7[YL*-)M[(J6PH>6D>"G6?+\*23T M$VL_^Z$`\O'S8.5!^S?XU5MKMAI1K-,XK9<][HT_?]YI\+:JTW2W\7X:K*N' M'_I4(3I.Y3V.!6-N/`,R):Z6XS.\+M-]LOCHCQ.IPC!(^5>0"I@VBKB4K M`K8\<*V>:3]3X^'+.D8L:VF:MV1&V<C#QWL48/^,4,:*+*(>RUE./AR_DS8CE+VSRG$4F_`HQ9DLJ[Y,Z3,$=P MNI1HUB$Y4/CZ_8)8O_O49W$M=Z_SAR02*+?S#`#%.*%1:L8!P5?K"V*U5E^" M9#Y/XL(!5[I8KI;;^3=6\5K_V M]N,0KI*<2'9F]0IZ@QJ[LH(M9/Z;UNR=0E^/DFR9$A;.4A(,.M2'V^A&6U0L29P6\6Q*Q")JO299GQ1J; MG=0);_S7(IQ&H\,UJ]@;#IM]LP[`R,EVPV6]V5+-WM#IY]&BL+O=WR8]W1\/ M*D>5;`0U5>I<2Z&*9U(4\\:5SXW%)II\)94EH:%.?=CZ9/(^BYKP.F_XG"-Q M#CZ'F_!*X#N>$3;Q+5JS:9[.Q\^D&F_\2XU^=#BX.E\VHWH`L-/^6%\D_G>K M!OC.]];:QT`=].GK=.;'].\"_B8ZG-E:'-YL47/]>$YC&&JI'VT"QS4ZNY7Z MO>'$U2``TRF:73]61'LM_ZO3^_4J$9.?:[VU>*/!@9DX`D^KF\\?V0P"IQE M.9T#1SR_+?]!;^@TP.Y0QL`!C2>"N;[H["P-,,3^QUPUSW[$^-`?,+3*>T.G MX7N',A%]+O!$5]>W'!:70P#N=?Y$TM48F=V2@`!P=NZL@"VQ'*WRWM!IL."A M+$>?"SP!W/4MYR9-%B3-7V\BOSP(!)UE4>QM:P\[NE5X(Q1^]+;MQX@./`'D M#18"K*.L0G*G64;TO+:24MX(Q4*V;4-1,8`G++V^;7Q+DO`[C2*@[`+HBF?L M&'0)=OTGY<=)NPYOY#1T[U!V8\8'GFCX5JRH^N\FUL2ORQNAV!]R:%427O#$ MZC<(?GC;_-K>'BLWCPLV`J"0/A/V05?;5XW:O)'3*,A#65A=9MR>,!#LK*TB M*$IJMC,UE.D^6-;2W3]?U;K]T9.8_C:MBW[7"$ZXM`@V(*DL%IE MG2;QDMR2()G%E&'1-Q!E66_T0[B?]7A` M=*"CB;ED!,AGKM130!TEA2?C[(5]OM5N18W2WNB'<$?K,H'H^$A]HSGSTYC& ML^R&I,5W6'^$493T1C^$!UJ'!42'4NH;RA7YOK6AFR8Q_!B4-)ENEIM6Y8U_ M"&=T+5I:.".#Z'S%*JUVCTY9C)T%=;.[+$E1*X?Y><,KM-;.GO2VQBH7:&,47A?K5M8"2_;#`]T>?:LSM3KT`;BQ MO2[)`6]Z]JUJ%&X#[O4IY'4--;+.KR,:7D'U?I)&X&2:6#R6NM%CK8(HB;[T M>6_2HT#!B>"DJ@Q[+R;D:RJ^1GZ6K9P?@AS\RC+>Q&D(H%HQP:Q8BJ<79UNV M@`FS]HL?]B9(?'LRG?C:"L#TX=C)17R3)@%\8_G;F[^3^0-))3IKE?"O)IF'PI%:]K@W0>&JU-.! M-[.6P')[:D(@VPE-@B3.H>9+.J-R;H/#]U99-!JL/QQ%@C0BH+NDS MV3N(,PLE61S2^_/OH'$?VZWM)+R67 MZ"G+>,>=\HWIX>E%E/UZ+O0UF3_0^,V/3,/59=GWJ1]G)9B!I-N:5.,=.W6H MZ8DK7WAIP^Q%4/WZ?*Y$__4CWK%3CUD3;7<@]"+&O?JQNB+YV4L0+=FZ4T-3 MG>+>,4JWF8[>VO`0W=O0("]HG-.01DMVQ/".!,L4EKTD*P&3\!P895$PR_5N M8?4RJTA65C`LH7J/72I&D(R.$:QG\832R$K'\I[V%(,1*#8;%,HQ9=7!*]`8_H]C4$DDC6.-R,%@* M,GHFZ4.2D4OW6JZSHNI*6GD>6$&Q9\732J8J%X:E""(,XO*3LD_SKWZ:OM)X M]C_]:"F;'6N5!]90I(&52"KXWNJCLQ2>A,$F]C.LPQ)[Q9JLWTN*`4Z06A$@=E6 M?!,&0]G:>EO%:7Y+DTPSTGV[!%"#PD5GRQRD,&U%2F&P`)-`M\$O*#QXMC3> MQ64KY`F#J#H,-9P:`&DHG'XMCO\"S+:"E=PO'4JDRN4?P$;DXM/W[Y;MMA4T MY%ZN=4Y=6ES.O9^U5&/2KUL%4(?"IV>V66.&SE9,D?L5X19N_:T<<2&@!X4G MSTQ.I4EP40J,H)M.O94_^\9_9_ M-E!!A(VQSQ"#K9RN&KRZ7$5M%OP"WAC'747U+$"&22!V!_V%Z]3$JS2?1H.! MLBR0A6)N6,\`-.$);*&3KD$C^;DC88<[O`B/0&!CEQZJ-<)5$@=U9H/[Y8`D M%.Y_RQ-"$5"!-1S8O2M]5X1`(S"9]]46@$P@9*=#.5;SU3O_1;S@EXMGH4""/$D3;NL-\:14Z9>/]='*)"XVPX]K3[.M_O! M%Q3;=;4[M@250&ICMQVJ";N>P$``MMYL8S)>PA(<=NI@6-X]F2^2U$]?2S;6 M4>5ETH-IGJ?T89D7%T(D-[ZB>QO7!62BV+ZQ82,UP0LLJ8/^NUH;?3*NOV#S MV-6V#15*@1%TTG&W=;N2\N!.Y5$@`\6&GDHNOLA\-`)IS5UVSOOW-`QI">/& MI^%%O+H[2[9%QR\!Q*#8CJLGLQ240.U.1MR5QTO>T*KEYA<`8E!XXNNI+<,D M$+N3D7BW[+JKF(3KY%?3(%C.E\5*]I0\TH#*/N+JPD`8"N]L/2/0Q21%4$K)WX..6IN[C%FMG+R6F3+4:;W$I?RU53+>$XJZ+23?2=E*%ZS_05>S@.G\AU$K@S^&#WJ49DWO,> MDN,D]49C(:(^7#>XATXY'`M*>#A.C8C5TE1W"PW*ZP2W!IZK)"?K\PO7,9$/ MQZIR'H[#'#(].*.Q%BJ4]PL*6G[_/:FEXULY#T>$MAT==U'UX<+!"\"9Y446 M4?7'=/]A#TZ:-S,K2KLX8C"%@BHH[80 M52_N^EO%("N5WGG.PQ%_K:D37^1]0(ZO][/LBUI%'27S11*S-#"Z_BA>.0]' M0&9#GY0062\N!ZR@4RZ&N,][.$(TU9+QI19CZL7=?EL!1N]9#T?TG%@B M@=>1BZ,75_YINB1ECWLXPF5-115"Z<7U?=L>V4N->R.XSWM((A]K?7+%B'IR M8=ZV^9:;X]-E_L0FGYL]=F47KA;T<$1!BL73ZOD M4G"V,E,YM0;F^[V(LSQ=%KOD6S[>)9NL7#^64Y[-([(/O'EE'H[H6%,KJ0G4 M5GXJ1./'*7VF(8G#6^@CT#L")MY,?_3@%_=PA-`V&SLDT&REKK([31`:]<4C M+;^+-\N'B`;7C]!$&L]NTB0@),Q^9Y>D7A(_RX47+@L0`"59!=5>D>_%G[*!R#XTBP,#*'QW1O(;8;.5[,JN MNNLD+OLHUA^]]1,B@?5K`!Y0./&,-#:%9RN+U:%D/GN!KQC-R$U*`])$;4%% MP`H*)Y\ET:4H;26Q.I3VQ>JGB>:5"H`%%&X_2UIST=E*;^5\?;A)Q7:=TAD% M-.RWY7R$]S77+@L\==(3J`G,5D8K1`:PFKB2<#.7+>'8,JO,&@>XX] M8WRV4EXY7O;7$%Q4$_#2/8]>79BVTF(Y'<7/?9H6:]YI^,]E&9DL=0YHE0-^ M.N7T,P!E*SN6VXT__[78REQ1PPS?CP/R-&Y7G>>2Y(/1*`WQ,2U^Q0DI'B!RAVW1+V@)'KX-)?8%YI0$^IH5N0X'% M"-WF6](4^)0$19.'H[HBBVL`&C"M:AL)K4+I-OE2BU_H2_W#C(*"0!"FR!8; M,[,*-I09FPX;HSK$Y-20BM5HWZH$:BFS$X8,[QN'/6"?%Y"R6YK]ZSPEY"+. M">B8LU,;6AL9\BJ`.TPA*09&4@^II4116*WD[&5!`G88,(E`0>82JV$G_$J` M/TQ!+)8L18;55EHI[,;"4NS5-!%6%,A"X==KQS`V"&UEI<)K#EMA`<;VL%76 M&XSP>OT:&,0>1%OIJO8M`M^>BL/+)EK;6AD-4:WJFFRMC%!X;W0(-]]:&8GS M$75J*7^W?,AH2/WT]!FV7EQUT4K2U\$(KX]&/=2KH?7A$@P[65\'(Q0^%@W-^&)+4/5B M,Z91WM?!"(6?1**18&[.1^)V@\7R>&WEPKC!&*_?0W^](5P*JA<7:/`0LA]3HA[.E66!)Q3N M+ZF,^LISL#F^;$,P"3^A29#$.=1\2>(: M#@^#8NQY=J.#WU-4'A\%)*Q!FU M31#VXJ*,U@Z*3#"YR6P,YQ5LCB^]:)2K?BCJX)K%@0&\OK&*3CR'J`E*G)=: M""#L1)O6EEM0"_"!PE5F5W4I6)P74HC/.#&'$E!S]K*@:2&+WI=<6@4P@<)C M5E-V8Z3OUU0`#WC]9DT4YP-]O["B>I7#!(7GS+K\4KSXKZZ09244/PSH4'C2 M+*A9P>3X(@IEEO"],S$BW21%`"E>MYA:/24RQW=)*'K=>L#8OQ1%U07%);W! M,5ZOEWY_5`%T?/F#0-BMF$3!;3=[^$1*UZ@*F,'K&%-+7QNQX^L<[#C*-D/9 M-Y_&+(O,^M\2)YFX$#"#UT$FM05=;+VXUZ&:+16HNB?S19+ZZ>M]`J8_]^.W M@'>)(1C5`_QUU+W6`&X+-T4<^#AT,3)>E\>^'::4/:59$"79,H4E#@O7)W%6 MH+PE$;OPNYA`%Z[.!Q]&Z'7*;XUSTG#V?" M+V*8:Y`W6BY7/4$Q!$A*`34H'/T''P24G/3A5+D`I')$D)8#>E!L#B@5-!)^ M&UL?CI5_(S%)_6@:A]-P3F/*YEYL9<[2D\69^@B%5GF@"X5O6D-3OC$8H+1T M#!U#$K=;$`D(?@+8I^291,FB.+*O:1D:I8$Q%#M.M>U"&Z.EL^S-K$)X)1(/ MA#R^4U;&&P^ZJ:HFLCZ<5+[K4B/ZT_"9OB..*U(-/1%OAT>WA?#NFO,*\ MNCUZCY+58"RQ4+T*@#`46W*MV`'?Y$R(:2$=@'NG_.#=*[_ECJW<5.K$*R\P M=[;M-"N^\MG)Z^:9%8;I=S\-]3WQ#=\!1*'PE]J06^5]MT+5N\=]SVLYP.%6 MM:NSL9=]((ZQ[I1Q-/:RX[@\5J&4OI==%]4H0ZK?-2 ME_]5C`!Z%0!A*!RI!QD.3"CI@^M=AE!4`8"I^,B;SF!E+%VP<'_=MZ M;[,\4;I>A66`%A2.>!,1%>X0/L0^)(-5CK*B05;'+=>\NEWF6^W%(XUEYS*X-,Q6]"V1`X<:S95"6S55.FZ6=CT5YB#[W MT]SI_F93EKZ5Y\WBTJ_Z+4VR5D9<\=M`%11'`W`;LY"X'MW5*$U4L>W9EIU6 MJE\9\(DBXKAE0ZS)BZV]D1SFR([-K&%7/$_21T+S)?"U[H\MCIB:^[;\FNEV,X]C906[&` M-ELYO,OUV%D<=MJ.5Y,NYLEIW8[WW@6"X-BC06W'`MILI2COAQUO=?8_"3M' M3<(I+#']&=&]0/M`+0#Q4.PIX;9Y(S)M)6KOC(=-Z)'G^F[:Z@_V6@$RHMA@ M<]PG;!-J*PM^!V;K*NK6[#CO%$8-\88C')N%N/M%#4YMW1C0@Z[!<5NYZAR& M30$IWW@@'&^8NZ^'45-`RO>=SI98M74[10$!2G#[[^R MV_O\(%_Z$;LI@G>)BL/6@*@_RD:Q"V)M7?R"9/;4@$+Q(".B<-!B3ZG1&A#T M1]F,=D&LK>MRD/04.Q/3"V"*QAD-1)<%M/Y.$.=]Z[HI?;9N!NK'G&EKB-@E MZT`#?N6E(-&/LE'=(G^VKCU"9.*]&<+'..[AZNH0/I9S&@O.,\28L3.FW8LN*5H$UO#E"U8-): M[/4HKQ'W8N&M#JWV/0B+>L-);XXDB2U-CP5;&8I0F,SF\OFO_H+F?E1V%G:Q M3_I,0N@KYTMVAH1-U/U8&L1J7!?0B<)?WK)1U:/%6O:@!-Z(:F_M'FI:`J;W M';;-ELOD_;H0O87:!(5#U(;^P3=ZO"^'M6$Q0N$,MZVR\PS9YORZD=#1. M4+A%%4KI[[!->G)=R$WDQU?^G"CZ^?9C`+YO;DEQU]X'WH<]L34J94_>?1`( M0.':VQ=%+MYVZ]WN6`ENN[W_GMP_)*TE]A6L;9M)+:O!&QZC\"?5$EH-#/,-UA6C M?:)I3DCO]H!<.GZ?OO;./K*LG_@^2W)$AF,?V;A-L[P#J?]C;?#WKAAW3(XD1TRGFC2L7U%ELHB@Z2_@L-,;I+$F?,([O7@SH/1:J&ELR M=IL86:&7:4S36)*9N%,B-XUI&B/)\BM72CNF:2S.LWNH);;>0"OS3DJ?!WMW M.A,WZH@:2-R&(@G$VIDBQ>$)B1%O6GZ6Y70.4T#]TT&*.@`HBHFMN3B"KFD& MO%?KU[N`Q'Y*$]VUZ_;S0`>R_7DM_13KV7V$?5C+KE']$6<+$M!'2D+EDE98 M!FC!L7,MUDS4TZ6(^G!@YY9D:U:FX3^76$Y MK9.1X*=9\OPI)+14&WZHB@R_\B[)S(_.8'`3AO]RGO+&7U#$^3<:JH6X\&29 MTQ6Q1"`<@:N/`$RG(=I"YO<%VF^VVTQP`B_4"4T"=N%+$LG/5U2?`TA.Y[Y\ MBCFN)G[#W68_$[EO%T]R$=X>`!!.9YS:[%=:;.E0BMO=$.&`+?.W&Y0&JE`< M3K*RG-#&Z_:0B>AL&IDODM1/UVL\D7JZ#?K,K(DW/RB\!G*!P0#6T M`2DZ6_'[V]1\6]*P3!7IQ@"^D9BD?C2-PVDXIS%E&S%LX_GLA6ULRX8'14EO M\AF%,ZNA06BAM!7";L.0,1N72:P,=6UB5(B\^1PGP<^NKRHU\`F MT+I;/KP-OF\^C2^3++N.-[^3S\Z498$G%&$AUFQ`BE-@#]W*#@-H+N(@F1,& M\RTQ_WVRE2O[*8D`67;B9S206(=A3<`ABM"1AK92"[4@G*23>>O/_#0&TK(; MDJY#5Z5FPGT>:.FR#U$#FT#R)A[$@\=XQED2P;HA)^&)'['EP]T3(7EV4U#[ M1'(:N(GT?`L"NGX\IS$TC/K131'C#,:CCO#4*>X-?QXX8A0WJ`681V$3^N.Z,3@\H9NMV,4&LE8Z M?<.:@$(4"R=CU8V-1XR^#_<,WT#WB@&DZ@NR\QS`1Q%-44LUO@%P\/7BNM[U M\'FIDS9U[V$@`D4,1(W9?05#'\)@IT&PG"^+Z\5.";0;%K0,#_P(:C,&_Z"(N;"S);JXNQ%8O=*T-F-GUZG!7UA$6JV=E/KA^F) M:H!E7@=MPPBJKO@W(5@0N4L7U+J-7%06J<&T[U-=^#Y6M@%QT!G!)_V+AG^74F2$A M\MOD=8H#9;CV*NH8@@29K2!<]\:P%9A28SZH41KFS[AD'2XCV&B??M6&(9'_O6'HV(/$$) M;UA)8=2%(#P<&2VDC"JV<+:`O,?=[85`N4W+)!-+(2L?RGO<70Q$X')J\)42 M?.T$16@''4F@9!K%O00U@\FD:AZ=@VE%2A#.ILZ9(RP%+*/QU"AGYVFL@ MLQ3GA4'_]O+F#'$DTZIE`UK8;,5M83"#!E?D#%",[[5DYF*Q%7V%0=8]5DP^ MX<`6M(*T%@+KJI<@N10VDU."!UQ-T][(QR)S6K.S*I`K`51N55^XK:3H$TB M]LYS0`**!;391(T#P59HDWL=M1.H;VYYTX]IUZD-F.^@3=0&VCA'(:(O@+LD ME^,Q"I][@W%$%Z2M!(?N1QIV[WI*GN!C""NBI80"B(MX863HW+=7E:`12=_"0I)TTMJ//*(9[N6AZ M0F\!$JC<22]?%>8IC9:Y]/B+H`10@V(CQH;6.Y`$:G?2E?!7$$[#@?5^C*MZHF8T0#%QYXFED)4/Y?T85PQ$ MX)J&\942.%L$>!1I0Q,5)-!+NAO"0]"%9N>`">Z6XTG)`#XKX-V.A-5#U(:GY+`2`$Q23,6&89G!Z=+-O*>5V$@7$V==7]7+<.8`]%A)QYGS=#V(M< MX4V3`HR&N/QE^G/P"@9;1\T*,1+M>85/6Z^'!DW#83 MO?Q>-55=4`O0@C5^V%!V*4`<6;=K=/8R^",K1K*M0)`[$L"3.27<5!X6:O5& M:&]AJC,C6"Z")N+].W"S?]^L!6=I\(O-0%.P\^ M#*G,A47BK!#XEL#B.*/Y.F%>R>0M"9)93-\.A$D]_>V^&L9_%+M"9K/9P[#2 M^%P>(A,^FR^BY)60$Q*31YIG+#AR=?9@ER#9GK%N'=YX@&('RLRH#.%9.X7G M?`FMTYNVAOI3\I#_2?.GS9?@G/CY4GJ9D:U70,?LH&791=^G0W^R2>D5^5[\ M1;X[HE$>:$.Q4UK#Q:X'S=;90,0644X^&YA$I0(@#L6&J16;X&+KTU'"1FO7 MFL.'LEZ@&=<^;.-A11-RGXXM-EOKUAV&=(CNZJYP0\PX3CK6<$6^#;^U7(Z; MTD!#A_:7C(&U=S*Q;1=B;8&KQ8&(#NTBFR,32-S)^P%DIEW\[;K`*=UWJEV7 M-T)[WWO-&88$IL!J.NDPEG872V8CJ0P([:"7I"Y.P4&]`[MI:\P82F2W)"+, MPW@.])UE0._W.O,'45U`48=\'PUA"BSAP%<7U)E;6#(%>65`4H=\'DUQ"HSA MP&[2)@N)8:.%Q!!HZ)!_PAB80-\#.ST;+21,!:X6!R(ZY"4P1R:0N+LNS/(( M.@FOTZ]^%'&,7#4-5%8`Q'7(>U`'F\`HC+V/[O==E:C+7M'$)LH:@+@..1QJ M@1-8124BX&(G`M;?E*\>45P>E#2KG&R0N0G9[4[ZL5#)92 MQ3D5\XKD['-TDR;/%*8])Z]_9"2\B-\N&9T&.7TN@C-@C@._6,+O5G^$.8_& M=,+."X!PM.O7B>QN%VO8+:6HP^`(JWGP_AC%>3N;F@JMI@K;4NHZ#.)O1<)? M)7$`5!;=B%V1%<"_:41V\-\GFFQK#$5MOQJT0N%V:=]$#\.DI?Q^&*R^Y?N. MCU%XA0YC%7R+U"2I:?9`1#YBMD_FQP%9KTCB<'VT_SQ)5V<;L^L45B)4.D,W MJ@=81!%7Y-+4:A#6IZ2&.U=47X#T\8Q%<4^SC.3Z-W97"P)/***47!J6#D.V MTA_B,R5VYG&=@.@F)7.ZG&M;$ZY*6`YI0N)==VI(&0;92/V*PHU,";0ZH*B'"]F-``@J'M=MI>)4/6UDC M,1B%<;X,0?:(T3$*#[A+0Y$Q8RLU)0:3.6S6E=&7'WX$,B0+1Y)+2QZ!.$A9 M(/PI*?^_Q>$JQ8B&DU2_$E`!Q9Z,4U^`(5NVTFNZ#UW=1SX-BJ5%!K03^JP( MTM$I[HU^1K'E8RJRKJF($#?.Q8G)2[F'NNR)]_X+J6LIW!J`.A2;+VT9BP1T MXYRDUQ8Y%RZZ->A=#_ M4.RUM65*^APT3K2)^@-W$<-LGF3Y:BR6!P/H%`?24.REM3<5XB/N4UK,9C$\ MK<5C`M$__*Z:#09MY>O,$^A%&`WU(GZ&'MIB`+'A"X!V%%MX!PD?M<97GS*( MPM=BG7\Y^&M)4P(,`>S\]2;RXQRF'>S,Z8(](C%&_4J`0!0+`9OFP#JT!O]@F*'R::9 M"#[2#?CI4S;7;1XJ%VYH6E>E%%"$8M_IL";$):%/^5MOR6(UK=W)5:ZP$TDI MH`C%CE+[=J(DH7&Z5OP+`$TZ6YMI`=$H]@[:MS8;/-G*&NM^`<"H@,\X^Q]; M=3_[$>N'9;*TJB-=8GPFU0"%*%S"9D?SS1':RB:+U4BFT(_2]!6ZARH/I59Y M(`V%P]6&67"AVU%EU"-+'YQ$-?@[RG/=C(223W"QO7 MY8V^H'`)6U21/U+49,9^[M$##Q$;GW>96]W!"%!FM];HRKL/@@`3=W[S[9T" MG9XG*`$@4*P+>=2*_-X2(`?K#O_XQ!KWX&>DH.[_`U!+`P04````"`!ABX]& M!'3LU!(+``"N<0``$0`<`&%P:&(M,C`Q-#`Y,S`N>'-D550)``.FURY5IM1:A1R(DY>RTT]_;[R#"`AY2]G#:^7ETW7W703_^\/UW[__4[:*?""," M*Q*B\0NZQ`J/!`X^RUP>]??Z>^^0?CCJGL6B.]CO'Z%?]P]/]H].#@Y_0_^Y M__!?=/5IA+KHZ>EI+P0-RFC8"_@,=;NZ'1E,R0PCA<4#47=X1F2,`W+:F2H5 MG_1Z6@[/XHC&4SJF7`OVH)G#_>,##3TB,\+4-1>S2S+!2:1..W\D.*(32L(. M`EN9/,'Q=.RISP@4ZCX=[''Q`%7V^[U?/MQ^,FASS1%EGPNUG\EH9H++%<^ZJ6%\ZJ10^\OMZ!X62EU5*9,*LR"!8@UT)F)_>/CXYXI MS:LFLON`<3RO/,%R;*IF!:;CNOO][D$_%PEXPI1X*=HH2;#WP!][6:$6.U@1 M2X2`86B3RTI+V@L)+9>!@I+JY#F8EM?7)24"E#T2J.K^,>%H'@ M$0$$@>J2YSC"#"LN7J[A][Q#.&/)K%Q)J$1/(^Y!I2[4(H(&<[G-0ID`K"0( MO<>,<5AB8&DRO_6;.*9LPK.?\$*/[Q,->`3B2#_\_/'&N3H8ZRYYD.B5YHR% M5TQ1]7(#6L7,M-5!%#K(66/>?HX@)!/*J$':W^_#^IB++S^"*I3J0DO*WO=6 M-7S_W:KZ1))PR'XPS\"A!&U&5B\01#?6@/<>17O@^30E1,B7)7NQF:`"T?((N)!E%RWI0I@BEFEIZZM!S MCV&%5U.B*"#;P%6QKINX`W_BT*\%Q;^U1'H2.>]?.9P,8^TP`IB2"6>IYR;P MT$7@0B/B$[30V5)7@[J/)"3@VXXC`C7`PU<4'N\%F1#POJ`F#S[#AF3^.^51 M"$>`JS\2V)O`\:8!56Z^MU7N'B1'_H-D`00M(4%S*,A@0)AE3QF:O_SYX/CO M*,6$WF2H_MJ.LQKC[`++Z77$GS:L$(MJ;N[?^G.O52*CLR7.0=P=5HD@P\EY M(BDC4NJ)21\8G*D##/YM8(YQE#W<0S<'E&0\5I9RT_HW[0A3&41<@EKXD>K7 M-.8MI)-TT09:-(+R5EJB'40OUM\I>#X9CZLOW32]6Z5I:2$U\BT!#@+^C86` M@:OG2OYX2_&81K#+I&PX:[BI.5ZE)E=@YLW\QUQ=RY2#*>,+#.,ES[;PQLE$ M?W^5B=3'R(3;?G?U.P$731_2+J8Z0)QU_I?$N`TXN#Q3S0 MK0XG5T)P,7?;UMZ[:1BLTK#0H#?U5$=+Q0[]LNW\,S\_K7^P&S\-O[)`K32([(LTKR3P=;ZG#SO*/(A(XBFE91UFP[+"K$*LI8 M=U=QD[HQCM'2M3,_)>O(S8Y*7M%-7=4XQYS)EL$M&2S,O@KUG7P.UJ(EOGRV M,[.J"UJ8B64%;J;6(RM%)[2=9_7XZ%L)Z6]@9"W(4LX(ZK><5.1D8.5DL(&3 MM0B)A9-!RTE%3@K[CZ/8\C(W.^N!CK53=;O-U(KC METVBC;7<9*V%0,IB_/_7,TK_HU,"/I(),G?M3_0UYM..I$":OJ-OWDWA\'G: MT7D+W3PWX7
N]Y%N55=`N.6_^&\]5^RAK.560WM]VY`*"$Q_J6%)&]''P' M]79H&#!2U;`BB&%4.$?VKF\MU]:MN?]`]Z.\]RW#1^U5`+&RL!B*7 MJP&B/!')L_E<0+=[Y-NB,Y/(TK!IM%2P1R(E\S?=A:I*]CNR>ER`2L2RY^Y" M12T@9=E2/DB6Y?(?6V,IR\#R`K,L./^U+4=KR5H^4.9"YFE;".N)7#X8%E+I M8W>AH!:*U>PP'PRYC'[8NOW5Q#$O`+F0>:H!83T)S6PVC#SH2[]^*UMGLO]T:AN?BN01![:1Y=RJ>+Z1E+5<+)340.A,R?49*+J,?:DQ8=\J@ M5X>L2FW+4WFV8S4DG-W5!N/.$ZV_\QI==HJR/&T#*`O5%-(\[K@B>61_<8#4 MY\/S".IV4.JCIGFD)RI_?Z/(3!^S.@B/I="8Y,QK5.BSX!QY'R<&2$ MPT1DZ9J,1I'^$G_:42+1CE8"TE0ENO0GP9/XM).*4]"?'HRU)_Q[#=R6'LAD MSEBX\M$RS4G1R?77Q'Q6GG_F,-^-LW^;UC&[,\VA^ID"I(B2,;D9J47K!AM1L73?\#T`\CR7KW>4!QP\?63,7&<.4+U&+GDIS>R.0]?M$HAHPTQL+-$*O9-GKB3;=M":+% MMB+)-SH2"MN&3G4,_X6CA-P383:1N8U@8)R]J[31I8$M5=]$?Z064R_)6-T` M"F'^(L92C]VD$6`WZ:=UQ^M<$3CL!V*OSH7T[:7FW\+!]D+K]:KFN`HY,,*6&D[Q&`XRM`K:RO5?/X')1"1L"#O-XF(CNUFSOX(1UC52T$<`]TBLIZ^EK-*M>\*Z*6R]#%8Q8^L% MH`G+726TNUH"^J]Q#;#;_Y$$$9;2./FZV6O!9XNAM$AZXFG$IL$3H+(E7B-B MR/Z9,#)XJ[\`I7YE8QQ@7Z#>=D8O_:-786L&?\-UNRK@RGO6B(B9'$ZNGF.:8_4+(7V3S:H$K8?%Y@HD MEU_7+0W)N*Y7NH1WHP=:\F=,&KO?.E%OX#$?\>L.^RL@U07>&DZ;?Z:P'%36 ME#>X(VI98^F9T1,?37DB,0O/6#AZ(M$CR:)=`=32QQD`V9C]N1I<+YOO*'L] M%KO!^G$\I4(1PEZ-S9L!5_-/OOU\K[K4[V:J.]V]#?W1//]T:[M-[RV",_I; M]CQT_8D$4%-?VNV_UG'A8UF=@5*UQYHW<79A]-`G'F/P_4$L!`AX#%`````@`88N/1B8(52BPB0``-1H'`!$` M&````````0```*2!`````&%P:&(M,C`Q-#`Y,S`N>&UL550%``.FURY5=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`88N/1N$^UV6N"0``:(4``!4`&``` M`````0```*2!^XD``&%P:&(M,C`Q-#`Y,S!?8V%L+GAM;%54!0`#IM`Q0````(`&&+CT:.',,3'RP``-W;`@`5`!@` M``````$```"D@?B3``!A<&AB+3(P,30P.3,P7V1E9BYX;6Q55`4``Z;7+E5U M>`L``00E#@``!#D!``!02P$"'@,4````"`!ABX]&-^Y=@Y=$``"ES0,`%0`8 M```````!````I(%FP```87!H8BTR,#$T,#DS,%]L86(N>&UL550%``.FURY5 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`88N/1CAG?D+R,```*V,#`!4` M&````````0```*2!3`4!`&%P:&(M,C`Q-#`Y,S!?<')E+GAM;%54!0`#IM`Q0````(`&&+CT8$=.S4$@L``*YQ```1 M`!@```````$```"D@8TV`0!A<&AB+3(P,30P.3,P+GAS9%54!0`#IM XML 22 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Options (Details 1) (Employee Stock Option [Member], USD $)
9 Months Ended 12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares, Outstanding at December 31, 2013 25,721,000

Shares, Granted 0

Shares, Exercised 0

Shares, Forfeited 3,137,378

Shares, Expired 2,000

Shares, Outstanding at September 30, 2014 22,581,622 25,721,000

Shares, Exercisable at September 30, 2014 19,972,558

Weighted Average Exercise Price, Outstanding at December 31, 2013 $ 0.19

Weighted Average Exercise Price, Granted $ 0

Weighted Average Exercise Price, Exercised $ 0

Weighted Average Exercise Price, Forfeited $ 0.19

Weighted Average Exercise Price, Expired $ 13.10

Weighted Average Exercise Price, Outstanding at September 30, 2014 $ 0.19 $ 0.19

Weighted Average Exercise Price, Exercisable at September 30, 2014 $ 0.19

Average Remaining Contractual Term (Years), Outstanding at September 30, 2014 2 years 1 month 24 days 9 years 1 month 24 days

Average Remaining Contractual Term (Years), Exercisable at September 30, 2014 1 year 4 months 6 days

Intrinsic Value, Outstanding at September 30, 2014 $ 862,982 $ 6,451,441

Intrinsic Value, Exercisable at September 30, 2014 822,989

Intrinsic Value, Outstanding at December 31, 2013 $ 6,451,441

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Options (Details Textual) (USD $)
9 Months Ended

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value $ 0.22

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 559,358

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 6 months

2012 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 35,000,000

2009 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 4,200,000

2013 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 40,000,000

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=aphb_TwoThousandAndNineStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=aphb_TwoThousandAndThirteenStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=aphb_TwoThousandAndTwelveStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 25 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

Nature of Business and Significant Accounting Policies
9 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description and Accounting Policies [Text Block]

1. Nature of Business and Significant Accounting Policies

Nature of Business

AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.

Basis of Presentation

The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries - Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All amounts on the financial statements and disclosures have been rounded to the nearest $1,000 except share and per share data.

The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments, reclassifications, and non-recurring adjustments) necessary to present fairly our results of operations for the three months and nine months ended September 30, 2014 and 2013, our cash flows for the nine months ended September 30, 2014 and 2013 and our financial position as of September 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.

Accounts Receivable

Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of September 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.



Property and Equipment

Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.

Prepaid Expenses and Other Current Assets

Prepaid and other current assets as of September 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.

Goodwill

Investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.

In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. Goodwill in the amount of $3,929,000 was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.

In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. Goodwill in the amount of $3,633,000 was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.

Patents

Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.

In 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. Patents in the amount of $493,000 have been recorded. These patents are being amortized over their useful life through December 2026.

Stock-Based Compensation

The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.

Warrant and Preferred Shares Conversion Feature Liability

The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require such warrants and the Series B preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.

Fair Value of Financial Assets and Liabilities — Derivative Instruments

The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.

GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 — inputs that are unobservable.

The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.

The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.

Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.

Revenue Recognition

The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.

The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:

•

The delivered items have value to the customer on a stand-alone basis;

•

Any undelivered items have objective and reliable evidence of fair value; and

•

Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.

The Company classifies advance payments received in excess of amounts earned as deferred revenue.

Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.



Research and Development

Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.

In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. In 2012, IPR&D in the amount of $5,161,000 was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.

In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. In 2011, IPR&D in the amount of $7,285,000 was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.

Net Income (Loss) per Common Share

Net income (loss) per common share is based on net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three months ended September 30, 2014 and the nine months ended September 30, 2014, both basic and diluted net income (loss) are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended September 30, 2013 and the nine months ended September 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B Preferred shares were antidilutive with respect to computing the net loss per share and therefore were excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share was 150,283,630 shares for the three month period ending September 30, 2013 and 63,155,331 shares for the nine month period ending September 30, 2013.

Recent Accounting Pronouncements

On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.

X

- Definition

The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Balance Sheets [Parenthetical] (USD $)

Sep. 30, 2014

Dec. 31, 2013

Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars) $ 559,000 $ 473,000

Common stock, par value (in dollars per share) $ 0.01 $ 0.01

Common stock, shares authorized 445,000,000us-gaap_CommonStockSharesAuthorized 445,000,000us-gaap_CommonStockSharesAuthorized

Common stock, shares issued 187,159,093us-gaap_CommonStockSharesIssued 182,535,562us-gaap_CommonStockSharesIssued

Common stock, shares outstanding 187,159,093us-gaap_CommonStockSharesOutstanding 182,535,562us-gaap_CommonStockSharesOutstanding

Patents [Member]

Finite-Lived Intangible Assets, Accumulated Amortization 116,000 93,000

Series B Redeemable Convertible Preferred Stock [Member]

Temporary Equity, par value (in dollars per share) $ 0.01

Temporary Equity, shares authorized 10,000,000

Temporary Equity, shares issued 8,859,978

Temporary Equity, shares outstanding 8,859,978

Temporary Equity, liquidation preference $ 13,712,000 $ 13,022,000

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityLiquidationPreference

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemablePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

Nature of Business and Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Significant Policies [Line Items]

Goodwill $ 7,562,000us-gaap_Goodwill $ 7,562,000us-gaap_Goodwill

Intangible Assets, Net (Excluding Goodwill) 12,446,000 12,446,000

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 150,283,630 63,155,331

Property, Plant and Equipment, Estimated Useful Lives three to seven years

Patents [Member]

Significant Policies [Line Items]

Finite-Lived Intangible Assets, Net 493,000

SPH Holdings Pty Ltd [Member]

Significant Policies [Line Items]

Business Combination, Consideration Transferred, Total 7,172,000

Goodwill 3,929,000

Biocontrol Limited [Member]

Significant Policies [Line Items]

Business Combination, Consideration Transferred, Total 8,584,000

Goodwill 3,633,000

In Process Research and Development [Member] | SPH Holdings Pty Ltd [Member]

Significant Policies [Line Items]

Intangible Assets, Net (Excluding Goodwill) 5,161,000

In Process Research and Development [Member] | Biocontrol Limited [Member]

Significant Policies [Line Items]

Intangible Assets, Net (Excluding Goodwill) $ 7,285,000

X

- Details

Name: aphb_SignificantPoliciesLineItems

Namespace Prefix: aphb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 35

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6539997&loc=d3e1205-110223

+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=aphb_BiocontrolLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=aphb_SphHoldingsPtyLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document And Entity Information
9 Months Ended

Sep. 30, 2014

Oct. 20, 2014

Document Information [Line Items]

Entity Registrant Name AmpliPhi Biosciences Corp

Entity Central Index Key 0000921114

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol APHB

Entity Common Stock, Shares Outstanding 187,159,093dei_EntityCommonStockSharesOutstanding

Document Type 10-Q/A

Amendment Flag true

Document Period End Date Sep. 30, 2014

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2014

Amendment Description The Company’s previously issued September 30, 2014 financial statements have been amended to: reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000. recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014. reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014. adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively. As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period. The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by ($5,139,000) to ($49,039,000). The net loss per share attributable to common stockholders increased by ($0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by ($7,098,000) to ($65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.

X

- Definition

Description of changes contained within amended document.

+ References

No definition available.

+ Details

Name: dei_AmendmentDescription

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Preferred Shares (Details Textual) (USD $)
9 Months Ended 12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Class of Stock [Line Items]

Debt Instrument, Convertible, Beneficial Conversion Feature $ 19,400,000

Derivative preferred shares conversion liability 14,043,000 40,791,000

Fair Value Adjustment of Warrants 0us-gaap_FairValueAdjustmentOfWarrants 759,000us-gaap_FairValueAdjustmentOfWarrants

Reclassification From Derivative Liability To Equity 707,000

Common Stock [Member]

Class of Stock [Line Items]

Warrants Issued During the Period, Number of Warrants 4,320,420

Warrants Issued During the Period, Exercise Price of Warrants $ 0.25

Conversion of Stock, Shares Converted 1,889,380

Preferred Stock [Member]

Class of Stock [Line Items]

Derivative Liability 6,917,000

Conversion of Stock, Shares Converted 188,938

Warrant [Member]

Class of Stock [Line Items]

Derivative Liability 1,886,000

Convertible Notes Payable One [Member]

Class of Stock [Line Items]

Debt Conversion, Original Debt, Amount 5,491,001

Warrants Issued During Period Number Of Warrants1 4,999,999

Warrants Issued During Period Exercise Price Of Warrants1 $ 0.14

Fair Value Adjustment of Warrants 759,000

Payments of Stock Issuance Costs 350,000

Convertible Notes Payable One [Member] | Preferred Stock [Member]

Class of Stock [Line Items]

Derivative Liability 6,029,000

Convertible Notes Payable One [Member] | Warrant [Member]

Class of Stock [Line Items]

Derivative Liability 1,644,000

Convertible Notes Payable Two [Member]

Class of Stock [Line Items]

Warrants Issued During the Period, Number of Warrants 1,645,361

Debt Conversion, Original Debt, Amount 829,277

Warrants Issued During Period Exercise Price Of Warrants1 $ 0.14

Convertible Notes Payable Two [Member] | Preferred Stock [Member]

Class of Stock [Line Items]

Derivative Liability 2,386,000

Convertible Notes Payable Two [Member] | Warrant [Member]

Class of Stock [Line Items]

Derivative Liability 674,000

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred Stock, Shares Authorized 10,016,080

Preferred Stock, Initial Stated Value Per Share $ 1.40

Preferred Stock, Par or Stated Value Per Share $ 0.01

Debt Instrument, Convertible, Number of Equity Instruments 10

Preferred Stock, Dividend Rate, Percentage 10.00%

Debt Instrument, Convertible, If-initial public offering proceeds meets Least amount 7,000,000

Stock Issued During Period, Shares, New Issues1 4,999,999

Warrants Issued During the Period, Number of Warrants 12,499,996

Warrants Issued During the Period, Exercise Price of Warrants $ 0.14

Warrants Issued During the Period, Value of Warrants $ 7,000,000

Series B Convertible Preferred Stock [Member] | Convertible Notes Payable One [Member]

Class of Stock [Line Items]

Warrants Issued During the Period, Number of Warrants 10,894,839

Warrants Issued During the Period, Exercise Price of Warrants $ 0.14

Debt Conversion, Converted Instrument, Shares Issued 4,357,936

Series B Convertible Preferred Stock [Member] | Convertible Notes Payable Two [Member]

Class of Stock [Line Items]

Debt Conversion, Converted Instrument, Shares Issued 658,145

X

- Definition

The amount by which the convertible debt's if-proceeds of an underwritten initial public offering of company meets the minimum amount agreed.

+ References

No definition available.

+ Details

Name: aphb_DebtInstrumentConvertibleIfinitialPublicOfferingProceedsMeetsLeastAmount

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of derivative liability of convertible preferred shares as of the balance sheet date.

+ References

No definition available.

+ Details

Name: aphb_DerivativePreferredSharesConversionLiability

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Initial stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

No definition available.

+ Details

Name: aphb_PreferredStockInitialStatedValuePerShare

Namespace Prefix: aphb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Reclassified from the derivative liability to equity due to conversion.

+ References

No definition available.

+ Details

Name: aphb_ReclassificationFromDerivativeLiabilityToEquity

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesNewIssues1

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the exercise price of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants

Namespace Prefix: aphb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the exercise price of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants1

Namespace Prefix: aphb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the number of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodNumberOfWarrants

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the number of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodNumberOfWarrants1

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the value of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodValueOfWarrants

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=36459792&loc=SL20226008-175313

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=aphb_ConvertibleNotesPayableOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=aphb_ConvertibleNotesPayableTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aphb_SeriesBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statements of Operations (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Revenue $ 103,000us-gaap_SalesRevenueServicesNet $ (3,000)us-gaap_SalesRevenueServicesNet $ 308,000us-gaap_SalesRevenueServicesNet $ 333,000us-gaap_SalesRevenueServicesNet

Operating expenses

Research and development 1,793,000us-gaap_ResearchAndDevelopmentExpense 1,123,000us-gaap_ResearchAndDevelopmentExpense 4,692,000us-gaap_ResearchAndDevelopmentExpense 5,359,000us-gaap_ResearchAndDevelopmentExpense

General and administrative 1,701,000us-gaap_GeneralAndAdministrativeExpense 1,215,000us-gaap_GeneralAndAdministrativeExpense 5,289,000us-gaap_GeneralAndAdministrativeExpense 4,772,000us-gaap_GeneralAndAdministrativeExpense

Severance charge 1,840,000us-gaap_SeveranceCosts1 0us-gaap_SeveranceCosts1 1,840,000us-gaap_SeveranceCosts1 0us-gaap_SeveranceCosts1

Total operating expenses 5,334,000us-gaap_OperatingExpenses 2,338,000us-gaap_OperatingExpenses 11,821,000us-gaap_OperatingExpenses 10,131,000us-gaap_OperatingExpenses

Loss from operations (5,231,000)us-gaap_OperatingIncomeLoss (2,341,000)us-gaap_OperatingIncomeLoss (11,513,000)us-gaap_OperatingIncomeLoss (9,798,000)us-gaap_OperatingIncomeLoss

Other income (expense)

Gain (loss) on derivative liabilities 26,438,000 (46,380,000) 35,286,000 (52,350,000)

Amortization of note discount and patents 0us-gaap_AmortizationOfDeferredCharges (23,000)us-gaap_AmortizationOfDeferredCharges 0us-gaap_AmortizationOfDeferredCharges (2,660,000)us-gaap_AmortizationOfDeferredCharges

Interest expense, net 0us-gaap_InterestExpense (9,000)us-gaap_InterestExpense 0us-gaap_InterestExpense (233,000)us-gaap_InterestExpense

Other income (expense), net 26,438,000us-gaap_OtherNonoperatingIncomeExpense (46,412,000)us-gaap_OtherNonoperatingIncomeExpense 35,286,000us-gaap_OtherNonoperatingIncomeExpense (55,243,000)us-gaap_OtherNonoperatingIncomeExpense

Net income (loss) 21,207,000us-gaap_NetIncomeLoss (48,753,000)us-gaap_NetIncomeLoss 23,773,000us-gaap_NetIncomeLoss (65,041,000)us-gaap_NetIncomeLoss

Accretion of Series B redeemable convertible preferred stock (323,000) (286,000) (955,000) (389,000)

Net loss attributable to common stockholders $ 20,884,000 $ (49,039,000) $ 22,818,000 $ (65,430,000)

Per share information:

Net income (loss) per share - basic (in dollars per share) $ 0.11us-gaap_EarningsPerShareBasic $ (0.49)us-gaap_EarningsPerShareBasic $ 0.12us-gaap_EarningsPerShareBasic $ (0.76)us-gaap_EarningsPerShareBasic

Net income (loss) per share - diluted (in dollars per share) $ 0.07us-gaap_EarningsPerShareDiluted $ (0.49)us-gaap_EarningsPerShareDiluted $ 0.07us-gaap_EarningsPerShareDiluted $ (0.76)us-gaap_EarningsPerShareDiluted

Weighted average number of shares of common stock outstanding - basic (in shares) 187,159,093 99,156,809 184,445,172 85,688,356

Weighted average number of shares of common stock outstanding - diluted (in shares) 315,990,084 99,156,809 323,604,642 85,688,356

X

- Definition

The amount of amortization of deferred charges applied against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AmortizationOfDeferredCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(10)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.

+ References

No definition available.

+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Correction of Errors
9 Months Ended

Sep. 30, 2014

Accounting Changes and Error Corrections [Abstract]

Accounting Changes and Error Corrections [Text Block]

6. Correction of Error

The Company’s previously issued September 30, 2014 financial statements have been amended to:

⋅

reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000.

⋅

recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014.

⋅

reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014.

⋅

adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.

⋅

modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively.

As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period.

The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by $(5,139,000) to $(49,039,000). The net loss per share attributable to common stockholders increased by $(0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by $(7,098,000) to $(65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22644-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=6368906&loc=d3e21914-107793

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22595-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 1.N.Q3)

-URI http://asc.fasb.org/extlink&oid=26874127&loc=d3e30840-122693

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 1

-Section N

+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Severance Charge
9 Months Ended

Sep. 30, 2014

Severance Charge Abstract [Abstract]

Severance Charge Disclosure [Text Block]

5. Severance Charge

On September 15, 2014, by mutual agreement of the Board of Directors (the “Board”) of the Company and Philip J. Young, Mr. Young stepped down from his role as President and Chief Executive Officer of the Company, effective September 15, 2014. In accordance with Mr. Young’s employment agreements, the Company recorded a severance charge in the quarter ended September 30, 2014 of $1,840,000 related to severance-period compensation and benefits, as well as stock-based compensation expense related to the accelerated vesting of stock options. The composition of the severance charge is as follows:

Compensation and benefits

$

679,000

Stock-based compensation expenses related to accelerated vesting

1,161,000

Total severance charge

$

1,840,000

X

- Details

Name: aphb_SeveranceChargeAbstractAbstract

Namespace Prefix: aphb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for severance Charge.

+ References

No definition available.

+ Details

Name: aphb_SeveranceChargeDisclosureTextBlock

Namespace Prefix: aphb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Options (Details 2) (Employee Stock Option [Member])

Sep. 30, 2014

Dec. 31, 2013

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock options outstanding 22,581,622 25,721,000

Available for future grants under the 2013 Stock Incentive Plan 39,250,000

Warrants 38,890,451

Total shares reserved 100,722,073

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 34 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Warrants and Warrants Liability (Details) (USD $)
12 Months Ended

Dec. 31, 2013

Warrants Issued on June 26, 2013 Member [Member]

Class of Warrant or Right [Line Items]

Warrants Issued 28,394,834

Risk free interest rate 0.0109%

Volatility 160.94%

Expected term 5 years

Exercise price $ 0.14

Warrants Issued on July 15, 2013 Member [Member]

Class of Warrant or Right [Line Items]

Warrants Issued 1,645,361

Risk free interest rate 0.0109%

Volatility 163.08%

Expected term 5 years

Exercise price $ 0.14

Warrants Issued on December 23, 2013 Member [Member]

Class of Warrant or Right [Line Items]

Warrants Issued 4,320,420

Risk free interest rate 0.0167%

Volatility 155.24%

Expected term 5 years

Exercise price $ 0.25

X

- Definition

This element represents that, the number of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodNumberOfWarrants

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Agreed upon price for the exchange of the underlying asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aphb_WarrantsIssuedOnDecember232013MemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aphb_WarrantsIssuedOnJuly152013MemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aphb_WarrantsIssuedOnJune262013MemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Options (Tables)
9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations:

Three Months Ended

Nine Months Ended

September

September

September

September

30, 2014

30, 2013

30, 2014

30, 2013

Income statement category:

Research and development

$

38,000

$

40,000

$

116,000

$

153,000

General and administrative

209,000

208,000

598,000

1,053,000

Severance charge

1,161,000

—

1,161,000

—

Total stock-based compensation expense

$

1,408,000

$

248,000

$

1,875,000

$

1,206,000

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

      The following table summarizes Option activity:

Average Remaining

Weighted Average

Contractual Term

Shares

Exercise Price

(Years)

Intrinsic Value

Outstanding at December 31, 2013

25,721,000

$

0.19

9.15

$

6,451,441

Granted

—

—

Exercised

—

—

Forfeited

3,137,378

0.19

Expired

2,000

13.10

Outstanding at September 30, 2014

22,581,622

$

0.19

2.15

$

862,982

Exercisable at September 30, 2014

19,972,558

$

0.19

1.35

$

822,989

Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]

As of September 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:

Shares Reserved

Stock options outstanding

22,581,622

Available for future grants under the 2013 Stock Incentive Plan

39,250,000

Warrants

38,890,451

Total shares reserved

100,722,073

X

- Definition

Tabular disclosure of components of common shares reserved for future issuance.

+ References

No definition available.

+ Details

Name: aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock

Namespace Prefix: aphb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Nature of Business and Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries - Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All amounts on the financial statements and disclosures have been rounded to the nearest $1,000 except share and per share data.

The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments, reclassifications, and non-recurring adjustments) necessary to present fairly our results of operations for the three months and nine months ended September 30, 2014 and 2013, our cash flows for the nine months ended September 30, 2014 and 2013 and our financial position as of September 30, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.

Trade and Other Accounts Receivable, Policy [Policy Text Block]

Accounts Receivable

Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of September 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.

Other Current Assets [Text Block]

Prepaid Expenses and Other Current Assets

Prepaid and other current assets as of September 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.

In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. Goodwill in the amount of $3,929,000 was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.

In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. Goodwill in the amount of $3,633,000 was recorded. In management’s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Patents

Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.

In 2011, the rights to Biocontrol Limited’s patents were acquired in a business combination. Patents in the amount of $493,000 have been recorded. These patents are being amortized over their useful life through December 2026.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.

Warrant and Preferred Shares Conversion Feature Liability, Policy [Policy Text Block]

Warrant and Preferred Shares Conversion Feature Liability

The Company accounts for warrants and the preferred shares conversion feature of the Company’s Series B preferred stock with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require such warrants and the Series B preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.

Derivatives, Policy [Policy Text Block]

Fair Value of Financial Assets and Liabilities — Derivative Instruments

The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.

GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 — inputs that are unobservable.

The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.

The Company estimates fair values of these derivatives utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments.

Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.

The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:

•

The delivered items have value to the customer on a stand-alone basis;

•

Any undelivered items have objective and reliable evidence of fair value; and

•

Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.

The Company classifies advance payments received in excess of amounts earned as deferred revenue.

Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.

In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least annually. In 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination for $7,172,000. In 2012, IPR&D in the amount of $5,161,000 was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.

In 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination $8,584,000. In 2011, IPR&D in the amount of $7,285,000 was recorded. In management’s opinion, this IPR&D has not been impaired as of September 30, 2014 and December 31, 2013.

Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) per Common Share

Net income (loss) per common share is based on net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three months ended September 30, 2014 and the nine months ended September 30, 2014, both basic and diluted net income (loss) are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended September 30, 2013 and the nine months ended September 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B Preferred shares were antidilutive with respect to computing the net loss per share and therefore were excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share was 150,283,630 shares for the three month period ending September 30, 2013 and 63,155,331 shares for the nine month period ending September 30, 2013.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.

X

- Definition

Disclosure of company policy for warrant and preferred shares conversion feature liability.

+ References

No definition available.

+ Details

Name: aphb_WarrantAndPreferredSharesConversionFeatureLiabilityPolicyPolicyTextBlock

Namespace Prefix: aphb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph n

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41675-113959

+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5093-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 15

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5212-111524

+ Details

Name: us-gaap_TradeAndOtherAccountsReceivablePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Warrants and Warrants Liability (Tables)
9 Months Ended

Sep. 30, 2014

Stockholders Equity Note [Abstract]

Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]

We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:

June 26, 2013

July 15, 2013

December 23, 2013

Warrants issued

28,394,834

1,645,361

4,320,420

Risk free interest rate

.0109

.0109

0.0167

Volatility

160.94

%

163.08

%

155.24

%

Expected term

5 years

5 years

5 years

Exercise price

$

0.14

$

0.14

$

0.25

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Severance Charge (Tables)
9 Months Ended

Sep. 30, 2014

Severance Charge Abstract [Abstract]

Severance Charge [Table Text Block]

The composition of the severance charge is as follows:

Compensation and benefits

$

679,000

Stock-based compensation expenses related to accelerated vesting

1,161,000

Total severance charge

$

1,840,000

X

- Details

Name: aphb_SeveranceChargeAbstractAbstract

Namespace Prefix: aphb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the severance Charge.

+ References

No definition available.

+ Details

Name: aphb_SeveranceChargeTableTextBlock

Namespace Prefix: aphb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Options (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Allocated Share-based Compensation Expense $ 1,408,000 $ 248,000 $ 1,875,000 $ 1,206,000

General and administrative expense [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Allocated Share-based Compensation Expense 209,000 208,000 598,000 1,053,000

Research and development expense [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Allocated Share-based Compensation Expense 1,161,000 0 1,161,000 0

Research and Development [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Allocated Share-based Compensation Expense $ 38,000 $ 40,000 $ 116,000 $ 153,000

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=aphb_ResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Correction of Errors (Details Textual) (USD $)
3 Months Ended 6 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Change in Accounting Estimate [Line Items]

Temporary Equity, Par Value $ 1,660,000 $ 1,660,000 $ 1,660,000

Sales Revenue, Services, Net, Total 103,000us-gaap_SalesRevenueServicesNet (3,000)us-gaap_SalesRevenueServicesNet 308,000us-gaap_SalesRevenueServicesNet 333,000us-gaap_SalesRevenueServicesNet

General and Administrative Expense, Total 1,701,000us-gaap_GeneralAndAdministrativeExpense 1,215,000us-gaap_GeneralAndAdministrativeExpense 5,289,000us-gaap_GeneralAndAdministrativeExpense 4,772,000us-gaap_GeneralAndAdministrativeExpense

Derivative warrants liability 6,035,000aphb_DerivativeWarrantsLiability 6,035,000aphb_DerivativeWarrantsLiability 6,035,000aphb_DerivativeWarrantsLiability 16,871,000aphb_DerivativeWarrantsLiability

Goodwill 7,562,000us-gaap_Goodwill 7,562,000us-gaap_Goodwill 7,562,000us-gaap_Goodwill 7,562,000us-gaap_Goodwill

Derivative, Gain (Loss) on Derivative, Net 26,438,000 (46,380,000) 35,286,000 (52,350,000)

Net Income (Loss) Available to Common Stockholders, Basic, Total 20,884,000 (49,039,000) 20,884,000 (49,039,000) 22,818,000 (65,430,000)

Earnings Per Share, Basic $ 0.11us-gaap_EarningsPerShareBasic $ (0.49)us-gaap_EarningsPerShareBasic $ 0.11us-gaap_EarningsPerShareBasic $ (0.49)us-gaap_EarningsPerShareBasic $ 0.12us-gaap_EarningsPerShareBasic $ (0.76)us-gaap_EarningsPerShareBasic

Restatement Adjustment [Member]

Change in Accounting Estimate [Line Items]

Temporary Equity Accretion To Par Value 87,000

Decrease In Warrant Liability 1,109,000

Temporary Equity, Accretion to Redemption Value 1,250,000

Sales Revenue, Services, Net, Total 103,000 2,000

General and Administrative Expense, Total 73,000 88,000

Derivative warrants liability 195,000 195,000 195,000

Derivative Liability 6,410,000 6,410,000 6,410,000

Derivative, Gain (Loss) on Derivative, Net 2,104,000 1,260,000

Net Income (Loss) Available to Common Stockholders, Basic, Total 1,496,000 (5,139,000) 56,000 (7,098,000)

Earnings Per Share, Basic $ 0.01 $ (0.05) $ 0.08

Restatement Adjustment [Member] | Biocontrol [Member]

Change in Accounting Estimate [Line Items]

Goodwill 1,685,000 1,685,000 1,685,000

Restatement Adjustment [Member] | SPH [Member]

Change in Accounting Estimate [Line Items]

Goodwill $ 1,548,000 $ 1,548,000 $ 1,548,000

X

- Definition

Represents the amount of decrease in derivative liability.

+ References

No definition available.

+ Details

Name: aphb_DecreaseInWarrantLiability

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value of derivative liability of warrants as of the balance sheet date.

+ References

No definition available.

+ Details

Name: aphb_DerivativeWarrantsLiability

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value of temporary equity to its par value during the period.

+ References

No definition available.

+ Details

Name: aphb_TemporaryEquityAccretionToParValue

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ChangeInAccountingEstimateLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=36459792&loc=SL20226008-175313

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of accretion of temporary equity to its redemption value during the period.

+ References

No definition available.

+ Details

Name: us-gaap_TemporaryEquityAccretionToRedemptionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Series B Redeemable Convertible Preferred Stock [Member]

Balances at Dec. 31, 2012 $ 12,943,000us-gaap_StockholdersEquity $ 669,000 $ 332,806,000 $ (320,532,000) $ 0

Balances (in shares) at Dec. 31, 2012 66,908,810 0

Net income (loss) (64,583,000)us-gaap_NetIncomeLoss 0 0 (64,583,000) 0

Accretion of Series B convertible preferred stock to its redemption value (618,000) 0 (618,000) 0 618,000

Preferred stock converted to common stock 7,084,000 115,000 6,969,000 0 (11,000)

Preferred stock converted to common stock (in shares) 11,561,020 (1,156,102)

Stock-based compensation 1,437,000 0 1,437,000 0 0

Beneficial conversion feature and warrants associated with issuance of convertible loan notes 2,635,000 0 2,635,000 0 0

Shares issued for Intrexon 3,000,000 240,000 2,760,000 0 0

Shares issued for Intrexon (in shares) 24,000,000

Issuance of preferred stock from conversion of convertible loan notes 0 0 0 0 50,000

Issuance of preferred stock from conversion of convertible loan notes (in shares) 0 5,016,081

Issuance of preferred stock 0 0 0 0 50,000

Issuance of preferred stock (in shares) 4,999,999

Stock options exercised 13,000 1,000 12,000 0 0

Stock options exercised (in shares) 61,018 0

Shares released from escrow 0 80,000 (80,000) 0 0

Shares released from escrow (in shares) 8,000,000 0

Issuance of common stock for December financing 15,464,000 720,000 14,744,000 0 0

Issuance of common stock for December financing (in shares) 72,007,000 0

Escheat shares 0 0 0 0 0

Escheat shares (in shares) (2,286) 0

Balances at Dec. 31, 2013 (22,625,000)us-gaap_StockholdersEquity 1,825,000 360,665,000 (385,115,000) 707,000

Balances (in shares) at Dec. 31, 2013 182,535,562 8,859,978

Net income (loss) 23,773,000us-gaap_NetIncomeLoss 0 0 23,773,000 0

Accretion of Series B convertible preferred stock to its redemption value (955,000) 0 (955,000) 0 955,000

Warrants exercised 1,594,000 28,000 1,566,000 0 0

Warrants exercised (in shares) 2,734,151 0

Preferred stock converted to common stock 706,000 19,000 687,000 0 (2,000)

Preferred stock converted to common stock (in shares) 1,889,380 (188,938)

Stock-based compensation 714,000 0 714,000 0 0

Stock-based compensation - severance 1,161,000 0 1,161,000 0 0

Balances at Sep. 30, 2014 $ 4,368,000us-gaap_StockholdersEquity $ 1,872,000 $ 363,838,000 $ (361,342,000) $ 1,660,000

Balances (in shares) at Sep. 30, 2014 187,159,093 8,671,040

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesNewIssues1

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesNewIssues2

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Stock Issued During Period, Shares, Shares Released from Escrow

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesSharesReleasedFromEscrow

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants exercised during the current period.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesWarrantsExercised

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodValueNewIssues1

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodValueNewIssues2

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period for shares released from escrow.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodValueWarrantsExercised

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=32707879&loc=d3e34017-109320

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of accretion of the preferred stock redemption discount during the period.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockAccretionOfRedemptionDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of stock bought back by the entity at the exercise price or redemption price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 42 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stock Options
9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

4. Stock Options

In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to 35,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants.

In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to 4,200,000 shares of our common stock in stock incentive awards to employees, directors and consultants.

In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to 40,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014.

The Company’s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company’s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plans.

Under ASC 718 Stock Compensation, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.

Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three and nine month periods ended September 30, 2013 and 2014.

Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations:

Three Months Ended

Nine Months Ended

September

September

September

September

30, 2014

30, 2013

30, 2014

30, 2013

Income statement category:

Research and development

$

38,000

$

40,000

$

116,000

$

153,000

General and administrative

209,000

208,000

598,000

1,053,000

Severance charge

1,161,000

—

1,161,000

—

Total stock-based compensation expense

$

1,408,000

$

248,000

$

1,875,000

$

1,206,000



      The following table summarizes Option activity:

Average Remaining

Weighted Average

Contractual Term

Shares

Exercise Price

(Years)

Intrinsic Value

Outstanding at December 31, 2013

25,721,000

$

0.19

9.15

$

6,451,441

Granted

—

—

Exercised

—

—

Forfeited

3,137,378

0.19

Expired

2,000

13.10

Outstanding at September 30, 2014

22,581,622

$

0.19

2.15

$

862,982

Exercisable at September 30, 2014

19,972,558

$

0.19

1.35

$

822,989

The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $0.22 on September 30, 2014.

As of September 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $559,358 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years.

As of September 30, 2014, the Company had reserved shares of its common stock for future issuance as follows:

Shares Reserved

Stock options outstanding

22,581,622

Available for future grants under the 2013 Stock Incentive Plan

39,250,000

Warrants

38,890,451

Total shares reserved

100,722,073

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 91 198 1 false 28 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.ampliphibio.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.ampliphibio.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 103 - Statement - Consolidated Balance Sheets [Parenthetical] Sheet http://www.ampliphibio.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets [Parenthetical] false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 105 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) false false R6.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R7.htm 107 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies false false R8.htm 108 - Disclosure - Preferred Shares Sheet http://www.ampliphibio.com/role/PreferredShares Preferred Shares false false R9.htm 109 - Disclosure - Warrants and Warrants Liability Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiability Warrants and Warrants Liability false false R10.htm 110 - Disclosure - Stock Options Sheet http://www.ampliphibio.com/role/StockOptions Stock Options false false R11.htm 111 - Disclosure - Severance Charge Sheet http://www.ampliphibio.com/role/SeveranceCharge Severance Charge false false R12.htm 112 - Disclosure - Correction of Errors Sheet http://www.ampliphibio.com/role/CorrectionOfErrors Correction of Errors false false R13.htm 113 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) false false R14.htm 114 - Disclosure - Warrants and Warrants Liability (Tables) Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiabilityTables Warrants and Warrants Liability (Tables) false false R15.htm 115 - Disclosure - Stock Options (Tables) Sheet http://www.ampliphibio.com/role/StockOptionsTables Stock Options (Tables) false false R16.htm 116 - Disclosure - Severance Charge (Tables) Sheet http://www.ampliphibio.com/role/SeveranceChargeTables Severance Charge (Tables) false false R17.htm 117 - Disclosure - Nature of Business and Significant Accounting Policies (Details Textual) Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsTextual Nature of Business and Significant Accounting Policies (Details Textual) false false R18.htm 118 - Disclosure - Preferred Shares (Details Textual) Sheet http://www.ampliphibio.com/role/PreferredSharesDetailsTextual Preferred Shares (Details Textual) false false R19.htm 119 - Disclosure - Warrants and Warrants Liability (Details) Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiabilityDetails Warrants and Warrants Liability (Details) false false R20.htm 120 - Disclosure - Warrants and Warrants Liability (Details Textual) Sheet http://www.ampliphibio.com/role/WarrantsAndWarrantsLiabilityDetailsTextual Warrants and Warrants Liability (Details Textual) false false R21.htm 121 - Disclosure - Stock Options (Details) Sheet http://www.ampliphibio.com/role/StockOptionsDetails Stock Options (Details) false false R22.htm 122 - Disclosure - Stock Options (Details 1) Sheet http://www.ampliphibio.com/role/StockOptionsDetails1 Stock Options (Details 1) false false R23.htm 123 - Disclosure - Stock Options (Details 2) Sheet http://www.ampliphibio.com/role/StockOptionsDetails2 Stock Options (Details 2) false false R24.htm 124 - Disclosure - Stock Options (Details Textual) Sheet http://www.ampliphibio.com/role/StockOptionsDetailsTextual Stock Options (Details Textual) false false R25.htm 125 - Disclosure - Severance Charge (Details) Sheet http://www.ampliphibio.com/role/SeveranceChargeDetails Severance Charge (Details) false false R26.htm 126 - Disclosure - Correction of Errors (Details Textual) Sheet http://www.ampliphibio.com/role/CorrectionOfErrorsDetailsTextual Correction of Errors (Details Textual) false false All Reports Book All Reports Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 364 days and at least 26 values. Shorter duration columns must have at least one fourth (6) as many values. Column '7/1/2013 - 9/30/2013' is shorter (91 days) and has only 3 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 364 days and at least 26 values. Shorter duration columns must have at least one fourth (6) as many values. Column '7/1/2014 - 9/30/2014' is shorter (91 days) and has only 3 values, so it is being removed. 'Monetary' elements on report '118 - Disclosure - Preferred Shares (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - Consolidated Balance Sheets [Parenthetical] Process Flow-Through: 104 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '6 Months Ended Sep. 30, 2014' Process Flow-Through: Removing column '6 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2013' Process Flow-Through: 106 - Statement - Consolidated Statements of Cash Flows Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2013' aphb-20140930.xml aphb-20140930.xsd aphb-20140930_cal.xml aphb-20140930_def.xml aphb-20140930_lab.xml aphb-20140930_pre.xml true true XML 44 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Warrants and Warrants Liability (Details Textual) (USD $)
9 Months Ended 12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2011

Class of Warrant or Right [Line Items]

Derivative warrants liability $ 6,035,000aphb_DerivativeWarrantsLiability 16,871,000aphb_DerivativeWarrantsLiability

Derivative, Gain on Derivative 7,100,000us-gaap_DerivativeGainOnDerivative

Warrants Issued on June 26, 2013 Member [Member]

Class of Warrant or Right [Line Items]

Warrants Issued During the Period, Number of Warrants 28,394,834

Warrants Exercised During Period Value 3,855,714

Common Stock Issued During Period Value Warrants Exercised 2,734,151

Reclassifications of Temporary to Permanent Equity 1,594,000

Biocontrol Limited [Member]

Class of Warrant or Right [Line Items]

Warrants Issued During the Period, Terms Of Expiration December 2016

Warrants Issued During the Period, Number of Warrants 1,355,164

Warrants Issued During the Period, Exercise Price of Warrants $ 0.46

Convertible Notes Payable [Member]

Class of Warrant or Right [Line Items]

Warrants Issued During the Period, Terms Of Expiration February through May 2018

Warrants Issued During the Period, Number of Warrants 7,030,387

Warrants Issued During the Period, Exercise Price of Warrants 0.14

Series B Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Warrants Issued During the Period, Number of Warrants 12,499,996

Warrants Issued During the Period, Exercise Price of Warrants 0.14

Common Stock [Member]

Class of Warrant or Right [Line Items]

Stock Issued During Period, Shares, New Issues2 72,007,000

Warrants Issued During the Period, Number of Warrants 4,320,420

Warrants Issued During the Period, Exercise Price of Warrants 0.25

Private Placement [Member] | Series B Convertible Preferred Stock [Member]

Class of Warrant or Right [Line Items]

Warrants Issued During the Period, Terms Of Expiration June 2018

Warrants Issued During the Period, Number of Warrants 30,040,195

Warrants Issued During the Period, Exercise Price of Warrants 0.14

Warrants Issuance Costs 1,400,000

Private Placement [Member] | Common Stock [Member]

Class of Warrant or Right [Line Items]

Stock Issued During Period, Shares, New Issues2 72,007,000

Stock Issued During Period, Exercise Price, New Issues2 0.25

Warrants Issued During the Period, Terms Of Expiration December 2018

X

- Definition

Value of common stock issued as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name: aphb_CommonStockIssuedDuringPeriodValueWarrantsExercised

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value of derivative liability of warrants as of the balance sheet date.

+ References

No definition available.

+ Details

Name: aphb_DerivativeWarrantsLiability

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

This element represents that, the exercise price of stock issued during the period.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodExercisePriceNewIssues2

Namespace Prefix: aphb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

No definition available.

+ Details

Name: aphb_StockIssuedDuringPeriodSharesNewIssues2

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of warrants exercised during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsExercisedDuringPeriodValue

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents that, the warrants issuance costs for during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuanceCosts

Namespace Prefix: aphb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents that, the exercise price of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants

Namespace Prefix: aphb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents that, the number of warrants issued during the period.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodNumberOfWarrants

Namespace Prefix: aphb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the warrants issued during the period, terms of expiration.

+ References

No definition available.

+ Details

Name: aphb_WarrantsIssuedDuringPeriodTermsOfExpiration

Namespace Prefix: aphb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainOnDerivative

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 40

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6445032&loc=d3e90193-114008

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=27011957&loc=SL6540498-122764

+ Details

Name: us-gaap_ReclassificationsOfTemporaryToPermanentEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=aphb_BiocontrolLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=aphb_WarrantsIssuedOnJune262013MemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=aphb_SeriesBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Severance Charge (Details) (USD $)	3 Months Ended		9 Months Ended
Severance Charge (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Severance Charge [Line Items]
Compensation and benefits			$ 679,000aphb_CompensationAndBenefits
Stock-based compensation expenses related to accelerated vesting			1,161,000	0
Total severance charge	$ 1,840,000us-gaap_SeveranceCosts1	$ 0us-gaap_SeveranceCosts1	$ 1,840,000us-gaap_SeveranceCosts1	$ 0us-gaap_SeveranceCosts1

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 9,786,000	$ 20,355,000
Accounts receivable	27,000us-gaap_AccountsReceivableNetCurrent	8,000us-gaap_AccountsReceivableNetCurrent
Prepaid expenses and other current assets	448,000	297,000
Total current assets	10,261,000us-gaap_AssetsCurrent	20,660,000us-gaap_AssetsCurrent
Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of September 30, 2014 and December 31, 2013, respectively	1,283,000us-gaap_PropertyPlantAndEquipmentNet	145,000us-gaap_PropertyPlantAndEquipmentNet
Intangible assets
In process research and development	12,446,000	12,446,000
Patents, net of accumulated amortization of $116,000 and $93,000 as of September 30, 2014 and December 31, 2013, respectively	377,000us-gaap_FiniteLivedPatentsGross	400,000us-gaap_FiniteLivedPatentsGross
Goodwill	7,562,000us-gaap_Goodwill	7,562,000us-gaap_Goodwill
Total intangible assets	20,385,000	20,408,000
Total assets	31,929,000us-gaap_Assets	41,213,000us-gaap_Assets
Current liabilities
Accounts payable and accrued expenses	1,840,000	2,147,000
Deferred revenue	246,000us-gaap_DeferredRevenueCurrent	244,000us-gaap_DeferredRevenueCurrent
Accrued severance	449,000	0
Total current liabilities	2,535,000us-gaap_LiabilitiesCurrent	2,391,000us-gaap_LiabilitiesCurrent
Long term liabilities
Derivative preferred shares conversion liability	14,043,000	40,791,000
Derivative warrants liability	6,035,000aphb_DerivativeWarrantsLiability	16,871,000aphb_DerivativeWarrantsLiability
Deferred tax liability	3,078,000	3,078,000
Accrued severance	210,000	0
Total long term liabilities	23,366,000us-gaap_LiabilitiesNoncurrent	60,740,000us-gaap_LiabilitiesNoncurrent
Total liabilities	25,901,000us-gaap_Liabilities	63,131,000us-gaap_Liabilities
Series B redeemable convertible preferred stock $0.01 par value, 10,000,000 shares authorized, 8,859,978 shares issued and outstanding at December 31, 2013 (liquidation preference of $13,712,000 and 13,022,000 at September 30, 2014 and December 31, 2014, respectively)	1,660,000	707,000
Stockholders' equity (deficit)
Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at September 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013	1,872,000us-gaap_CommonStockValue	1,825,000us-gaap_CommonStockValue
Additional paid-in capital	362,001,000us-gaap_AdditionalPaidInCapital	358,828,000us-gaap_AdditionalPaidInCapital
Paid-in-capital - contingent shares	1,837,000us-gaap_OtherAdditionalCapital	1,837,000us-gaap_OtherAdditionalCapital
Accumulated deficit	(361,342,000)	(385,115,000)
Total stockholders' equity (deficit)	4,368,000us-gaap_StockholdersEquity	(22,625,000)us-gaap_StockholdersEquity
Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity (deficit)	$ 31,929,000	$ 41,213,000

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities
Net income (loss) from operations	$ 23,773,000us-gaap_NetIncomeLoss	$ (65,041,000)us-gaap_NetIncomeLoss
Adjustments required to reconcile net income (loss) to cash used in operating activities:
Derivative liability (gain) loss	(35,286,000)	52,350,000
Shares issued for technology access fee	0	3,000,000
Amortization of patents	23,000us-gaap_AmortizationOfIntangibleAssets	23,000us-gaap_AmortizationOfIntangibleAssets
Amortization of note discount	0	2,637,000
Warrants issued as investment fees	0us-gaap_FairValueAdjustmentOfWarrants	759,000us-gaap_FairValueAdjustmentOfWarrants
Depreciation	59,000us-gaap_Depreciation	66,000us-gaap_Depreciation
Stock-based compensation	714,000us-gaap_ShareBasedCompensation	1,206,000us-gaap_ShareBasedCompensation
Stock-based compensation - severance	1,161,000	0
Changes in operating assets and liabilities net of acquisitions:
Accounts receivable	(19,000)	(125,000)
Tax refund	0	618,000
Accounts payable and accrued expenses	(305,000)	(453,000)
Accrued severance	659,000	0
Prepaid expenses and other current assets	(151,000)	(153,000)
Interest on loan notes	0	233,000
Net cash used in operating activities	(9,372,000)	(4,880,000)
Cash flows from investing activities
Purchases of property and equipment	(1,197,000)	(97,000)
Net cash used in investing activities	(1,197,000)	(97,000)
Cash flows from financing activities
Proceeds from Series B redeemable convertible preferred stock	0	7,000,000
Proceeds from convertible loan notes	0us-gaap_ProceedsFromConvertibleDebt	2,000,000us-gaap_ProceedsFromConvertibleDebt
Payment of convertible loan note	0us-gaap_RepaymentsOfConvertibleDebt	(26,000)us-gaap_RepaymentsOfConvertibleDebt
Net cash provided by financing activities	0	8,974,000
Net increase (decrease) in cash and cash equivalents	(10,569,000)	3,997,000
Cash and cash equivalents, beginning of period	20,355,000	862,000
Cash and cash equivalents, end of period	9,786,000	4,859,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	$ 955,000	$ 618,000

Stock Options (Details 1) (Employee Stock Option [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding at December 31, 2013	25,721,000
Shares, Granted	0
Shares, Exercised	0
Shares, Forfeited	3,137,378
Shares, Expired	2,000
Shares, Outstanding at September 30, 2014	22,581,622	25,721,000
Shares, Exercisable at September 30, 2014	19,972,558
Weighted Average Exercise Price, Outstanding at December 31, 2013	$ 0.19
Weighted Average Exercise Price, Granted	$ 0
Weighted Average Exercise Price, Exercised	$ 0
Weighted Average Exercise Price, Forfeited	$ 0.19
Weighted Average Exercise Price, Expired	$ 13.10
Weighted Average Exercise Price, Outstanding at September 30, 2014	$ 0.19	$ 0.19
Weighted Average Exercise Price, Exercisable at September 30, 2014	$ 0.19
Average Remaining Contractual Term (Years), Outstanding at September 30, 2014	2 years 1 month 24 days	9 years 1 month 24 days
Average Remaining Contractual Term (Years), Exercisable at September 30, 2014	1 year 4 months 6 days
Intrinsic Value, Outstanding at September 30, 2014	$ 862,982	$ 6,451,441
Intrinsic Value, Exercisable at September 30, 2014	822,989
Intrinsic Value, Outstanding at December 31, 2013	$ 6,451,441

Stock Options (Details Textual) (USD $)	9 Months Ended
Stock Options (Details Textual) (USD $)	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 0.22
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 559,358
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	35,000,000
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,200,000
2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	40,000,000

Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)	$ 559,000	$ 473,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	445,000,000us-gaap_CommonStockSharesAuthorized	445,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares issued	187,159,093us-gaap_CommonStockSharesIssued	182,535,562us-gaap_CommonStockSharesIssued
Common stock, shares outstanding	187,159,093us-gaap_CommonStockSharesOutstanding	182,535,562us-gaap_CommonStockSharesOutstanding
Patents [Member]
Finite-Lived Intangible Assets, Accumulated Amortization	116,000	93,000
Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity, par value (in dollars per share)		$ 0.01
Temporary Equity, shares authorized		10,000,000
Temporary Equity, shares issued		8,859,978
Temporary Equity, shares outstanding		8,859,978
Temporary Equity, liquidation preference	$ 13,712,000	$ 13,022,000

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2014	Oct. 20, 2014
Document Information [Line Items]
Entity Registrant Name	AmpliPhi Biosciences Corp
Entity Central Index Key	0000921114
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	APHB
Entity Common Stock, Shares Outstanding		187,159,093dei_EntityCommonStockSharesOutstanding
Document Type	10-Q/A
Amendment Flag	true
Document Period End Date	Sep. 30, 2014
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014
Amendment Description	The Company’s previously issued September 30, 2014 financial statements have been amended to: reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at September 30, 2014 of $1,660,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $87,000 and the accretion of the stock’s redemption value of $1,250,000. recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase of in revenue of $103,000 and an increase of in G&A expense of $73,000 in the third quarter of 2014 and a reduction in revenues of $2,000 and a reduction in G&A expense of $88,000 for the nine months ended September 30, 2014. reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded by error as equity instruments. This adjustment resulted in the in the recording of a liability of $195,000 as of September 30, 2014. adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants under a Monte Carlo valuation model. The change in assumptions resulted in a increase of $6,410,000 for the compound derivative liability and a decrease in the liability for 2013 warrants of $1,109,000. The gain on derivative liabilities was increased by $2,104,000 and $1,260,000 for the third quarter and the nine months ended September 30, 2014, respectively. As a result of these corrections, the Company’s net income attributable to common stockholders for the third quarter of 2014, as amended, increased $1,496,000 to $20,884,000. Net income per share attributable to common stockholders rose by $0.01 per share to $0.11 per share. Net income attributable to common stockholders for the nine months ended September 30, 2014, as amended, increased by $56,000 to $22,818,000. Net income per share attributable to common stockholders was unchanged for the period. The Company’s net loss attributable to common stockholders for the third quarter of 2013, as amended, increased by ($5,139,000) to ($49,039,000). The net loss per share attributable to common stockholders increased by ($0.05) per share to $(0.49) per share. The net loss attributable to common stockholders for the nine months ended September 30, 2013, as amended, increased by ($7,098,000) to ($65,430,000). The net loss per share attributable to common stockholders increased by ($0.08) per share to $(0.76) per share for the period.

Preferred Shares (Details Textual) (USD $)	9 Months Ended		12 Months Ended
Preferred Shares (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Class of Stock [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 19,400,000
Derivative preferred shares conversion liability	14,043,000		40,791,000
Fair Value Adjustment of Warrants	0us-gaap_FairValueAdjustmentOfWarrants	759,000us-gaap_FairValueAdjustmentOfWarrants
Reclassification From Derivative Liability To Equity	707,000
Common Stock [Member]
Class of Stock [Line Items]
Warrants Issued During the Period, Number of Warrants			4,320,420
Warrants Issued During the Period, Exercise Price of Warrants			$ 0.25
Conversion of Stock, Shares Converted	1,889,380
Preferred Stock [Member]
Class of Stock [Line Items]
Derivative Liability			6,917,000
Conversion of Stock, Shares Converted	188,938
Warrant [Member]
Class of Stock [Line Items]
Derivative Liability			1,886,000
Convertible Notes Payable One [Member]
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount			5,491,001
Warrants Issued During Period Number Of Warrants1			4,999,999
Warrants Issued During Period Exercise Price Of Warrants1			$ 0.14
Fair Value Adjustment of Warrants			759,000
Payments of Stock Issuance Costs			350,000
Convertible Notes Payable One [Member] \| Preferred Stock [Member]
Class of Stock [Line Items]
Derivative Liability			6,029,000
Convertible Notes Payable One [Member] \| Warrant [Member]
Class of Stock [Line Items]
Derivative Liability			1,644,000
Convertible Notes Payable Two [Member]
Class of Stock [Line Items]
Warrants Issued During the Period, Number of Warrants			1,645,361
Debt Conversion, Original Debt, Amount			829,277
Warrants Issued During Period Exercise Price Of Warrants1			$ 0.14
Convertible Notes Payable Two [Member] \| Preferred Stock [Member]
Class of Stock [Line Items]
Derivative Liability			2,386,000
Convertible Notes Payable Two [Member] \| Warrant [Member]
Class of Stock [Line Items]
Derivative Liability			674,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized			10,016,080
Preferred Stock, Initial Stated Value Per Share			$ 1.40
Preferred Stock, Par or Stated Value Per Share			$ 0.01
Debt Instrument, Convertible, Number of Equity Instruments			10
Preferred Stock, Dividend Rate, Percentage			10.00%
Debt Instrument, Convertible, If-initial public offering proceeds meets Least amount			7,000,000
Stock Issued During Period, Shares, New Issues1			4,999,999
Warrants Issued During the Period, Number of Warrants			12,499,996
Warrants Issued During the Period, Exercise Price of Warrants			$ 0.14
Warrants Issued During the Period, Value of Warrants			$ 7,000,000
Series B Convertible Preferred Stock [Member] \| Convertible Notes Payable One [Member]
Class of Stock [Line Items]
Warrants Issued During the Period, Number of Warrants			10,894,839
Warrants Issued During the Period, Exercise Price of Warrants			$ 0.14
Debt Conversion, Converted Instrument, Shares Issued			4,357,936
Series B Convertible Preferred Stock [Member] \| Convertible Notes Payable Two [Member]
Class of Stock [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			658,145

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	$ 103,000us-gaap_SalesRevenueServicesNet	$ (3,000)us-gaap_SalesRevenueServicesNet	$ 308,000us-gaap_SalesRevenueServicesNet	$ 333,000us-gaap_SalesRevenueServicesNet
Operating expenses
Research and development	1,793,000us-gaap_ResearchAndDevelopmentExpense	1,123,000us-gaap_ResearchAndDevelopmentExpense	4,692,000us-gaap_ResearchAndDevelopmentExpense	5,359,000us-gaap_ResearchAndDevelopmentExpense
General and administrative	1,701,000us-gaap_GeneralAndAdministrativeExpense	1,215,000us-gaap_GeneralAndAdministrativeExpense	5,289,000us-gaap_GeneralAndAdministrativeExpense	4,772,000us-gaap_GeneralAndAdministrativeExpense
Severance charge	1,840,000us-gaap_SeveranceCosts1	0us-gaap_SeveranceCosts1	1,840,000us-gaap_SeveranceCosts1	0us-gaap_SeveranceCosts1
Total operating expenses	5,334,000us-gaap_OperatingExpenses	2,338,000us-gaap_OperatingExpenses	11,821,000us-gaap_OperatingExpenses	10,131,000us-gaap_OperatingExpenses
Loss from operations	(5,231,000)us-gaap_OperatingIncomeLoss	(2,341,000)us-gaap_OperatingIncomeLoss	(11,513,000)us-gaap_OperatingIncomeLoss	(9,798,000)us-gaap_OperatingIncomeLoss
Other income (expense)
Gain (loss) on derivative liabilities	26,438,000	(46,380,000)	35,286,000	(52,350,000)
Amortization of note discount and patents	0us-gaap_AmortizationOfDeferredCharges	(23,000)us-gaap_AmortizationOfDeferredCharges	0us-gaap_AmortizationOfDeferredCharges	(2,660,000)us-gaap_AmortizationOfDeferredCharges
Interest expense, net	0us-gaap_InterestExpense	(9,000)us-gaap_InterestExpense	0us-gaap_InterestExpense	(233,000)us-gaap_InterestExpense
Other income (expense), net	26,438,000us-gaap_OtherNonoperatingIncomeExpense	(46,412,000)us-gaap_OtherNonoperatingIncomeExpense	35,286,000us-gaap_OtherNonoperatingIncomeExpense	(55,243,000)us-gaap_OtherNonoperatingIncomeExpense
Net income (loss)	21,207,000us-gaap_NetIncomeLoss	(48,753,000)us-gaap_NetIncomeLoss	23,773,000us-gaap_NetIncomeLoss	(65,041,000)us-gaap_NetIncomeLoss
Accretion of Series B redeemable convertible preferred stock	(323,000)	(286,000)	(955,000)	(389,000)
Net loss attributable to common stockholders	$ 20,884,000	$ (49,039,000)	$ 22,818,000	$ (65,430,000)
Per share information:
Net income (loss) per share - basic (in dollars per share)	$ 0.11us-gaap_EarningsPerShareBasic	$ (0.49)us-gaap_EarningsPerShareBasic	$ 0.12us-gaap_EarningsPerShareBasic	$ (0.76)us-gaap_EarningsPerShareBasic
Net income (loss) per share - diluted (in dollars per share)	$ 0.07us-gaap_EarningsPerShareDiluted	$ (0.49)us-gaap_EarningsPerShareDiluted	$ 0.07us-gaap_EarningsPerShareDiluted	$ (0.76)us-gaap_EarningsPerShareDiluted
Weighted average number of shares of common stock outstanding - basic (in shares)	187,159,093	99,156,809	184,445,172	85,688,356
Weighted average number of shares of common stock outstanding - diluted (in shares)	315,990,084	99,156,809	323,604,642	85,688,356

Warrants and Warrants Liability (Details) (USD $)	12 Months Ended
Warrants and Warrants Liability (Details) (USD $)	Dec. 31, 2013
Warrants Issued on June 26, 2013 Member [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	28,394,834
Risk free interest rate	0.0109%
Volatility	160.94%
Expected term	5 years
Exercise price	$ 0.14
Warrants Issued on July 15, 2013 Member [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	1,645,361
Risk free interest rate	0.0109%
Volatility	163.08%
Expected term	5 years
Exercise price	$ 0.14
Warrants Issued on December 23, 2013 Member [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	4,320,420
Risk free interest rate	0.0167%
Volatility	155.24%
Expected term	5 years
Exercise price	$ 0.25

Stock Options (Details) (USD $)	3 Months Ended		9 Months Ended
Stock Options (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 1,408,000	$ 248,000	$ 1,875,000	$ 1,206,000
General and administrative expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	209,000	208,000	598,000	1,053,000
Research and development expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,161,000	0	1,161,000	0
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 38,000	$ 40,000	$ 116,000	$ 153,000

Correction of Errors (Details Textual) (USD $)	3 Months Ended		6 Months Ended		9 Months Ended
Correction of Errors (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Change in Accounting Estimate [Line Items]
Temporary Equity, Par Value	$ 1,660,000		$ 1,660,000		$ 1,660,000
Sales Revenue, Services, Net, Total	103,000us-gaap_SalesRevenueServicesNet	(3,000)us-gaap_SalesRevenueServicesNet			308,000us-gaap_SalesRevenueServicesNet	333,000us-gaap_SalesRevenueServicesNet
General and Administrative Expense, Total	1,701,000us-gaap_GeneralAndAdministrativeExpense	1,215,000us-gaap_GeneralAndAdministrativeExpense			5,289,000us-gaap_GeneralAndAdministrativeExpense	4,772,000us-gaap_GeneralAndAdministrativeExpense
Derivative warrants liability	6,035,000aphb_DerivativeWarrantsLiability		6,035,000aphb_DerivativeWarrantsLiability		6,035,000aphb_DerivativeWarrantsLiability		16,871,000aphb_DerivativeWarrantsLiability
Goodwill	7,562,000us-gaap_Goodwill		7,562,000us-gaap_Goodwill		7,562,000us-gaap_Goodwill		7,562,000us-gaap_Goodwill
Derivative, Gain (Loss) on Derivative, Net	26,438,000	(46,380,000)			35,286,000	(52,350,000)
Net Income (Loss) Available to Common Stockholders, Basic, Total	20,884,000	(49,039,000)	20,884,000	(49,039,000)	22,818,000	(65,430,000)
Earnings Per Share, Basic	$ 0.11us-gaap_EarningsPerShareBasic	$ (0.49)us-gaap_EarningsPerShareBasic	$ 0.11us-gaap_EarningsPerShareBasic	$ (0.49)us-gaap_EarningsPerShareBasic	$ 0.12us-gaap_EarningsPerShareBasic	$ (0.76)us-gaap_EarningsPerShareBasic
Restatement Adjustment [Member]
Change in Accounting Estimate [Line Items]
Temporary Equity Accretion To Par Value					87,000
Decrease In Warrant Liability					1,109,000
Temporary Equity, Accretion to Redemption Value					1,250,000
Sales Revenue, Services, Net, Total	103,000				2,000
General and Administrative Expense, Total	73,000				88,000
Derivative warrants liability	195,000		195,000		195,000
Derivative Liability	6,410,000		6,410,000		6,410,000
Derivative, Gain (Loss) on Derivative, Net			2,104,000		1,260,000
Net Income (Loss) Available to Common Stockholders, Basic, Total			1,496,000	(5,139,000)	56,000	(7,098,000)
Earnings Per Share, Basic			$ 0.01	$ (0.05)		$ 0.08
Restatement Adjustment [Member] \| Biocontrol [Member]
Change in Accounting Estimate [Line Items]
Goodwill	1,685,000		1,685,000		1,685,000
Restatement Adjustment [Member] \| SPH [Member]
Change in Accounting Estimate [Line Items]
Goodwill	$ 1,548,000		$ 1,548,000		$ 1,548,000

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Series B Redeemable Convertible Preferred Stock [Member]
Balances at Dec. 31, 2012	$ 12,943,000us-gaap_StockholdersEquity	$ 669,000	$ 332,806,000	$ (320,532,000)	$ 0
Balances (in shares) at Dec. 31, 2012		66,908,810			0
Net income (loss)	(64,583,000)us-gaap_NetIncomeLoss	0	0	(64,583,000)	0
Accretion of Series B convertible preferred stock to its redemption value	(618,000)	0	(618,000)	0	618,000
Preferred stock converted to common stock	7,084,000	115,000	6,969,000	0	(11,000)
Preferred stock converted to common stock (in shares)		11,561,020			(1,156,102)
Stock-based compensation	1,437,000	0	1,437,000	0	0
Beneficial conversion feature and warrants associated with issuance of convertible loan notes	2,635,000	0	2,635,000	0	0
Shares issued for Intrexon	3,000,000	240,000	2,760,000	0	0
Shares issued for Intrexon (in shares)		24,000,000
Issuance of preferred stock from conversion of convertible loan notes	0	0	0	0	50,000
Issuance of preferred stock from conversion of convertible loan notes (in shares)		0			5,016,081
Issuance of preferred stock	0	0	0	0	50,000
Issuance of preferred stock (in shares)					4,999,999
Stock options exercised	13,000	1,000	12,000	0	0
Stock options exercised (in shares)		61,018			0
Shares released from escrow	0	80,000	(80,000)	0	0
Shares released from escrow (in shares)		8,000,000			0
Issuance of common stock for December financing	15,464,000	720,000	14,744,000	0	0
Issuance of common stock for December financing (in shares)		72,007,000			0
Escheat shares	0	0	0	0	0
Escheat shares (in shares)		(2,286)			0
Balances at Dec. 31, 2013	(22,625,000)us-gaap_StockholdersEquity	1,825,000	360,665,000	(385,115,000)	707,000
Balances (in shares) at Dec. 31, 2013		182,535,562			8,859,978
Net income (loss)	23,773,000us-gaap_NetIncomeLoss	0	0	23,773,000	0
Accretion of Series B convertible preferred stock to its redemption value	(955,000)	0	(955,000)	0	955,000
Warrants exercised	1,594,000	28,000	1,566,000	0	0
Warrants exercised (in shares)		2,734,151			0
Preferred stock converted to common stock	706,000	19,000	687,000	0	(2,000)
Preferred stock converted to common stock (in shares)		1,889,380			(188,938)
Stock-based compensation	714,000	0	714,000	0	0
Stock-based compensation - severance	1,161,000	0	1,161,000	0	0
Balances at Sep. 30, 2014	$ 4,368,000us-gaap_StockholdersEquity	$ 1,872,000	$ 363,838,000	$ (361,342,000)	$ 1,660,000
Balances (in shares) at Sep. 30, 2014		187,159,093			8,671,040

Warrants and Warrants Liability (Details Textual) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2011
Class of Warrant or Right [Line Items]
Derivative warrants liability	$ 6,035,000aphb_DerivativeWarrantsLiability	16,871,000aphb_DerivativeWarrantsLiability
Derivative, Gain on Derivative	7,100,000us-gaap_DerivativeGainOnDerivative
Warrants Issued on June 26, 2013 Member [Member]
Class of Warrant or Right [Line Items]
Warrants Issued During the Period, Number of Warrants		28,394,834
Warrants Exercised During Period Value	3,855,714
Common Stock Issued During Period Value Warrants Exercised	2,734,151
Reclassifications of Temporary to Permanent Equity	1,594,000
Biocontrol Limited [Member]
Class of Warrant or Right [Line Items]
Warrants Issued During the Period, Terms Of Expiration			December 2016
Warrants Issued During the Period, Number of Warrants			1,355,164
Warrants Issued During the Period, Exercise Price of Warrants			$ 0.46
Convertible Notes Payable [Member]
Class of Warrant or Right [Line Items]
Warrants Issued During the Period, Terms Of Expiration		February through May 2018
Warrants Issued During the Period, Number of Warrants		7,030,387
Warrants Issued During the Period, Exercise Price of Warrants		0.14
Series B Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Warrants Issued During the Period, Number of Warrants		12,499,996
Warrants Issued During the Period, Exercise Price of Warrants		0.14
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues2		72,007,000
Warrants Issued During the Period, Number of Warrants		4,320,420
Warrants Issued During the Period, Exercise Price of Warrants		0.25
Private Placement [Member] \| Series B Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Warrants Issued During the Period, Terms Of Expiration		June 2018
Warrants Issued During the Period, Number of Warrants		30,040,195
Warrants Issued During the Period, Exercise Price of Warrants		0.14
Warrants Issuance Costs		1,400,000
Private Placement [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues2		72,007,000
Stock Issued During Period, Exercise Price, New Issues2		0.25
Warrants Issued During the Period, Terms Of Expiration		December 2018